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Neutrophil dysfunction has been described in various inflammatory and autoimmune 
rheumatic diseases (ARDs), including rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE) and antiphospholipid syndrome (APS). These ARDs are typically characterised by 
circulating autoantibodies, which contribute to immunopathology. Studies have also reported 
low oxygen levels, or hypoxia, in association with disease manifestations.  
One mechanism of neutrophil activation, results in the release of a meshwork of 
chromatin fibres decorated with antimicrobial proteins, called neutrophil extracellular traps 
(NETs), which promote pathogen killing. Whilst NETs are important in fighting infection, if 
unchecked severe damage to host organs can be caused. Aberrant NETosis has been described 
in ARDs. Integrin engagement modulates several aspects of neutrophil activation including 
NETosis, cytokine production and reactive oxygen species (ROS) generation, which are 
associated with pathology in certain ARDs. Therefore, my PhD aimed to examine the effects of 
hypoxia and purified ARD-IgG on integrin activation, ROS generation and NETosis.  
Isolated neutrophils were cultured under normoxia (21% oxygen) or hypoxia (1% 
oxygen) and integrin expression, adhesion, ROS generation and NETosis examined. Hypoxic 
neutrophils had higher αM and αX expression and increased adhesion to endothelial cells. Trans-
endothelial migration was also enhanced under hypoxia. Whilst hypoxia did not have an effect 
on ROS generation, NETosis was higher in hypoxic cells. IgG was purified from the serum of 
RA, SLE and APS patients. The effects of purified IgG upon neutrophil adhesion, ROS 
generation and NETosis were examined. ARD-IgG had a differential effect upon integrin 
activation, with RA- and SLE-IgG promoting αMβ2 (Mac-1)-mediated adhesion whilst APS-IgG 
enhanced β1-integrin mediated adhesion. Moreover, RA- and SLE-IgG increased rates of 
hydrogen peroxide generation and NETosis. 
The results obtained in this thesis demonstrate that hypoxia modulates neutrophil 
function. Purified ARD-IgG was also identified as having differential effects on neutrophil 
integrin activation, ROS generation and NETosis. 
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NADPH   nicotinamide adenine dinucleotide phosphate  
NE     neutrophil elastase 
NEPAS    neonatal and embryonic PAS protein 
NET    neutrophils extracellular trap 
NF-κΒ     nuclear factor-κΒ 
NK    natural killer 
NKT    natural killer T  
NSAID    non-steroidal anti-inflammatory drug 
OA    osteoarthritis 
OD    optical density  
PAD     peptidyl arginine deiminase 
PAF    platelet-activating factor 
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PAR-2     protease-activated receptor-2  
PBMC    peripheral blood mononuclear cell 
PBS     phosphate buffered saline 
pDC    plasmacytoid DC 
PDGF    platelet-derived growth factor 
PECAM-1    platelet-endothelial cell adhesion molecule 1 
PER     period circadian protein  
PFA    paraformaldehyde 
PHA    phytohaemagglutinin  
PHD     prolyl hydroxylase 
PI3K    phosphatidylinositol-3-kinase 
PKB    protein kinase B  
PKC     protein kinase C  
PMA    phorbol 12-myristate 13-acetate 
PMN    polymorphonuclear leukocytes 
PR3     proteinase 3 
PSGL-1    P-selectin glycoprotein 1 
PSI    plexin/semaphoring/integrin  
PVDF     polyvinylidene difluoride 
pVHL     von Hippel-Lindau protein 
R3-IGF-1    recombinant insulin-like growth factor 1 
RA     rheumatoid arthritis  
RANK    receptor activator of NF-κB 
RANKL   receptor activator of NF-κB ligand 
RBC    red blood cell 
RhF    rheumatoid factor 
ROS     reactive oxygen species 
RPMI     Roswell Park Memorial Institute medium 
SD    standard deviation 
SDL     specificity-determining loop 
SF    synovial fluid  
SFK    Src family kinase 
SIM     single-minded protein  
SLE     systemic lupus erythematosus 
sLex      Lewis x blood group  
Syk    spleen tyrosine kinase 
TAD     transactivation domain 
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TBS     tris buffered saline 
TCA     tricarboxylic acid 
TCR    T cell receptor 
TF    tissue factor 	  
TFG-β    transforming growth factor β 
Th    T helper cell 
TLR     toll-like receptor 
TNF-α    tumour necrosis factor-α 
Treg    regulatory T cell 
TSC     tumor suppressor complex 
VCAM-1    vascular cell adhesion molecule 1 
VEGF     vascular endothelial growth factor 
VLA     very late antigen  
VNTR    variable number of tandem repeats 
β2GP1     β2-glycoprotein 1 
  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Chapter One: 
Introduction 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Chapter One: Introduction 
	   19	  
1.1 Cells of the immune system 
 
The immune system is composed of an intricate network of cells, humoral factors, 
cytokines and lymphoid organs, all of which are important in maintaining host health and 
wellbeing. Immune defence can be divided into two categories: innate immunity, which is 
present and active at all times; and adaptive immunity, which provides long-lasting immune 
protection. All immune cells are derived from haematopoietic stem cells and can be referred to 
as leukocytes. As haematopoietic stem cells differentiate into specialised immune cells, they can 




Lymphocytes largely form part of the adaptive immune system and confer long-lasting 
immune protection. The common lymphoid progenitor cell is capable of differentiating into 
natural killer (NK) cells, dendritic cells (DCs) or small lymphocytes. Small lymphocytes further 
differentiate into either B lymphocytes (B cells) or T lymphocytes (T cells), depending on the 
compartmental microenvironment and cytokines present during development.  
 
1.1.1.1 B lymphocytes 
 
B cells are produced within the bone marrow, but mature in the Bursa of Fabricus 
(Ribatti et al., 2006). On leaving the bone marrow, each B cell expresses a unique antigen-
binding B cell receptor (BCR) on its cell membrane. This BCR is a membrane-bound antibody 
molecule. When a naïve B cell first recognises an antigen via its BCR, the binding of antigen 
induces rapid cell division. B cells can differentiate into memory B cells or plasma cells. 
Regulatory subsets of B cells (Bregs) are also produced, which can suppress and regulate B cell 
activity (Fillatreau et al., 2002). Memory B cells have a longer life span than naïve B cells and 
express the same BCR as their parent B cell. Plasma cells produce antibodies in a form that can 
be secreted and have little or no membrane-bound antibody (Delves and Roitt, 2000, Goldsby et 
al., 2003). 
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Antibodies are glycoproteins that consist of two identical heavy and light polypeptide 
chains. Each heavy chain is joined to a light chain by a disulphide bond, with additional 
disulphide bonds holding the two pairs together (Edelman, 1973) (Figure 1.2). The N-terminal 
variable ends of the heavy and light chains form a cleft that binds antigen. The C-terminal 
domains of the heavy and light chains form the constant region, which define the class and 
subclass of the antibody. There are five classes of immunoglobulin (Ig) (IgG, IgA, IgM, IgD 
and IgE), four subclasses of IgG (IgG1-4) and two subclasses of IgA (IgA1-2). These classes 
and subclasses have different functions (Janeway, 1993, Delves and Roitt, 2000, Goldsby et al., 
2003), which are outlined in Table 1.1. 
When a microorganism is coated with antibodies, or opsonised, it can be eliminated in 
several ways. For example, antibodies can cross-link several antigens to form clusters that are 
more readily ingested by phagocytic cells. Binding of antibody to antigen can also activate the 
complement system, resulting in lysis of the foreign organism. Antibodies can also neutralise 
toxins or viral particles by coating them, which prevents binding to host cells (Janeway, 1993). 
 
1.1.1.2 T lymphocytes 
 
T cells are also produced in the bone marrow but migrate to the thymus to mature 
(Kruisbeek, 1999). During maturation, T cells develop a unique antigen-binding molecule on 
their membrane: the T cell receptor (TCR). Unlike the BCR that can directly recognise antigen, 
TCRs can only recognise antigens that are presented by major histocompatibility complex 
(MHC) molecules on the surface of antigen presenting cells (APCs), such as macrophages, B 
cells and DCs, which are described in further detail in section 1.1.2.1. There are two types of 
MHC molecules: class I MHC molecules, which are expressed by nearly all nucleated cells and 
class II MHC molecules that are only expressed by APCs. When naïve T cells encounter antigen 
presented by MHC, they proliferate and differentiate into memory or effector T cells (Ellmeier 
et al., 1999, Delves and Roitt, 2000, Goldsby et al., 2003). 
There are two well-defined subpopulations of T cells: T helper (Th) cells and cytotoxic 
T lymphocytes (CTL), which are distinguished from one another by surface expression of either  
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Figure 1.2: Schematic of antibody structure. This diagram illustrates the basic structure of an 
antibody, highlighting the constant region, which determines the class and subclass of the antibody, 
and the variable domains, which bind antigen. 
Table 1.1: Immunoglobulin class, subclass and function. The above table details the different 
classes and subclasses of the five Ig produced by humans with an overview of their function. 
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cluster of differentiation (CD)4 or CD8. CD4+ T cells recognise antigens bound to class II MHC 
molecules, whereas CD8+ T cells recognise antigen bound to class I MHC molecules. The 
classification of CD4+ MHC class II restricted cells as Th cells and CD8+ MHC class I restricted 
cells as CTLs is not absolute and there is some overlap between functional activities (Goldsby 
et al., 2003, Delves and Roitt, 2000). 
Naïve CD4+ T cells can differentiate into several Th cell lineages, defined by their 
pattern of cytokine production and function, including Th1, Th2, Th17 and induced regulatory T 
cells (iTregs). Other types of CD4+ T cells have been described, such as natural killer T (NKT) 
cells and natural Tregs (nTregs), however, these cells are not derived from naïve CD4+ T cells, 
but develop in parallel from small lymphocytes within the thymus (Zhu et al., 2010).  
 
1.1.2 Myeloid cells 
 
Myeloid cells form part of the innate immune system and can directly recognise and kill 
pathogens. The common myeloid progenitor cell can differentiate into several immune cells, 
including DCs, erythrocytes, megakaryocytes, mast cells and myeloblasts. Myeloblasts can 
differentiate into basophils, eosinophils, neutrophils and monocytes, which can further 
differentiate into either macrophages or monocyte-derived DCs (Ma et al., 2012).  
Microbial killing is facilitated by phagocytosis, aided by opsonisation with Ig or the 
complement product iC3b. Most myeloid cells express Fc receptors (FcR) that bind the constant 
region of Ig, as well as complement receptor (CR)1, CR3 and CR4, which bind complement 
products. Successful phagocytosis is achieved by the synergistic activation of these receptors. 
When APCs phagocytose pathogens, they are able to degrade and present pathogen-derived 
antigens to lymphocytes (Delves and Roitt, 2000). 
 
1.1.2.1 Antigen presenting cells 
 
APCs are specialised cells, including macrophages, B cells and DCs, which express 
class II MHC molecules and are able to deliver the co-stimulatory signals required for CD4+ T 
cell activation. APCs internalise antigen, either by phagocytosis or endocytosis, and then 
display antigen-derived peptides in a complex with class II MHC molecules that are recognised 
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by CD4+ T cells. Additional co-stimulatory signals, provided by the APC, are then required for 
full CD4+ T cell activation (Goldsby et al., 2003). In the absence of these co-stimulatory signals, 
cells can undergo anergy.  
Most leukocytes can be found circulating within the vasculature. These leukocytes are 
endowed with the vital ability to migrate from the circulation into the underlying tissues, where 
they can mediate their immunological roles. The process whereby leukocytes migrate into 
tissues is referred to as leukocyte extravasation. 
 
1.2 Leukocyte adhesion and transmigration  
 
Leukocyte extravasation is achieved via an orchestrated series of reversible and 
transient adhesive events. The most extensively studied form of leukocyte extravasation is 
migration across the endothelium, which represents the first barrier for immune surveillance. 
Trans-endothelial migration can be divided into three stages: attachment and rolling, activation-
dependent firm adhesion and transmigration.  
 
1.2.1 Attachment and rolling 
 
Leukocytes can roll along activated endothelial cells (ECs), primarily mediated by 
selectins (Figure 1.3). Selectins are specialised receptors that recognise proteins modified with 
sialyated fucosylated carbohydrate residues belonging to the sialyl Lewis X family (sLeX). 
These interactions are known for their fast on/off rates, with cell contacts being rapidly formed 
and broken. To date, three members of the selectin family have been described: E-selectin 
(endothelial; CD62E) (Bevilacqua et al., 1989), L-selectin (leukocyte; CD62L) (Gallatin et al., 
1983) and P-selectin (platelet; CD62P) (Hsu-Lin et al., 1984), each named after the cell in 
which they were first described. Activated ECs also express P-selectin (Bonfanti et al., 1989).  
The most characterised selectin ligand is P-selectin glycoprotein ligand (PSGL)-1, 
which is expressed on leukocytes (McEver and Cummings, 1997). On activation, ECs 
upregulate E-selectin and externalise P-selectin within Weibel-Palade bodies, both of which 
bind PSGL-1. Leukocytes can facilitate cell rolling via the redistribution of PSGL-1 to 
protruding pseudopods (Bruehl et al., 1997). ECs can also enhance interactions by modifying  
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Figure 1.3: Leukocyte rolling is mediated by L-selectin, PSGL-1 and VLA-4. This 
schematic details some of the key adhesive molecules involved in initial tethering and rolling 
of leukocytes within the vasculature. Both E-selectin and P-selectin expressed on endothelial 
cells bind PSGL-1. L-selectin expressed by leukocytes can interact with modified CD34, 
GlyCAM-1 and MAdCAM-1 found on endothelial cells. VLA-4 and LPAM-1 can interact 
with VCAM-1 and MAdCAM-1 respectively. Abbreviations: GlyCAM-1, glycosylation-
dependent cell adhesion molecule-1; LPAM-1, lymphocyte Peyer patch adhesion molecule; 
MAdCAM-1, mucosal vascular addressin cell adhesion molecule-1; PSGL-1, P-selectin 
glycoprotein ligand-1; VCAM-1, vascular cell adhesion molecule-4; VLA-4, very late 
antigen-4. 
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surface CD34 with the sLex group, transforming CD34 into a L-selectin ligand (Hiraoka et al., 
1999). L-selectin has also been shown to bind glycosylation-dependent cell adhesion molecule 
(GlyCAM)-1 (Imai et al., 1991) and mucosal vascular addressin cell adhesion molecule 
(MAdCAM)-1 (Bargatze et al., 1995), which further promotes leukocyte rolling. 
There is also evidence that α4 integrins contribute to leukocyte rolling. Integrins are a 
family of adhesive molecules, which will be discussed in section 1.3. Studies using cultured T 
cells found very late antigen (VLA)-4 (CD49d/CD29, α4β1) and lymphocyte Peyer patch 
adhesion molecule (LPAM)-1 (α4β7) mediate rolling via interactions with vascular cell adhesion 
molecule (VCAM)-1 (CD106) and MAdCAM-1 respectively, independent of selectins (Berlin 
et al., 1995, Alon et al., 1995). Work using freshly isolated T cells however, found VLA-4 and 
P-selectin initiated rolling together. Furthermore, ex vivo transmigration assays found VLA-4 to 
initiate rolling in cooperation with L-selectin in both freshly isolated monocytes (Luscinskas et 
al., 1994) and eosinophils (Sriramarao et al., 1994).  
The discrepancy between freshly isolated and cultured cells suggests that selectin 
dependency may be linked to leukocyte activation, with resting cells having a higher degree of 
selectin-independent integrin-mediated tethering. Given that T cells are easily cultured over 
longer periods of time, whilst eosinophils and monocytes cannot be extensively cultured 
without cell death or differentiation, interpreting these observations is difficult. As VLA-4 has 
been implicated in both freshly isolated and cultured cells, it is reasonable to conclude that 
selectins and α4 integrins work cooperatively to mediate leukocyte attachment and rolling. 	  
1.2.2 Activation-dependent firm adhesion 
 
Firm adhesion is predominantly mediated by endothelial intercellular adhesion 
molecule (ICAM)-1 (CD54) binding to lymphocyte function-associated antigen-1 (LFA-1; 
CD11a/CD18; αLβ2) and macrophage-1 antigen (Mac-1; CD11b/CD18; αMβ2) expressed on 
leukocytes. Following initial adhesion, ECs can redistribute ICAM-1, enriching the areas 
beneath leukocytes to further stabilise interactions with LFA-1 and Mac-1 (Shaw et al., 2004). 
This observation demonstrates the importance of ICAM-1 in leukocyte firm adhesion. 
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ICAM-2 (CD102) has also been implicated in extravasation, with inhibition of 
neutrophil transmigration being reported in both ICAM-2 knockout mice and wild-type mice 
administered ICAM-2 blockade (Huang et al., 2006, Woodfin et al., 2009). These results have 
not been replicated in vitro, which may suggest that whilst ICAM-2 may be important in murine 
leukocyte extravasation, it mediates a subtler role in human leukocyte transmigration. 
Interestingly, a similar pattern of adhesion molecule clustering has been documented 
with endothelial VCAM-1 around VLA-4 on adherent leukocytes (Barreiro et al., 2002, Carman 
and Springer, 2004). Taken together, these results indicate that firm adhesion is achieved by the 
collaborative action of the β1 and β2 integrins binding VCAM-1 and ICAM-1, and possibly 
ICAM-2, rich regions on ECs (Figure 1.4). These stronger interactions allow for the cessation of 




Following firm adhesion, leukocytes initiate diapedesis and migrate across the 
endothelium. This process is mediated by junctional adhesion molecule (JAM)-A, JAM-B and 
JAM-C, all of which are highly expressed at EC borders. There is also evidence for the 
contribution of platelet-endothelial cell adhesion molecule (PECAM)-1 (CD31) and CD99. 
JAM proteins preserve the integrity of resting endothelial monolayers. JAM-A engages 
in homophilic interactions with other JAM-A molecules, whereas JAM-B and JAM-C partake 
in both homophilic and heterophilic binding. During inflammation, JAM proteins can bind 
leukocyte integrins and facilitate extravasation. LFA-1 can bind JAM-A (Ostermann et al., 
2002), however conflicting results arise from JAM-A inhibition. Whilst some groups report 
reduced transmigration (Martin-Padura et al., 1998, Woodfin et al., 2009), others found JAM-A 
blockade had no significant effect (Liu et al., 2000, Schenkel et al., 2004b). Schenkel et al. did 
describe a 10% decrease in transmigration on JAM-A inhibition, but suggested that this effect 
was insignificant. Taken together, the evidence suggests that JAM-A contributes to leukocyte 
transmigration. JAM-B has been shown to interact with VLA-4, promoting leukocyte rolling 
and adhesion in vitro (Ludwig et al., 2009), however the effects on migration were not explored. 
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Figure 1.4: Firm adhesion of leukocytes is mediated by LFA-1, Mac-1 and VLA-4. This 
schematic depicts the key adhesive molecules mediating activation-dependent firm 
adhesion. The key interactions mediating firm adhesion are those between endothelial 
ICAM-1 and LFA-1 and Mac-1 expressed on leukocytes. ICAM-2 also interacts with both 
LFA-1 and Mac-1, whilst VLA-4 binds to VCAM-1. Endothelial cells are able to 
redistribute cell surface ICAM-1 and VCAM-1 underneath adherent cells to further facilitate 
adhesion. Abbreviations: ICAM-1, intercellular adhesion molecule-1; LFA-1, lymphocyte 
function-associated antigen-1; Mac-1, macrophage-1 antigen; VCAM-1, vascular cell 
adhesion molecule-1; VLA-4, very late antigen-4. 
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Mac-1 has been shown to interact with JAM-C, allowing for transmigration both in vitro and in 
vivo (Johnson-Leger et al., 2002, Chavakis et al., 2004).  
 PECAM-1 is a member of the Ig superfamily (IgSF) and is expressed in a variety of cell 
types including platelets, monocytes, neutrophils and some T cell subsets. PECAM-1 is also 
found on EC borders, where it binds leukocyte-expressed PECAM-1 and mediates the 
beginnings of diapedesis. PECAM-1 blockade both in vitro and in vivo does not inhibit 
adhesion to the endothelium, however leukocytes are unable to transmigrate (Muller et al., 
1993, Bogen et al., 1994, Mamdouh et al., 2003, Schenkel et al., 2004a, Schenkel et al., 2004b). 
PECAM-1 stimulation has been reported to increase leukocyte adhesion via LFA-1 (Piali et al., 
1993, Berman et al., 1996), Mac-1 (Berman and Muller, 1995, Berman et al., 1996), VLA-4 
(Leavesley et al., 1994, Chiba et al., 1999) and αvβ3 (Chiba et al., 1999). These observations 
suggest that PECAM-1 engagement may enhance β1, β2 and β3 integrin affinity. In addition, 
studies in which PECAM-1 was transfected into cells that do not express it, found that 
transfected cells supported leukocyte transmigration, a phenomenon that has not been replicated 
with any other adhesion molecule (Dasgupta et al., 2009). 
CD99 is an evolutionary conserved protein, believed the earliest cell adhesion molecule 
(Suh et al., 2003). As well as being expressed by ECs, CD99 expression has also been found on 
monocytes (Schenkel et al., 2002) and neutrophils (Lou et al., 2007). Homophilic CD99 
interactions are essential for transmigration and mediate the final stages of diapedesis. In 
agreement with previous work, both studies found that with PECAM-1 blockade, monocytes 
and neutrophils could adhere to the endothelium but remained at the cell membrane. Following 
CD99 blockade, leukocytes could partially migrate across the endothelium, with cell protrusions 
visible between ECs, but were unable to achieve complete transmigration (Schenkel et al., 2002, 
Lou et al., 2007). A schematic of diapedesis can be seen in Figure 1.5. 
To conclude, leukocyte extravasation is a highly regulated process, mediated by the 
sequential activation of adhesion molecules and integrins. Moreover, experimental evidence 
highlights the importance of the β1 and β2 integrins in extravasation, given their roles throughout 
the stages of transmigration.  
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Figure 1.5: Leukocyte diapedesis is mediated by junctional adhesion molecules, 
PECAM-1 and leukocyte integrins. Depicted above are the key adhesion molecules that 
regulate the final step of extravasation. Homophilic PECAM-1 interactions are believed to 
be one of the first steps of leukocyte diapedesis across the endothelium. JAM-A interacts 
with LFA-1, JAM-B with VLA-4 and JAM-C with Mac-1, all of which allow the leukocyte 
to move between endothelial cells. CD99 mediates the final step of transmigration, which 
undergoes homophilic associations and enables the leukocyte to successfully cross the 
endothelial monolayer. Abbreviations: JAM, junctional adhesion molecule; LFA-1, 
lymphocyte function-associated antigen; Mac-1, macrophage-1 antigen; PECAM-1, platelet-
endothelial adhesion molecule; VLA-4, very late antigen-4. 
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1.3 Integrins 
 
The term ‘integrin’ was first used in 1986 to describe transmembrane protein complexes 
integral to leukocyte interactions with the extracellular matrix (ECM) (Tamkun et al., 1986). As 
homologous proteins were identified, the term integrin was adopted to describe the family of 
structurally related cell surface receptors. Integrins are expressed by all multicellular organisms, 
with differential integrin expression being observed between phyla (Hynes, 2002). The immune 
system is highly dependent on integrins for orchestrating leukocyte migration. Integrin function 
also facilitates immune synapse formation, phagocytosis and cell signalling transduction. It is 
therefore vital that leukocytes regulate integrin expression and activity. 
Integrin ligands can be divided into three major groups: basal ECM (e.g. laminins, 
collagens), provisional ECM (e.g. fibrinogen, fibronectin) and cell surface adhesion molecules. 
The majority of the cell surface adhesion molecules that function as integrin ligands are IgSF 
proteins, which are characterised by multiple Ig-like domains. Members of the IgSF, such as 
ICAM-1 and VCAM-1, are expressed by numerous cell types and are upregulated on cell 
activation (Marui et al., 1993, Lee et al., 2001, Chiu et al., 2004, Min et al., 2005, Hortelano et 
al., 2010), which promotes leukocyte extravasation. 
 
1.3.1 Leukocyte integrins 
 
Integrins are heterodimeric type I transmembrane glycoprotein receptors, composed of 
non-covalently associated α and β subunits. To date, 18 α subunits and 8 β subunits have been 
described within the human integrin family, which through combinational variation give rise to 
24 different heterodimeric αβ integrin molecules (Figure 1.6). Integrin expression varies 
between cell types and can be restricted to specific cell lineages or subsets. For example, β2 
integrins are only expressed by haematopoietic cells and the αEβ7 integrin is expressed by 
mucosal T cells (Kilshaw, 1999).  
Electron microscopy demonstrates that integrin subunits are composed of a globular N-
terminal ligand-binding ‘head’, representing a critical interface between the α and β subunits. 
The extracellular domain is attached to a ‘leg’ domain that connects the extracellular head to the  
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Figure 1.6: All 24 αβ integrins found in human cells. Depicted above are all of the integrin pairs 
found within human cell types. Integrin pairs connected with a red line are expressed on 
leukocytes. The α subunits boxed represent those subunits that contain the I-domain. 
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single spanning transmembrane domain. With the exception of the β4 subunit, integrin subunits 
possess a short cytoplasmic tail (Nermut et al., 1988). Debate arose when X-ray crystallography 
of the αVβ3 integrin found the ‘legs’ in a bent topology, with the extracellular ‘head’ juxtaposed 
to the cell membrane (Xiong et al., 2001, Xiong et al., 2002). Electron microscopy and Förster 
resonance energy transfer analysis confirmed the existence of two conformations (Takagi et al., 
2002b, Takagi et al., 2003, Kim et al., 2003), with the bent conformation representing a low-
affinity state and the extended conformation being a high-affinity state with the ligand-binding 
site exposed. 
X-ray crystallography of the α subunit found seven repeated domains, numbered I-VII, 
which forms a seven-bladed β-propeller motif (Xiong et al., 2001, Xiao et al., 2004). Of the 18 
α subunits, half contain an inserted (I)-domain, residing between the second and third β-sheets 
of the β-propeller motif. Multiple interactions are formed between extracellular ligands and the 
I-domain, functioning as either the exclusive or major ligand-binding site (Emsley et al., 2000, 
Shimaoka et al., 2003, Song et al., 2005). In vitro expression of the I-domain, independent of 
the parent integrin, found high retention of ligand-binding activity, emphasising the functional 
importance of the I-domain. This phenomenon has been demonstrated in I-domains of LFA-1 
(Randi and Hogg, 1994), Mac-1 (Ueda et al., 1994, Zhou et al., 1994) and VLA-2 
(CD49b/CD29, α2β1) (Kamata and Takada, 1994).  
Crystallography studies also highlighted a β subunit I-domain, similar in structure to the 
α subunit I-domain but containing two extra segments, termed the I-like domain. Mutations in 
the I-like domain result in defective binding of immobilised ligands (Bilsland et al., 1994, 
Huang et al., 2000). Microscopic analysis and functional adhesion assays found that one of the 
extra segments forms an interface with the β-propeller of the α subunit, whilst the other 
mediates ligand binding (Takagi et al., 2002a, Tsuruta et al., 2003). This observation suggests 
that whilst the I-domain may be directly involved in binding, the I-like domain may play an 
auxiliary role by ensuring the correct conformation is adopted to expose the ligand-binding site. 
Divalent cations are essential for integrin-mediated adhesion, demonstrated by the 
inhibition of adhesion following cation chelation by ethylenediaminetetraacetic acid (EDTA) 
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(Dransfield et al., 1992). Divalent cations act as coordination centres, which interact with and 
stabilise the I-domain. Due to the dependency of cations, the region surrounding the I-domain is 
termed the metal ion-dependent adhesion site (MIDAS), which contains several key Mg2+ and 
Ca2+ binding sites that aid molecular coordination and support integrin structure (Lee et al., 
1995). The MIDAS structure has also been identified in the I-like domain, which adopts a 
similar fold as the α subunit counterpart (Xiao et al., 2004). 
 The ‘leg’ domain connects the extracellular ‘head’ to the transmembrane domain and is 
composed of three β-sandwich motifs, referred to as the thigh, calf-1 and calf-2 domains. A Ca2+ 
binding site lies in between the thigh and calf-1 domains to form a flexible region, often called 
the ‘genu’, which is a key pivotal point. The β subunit ‘leg’ domain is organised differently, 
with the I-like domain inserted into a hybrid domain, forming part of the upper β subunit ‘leg’ 
domain. The hybrid domain is inserted within a plexin/semaphoring/integrin (PSI) domain, 
which completes the upper β subunit ‘leg’. The lower portion of the β subunit ‘leg’ is composed 
of four integrin epidermal growth factor-like (I-EGF) domains and a β-tail domain. Electron 
microscopy has found that the α subunit ‘genu’ and the β subunit ‘leg’ I-EGF-1 and I-EGF-2 
interface are within close geometric proximity of one another (Takagi et al., 2002b, Nishida et 
al., 2006). The conformational changes during integrin activation are achieved by rotations 
around the axis generated by the region formed by the α and β subunit ‘leg’ domains. A basic 
schematic of the primary structure of integrins can be seen in Figure 1.7. 
 
1.3.2 Integrin activation 
 
Integrin activation is vital in enabling leukocyte interactions and is achieved by either 
inside-out or outside-in signalling. Inside-out signalling induces a conformational change that 
exposes the ligand-binding site and adopts a high-affinity state (Anthis and Campbell, 2011, 
Springer and Dustin, 2012, Zhang and Chen, 2012, Zhu and Springer, 2013).  
When in a low-affinity state, the integrin extracellular ‘head’ sits in close proximity to 
the cell surface (Takagi et al., 2002b). On activation, cytoskeletal proteins talin and kindlin bind 
the cytoplasmic tail of the integrin β subunit cytoplasmic tail, causing the dissociation of the α  
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Figure 1.7: Schematic of the primary structure of leukocyte integrins. Structures for both 
non I-domain and I-domain containing α subunits are shown in this diagram. The α subunit is 
non-covalently linked to the β subunit on the cell membrane. 
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and β subunit cytoplasmic tails (Vinogradova et al., 2002). A cascade of molecular movements 
is subsequently initiated, dissociating the transmembrane helices. Extension of the ‘leg’ 
domains followed by the rotation of the ‘head’ domain, described as a ‘switchblade motion’, 
allows greater access to ligands. An intermediate state with extended ‘leg’ domains but closed 
‘head’ has also been described (Lefort et al., 2012, Cheng et al., 2013). This intermediate 
conformational state may represent a mechanism whereby surroundings are surveyed without 
full integrin activation and signalling induction. Inside-out signalling is a dynamic process, 
where integrins exist in equilibrium between low- and high-affinity states. This conformational 
equilibrium allows leukocytes to constantly survey their surroundings. A schematic overview of 
inside-out integrin activation can be seen in Figure 1.8. 
Outside-in signalling induces integrin clustering at the cell membrane and high-avidity 
interactions, typically occurring following intracellular signalling via the guanine nucleotide-
binding protein Gα13 (Gong et al., 2010). On activation, Gα13 phosphorylates Src family 
kinases (SFKs), initiating numerous downstream signalling events (Klinghoffer et al., 1999, 
Obergfell et al., 2002, Inoue et al., 2003, Gong et al., 2010). One of these events is the 
activation p115RhoGEF and phosphorylation of Rho (Gong et al., 2010). Rho can activate 
formin homology proteins, referred to as formins, which mediate actin polymerisation (Pruyne 
et al., 2002). Formin activation promotes stress fibre formation (Kitzing et al., 2010), resulting 
in cytoskeletal rearrangement and integrin clustering (Vega et al., 2011). Whilst p115RhoGEF 
activation is one mechanism induced by outside-in signalling, several other pathways are also 
involved (Shen et al., 2012). 
Divalent cations are essential for integrin function, stabilising structure and modulating 
integrin-ligand interactions in both enhancing and suppressive manners (Kunicki et al., 1981, 
Ginsberg et al., 1986, Staatz et al., 1989, Steiner et al., 1991, Dransfield et al., 1992). 
Leukocytes are typically exposed to 1mM Ca2+ and 1mM Mg2+ in the vasculature, with each 
cation conferring opposing effects. Whilst evidence suggests Ca2+ suppresses integrin activation 
(van Kooyk et al., 1993, Hu et al., 1995, Mandeville and Maxfield, 1997), Mg2+ has been shown 
to induce integrin-mediated binding (Staatz et al., 1989). Interestingly, these same studies found  
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Figure 1.8: Inside-out signalling is mediated by a series of conformational changes. 
Integrin activation involves a series of molecular movements and conformational changes that 
exposes the ligand-binding site. Schematics for these molecular movements can be seen for 
both (A) I-domain containing αβ integrins and (B) non-I-domain αβ integrins. 
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that micromolar ranges of Ca2+ could synergise with suboptimal levels of Mg2+to increase 
integrin affinity, suggesting dynamic interactions between integrins and divalent cations.  
 
1.3.3 Integrin ligands 
 
Integrin ligands can be divided into three major groups: basal ECM, provisional ECM 
and cell surface adhesion molecules. Many of these cell surface adhesion molecules are IgSF 
proteins, which are upregulated upon cellular activation. The most studied IgSF integrin ligands 
include ICAM-1, ICAM-2, ICAM-3 (CD50), VCAM-1 and MAdCAM-1.  
ICAM-1 is the most ubiquitously expressed ICAM isotype and is weakly expressed on 
both resting leukocytes and endothelium and is upregulated on cell activation (Chiu et al., 2004, 
Min et al., 2005). ICAM-1 has been shown to bind both LFA-1 and Mac-1 (Diamond et al., 
1991, Stanley et al., 1994). LFA-1 and Mac-1 also bind ICAM-2 (de Fougerolles et al., 1991, 
Xie et al., 1995). ICAM-2 has constitutively high expression on ECs, but has also been 
described in bronchial epithelial cells, eosinophils, monocytes, T cells, B cells and platelets (de 
Fougerolles et al., 1991, Diacovo et al., 1994, Porter and Hall, 2009). When initially 
characterised, ICAM-2 was not identified on neutrophils (de Fougerolles et al., 1991), however 
more recently ICAM-2 expression has been reported in bone marrow and peripheral blood 
neutrophils (Sundd et al., 2012). Initial ICAM-2 characterisation by de Fougerolles et al. used 
human cells, whilst Sundd and colleagues examined murine neutrophils, so differential ICAM-2 
expression between human and mouse leukocytes may explain this discrepancy.  
ICAM-3 is only expressed by leukocytes and is thought to mediate the early phases of 
antigen presentation via interactions with LFA-1 (de Fougerolles and Springer, 1992). ICAM-4 
expression is restricted to erythrocytes and erythroid precursors, where it interacts with αIIbβ3 on 
platelets (CD41/CD61, also referred to as glycoprotein IIb/IIIa) (Hermand et al., 2003), and 
p150,95 (CD11c/CD18, αXβ2) expressed on monocytes and macrophages (Ihanus et al., 2007). 
The final ICAM isotype, ICAM-5 is only found in the grey matter of the telencephalon. ICAM-
5 interacts with LFA-1 (Tian et al., 2000, Zhang et al., 2008) and VLA-5 (CD49e/CD29, α5β1) 
(Ning et al., 2013) expressed by T cells, implicating a role in T cell cerebral migration. 
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ECs also express VCAM-1, which rapidly increases on activation (Marui et al., 1993, 
Lee et al., 2001, Min et al., 2005, Hortelano et al., 2010). VCAM-1 is a ligand for the α4 
integrins VLA-4 and α4β7 expressed on circulating leukocytes (Elices et al., 1990, Chan et al., 
1992). VCAM-1 has also been described as a novel ligand for the β2 integrins Mac-1 and αDβ2 
(Yakubenko et al., 2006). MAdCAM-1 is a member of both the IgSF and the mucin family of 
proteins and is selectively expressed on the venules involved in lymphocyte trafficking to 
mucosal tissues. MAdCAM-1 is the physiological ligand for α4β7 and mediates recruitment of T 
cells to mucosal Peyer’s patches and the lamina propria (Berlin et al., 1993).  
In conclusion, cells express a multitude of adhesion molecules and integrin ligands to 
interact with circulating leukocytes. Integrins can either be highly specific for their ligand or 
display a degree of promiscuity in their binding partners. Common physiological integrin 
ligands are listed in Table 1.2. The expression of integrins and their ligands are influenced by 
inflammatory and infective signals. This regulation means that leukocytes can preferentially 
migrate into infected or inflamed tissue, where they mediate their immune function. One such 
leukocyte that relies on integrins to exert immune surveillance is the neutrophil. 
 
1.4 The role of neutrophils in the innate immune system 
 
Innate immunity is maintained through the combined function of multiple cell types 
including DCs, monocytes, mast cells, NK cells and granulocytes. Granulocytes, often referred 
to as polymorphonuclear leukocytes (PMNs), are immune cells that possess microscopic 
granules containing proteolytic enzymes. Basophils, eosinophils and neutrophils are all 
granulocytes. Basophils are the smallest population of granulocytes, which mediate 
hypersensitivity and allergic inflammation (Mukai et al., 2005, Obata et al., 2007, Tsujimura et 
al., 2008). Eosinophils were traditionally considered to be proinflammatory effector cells 
involved in parasitic defence, however emerging work implicate roles for eosinophils in innate 
and adaptive immune system regulation (Travers and Rothenberg, 2015). Neutrophils are the 
predominant granulocyte subset, which contribute to immune surveillance and microbial killing. 
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Table 1.2: Physiologically relevant integrin ligands. Listed in the above table are key 
physiological integrin ligands. Integrins expressed by leukocytes are indicated by red α subunits. 
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Neutrophils are crucial for the resolution and clearance of a multitude of pathogens. 
Circulating neutrophils have an estimated lifespan of 4-10 hours, however neutrophil survival 
can range between 1-2 days in response to cytokines and proinflammatory stimuli (Faurschou 
and Borregaard, 2003). Neutrophils fight infection via three main mechanisms: phagocytosis, 
degranulation and the release of neutrophil extracellular traps (NETs).  
 
1.4.1 Immunoglobulin- and complement-mediated phagocytosis 	  
Microbial killing is a critical function mediated in part by neutrophils, which is 
facilitated by opsonisation with Ig and iC3b. Neutrophils express FcRs that recognise IgG 
(FcγRI, FcγRIIA, and FcγRIIIB), IgA (FcαRI) and in some circumstances IgE (FcεRI and 
FcεRII). The most important neutrophil FcγRs are considered to be FcγRIIA and FcγRIIIB 
(Bruhns, 2012). Engagement of both these low-affinity FcγRs is required for cellular activation 
(Walker et al., 1991, Brennan et al., 1991, Naziruddin et al., 1992, Strohmeier et al., 1995, Jakus 
et al., 2008). Studies show that FcγRIIIB makes initial contact and tethers the immune complex 
(IC) (Coxon et al., 2001), with activation being induced by the synergistic ligation of FcγRIIA 
and FcγRIIIB (Zhou et al., 1995). Activated neutrophils have also been shown to bind IgG via 
the high-affinity FcγRI (Guyre et al., 1990, Repp et al., 1991, McKenzie and Schreiber, 1998).  
The cytoplasmic domain of FcγRIIA contains an immunoreceptor tyrosine-based 
activating motif (ITAM) (Sanchez-Mejorada and Rosales, 1998), which enables intracellular 
signalling. FcγRI and FcγRIIIB lack this motif, however associate with a dimeric ITAM-
containing γ-subunit that allows for intracellular signalling (Sanchez-Mejorada and Rosales, 
1998). On binding IgG, FcγR-associated ITAMs are phosphorylated by SFK members (Fitzer-
Attas et al., 2000), which recruit spleen tyrosine kinase (Syk) (Agarwal et al., 1993, Ghazizadeh 
et al., 1995). Syk is subsequently phosphorylated and activated (Greenberg et al., 1994, Darby 
et al., 1994). Early reports found that macrophages lacking Syk were unable to phagocytose 
IgG-opsonised particles, demonstrating the importance of Syk (Matsuda et al., 1996, Crowley et 
al., 1997, Kiefer et al., 1998). Whilst Syk is critical for FcγR-mediated phagocytosis, the 
downstream signalling events are unclear. FcγR-mediated signalling induces actin remodelling 
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and the production of pseudopods that surround and engulf opsonised microbes, which are then 
taken up into a specialised structure, the phagosome, and degraded by proteolytic enzymes 
stored in cytosolic granules (Nordenfelt and Tapper, 2011).  
Alternatively, when opsonised with complement fragment iC3b, neutrophils can engage 
microbes via CRs. Neutrophils express CR1, CR3 (Mac-1) and CR4 (p150,95), all of which 
have been implicated in phagocytosis (Gordon et al., 1987, Myones et al., 1988, Brown, 1991, 
Ueda et al., 1994). CR1 is a transmembrane protein that binds opsonised pathogens (Brown, 
1991, Fallman et al., 1993). Mac-1 (CR3) and p150,95 (CR4) mediate phagocytosis of iC3b-
opsonised pathogens (Allen and Aderem, 1996a). Whilst FcγR-mediated phagocytosis requires 
generation of pseudopods, CR-mediated phagocytosis occurs via a ‘sinking’ of the iC3b-
opsonised particle that generates very little membrane protrusion (Roubey et al., 1991, Allen 
and Aderem, 1996b). Mac-1 mediated phagocytosis is dependent on serine phosphorylation of 
the β2 integrin subunit by protein kinase C (PKC) (Roubey et al., 1991, Allen and Aderem, 
1996b). Additional signalling differences between FcR- and CR-mediated phagocytosis have 
been highlighted. Rho guanosine triphosphatases, which act as a molecular switch and control 
cytoskeletal remodelling, are important in both forms of phagocytosis (Caron and Hall, 1998). 
Further molecular dissection found that Cdc42 and Rac mediate FcR-dependent phagocytosis, 
but CR-dependent phagocytosis is mediated by RhoA (Caron and Hall, 1998). As Mac-1 can 
form lateral associations with numerous membrane proteins, including FcγRs (Zhou et al., 1993, 
Huang et al., 2011b), the precise pathways that regulate CR-mediated phagocytosis remain 
unclear. 
 
1.4.2 Neutrophil degranulation 
 
 As well as phagocytosis, neutrophils can secrete antimicrobial proteins, reactive oxygen 
species (ROS) and cytokines to combat microorganisms and recruit other leukocytes to the site 
of infection. The secretion of cytotoxic mediators via exocytosis is referred to as degranulation. 
To date, five different types of neutrophil granules have been identified: primary granules; 
secondary granules; tertiary granules; phosphasomes; and secretory vesicles.  
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Primary granules, or azurophilic granules, contain a multitude of antimicrobial and 
highly toxic compounds including myeloperoxidase (MPO), neutrophil elastase (NE), defensins, 
lysozyme, cathepsin G, proteinase (PR)-3 and various proteoglycans (West et al., 1974, Garcia 
et al., 1985, Egesten et al., 1994). Primary granules can either be secreted via exocytosis or fuse 
with internalised phagosomes to kill engulfed microbes.  
Secondary granules, or specific granules, are comprised of lactoferrin, alkaline 
phosphatase, lysozyme and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. 
The cell adhesion molecules Mac-1, VLA-4 and VLA-5 have also been identified in secondary 
granules (O'Shea et al., 1985, Stevenson et al., 1987, Suchard et al., 1992). Secondary granules 
are rapidly released (Borregaard et al., 1992, Tapper and Grinstein, 1997), promoting pathogen 
killing and cell adhesion. 
Tertiary granules contain matrix metalloproteinase (MMP)-9 and heparanase 
(Mollinedo et al., 1991, Mollinedo et al., 1997). Adhesion molecules have also been reported 
within tertiary granules (Todd et al., 1984, Petrequin et al., 1987, Sengelov et al., 1993). 
Phosphasomes are similar in structure to secondary granules, but are not as dense and have been 
reported to only contain alkaline phosphatase (Smith et al., 1985, Sengelov et al., 1992).  
Secretory vesicles are rich in Mac-1 (Sengelov et al., 1993), CR1 (Sengelov et al., 
1994b), formyl-methionyl-leucyl-phenylalanine (fMLP) receptors (Sengelov et al., 1994a), the 
lipopolysaccharide (LPS) co-receptor CD14 and FcγRIIIB (Detmers et al., 1995). Exocytosis of 
secretory vesicles is also accompanied by shedding of L-selectin from the neutrophil cell 
surface (Borregaard et al., 1994). 
 
1.4.3 Neutrophil extracellular trap formation 
 
Early studies found that stimulation with the potent PKC activator, phorbol 12-
myristate 13-acetate (PMA), initiated a form of neutrophil cell death distinct from both 
apoptosis and necrosis that was dependent on ROS generation (Takei et al., 1996). PMA 
stimulation decreased chromatin compactness and induced nuclear membrane degeneration. 
Stimulation for 3 hours increased cell membrane permeability, with cell death peaking after 4 
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hours incubation. Agarose and pulsed field gel electrophoresis confirmed DNA had not been 
degraded (Takei et al., 1996), demonstrating that PMA induces the release of intact DNA. 
The term NET was first used in 2004 to describe the meshwork of chromatin fibres 
embellished with granule-derived antimicrobial peptides and proteases released by stimulated 
neutrophils (Brinkmann et al., 2004). Following this study, NETosis was recognised as an 
important neutrophil response to infection. In vitro stimulation of neutrophils with PMA or 
interleukin (IL)-8 induced NETosis via a PKC-dependent mechanism (Brinkmann et al., 2004). 
Further investigation from this group found that NETosis represents a form of cell death distinct 
from apoptosis and necrosis (Fuchs et al., 2007), supporting earlier work by Takei and 
colleagues. Live-cell imaging confirmed that PMA induced a succession of nuclear remodelling 
events prior to NETosis, with changes in nuclear shape and chromatin decondensation. The 
nuclear envelope and granule membranes dissolved, allowing for the mixing of NET 
components, before the cell membrane was disrupted and NETs released. This process required 
NADPH oxidase-dependent ROS generation (Fuchs et al., 2007). Human neutrophils release 
NETs in response to a wide range of stimuli (Urban et al., 2006, Clark et al., 2007). Exploration 
of the mechanisms underlying NETosis highlighted two forms of NETosis: vital NETosis and 
suicidal NETosis. 
 
1.4.3.1 Vital NETosis 
 
Vital NETosis describes a process whereby NETs are released without compromising 
cell viability, thus allowing neutrophils to mediate ‘conventional’ host defence functions. 
Whilst the concept of a cell functioning without a nucleus is controversial, examples of this 
phenomenon exist. Early investigations described anuclear granulocytes that retained degrees of 
cellular functionality. These anuclear and granular-free granulocytes were termed cytoplasts or 
cytokineplasts (Malawista and De Boisfleury Chevance, 1982, Dyett et al., 1985). Cytoplasts 
were found to migrate towards fMLP (Dyett et al., 1985, Huang et al., 1991), as well as 
adhering and transmigrating across endothelial monolayers (Huang et al., 1991). Cytoplasts 
have also been suggested to migrate to inflammatory sites in vivo (Malawista et al., 2006). As 
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the majority of this work was conducted before the recognition of NETs, these observations 
may represent neutrophils following vital NETosis. Whilst cytoplasts may be controversial, red 
blood cells (RBCs) and platelets are accepted examples of functional anucleate cells, 
demonstrating the capability of cells to function in the absence of a nucleus. 
More recent work also provides evidence to support vital NETosis. LPS-stimulated 
neutrophils have been shown to produce NETs but restrict intracellular access of SYTOX® 
Green (Clark et al., 2007). SYTOX® Green is a high-affinity nucleic acid stain that penetrates 
cells with compromised plasma membranes but cannot permeate live cells. This observation 
indicates that neutrophils cell membranes remain intact following LPS-induced NETosis.  
Similar observations were reported in granulocyte/macrophage colony-stimulating 
factor (GM-CSF) primed neutrophils stimulated with LPS or C5a (Yousefi et al., 2009). 
Interestingly, the authors found that NETs were composed of mitochondrial DNA and not 
nuclear chromatin. Moreover, stimulated neutrophil did not uptake ethidium bromide, indicating 
that the cells were not dead. These results suggest that GM-CSF primed neutrophils produce 
NETs with mitochondrial DNA, which does not compromise cell viability. In a further study, 
PMA primed neutrophils co-cultured with Staphylococcus aureus rapidly released NETs via 
vesicular exportation, which also maintained cell integrity (Pilsczek et al., 2010).  
 NETosis has been observed in vivo following culture with S. aureus and Streptococcus 
pyogenes (Yipp et al., 2012). Both toll-like receptor (TLR)-2 and complement C3 knockout 
mice were resistant to S. aureus- and S. pyogenes-induced NETosis, implicating a TLR-2 and 
complement C3-dependent mechanism. Following NETosis, the anuclear neutrophils displayed 
a novel crawling phenotype (Yipp et al., 2012), supporting vital NETosis. Candida albicans 
was also found to induce vital NETosis, which was independent of ROS generation, but 
required Mac-1 engagement and signalled via the mitogen-activated protein kinase/extracellular 
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1.4.3.2 Suicidal NETosis 
 
Suicidal NETosis is a form of neutrophil cell death, arising from the sequential 
progression of chromatin decondensation and cytoplasmic localisation of DNA to cell 
membrane perforation and externalisation of NETs. Early investigations provide evidence 
consistent with suicidal NETosis. PMA stimulation of neutrophils, but not lymphocytes, was 
found to induce ROS-dependent cell death (Tsan, 1980). PMA stimulation also decreases 
neutrophil size and granularity (Esaguy et al., 1991). Microscopic analysis also highlighted 
numerous empty vesicles, smoothing of cell surfaces, a decrease in cytoplasmic compactness 
and some cytological features of cell death (Esaguy et al., 1991), suggesting that PMA-induced 
NETosis results in neutrophil cell death. 
Pilsczek et al. noted that whilst NETs were released without compromising neutrophil 
viability in their model, at later time points there was disruption of the nuclear membrane 
(Pilsczek et al., 2010). Following stimulation for an hour, nuclear envelope rupture and 
cytoplasmic DNA were observed, which was hypothesised to be the beginnings of lytic cell 
death and suicidal NETosis, however this finding was not further explored. This observation 
may suggest that there is a signalling overlap in the pathways regulating both forms of NETosis.  
 
1.4.4 Mechanisms underlying neutrophil extracellular trap formation 	  
Since the identification of NETs, substantial work has been conducted to determine the 
mechanisms underpinning their generation. This section will explore how neutrophil integrins 
contribute to NETosis, evaluate the cell signalling pathways implicated in NETosis and discuss 
the key molecular mechanisms involved during NET generation    
 
1.4.4.1 Integrin involvement in neutrophil extracellular trap formation 
 
Integrin engagement is thought to be crucial in initiating NETosis, however limited 
work has been conducted to further dissect their precise contribution. Several groups have 
shown that Mac-1 blockade suppresses NETosis (Neeli et al., 2009, Raftery et al., 2014, 
Rossaint et al., 2014, Yalavarthi et al., 2015). Inhibition of the β1 integrins, in particular VLA-3 
(CD49c/CD29; α3β1) and VLA-5, has been shown to suppress neutrophil ROS generation 
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(Lavigne et al., 2007). Another group found that pan-β1 integrin blockade suppressed NETosis 
(Gillenius and Urban, 2015), suggesting that the β1 integrins may also regulate NET production. 
 Interestingly, recent work has proposed a novel mechanism of NETosis that focuses on 
the contribution of L-selectin (Mohanty et al., 2015). Mohanty et al. found that NETosis could 
be induced by saliva and identified the presence of NETs within the oral cavity. Saliva-induced 
NETosis was rapid and did not require ROS generation and had reduced contributions of NE 
and NADPH compared to ‘conventional’ NETosis (Mohanty et al., 2015). Molecular dissection 
found that saliva-induced NETosis is mediated by L-selectin-dependent signalling, induced by 
interactions with mucins containing sLeX residues. The authors also found that saliva-induced 
NETosis was deficient in patients with Behçets disease, an inflammatory condition 
characterised by recurrent oral ulcers, suggesting that L-selectin-mediated signalling may 
represent a novel mechanism important to mucosal immunity. Moreover, blockade of PSGL-1 
in mice has also been shown to suppress NETosis (Etulain et al., 2015), suggesting that PSGL-1 
may also provide neutrophils with the stimulatory signals to induce NETosis. These recent 
observations demonstrate the complexity of the interactions and signalling involved in 
neutrophil biology and the induction of NETosis. 
 
1.4.4.2 Cell signalling transduction in neutrophil extracellular trap formation 
 
Limited work has addressed the signalling pathways involved in NETosis, which can be 
found summarised at the end of section in Figure 1.9. There are conflicting results regarding 
mammalian target of rapamycin (mTOR) involvement. McInturff et al. report that mTOR 
enhances NETosis through post-transcriptional regulation of hypoxia-inducible factor (HIF)-1α 
(McInturff et al., 2012). Inhibition of mTOR, HIF-1α, or both, reduced NETosis; thus 
demonstrating a role for mTOR and HIF-1α in the regulation of NETosis. In contrast, Itakura 
and McCarty propose that mTOR inhibits NETosis by suppressing autophagy (Itakura and 
McCarty, 2013). Autophagy is a process that mediates protein homeostasis by regulating 
intracellular protein turnover (Ravikumar et al., 2010). A feature of autophagy is the formation 
of autophagosomes that fuse with lysosomes to degrade proteins. Itakura and McCarty found 
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mTOR inhibition increased both autophagosome formation and NETosis (Itakura and McCarty, 
2013).  
Discrepant findings may be explained by the differing experimental stimuli, leading to 
activation of two different mTOR complexes (mTORC): mTORC1 and mTORC2. McInturff et 
al. stimulated neutrophils with LPS, binding TLR-4 and activating nuclear factor (NF)-κΒ, 
which is known to promote HIF-1α signalling. Hypoxia has been shown to activate tumor 
suppressor complex 1/2 (TSC1/2) (DeYoung et al., 2008). It is therefore possible that HIF-1α 
can activate TSC1/2, leading to the activation of mTORC2 whilst supressing mTORC1 (Huang 
et al., 2008). Activation of mTORC2 activates protein kinase B (PKB, also referred to as Akt), 
which subsequently activates NF-κΒ and HIF-1α. There is also evidence to suggest that LPS 
can bind TLR-2 (Yang et al., 1998b, Takeuchi et al., 1999, Sabroe et al., 2002, Good et al., 
2012). LPS could therefore activate phosphatidylinositol-3-kinase (PI3K) and Akt, which 
suppresses TSC1/2 and promotes mTORC1 activity. Inhibition of either HIF-1α or mTORC1 
would therefore inhibit NETosis, as observed by McInturff and colleagues. 
In contrast, Itakura and McCarty used fMLP, which stimulates the Ras-Raf pathway 
and activates ERK (Worthen et al., 1994). Stimulation of ERK leads to the activation of RSK, 
which suppresses TSC1/2 and enhances mTORC1 activity. Reports have found that fMLP 
increases intracellular calcium concentrations and stimulate PKC (Carter et al., 1989, O'Flaherty 
et al., 1990). PKC activation initiates ROS generation, a prerequisite for NETosis, which has 
also been linked to autophagy. Therefore, mTORC1 may reduce NETosis by suppressing 
autophagy signals induced by fMLP stimulation. 
Screening of small molecule inhibitors found a Raf inhibitor was a potent suppressor of 
NETosis (Hakkim et al., 2011), implicating the MAPK/ERK pathway. As mTORC1 is activated 
by ERK and Raf inhibition reduces NET release, observations by Hakkim et al. suggest that 
mTORC1 promotes NETosis. Recent reports found Akt inhibition reduced PMA-induced 
NETosis, implicating the PI3K-Akt pathway (Douda et al., 2014). Akt inhibition would also 
suppress mTORC1, suggesting mTORC1 promotes PMA-induced NETosis. 
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Autophagy-related signalling has been implicated in NETosis. PI3K signalling regulates 
autophagy in neutrophils, with PI3K inhibition disrupting autophagosome production (Mitroulis 
et al., 2010). Examination of neutrophils from patients with acute gout and healthy controls 
(HCs), found that PI3K inhibition reduced both autophagosome-lysosome fusion and NETosis 
(Mitroulis et al., 2011). Microtubule-associated protein light chain 3 (LC3), a marker for 
autophagy, has been reported in PMA-stimulated neutrophils (Remijsen et al., 2011b). This 
group also found that superoxide generation and autophagy were required to generate NETs, 
with inhibition of ROS production or autophagy reducing NETosis (Remijsen et al., 2011b). 
Inhibition of p38 MAPK has also been shown to reduce NETosis in PMA-stimulated 
neutrophils (Riyapa et al., 2012). Studies have found that PMA-induced NETosis is mediated by 
the ROS-dependent activation of p38 MAPK and ERK (Keshari et al., 2013). NETosis induced 
by ICs has been shown to require both FcγRIIIB and Mac-1, which activate SFK and Syk 
(Behnen et al., 2014). Activation of these tyrosine kinases is known to regulate the PI3K/Akt, 
MAPK/ERK and p38 MAPK pathways. Figure 1.9 illustrates how these cell signalling 
pathways may interact. 
 
1.4.4.3 Molecular mechanisms of neutrophil extracellular trap formation 
 
Regarding the molecular mechanisms of NETosis, peptidyl arginine deiminase (PAD)-4 
has been shown to translocate to the nucleus, where it citrullinates histones (Nakashima et al., 
2002, Wang et al., 2004). Neutrophils isolated from PAD-4 knockout mice fail to produce 
NETs, which supports a PAD-4-dependent mechanism (Li et al., 2010a). Defective bacterial 
killing and increased susceptibility to sepsis following Klebsiella pneumoniae or Escherichia 
coli infection were reported in NE knockout mice (Belaaouaj et al., 1998). Increased 
susceptibility to infection was also reported in NE and cathespin G knockout mice following 
infection with Aspergillus fumigatus spores (Tkalcevic et al., 2000). Following the 
establishment of NETosis as an antimicrobial response, Papayannaopoulos et al. demonstrated 
that NE knockout mice failed to produce NETs (Papayannopoulos et al., 2010). Defective C. 
albicans killing was also observed in neutrophils isolated from MPO-deficient mice compared  
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Figure 1.9: NETosis is regulated by PI3K/Akt, MAPK/ERK, mTOR and p38 MAPK 
signalling. Depicted are the signalling pathways implicated in NETosis. Green arrows represent 
activation signals, with solid lines being through known mechanism and dashed lines via unknown 
mechanisms. Red lines indicate suppressive signals. Abbreviations: Akt, protein kinase B; ERK, 
extracellular signal-related kinase; fMLP, N-formyl-methionine-leucyl-phenylalanine; HIF-1α, 
hypoxia inducible factor-1α; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; 
MEK, MAPK/ERK kinase; mTORC, mammalian target of rapamycin complex; NF-κB, nuclear 
factor κB; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-
acetate; Rheb, Ras homolog enriched in brain; RSK, ribosomal S6 kinase; S6K, S6 kinase; TLR, 
toll-like receptor; TSC, tumor suppressor complex. 
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to control (Aratani et al., 1999). Similar findings have been reported in humans, with MPO-
deficient patients exhibiting delayed NETosis and neutrophils isolated from patients with a 
complete absence of MPO expression unable to produce NETs (Metzler et al., 2011).  
Given these observations, NE and MPO are believed to be important in NETosis. 
Neutrophil extracts can promote in vitro chromatin decondensation (Papayannopoulos et al., 
2010). NE was found to be both necessary and sufficient to degrade histones, whilst MPO could 
synergise with NE to enhance in vitro chromatin decondensation (Papayannopoulos et al., 
2010). Papayannopoulos and colleagues therefore proposed that NE translocates to the nucleus 
first and begins to digest histones, with MPO subsequently trafficking to the nucleus and 
synergising with NE to enhance chromatin decondensation. 
Papayannopoulos and colleagues subsequently examined NETosis in response to C. 
albicans, reporting impaired NETosis when hyphae morphology was disrupted (Branzk et al., 
2014). Whilst wild-type hyphae induced NETosis, fragmented hyphae induced lower levels of 
NET release and promoted phagocytosis, suggesting neutrophils could modulate responses 
based on pathogen size. Phagocytosis inhibited NETosis by sequestering NE to phagosomes 
(Branzk et al., 2014). Therefore, an intracellular balance of NE and MPO may regulate 
NETosis. In this molecular model, when neutrophils encounter smaller pathogens and undergo 
phagocytosis, NE and MPO are trafficked to the phagosome and not the nucleus. If neutrophils 
encounter larger microbes that cannot be engulfed, there is a shift to nuclear localisation of both 
NE and MPO, where they facilitate nuclear decondensation and the generation of NETs. 
 In conclusion, integrin engagement, in particular the β1 and β2 integrins are thought to 
promote NETosis, however the precise signalling pathways are unknown. More recent work has 
also implicated selectin-mediated signalling, which further complicates the signalling pathways 
regulating NET generation. Various groups have presented evidence to support MAPK/ERK, 
PI3K/Akt, mTOR and p38 MAPK signalling pathways as regulators of NETosis. There is likely 
to be a fine balance between these signalling pathways in vivo, which determine the degree of 
ROS-dependency and whether neutrophils undergo vital or suicidal NETosis.  
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1.5 Disorders of immune regulation in autoimmune rheumatic disease 	  
Autoimmunity arises when the immune system fails to recognise constituents of the 
host organism as ‘self’, in a process referred to as ‘loss of tolerance’, resulting in an immune 
response against self-antigens. Autoimmune diseases can be divided into either organ-specific 
or systemic diseases. Organ-specific autoimmunity is directed against a single organ or cell 
type, examples of which include Addison’s disease, Hashimoto’s thyroiditis, insulin-dependent 
diabetes mellitus and myasthenia gravis. In contrast, systemic autoimmune diseases target a 
broad range of tissues and can affect multiple organs. Autoimmune rheumatic disease (ARD) is 
a term used to describe a group of systemic autoimmune disorders associated with substantial 
morbidity and mortality, generally characterised by dysregulation of the immune system and the 
presence of circulating autoantibodies Three ARDs will be explored in this thesis: rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). 
Neutrophil dysfunction and aberrant NETosis have been described in all three of these ARDs, 
which will be discussed in section 1.6.	  
 
1.5.1 Rheumatoid arthritis  	  	  
RA is a chronic inflammatory autoimmune disease, which affects more women than 
men, and is characterised by the progressive destruction of synovial joints. Patients typically 
have circulating autoantibodies, which contribute to disease pathology. Multiple immune cells 
also contribute to the immunopathology underpinning RA. 	  
 
1.5.1.1 Aetiology of rheumatoid arthritis  
 
Recent reports estimate RA to affect between 18-32 men per 100,000 and 44-65 women 
per 100,000 in the UK (Humphreys et al., 2013). Early studies identified a class of 
autoantibodies termed rheumatoid factor (RhF), which bound the Fc portion of IgG and forms 
ICs, in RA patients (Rose et al., 1948). RhF was found to be 75% sensitive and 74% specific for 
RA (Bas et al., 2002). In contrast, autoantibodies recognising citrullinated antigens, anti-
citrullinated protein antibodies (ACPA) (Schellekens et al., 1998), are highly specific for RA 
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(Schellekens et al., 2000, Vincent et al., 2002). Whilst ACPA are only 68% sensitive for RA, 
comparative analysis found ACPA to be 94% specific (Bas et al., 2002). ACPA can be detected 
many years prior to disease onset (van der Woude et al., 2010), making them a powerful 
diagnostic tool.  	  
There is a complex interplay between genetic and environmental risk factors in RA. The 
human leukocyte antigen (HLA)-DR, a class II MHC molecule, is the strongest genetic 
determinant of RA. A strong association between the presence of a particular ACPA and HLA-
DRB1*04 has been demonstrated, with HLA-DRB1*04 expressing the shared epitope motif 
found in 60-70% of patients (Gorman et al., 2004). Higher ACPA titres have been seen in 
patients with the non-shared epitope HLA-DRB1*15 allele, in particular among smokers with 
RA (Laki et al., 2012). An association with HLA-DR3 has been reported in ACPA negative RA 
patients (Verpoort et al., 2005). These reports highlight the complex relationship between HLA 
haplotype and RA. 	  
Genome-wide association studies have implicated polymorphisms in PADI4, the gene 
encoding PAD-4, with an increased risk of RA in several Asian populations (Kang et al., 2006, 
Cheng et al., 2012, Suzuki et al., 2013). Some studies show that this association exists in some 
Caucasian communities (Iwamoto et al., 2006, Hoppe et al., 2006), however other reports have 
failed to replicate this association (Barton et al., 2004, Martinez et al., 2005, Caponi et al., 2005, 
Burr et al., 2010). Polymorphisms in the PTPN22 gene, which regulates B and T cell activation 
thresholds, are also associated with RA pathology (Plenge et al., 2005, Hinks et al., 2005), with 
mutations rendering lymphocytes hyperactive. 	  
Environmental factors, such as smoking, are also linked to the initiation of RA, as 
demonstrated by the aforementioned association between the non-shared epitope HLA-
DRB1*15 allele and RA smokers. In addition, PAD-2 expression is significantly increased in 
cells derived from the bronchoalveolar lavage (BAL) of smokers compared to non-smokers 
(Makrygiannakis et al., 2008), which is thought to increase citrullinated autoantigens within the 
pulmonary vasculature. Further investigations have implicated mucosal inflammation and the 
microbiome as extra-articular triggers of RA (Farquharson et al., 2012, Brusca et al., 2014). 	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To conclude, the initiation and progression of RA is dependent on a complex interplay 
between genetic predisposition and environmental factors. Growing evidence suggests that 
mucosal inflammation may contribute to the initiation of RA, however the precise mechanism 
underlying loss of tolerance remains unclear.	  
 
1.5.1.2 Clinical features of rheumatoid arthritis  	  
RA patients typically present with symmetrical peripheral polyarthropathy affecting 
synovial joints. Synovitis of the hands and feet are common early features of RA. With disease 
progression, additional joints including the knees, hips, shoulders, elbows and spine are 
affected. Joint involvement is progressive, with synovial inflammation leading to thinning of 
cartilage, erosion of bone, and formation of an abnormal layer of fibrovascular tissue called the 
pannus. 	  
To ensure consistency amongst international groups conducting research into RA, the 
American College of Rheumatology (ACR) and European League Against Rheumatism 
(EULAR) devised RA classification criteria. The most recent revision of these criteria was in 
2010 (Aletaha et al., 2010). Clinicians often refer to these research criteria to aid diagnosis of 
RA in clinical practice. These classification criteria can be grouped into 4 main categories: joint 
involvement, serology, acute-phase reactants and symptom duration. Joint involvement refers to 
the presence of tender or swollen joints on examination, taking into consideration the size and 
number of affected joints. Serologic tests determine the presence of RhF and ACPA. C-reactive 
protein (CRP) levels and erythrocyte sedimentation rate (ESR) are measured to assess levels of 
inflammation. The duration of symptoms is also considered, with symptoms lasting for more 
than 6 weeks being required for diagnosis As well as aiding diagnosis, several of these 
parameters are also included in the disease activity score (DAS)28, which is derived from 
examination of 28 joints for tenderness and swelling, measurement of ESR and global health 
score (Figure 1.10). This score is routinely used in clinical practice to evaluate disease activity 
and guide treatment. 
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Figure 1.10: Formula for calculation of DAS28. Clinical assessment of RA relies on the 
assessment of tenderness or swollenness of 28 joints. These joints are marked in green in the 
above diagram. DAS28 is then calculated by considering joint involvement, with ESR or 
CRP and a global assessment of health. Skeletal image was adapted from the Arthritis 
Research UK website. 
DAS28 Calculations 0.56 ! + 0.28 ! + 0.7 ln !"# + 0.014! 
or 0.56 ! + 0.28 ! + 0.36 ln !"# + 1 + 0.014! + 0.96   
Clinical Variable Value 
Tender Joint Count (0-28) x 







Global Assessment of Health Score z 
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Whilst RA is typically characterised by articular features, extra-articular manifestations 
are also important. UK cross-sectional studies report an increase in mortality associated with 
cardiovascular disease, pulmonary complications and solid tumours in RA patients (Young et 
al., 2007, Olson et al., 2011). RA patients are at increased risk of atherosclerosis and heart 
disease (Wallberg-Jonsson et al., 1999, Riise et al., 2001, Goodson and Symmons, 2002, Nicola 
et al., 2006, Cojocaru et al., 2010). Pulmonary manifestations are increasingly recognised, with 
estimates of both preclinical and clinical RA-associated interstitial lung disease (ILD) ranging 
between 10-30% (Cortet et al., 1995, Gabbay et al., 1997, Demir et al., 1999, Tanaka et al., 
2004, Ayhan-Ardic et al., 2006, Mori et al., 2008, Georgiadis et al., 2009, Kim et al., 2010). A 
study following 1429 RA patients across England for up to 18 years, reported similar findings to 
previous population-based studies, with 31% of deaths attributed to cardiovascular disease and 
22% of deaths due to respiratory complications (Young et al., 2007). In addition, further 
analysis of this study found 32% of patients presenting with rheumatoid nodules on the skin, 3% 
with vasculitis and 1% with neuromyopathy (Young and Koduri, 2007). 	  
 
1.5.1.3 Immunopathology of rheumatoid arthritis  	  
B and T cell dysregulation, proinflammatory cytokine production and autoantibody 
generation are key features of RA immunopathology. RA was largely considered a lymphocyte-
mediated disorder, therefore extensive work has examined the contribution of adaptive 
immunity to RA pathology. The contribution of innate immune cells is being increasingly 
recognised in RA pathogenesis. Given the importance to this thesis, the relevance of neutrophils 
will be discussed in greater detail in section 1.6.1. 
The earliest event in RA pathology is believed to be activation of the innate immune 
response, in particular DCs (Smolen and Steiner, 2003, Smolen et al., 2007). Studies have found 
DCs to be elevated in the synovial fluid (SF) of RA patients compared to peripheral blood 
(Moret et al., 2013), suggesting DCs may migrate to the synovium and facilitate T cell 
activation. 
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Whilst substantial evidence supports T cell involvement in RA, direct targeting of T 
cells has limited efficacy in treatment (Panayi, 2006), suggesting a more complex pathological 
mechanism. Activated CD4+ T cells are a major cell type within the RA pannus (Panayi et al., 
1992). Phenotypic analysis of synovial T cells found a large subpopulation of CD45RO+ T cells, 
indicative of mature memory T cells, which can stimulate B cells to produce antibodies (Panayi 
et al., 1992).  
Th1 cells have conventionally been considered to drive RA pathology, however there is 
growing interest in the involvement of Th17 cells. Th17 cells secrete proinflammatory 
mediators that can suppress Treg generation (Chabaud et al., 1998, Miossec et al., 2009). 
Elevated Th17 and reduced Treg differentiation have been described in RA patients, which 
promote inflammatory cell phenotypes (Miao et al., 2014). Inflammatory monocyte-derived 
DCs enhance Th17 cell generation through the secretion of cytokines such as IL-1β, IL-6 and 
IL-23 (Estrada-Capetillo et al., 2013). In addition, Tregs isolated from RA patients have limited 
suppressive activity (Behrens et al., 2007, Cribbs et al., 2014), which is attributed to low 
expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (Cribbs et al., 2014). This 
reduced Treg population, with defective suppressive capability, fails to suppress autoreactive T 
cells (Rapetti et al., 2015). 
Other cells types have also been implicated in RA pathology. NKT cells have been 
identified in RA patients (Aggarwal et al., 2014), however their contribution to pathology is 
unclear, as evidence suggests a reduced proliferative capacity (Gutowska-Owsiak et al., 2014). 
CD4+CD8+ double positive T cells are more abundant in ACPA positive RA patients, which 
secrete IL-4, IL-21 and interferon (IFN)-γ in the synovium (Quandt et al., 2014), thus 
contributing to the proinflammatory cytokine milieu. 
B cells are also found in RA synovium, where they form aggregates with T cells. The 
efficacy of rituximab, which selectively depletes CD20+ B cells, supports B cell involvement in 
RA (Edwards et al., 2004). B cells contribute to RA pathology not only through antigen 
presentation, but also by producing autoantibodies (Smolen et al., 2007). Autoantibodies form 
ICs that stimulate the production of proinflammatory cytokines (Smolen et al., 2007), which 
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promote T cell, B cell and macrophage activation (Smolen and Steiner, 2003, Smolen et al., 
2007). There are reduced numbers of Bregs in RA patients, which inversely correlate with both 
DAS28 scores and levels of RhF and ACPA (Daien et al., 2014). Moreover, the number of 
Bregs positively correlates with Treg numbers in new-onset RA patients, leading to the 
hypothesis that Bregs support Treg differentiation via IL-10 secretion (Ma et al., 2014). 
Macrophages also contribute to synovitis through a combination of proinflammatory 
cytokine production, ROS generation, release of matrix-degrading enzymes, phagocytosis and 
antigen presentation (Haringman et al., 2005). Macrophages therefore contribute to the 
proinflammatory synovial environment, whilst supporting the differentiation and activation of B 
cells and T cells. Macrophage-derived cytokines also drive fibroblast-like synoviocyte (FLS) 
proliferation and activation, whilst the release of ROS induces chondrocyte apoptosis, both of 
which facilitate cartilage erosion. Proinflammatory cytokine secretion amplifies osteoclast 
differentiation and activation (Schett and Teitelbaum, 2009), which promotes bone destruction.  
The immunopathology of RA is complex with numerous cellular interactions crossing 
both innate and adaptive immunity. Abnormal cellular activation and the promotion of 
proinflammatory cell subsets results in the production and maintenance of a proinflammatory 
environment that supports the destruction of cartilage and bone. 
 
1.5.1.4 Current treatment for rheumatoid arthritis  	  
Patients are regularly assessed to monitor disease activity and response to therapy. 
Assessment is comprised of two components: clinical assessment of disease activity and blood 
tests for inflammatory markers and evidence of toxicity. Clinical assessment of disease activity 
is made using the DAS28 (Figure 1.10) (Wells et al., 2009), which not only monitors disease 
activity but also defines eligibility for biological therapy. Laboratory tests normally include 
inflammatory markers such as CRP and ESR to gauge systemic inflammation, as well as full 
blood count, renal and liver function to assess for disease complications and toxicity of 
treatment. DAS28 scores of 2.6 or below indicate disease remission, a score between 2.6-3.2 
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implies low disease activity, whilst a value of 3.2-5.1 is classified as moderate disease activity 
and a DAS28 score of 5.1 or higher indicates high disease activity.  
RA management is achieved through both medical and non-medical therapy. Prompt 
diagnosis is essential to reduce permanent joint damage and patients benefit from the	  specialist 
input of a team within a rheumatology unit (including doctors, nurses, physiotherapists, 
podiatrists and psychologists), as well as information from leaflets, websites and local patient 
groups. Drug therapy includes: analgesics; non-steroidal anti-inflammatory drugs (NSAIDs); 
glucocorticoids; disease-modifying anti-rheumatic drugs (DMARDs); and biologics. Analgesics 
do not alter disease progression nor reduce inflammation but are used to ease pain.   
NSAIDs are used to relieve inflammation, pain and stiffness but do not slow the 
progression of RA. This group of drugs can be categorised based upon their ability to inhibit 
cyclooxygenase (COX)-1 and/or -2 into traditional non-selective NSAIDs, such as ibuprofen, 
naproxen and diclofenac, and COX-2-selective inhibitors, including celecoxib and etoricoxib. 
NSAID treatment has been associated with an increased risk of cardiovascular and 
gastrointestinal complications (Ong et al., 2007), so patients are evaluated to determine the most 
appropriate NSAID treatment. For additional pain relief, paracetamol and co-codamol are 
commonly prescribed analgesics.  
Glucocorticoids are ideally given on a short-term basis to reduce pain, stiffness and 
swelling in patients who have yet to start, or are failing to respond to, DMARDs. Prednisolone 
is a commonly prescribed glucocorticoid. Pain relief varies between patients and often depends 
on disease severity. The mainstay however, of long-term therapy is the use of multiple 
DMARDs as combination therapy, started early in the disease, to	  reduce inflammation and help 
prevent further joint damage. Methotrexate, hydroxychloroquine (HCQ) and sulfasalazine are 
commonly prescribed DMARDs, which require regular monitoring for side effects and efficacy.  
Biological therapies are routinely used as second line agents to treat RA. In the UK, 
biologics are given to patients who have failed to respond to at least two different DMARDs, 
one of which should be methotrexate unless contraindication, and have a DAS28 score of 5.1 or 
higher on two separate occasions one month apart. Biological treatments are usually 
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monoclonal antibodies or fusion proteins, which modulate the immune system by targeting the 
cytokines or cells that contribute to RA pathology. Biologics prescribed in RA can deplete 
peripheral CD20+ B cells (rituximab), block IL-6 signalling (tocilizumab), suppress T cells 
activation (abatacept) or inhibit tumour necrosis factor (TNF)-α signalling (infliximab, 
etanercept, adalimumab, certolizumab pegol and golimumab). First line biological treatment is 
anti-TNF-α therapy, however if unsuccessful other therapies may be prescribed. Biological 
therapy is commonly given in combination with DMARDs, such as methotrexate, with the goal 
to treat-to-target to induce remission and suppress disease activity. 
	  
1.5.2 Systemic lupus erythematosus 	  
SLE is an ARD with a wide range of clinical features and a predilection for women and 
certain ethnic groups (Rahman and Isenberg, 2008). SLE patients commonly have circulating 
autoantibodies that contribute to SLE pathology, which can affect several organ systems. In 
addition, multiple immune cells have been shown to be important to the immunopathology 
underlying SLE.  
 
1.5.2.1 Aetiology of systemic lupus erythematosus    
 
The prevalence of SLE in the UK varies by ethnicity and is estimated to be 134 cases 
per 100,000 amongst Caucasian women, rising to 516 cases per 100,000 amongst Afro-
Caribbean women (Rees et al., 2016). SLE is characterised by the dysregulation of both innate 
and adaptive immunity, with immune manifestations including defects in apoptotic cell 
clearance, disturbances in cytokine production, B cell immunity and T cell signalling. SLE is a 
multifactorial disease, arising from various genetic, environmental and hormonal factors. 
The first genetic associations with SLE were made with HLA haplotypes (Grumet et al., 
1971). Genetic studies have estimated that the HLA-DRB1*1501 and HLA-DRB1*0301 alleles 
confer a 2-3 fold increased risk of developing SLE in Caucasian populations (Fernando et al., 
2007, Graham et al., 2007). Deficiencies in components of the complement cascade are also 
associated with SLE (Agnello et al., 1972, Nishino et al., 1981), implicating defects in 
complement activation and opsonisation. Polymorphisms in FcγRI, FcγRIIA and FcγRIIIB have 
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been associated with both increased susceptibility to SLE and disease severity (Brown et al., 
2007). These polymorphisms alter FcγR affinity, modulating how immune cells engage with 
ICs (Salmon et al., 1996, Wu et al., 1997, Kyogoku et al., 2002, Karassa et al., 2002, Karassa et 
al., 2003, Lee et al., 2009), suggesting that defective immune recognition may contribute to 
pathology. Mutations in ITGAM, the gene encoding the αM integrin subunit, have been strongly 
associated with SLE. This mutation will be discussed in greater detail in section 1.7.2. Whilst 
these genes are examples of some genetic factors underlying SLE pathology, many other genes 
have been implicated, including those involved in lymphocyte signalling (BANK1, CD80, CSK, 
IL10, SLK, STAT4), innate immune signalling (IRAK1, IRF5, IRF7, IRF8, TLR7, TLR9, TYK2) 
and IC clearance (ATG5, DNASE1, TREX1) (Ramos et al., 2010, Mohan and Putterman, 2015). 
A common environmental factor for SLE is ultraviolet light, which can provoke a 
photosensitive rash. This effect is dose dependent and is thought to act by inducing apoptosis 
and cytokine production (Caricchio et al., 2003). Additional environmental factors that are 
implicated include cigarette smoke, infection, vitamin D deficiency, exogenous oestrogen 
uptake, conventional drugs, biological agents, and pesticides (Zandman-Goddard et al., 2012).  
Given the gender bias towards women, female sex hormones are thought to contribute 
to SLE aetiology and pathophysiology (Straub et al., 2013). In humans, oestrogen metabolites 
are thought to enhance humoral immune responses (Cutolo et al., 2010). Early studies found 
abnormal oestrogen metabolism in SLE patients of both sexes (Lahita et al., 1983, Sequeira et 
al., 1993, Mok and Lau, 2000). Furthermore, antibodies targeting oestrogen receptor (ER)-α 
were identified in 45% of an Italian SLE cohort but not in HCs (Colasanti et al., 2012), which 
induced T cell activation and subsequently apoptosis. In addition, anti-ER-α antibodies were 
shown to drive proliferation of CD3-stimulated T cells (Colasanti et al., 2012), which was 
proposed as a mechanism that promotes autoreactive T cell expansion.  
 
1.5.2.2 Clinical features of systemic lupus erythematosus    	  
Given the multi-systemic nature of SLE, patients can present with a broad range of 
clinical symptoms. The largest prospective lupus cohort, the Euro-Lupus cohort, consists of 
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1000 patients followed since 1991 (Cervera et al., 2009c) and has documented the following 
disease manifestations in patients: arthritis in 48.1%; malar rash in 31.1%; nephropathy in 
27.9%; photosensitivity in 22.9%; neurologic involvement in 19.4% (including acute 
confusional state, aseptic meningitis, cerebrovascular disease, cognitive dysfunction, cranial 
neuropathy, demyelinating syndrome, headache, myelopathy, polyneuropathy and seizure); 
thrombocytopenia in 13.4%; oral ulcers in 12.5%; discoid lesions in 7.8%; and haemolytic 
anaemia in 4.8%. 
Frequencies of clinical manifestations vary between published cohorts, most likely due 
to ethnic differences. For example, Asian SLE patients have higher frequencies of skin and 
renal involvement, with 76.1% of patients having malar rash and 74% diagnosed with 
nephropathy (Wang et al., 1997). A greater prevalence of arthritis (88.1%), photosensitivity 
(60.2%) and oral ulcers (52.8%) have also been reported in an American SLE cohort (Alarcon et 
al., 2002). 
Several indices exist to measure disease activity in SLE, each of which assigns scores 
based on the extent of organ involvement and clinical manifestations, alongside laboratory-
based investigations. The disease activity index used will depend on the country in which 
patients are diagnosed and managed (Nuttall and Isenberg, 2013).	  
	  
1.5.2.3 Immunopathology of systemic lupus erythematosus    	  
Immune cell dysregulation is central to SLE pathology, affecting both innate and 
adaptive immune cells, culminating in the activation of polyclonal B cells, increased number of 
plasma cells, hypergammaglobulinaemia and IC formation. Given the relevance to this thesis, 
neutrophil involvement in SLE will be discussed in section 1.6.2. 
SLE patients have greater populations of activated polyclonal peripheral B cells 
compared to controls (Klinman et al., 1991). Studies have found a shift towards an immature B 
cell phenotype that is independent of disease activity (Dorner et al., 2011). Moreover, raised 
levels of CD27+IgD- peripheral memory B cells have been identified in SLE patients and these 
cells are less susceptible to immunosuppression (Dorner et al., 2011). This increase in 
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CD27+IgD- peripheral memory B cells is also associated with higher disease activity and lupus 
nephritis (Dorner et al., 2011). Reports also suggest that SLE B cells are more sensitive to 
cytokine stimulation (Linker-Israeli et al., 1991), display abnormal receptor-mediated signalling 
(Liossis et al., 1996) and have a greater propensity to undergo epitope spreading (Monneaux 
and Muller, 2002). Defective Breg activity has also been reported in SLE, with a population of 
IL-10 secreting Bregs identified that lack suppressive functionality within in vitro assays (Blair 
et al., 2010). 
Aberrant T cell activation has also been linked to SLE pathology, with reports 
documenting abnormal TCR signalling and T cell hyper-responsiveness. Decreased expression 
of the TCRζ chain has been observed in SLE patients (Takeuchi et al., 2012), however studies 
have found that SLE T cells can replace TCRζ with the more potent FcγR (Kyttaris and Tsokos, 
2011). Studies also report impaired CTLA-4 function in SLE patients (Jury et al., 2010). 
Normally, CTLA-4 activates the tyrosine phosphatase SHP-2, which inactivates TCRζ and 
disrupts TCR signalling (Lee et al., 1998). Due to the combination of decreased TCRζ 
expression and impaired CTLA-4 function, this pathway is impaired in SLE patients.  
Impaired TCRζ signalling has been suggested to interfere with thymic T cell selection 
and promote the release of autoreactive T cells into the periphery (Tanaka et al., 2010). 
Abnormalities in other signalling molecules have been reported, including Ras, Syk and ERK 
(Cedeno et al., 2003, Krishnan et al., 2008, Tanaka et al., 2010), which contribute to T cell 
anergy (Yi et al., 2000). SLE CD4+ T cells overexpress the αL integrin subunit, perforin 1 and 
CD70 (Balada et al., 2014), however the significance of this overexpression is unclear, but may 
contribute to pathogenesis through increased cellular interactions and co-stimulatory signals. It 
is important to note that other signalling molecules and pathways, including PKC and mTOR, 
are abnormal in SLE T cells (Moulton and Tsokos, 2011). 
Th17 cells also contribute to SLE pathology, with high levels of Th17 cells and IL-17 
found in both mouse models and patients (Wong et al., 2000, Hsu et al., 2008). For example, in 
the BXD2 mouse, which displays a lupus-like phenotype, Th17 cells contribute to the formation 
of germinal centres and autoantibody production (Hsu et al., 2008). Elevated Th17 cells and IL-
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17 have also been reported in other mouse models, where they promote renal inflammation 
(Moisan et al., 2007). Expression of signal transducer and activator of transcription 3 (STAT3), 
a transcription factor mediating Th17 development, is increased in human SLE T cells (Harada 
et al., 2007). Moreover, STAT3 inhibition in lupus prone mice has been shown to delay disease 
onset (Edwards et al., 2015), implicating Th17 cells in pathophysiology. 
The contribution of Tregs to SLE pathology remains controversial. Some groups report 
decreased Treg populations in SLE patients (Miyara et al., 2005, Bonelli et al., 2008), whilst 
others find no difference (Alvarado-Sanchez et al., 2006, Vargas-Rojas et al., 2008). Discrepant 
results may be due to differences in cell isolation techniques and Treg characterisation. Some 
studies suggest that Treg-mediated suppression is impaired in SLE patients (Alvarado-Sanchez 
et al., 2006, Valencia et al., 2007, Bonelli et al., 2008). In contrast, others studies found that 
SLE Treg function is unaffected but that autoreactive SLE T cells are less susceptible to 
suppression (Vargas-Rojas et al., 2008). Moreover, HC Tregs have been shown to suppress SLE 
effector T cells (Valencia et al., 2007), which may suggests that defective SLE Treg-mediated 
suppression contributes to SLE pathology. 
Monocytes and macrophages are also important in SLE pathology. Monocytes isolated 
from SLE patients have elevated expression of activation markers and adhesion molecules 
(Funauchi et al., 1993, Nockher et al., 1994, Egerer et al., 2000, Jin et al., 2005). Some groups 
have documented elevated CD14+CD11+ and CD14+CD16+ monocytes populations in SLE 
patients (Figueroa-Vega et al., 2006, Sullivan et al., 2007), which have increased expression of 
tissue factor (TF) (Nojima et al., 2008). There is also evidence for deregulated cytokine 
production, with SLE monocytes secreting greater levels of IL-6 and IL-10 compared to control 
(Linker-Israeli et al., 1991, Llorente et al., 1993, Llorente et al., 1994). Increased IL-6 and IL-10 
section promotes the production of anti-dsDNA autoantibodies by B cells (Llorente et al., 1995, 
Kanda et al., 1999). SLE monocytes differentiating into macrophages also exhibit elevated 
expression of genes involved in immune processes and signal transduction (Korman et al., 
2014). Elevated macrophage activation marker expression has also been identified in renal 
tissue from lupus nephritis patients (Yang et al., 1998a, Tomasoni et al., 1998, Frosch et al., 
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2004, Ikezumi et al., 2005). Macrophage infiltration also correlates with renal disease (Yang et 
al., 1998a). SLE macrophages display reduced phagocytosis of apoptotic cells and elevated 
production of proinflammatory cytokines (Lovgren et al., 2006, Sestak et al., 2011). Aberrant 
autophagy has been reported in splenic and renal macrophages isolated from an activated 
lymphocytes-derived DNA-induced murine lupus model, which is believed to promote the 
production of proinflammatory cytokines (Li et al., 2014). 
The precise function of NK cells in SLE is unclear. Several groups have reported 
reduced NK cell populations in SLE patients (Erkeller-Yuksel et al., 1997, Park et al., 2009, 
Huang et al., 2011a), which are associated with elevated IFN-α secretion (Huang et al., 2011a). 
Several groups have reported lower levels of NK cell inhibitory receptors in SLE patients 
(Schepis et al., 2009, Hervier et al., 2011, Puxeddu et al., 2012, Ye et al., 2014). Discrepancies 
arise when examining activating NK receptors, with some groups finding increased expression 
compared to controls (Hervier et al., 2011), whilst others report lower expression (Li et al., 
2010b, Puxeddu et al., 2012, Ye et al., 2014) and some finding no difference (Schepis et al., 
2009). Discrepant results may be attributed to variations in patient demographics, treatment 
regimens, cell characterisation and the specific receptors studied. A new class of autoantibodies 
have been identified, which target lectin-like NK cell receptors and interfere with their 
regulation (Hagberg et al., 2015), further implicating NK cell involvement in SLE. 
DCs are important to SLE pathology, with DC depletion in lupus prone mice 
ameliorating disease, reducing B and T cell expansion and suppressing autoantibody titres 
(Teichmann et al., 2010, Rowland et al., 2014). Peripheral DCs are reduced in SLE patients 
(Migita et al., 2005, Fiore et al., 2008, Tucci et al., 2008), however this reduction may be due to 
greater migration into the tissues. In support of this hypothesis, plasmacytoid DCs (pDC), a DC 
subset, have been found to be elevated in skin and renal tissues taken from SLE patients (Farkas 
et al., 2001, Blomberg et al., 2001, Fiore et al., 2008, Tucci et al., 2008). SLE pDCs have a 
reduced response to in vitro TLR-9 stimulation compared to control (Kwok et al., 2008). 
Studies have found greater expression of CD40 and CD86 in SLE pDCs, which potently induce 
T cell proliferation (Jin et al., 2010, Nie et al., 2010). Interestingly, whilst promoting effector T 
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cell expansion, SLE pDCs fail to induce Treg differentiation (Jin et al., 2010). Recent work has 
found that SLE pDCs also fail to induce Breg differentiation, but promote plasmablast 
expansion and autoantibody production (Menon et al., 2016). Circulating ICs lead to the chronic 
activation of pDCs (Barrat et al., 2005), inducing the secretion of type I IFNs (Obermoser and 
Pascual, 2010). Secreted IFN can subsequently activate other cells and drive SLE pathology.  
	  
1.5.2.4 Current treatment for systemic lupus erythematosus   	  
SLE patients are regularly monitored, by clinical assessment of disease activity and 
measurement of laboratory tests. Laboratory tests normally include inflammatory markers, 
similar to those assessed for RA, to evaluate levels of systemic inflammation. Current 
pharmacological treatments for SLE can be divided into 4 broad groups: NSAIDs; 
glucocorticoids; immunosuppressive drugs; and biologics. Treatment strategies depend upon the 
degree of disease activity and organ involvement with NSAIDs and HCQ given to treat mild 
disease with the addition of glucocorticoids and immunosuppressive therapy, such as 
azathioprine, to treat moderate and severe disease. Increasingly, biologic drugs are considered in 
patients who fail to respond to these conventional therapies (Lisnevskaia et al., 2014). 
Patients prescribed NSAIDs are monitored for adverse effects on bowel, gastrointestinal 
and renal function (Bertsias and Boumpas, 2008). Glucocorticoids, commonly prednisolone, 
may be used to treat all features of SLE. HCQ is the most commonly prescribed 
immunomodulatory drug in SLE patients, particularly to treat arthritis, rash and fatigue. Its 
precise mechanism of action however, is unclear with HCQ being shown to block inflammatory 
pathways (Willis et al., 2012), as well as disrupting TLR-3, TLR-7 and TLR-9 signalling 
(Kuznik et al., 2011).	  
Those patients who fail to respond to conventional immunosuppressive drugs may be 
considered for biological therapy. Rituximab is the most common biologic prescribed to SLE 
patients. It is a chimeric monoclonal antibody originally developed for the treatment of B cell 
lymphomas (Grillo-Lopez et al., 1999), which targets CD20 and induces apoptosis (Eisenberg, 
2005). The National Institute for Health and Care Excellence (NICE) has also recently approved 
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belimumab, which inhibits B cells survival, for the treatment of SLE. Additional biologics are 
currently in development and subject to pre-clinical studies. These include drugs that modulate 
B cell function (epratuzumab), inhibit B cell survival (atacicept) and target plasma cells 
(bortezomib). In addition, biologic therapy can also target T cells (abatacept, ruplizumab, 
toralizumab), IFN (rontalizumab, sifalimumab), IL-6 (tocilizumab) and TNF-α (infliximab, 
etanercept) (Lisnevskaia et al., 2014). These therapies however, require further clinical studies 
to evaluate any potential benefits to patients. 
 
1.5.3 Antiphospholipid syndrome 	  
The hallmarks of APS are recurrent thrombosis and/or pregnancy morbidity, such as 
recurrent pregnancy loss (Hughes, 1993, Cervera et al., 2002, Levine et al., 2002). The full 
clinical description of this unique form of autoantibody-induced thrombophilia was made in the 
early 1980s, reporting an association between recurrent thrombosis and pregnancy morbidity 
with the persistent presence of circulating antiphospholipid antibodies (aPL) (Hughes, 1983). 
In contrast to their name, aPL do not directly bind phospholipids but target serum 
cofactors, which in turn bind anionic phospholipids. The most important of these serum 
cofactors is β2-glycoprotein I (β2GPI) (Matsuura et al., 1990, McNeil et al., 1990). Lupus 
anticoagulants (LA) are a heterogeneous class of Ig that can develop spontaneously or in 
association with ARDs. LA bind serum cofactor-phospholipid complexes, such that 
phospholipid-dependent coagulation is prolonged (Arnout, 2001). Anti-cardiolipin antibodies 
(aCL), which are closely related to LA, have been shown to bind cardiolipin associated with 
serum cofactors (Galli et al., 1990). Persistent aCL positivity has been associated with an 
increased risk of arterial or venous thrombosis (Ginsburg et al., 1992). Therefore, the three 
standard (known as criteria) tests for detection of aPL are LA, aCL and anti-β2GPI antibodies. 
The persistent presence of one or more of these criteria aPL tests in the presence of vascular 
thrombosis and/or pregnancy morbidity defines APS. APS can be further characterised as either 
primary APS, which occurs in the absence of another ARD, or ARD-associated APS when 
diagnosed in the presence of other ARD, most commonly being SLE (Miyakis et al., 2006). 
Chapter One: Introduction 
	   68	  
1.5.3.1 Aetiology of antiphospholipid syndrome     
 
Early family-based studies reported higher incidences of aCL in first-degree relatives of 
APS patients (Mackworth-Young et al., 1987, Goldberg et al., 1995), suggesting a genetic 
component to APS. Several reports have associated HLA alleles with aCL and anti-β2GPI 
antibodies. HLA-DR4 and -DR7 were increased in European aCL positive patients (Hartung et 
al., 1992). HLA-DR7 was also increased in Mexican aCL positive patients (Granados et al., 
1997). Studies in European cohorts found positive associations between aCL and HLA-
DRB1*04, -DRB1*0402|3, -DRB1*07, -DRB3*0301, -DQA1*0201, -DQA1*0301 and -
DQB1*0302 (Galeazzi et al., 2000). The authors also reported positive associations between 
anti-β2GPI antibodies and HLA-DRB1*0402|3 and -DQB1*0302. An association between 
HLA-DQB1*0302 and anti-β2GPI antibodies was also observed in a Mexican population 
(Arnett et al., 1999). More recently, positive correlations between HLA-DQB1*0604|5|6|7|9, -
DQA1*0102 and -DRB1*1303 with the presence of anti-β2GPI antibodies were reported, which 
associated with an increased thrombotic risk (Caliz et al., 2001). These studies demonstrate that 
contribution of HLA is complex and varies between ethnic groups. The expression of certain 
HLA haplotypes may increase the presentation of peptides derived from β2GPI or its associated 
proteins, making patients prone to generating aPL and drive pathology. 
Chromosome mapping has highlighted four major β2GPI polymorphisms: S85N, 
L247V, C306G and W316S. The functional effects of these polymorphisms are not fully 
defined. The L247V polymorphism has been located to domain V, which is thought to be a 
potential epitope for anti-β2GP1 antibodies (Ichikawa et al., 1994). The L247V polymorphism 
was more frequently detected in an Asian APS cohort compared to control, which is associated 
with the presence of anti-β2GPI antibodies, but did not associate with increased thrombotic risk 
(Hirose et al., 1999). A similar distribution of the L247V polymorphism was observed in APS 
patients and controls in Caucasian populations (Pardos-Gea et al., 2012). This group did report 
an enrichment of the W316S polymorphism amongst patients, however this finding did not 
associate with aPL or clinical manifestations. Overall, these results do not provide strong 
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evidence that β2GPI polymorphisms contribute to APS pathology, although they may promote 
the generation of anti-β2GPI antibodies. 
PSGL-1 polymorphisms have been implicated in the predisposition to thrombosis in 
APS patients. Examination of the variable number of tandem repeats (VNTR) polymorphisms 
in PSGL-1 highlighted three alleles, encoding 14, 15 or 16 tandem repeats within the mucin-like 
regions of PSGL-1 (Afshar-Kharghan et al., 2001). Enrichment of the allele encoding 15 VNTR 
was observed in thrombotic APS patients compared to patients without thrombosis and HCs 
(Diz-Kucukkaya et al., 2007). This observation suggests that PSGL-1 polymorphisms may 
predispose patients to thrombotic events, most likely by promoting aberrant leukocyte 
interactions with ECs and platelets. 
TLR-4 polymorphisms D299G and T399I have been implicated in hypo-responsiveness 
to inhaled LPS in humans (Arbour et al., 2000, Fageras Bottcher et al., 2004). Significantly 
reduced frequencies of both polymorphisms have been found in APS patients (Pierangeli et al., 
2007). The reduced prevalence of hypo-responsive TLR-4 polymorphisms may indicate that 
APS patients are more susceptible to TLR-4 mediated signalling, which is important in aPL-
induced cellular activation (Raschi et al., 2003, Mulla et al., 2009). Other groups however, have 
been unable to replicate these results in other cohorts (Erridge et al., 2003), which make the 
significance of these results unclear. 
Limited studies examine the environmental factors that trigger clinical events in APS 
patients, however infection is generally considered to be the most influential environmental 
factor (Blank et al., 2002, Cervera et al., 2004, Shoenfeld et al., 2006). To conclude, aPL induce 
a pro-thrombogenic state through cellular activation. Combined with a genetic predisposition 
arising through polymorphisms in numerous genes, the vasculature of APS patients is primed 
such that when challenged, thrombosis is rapidly induced. 
	  
1.5.3.2 Clinical features of antiphospholipid syndrome     
 
To diagnose patients with APS, physicians often refer to APS classification criteria, 
which require patients to present with at least one clinical manifestation consistent with APS, as 
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well as two positive tests for aPL at least 12 weeks apart (Wilson et al., 1999, Miyakis et al., 
2006). This timing of aPL tests was chosen to ensure the detection of persistent aPL and avoid 
misdiagnosis through identification of aPL that are only transiently positive, such as may occur 
in certain infections. Data obtained from the Euro-Phospholipid project, comprising 1000 APS 
patients, found that peripheral thrombosis was the most common clinical feature, affecting 
63.7% of patients (Cervera et al., 2009a). The most common manifestation was deep vein 
thrombosis in the leg (38.9%), but venous thrombosis was also observed in the arms (3.4%). 
Arterial thrombosis in both arms and legs were seen in smaller numbers of patients (2.7% and 
4.3% respectively). Obstetric and foetal manifestations were also common in female patients, 
with 9.5% of the 590 pregnant patients developing pre-eclampsia. Moreover, in the 1580 
pregnancies, 52.3% miscarried and 67.7% of these miscarriages occurred within the first 10 
weeks of pregnancy (Cervera et al., 2009a).  
Neurological manifestations were also common amongst the Euro-Phospholipid cohort, 
affecting 65.8% of patients. Migraine was the most frequent symptom, which was reported in 
20.2% of patients. Thrombosis also contributed to neurological complications, with 19.8% of 
patients having suffered from a stroke and 11.1% diagnosed as having a transient ischaemic 
attack (Cervera et al., 2009a). Other clinical features include thrombocytopenia (29.6%), cardiac 
involvement (26.9%), livedo reticularis (24.1%), pulmonary embolism (14.1%), haemolytic 
anaemia (9.7%) and retinal thrombosis (2.4%) (Cervera et al., 2009a).  
Catastrophic APS (CAPS) is the most severe presentation of APS, but only occurs in 
0.8% of patients (Cervera et al., 2009a). CAPS is classified by widespread small-vessel 
thromboses affecting at least three different organs within one week, micro-thrombosis in at 
least one organ and persistent aPL positivity (Asherson et al., 2003, Cervera et al., 2005). CAPS 
is associated with multiple organ failure and a high mortality rate (Asherson et al., 2003). 
	  
1.5.3.3 Immunopathology of antiphospholipid syndrome    
 
Studies have shown that aPL targeting β2GPI can activate ECs and monocytes 
(Pierangeli et al., 2008). β2GPI is formed of 5 domains, with domain V mediating phospholipid 
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binding (Wurm, 1984, Sheng et al., 1996). Multiple groups suggest that pathogenic anti-β2GPI 
antibodies target domain I (Iverson et al., 1998, de Laat et al., 2006, Ioannou et al., 2007), 
although anti-β2GPI antibodies targeting other domains have also been described (George et al., 
1998), which may be clinically relevant (Andreoli et al., 2015).  
Multiple studies have shown that aPL activate ECs, monocytes and platelets (Pierangeli 
et al., 1999, Shoenfeld et al., 2006, de Laat et al., 2008). Anti-β2GPI antibodies have been 
shown to activate cells by cross-linking membrane bound β2GPI with TLR-4 (Raschi et al., 
2003, Mulla et al., 2009). Evidence exists implicating other receptors, including apolipoprotein 
E receptor 2 (Romay-Penabad et al., 2011, Ramesh et al., 2011, Ulrich et al., 2016) and TLR-2 
(Satta et al., 2007, Satta et al., 2011) in aPL-mediated cellular activation. 
Treatment with aPL upregulates endothelial ICAM-1, VCAM-1, E-selectin and P-
selectin, as well as inducing TF expression in ECs and monocytes (Pierangeli et al., 2001, 
Lopez-Pedrera et al., 2008). ICAM-1 deficient mice, ICAM-1/P-selectin deficient mice and 
mice injected with VCAM-1 blocking antibodies are all resistant to aPL-induced leukocyte 
adhesion and thrombosis in a pinch-injury mouse model (Pierangeli et al., 2000), suggesting 
that cell adhesion molecule upregulation is important to APS pathogenesis. Moreover, thrombus 
formation is either reduced or completely abrogated in mice lacking ICAM-1, E-selectin or P-
selectin (Pierangeli et al., 2001, Espinola et al., 2003). Endothelial activation contributes to 
thrombosis in mice (Meroni et al., 2004), which is mediated by NF-κB and p38 MAPK (Vega-
Ostertag et al., 2005, Montiel-Manzano et al., 2007). These studies demonstrate the importance 
of EC adhesion molecules, which contribute to pathology through increased interactions with 
circulating leukocytes and platelets. 
Infections, inflammation and other pro-coagulant stimuli can initiate thrombosis (de 
Groot and Derksen, 2005), leading to the ‘two-hit hypothesis’ underpinning APS. The basis of 
this hypothesis stems from the observations that aPL are necessary but not sufficient to trigger 
the coagulation cascade. According to this hypothesis, circulating aPL provide the first hit by 
activating the cells within the vasculature, inducing a pro-thrombotic state. A second hit is then 
required, such as mechanical, physical, inflammatory and/or infectious stimuli (Blank et al., 
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2002, Cervera et al., 2004, Fischetti et al., 2005, Shoenfeld et al., 2006), which promotes β2GPI 
deposition on ECs and initiates thrombus formation (Meroni and Riboldi, 2001, Agostinis et al., 
2011). 
Autoantibodies can disrupt mitochondrial function in monocytes and neutrophils, 
leading to ROS generation and TF expression (Perez-Sanchez et al., 2012). Anti-β2GPI 
antibody-induced TF expression has been shown to increase TNF-α secretion in monocytes 
(Sorice et al., 2007). Studies have shown aPL can directly activate complement and interact 
with various complement-regulatory proteins including Factor X, plasmin, prothrombin and 
protein C, all of which inhibit fibrinolysis (de Groot and Derksen, 2005, Pierangeli et al., 2008). 
In addition, aPL can activate platelets, increasing expression of thromboxane A2 and the platelet 
integrin αIIbβ3, enhancing binding to von Willebrand factor and fibrinogen (Robbins et al., 
1998). Interactions between activated cells promote thrombus formation. Furthermore, through 
the inhibition of fibrinolysis, aPL can delay the breakdown of clots and drive thrombosis.  
Complement activation has also been implicated in the mechanisms underlying APS 
immunopathology. Reports have shown that anti-β2GPI antibody-mediated complement 
activation contributes to thrombogenesis, as demonstrated by the efficacy of C5 inhibition in 
preventing blood clots in mice and rats administered intravascular infusions of purified anti-
β2GPI antibodies (Fischetti et al., 2005, Agostinis et al., 2014, Romay-Penabad et al., 2014). 
Moreover, C3-/- and C5-/- mice subjected to a pinch-injury thrombosis model were found to have 
reduced thrombus size compared to C3+/+ and C5+/+ littermate controls (Pierangeli et al., 2005). 
These findings suggest that complement activation may contribute to the pathology of aPL-
induced thrombosis. 
Whilst the precise mechanisms underlying obstetric APS are poorly understood, there is 
evidence implicating complement activation in aPL-induced pregnancy morbidity. 
Administration of aPL-IgG has been shown to localise to the placenta (Ikematsu et al., 1998), 
where it can restrict intrauterine growth and induce foetal loss in pregnant mice (Holers et al., 
2002). Studies have found that mice deficient in C3, C4 or C5 were protected from aPL-induced 
pregnancy morbidity (Salmon et al., 2002, Girardi et al., 2003). In addition, administration of 
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monoclonal antibodies targeting C3 or C5 also prevented foetal loss (Xu et al., 2000, Girardi et 
al., 2003). These observations indicate that complement activation may be required in the 
pathogenesis of aPL-induced pregnancy morbidity. Other studies have associated placental 
thrombosis and abnormalities of annexin V with aPL-mediated pregnancy morbidity in animal 
models and patients (Rand et al., 1994, Rand et al., 1997). Reports also suggest that aPL reduce 
trophoblast invasion, induce extravillous and syncytiotrophoblast activation, disrupt syncytium 
formation and promote thromboembolism within the decidual vessels that lead to pre-eclampsia 
(Abrahams, 2009, Kwak-Kim et al., 2013). 
 
1.5.3.4 Current treatment for antiphospholipid syndrome  	  
Pharmacological management of thrombotic APS centres on reducing the risk of clot 
development (Giannakopoulos and Krilis, 2009). Patients with a history of either arterial or 
venous thrombosis are normally treated with an anticoagulant, most commonly warfarin. 
Duration and intensity of anticoagulation are dependent on the site (arterial vs. venous) and 
recurrence of clot. In the event of thrombosis or sudden deterioration, heparin may be 
administered as it has a faster mode of action. Treatment regimens are complex in ARD-
associated APS, where patients are treated for both APS and the associated ARD.  
Obstetric APS is treated by a combination of aspirin and heparin, however 
recommendations vary depending on disease history (Bates et al., 2008). Due to possible 
beneficial effects during the early stages of implantation, aspirin is recommended prior to 
conception (Carmona et al., 2001). APS patients without previous thrombosis but recurrent 
early miscarriage during the pre-embryonic or embryonic stages are typically prescribed low-
dose aspirin with low molecular weight heparin (LMWH) (de Jesus et al., 2014). If patients 
have had previous foetal death after 10 weeks gestation or early delivery due to severe pre-
eclampsia, low-dose aspirin is prescribed combined with LMWH. In both cases, women are 
treated with aspirin or LMWH for up to 6 weeks postpartum.  
Given the rarity of CAPS, randomised controlled trials evaluating the efficacy of drugs 
do not exist. There is however a CAPS registry, which documents 280 reports of CAPS patients, 
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so treatment recommendations are based on these case studies (Bucciarelli et al., 2009, Cervera 
et al., 2009b). Initial treatment involves intravenous heparin and oral anticoagulants 
administration to prevent further thrombosis. Corticosteroids are given to suppress 
inflammation. Plasma exchange and intravenous Ig may also be administered. If patients 
continue to deteriorate then cyclophosphamide or rituximab may also be prescribed (Asherson 
et al., 2003). 
 
1.6 Neutrophil involvement in autoimmune rheumatic diseases 
 
Neutrophils are emerging as important regulators of both innate and adaptive immune 
responses. Abnormalities in neutrophil phenotype and function have been described in various 
ARDs and suggest that neutrophils may contribute to immunopathology. This section evaluates 
the current evidence implicating neutrophil involvement in the pathology of RA, SLE and APS. 
	  
1.6.1 Neutrophils in rheumatoid arthritis 	  
RA is a complex disorder affecting both cellular and humoral immunity. A key feature 
of RA is the erosion of cartilage and destruction of the underlying bone. Hyaluronic acid, a 
macromolecule endowing the SF with lubricant properties (Ogston and Stanier, 1953), protects 
the joint from erosion. ROS and granular enzymes secreted by neutrophils have been shown to 
depolymerise long chain hyaluronic acid in vitro (Grootveld et al., 1991, Parkes et al., 1991). 
Therefore, activated neutrophils within the synovium may reduce the lubricant properties of the 
SF and promote joint destruction. Exposure to ICs, Ig and cytokines within the SF activate 
neutrophils and contributed to cartilage destruction via the externalisation of neutrophil granule 
contents (Emery et al., 1988, Chatham et al., 1990). 
Early studies identified neutrophils in the SF of RA patients, implicating neutrophils in 
joint destruction (Dularay et al., 1988, Dularay et al., 1990, den Broeder et al., 2003). Activated 
neutrophils have been reported in the SF and synovial tissue (Barnhart et al., 1967, Hughes et 
al., 1995, Belcher et al., 2002). Neutrophils have also been shown to contribute to pathology in 
three RA mouse models: the collagen-induced arthritis (CIA) model (Griffiths et al., 1995), 
K/BxN serum transfer model (Wipke and Allen, 2001) and proteoglycan-induced arthritis 
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model (Gal et al., 2005). Interestingly, disease remission in RA patients has been linked with 
reduced neutrophil synovial migration (Dominical et al., 2011). 
Neutrophils migrate into the RA joint, attracted by IL-8 (Brennan et al., 1990), TNF-α 
(den Broeder et al., 2003) and granulocyte colony-stimulating factor (G-CSF) (Eyles et al., 
2008). Evidence suggests that neutrophils can orchestrate their own recruitment via C5a 
receptor and FcγRIIIB signaling (Sadik et al., 2012). Neutrophils can also contribute to the 
proinflammatory environment within the synovium. Following activation by GM-CSF, IL-1, 
LPS or TNF-α, neutrophils can initiate de novo cytokine synthesis and secretion, including IFN-
α (Shirafuji et al., 1990), IL-1β (Marucha et al., 1990, Lord et al., 1991, Malyak et al., 1994, 
Quayle et al., 1995), IL-6 (Cicco et al., 1990, Palma et al., 1992, Melani et al., 1993, 
Zimmermann et al., 2016), IL-8 (Strieter et al., 1992, Takahashi et al., 1993, Fujishima et al., 
1993), transforming growth factor (TGF)-β (Grotendorst et al., 1989) and TNF-α (Dubravec et 
al., 1990, Djeu et al., 1990).  
Neutrophils have also been implicated in bone resorption. Studies examining receptor 
activator of NF-κB (RANK) and RANK ligand (RANKL) expression reported higher levels in 
RA SF-derived neutrophils compared to osteoarthritis (OA) controls (Poubelle et al., 2007). 
LPS can induce neutrophil RANKL expression, which activates osteoclasts and stimulates bone 
resorption (Chakravarti et al., 2009). Moreover, neutrophils cultured in cell-free RA SF, but not 
OA SF, have been shown to induce RANKL-dependent osteoclastogenesis and bone resorption.  
Neutrophils engulf opsonised pathogens via phagocytosis, which are then destroyed by 
the granular proteases and ROS released into the phagosome. When neutrophils encounter Ig-
opsonised cartilage, they are unable to phagocytose the cartilage and underlying bone, therefore 
undergo ‘frustrated phagocytosis’. As a result of frustrated phagocytosis, neutrophils release 
their granular contents into the extracellular space, a process with parallels to NETosis (Dularay 
et al., 1988, Edwards et al., 1988, Nurcombe et al., 1991a, Nurcombe et al., 1991b, Robinson et 
al., 1992, Robinson et al., 1993), which contributes to joint destruction. 
Peripheral blood- and SF-derived RA neutrophils are both prone to spontaneous 
NETosis. Elevated NETs have been reported in RA serum and SF compared to OA and HCs, 
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with levels of NETs correlating with ACPA titres and markers of inflammation (Sur 
Chowdhury et al., 2014). Serum, purified IgG and SF of ACPA high patients enhance NETosis 
of control neutrophils (Khandpur et al., 2013), which expose citrullinated autoantigens that are 
targeted by autoantibodies (Khandpur et al., 2013, Pratesi et al., 2013). NETs can activate 
synovial fibroblasts, inducing the synthesis of proinflammatory cytokines, chemokines and 
adhesion molecules (Khandpur et al., 2013). The importance of NETs has also been 
demonstrated in mice, with PAD-4 inhibition preventing NETosis and reducing disease severity 
in the CIA mouse model (Willis et al., 2011). 
Analysis of mRNA and protein expression in models of acute and chronic arthritis, 
using the streptococcal cell wall-induced arthritis and CIA models respectively, found PAD-4 
mRNA and protein were only detected in neutrophils of arthritic mice (Vossenaar et al., 2003). 
Neutrophils have also been shown to release functionally active PAD-2 and PAD-4 during 
NETosis, which can be detected in RA SF, but not in OA or psoriatic arthritis controls 
(Spengler et al., 2015). Therefore, synovial neutrophils may contribute to RA pathology, not 
only through the generation of NETs, but also by releasing active PAD isoforms that can 
citrullinate extracellular synovial autoantigens. 
To conclude, there is increasing evidence that neutrophils contribute to RA pathology. 
Through the secretion of proinflammatory and chemotactic cytokines, ROS and NETs, 
neutrophils can facilitate cartilage erosion and bone destruction. 
 
1.6.2 Neutrophils in systemic lupus erythematosus 
 
Adaptive immunity has an established role in SLE pathology, however in more recent 
years, neutrophils are being increasingly studied. Early studies noted that SLE sera induced 
neutrophil aggregation and interfered with phagocytosis and degranulation (Abramson et al., 
1983). Defective phagocytosis, reduced responsiveness to cytokines and increased senescence 
are reported in SLE neutrophils (Brandt and Hedberg, 1969, Wu et al., 2007, Hsieh et al., 2008). 
Uptake of circulating nucleosomes activates neutrophils (Ronnefarth et al., 2006), which leads 
to the section of antibacterial proteins. Elevated bactericidal proteins have been documented in 
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SLE sera, which correlate with autoantibody titres (Bakkaloglu et al., 1998) and disease activity 
(Sthoeger et al., 2009, Vordenbaumen et al., 2010, Ma et al., 2012). 
 Increased neutrophil apoptosis has also been reported in SLE, correlating with disease 
activity and anti-dsDNA antibody titres. Anti-dsDNA and anti-La antibodies are thought to 
modulate neutrophil cell death and function respectively (Armstrong et al., 2006). In SLE, 
apoptotic neutrophils are not recognized by C1q-calreticulin and CD91 mediated clearance 
pathways (Donnelly et al., 2006). In addition, scavenger receptors display reduced binding to 
NETs (Schorn et al., 2012), which prevents their clearance. 
 Aberrant NETosis and impaired clearance contribute to SLE pathology (Hakkim et al., 
2010, Villanueva et al., 2011, Garcia-Romo et al., 2011, Lande et al., 2011). NETosis releases 
dsDNA and inflammatory cytokines, which correlates with anti-dsDNA antibodies titres 
(Villanueva et al., 2011). ICs bind NETs and prevent their degradation and promote uptake by 
pDCs, which stimulates IFN-α secretion (Lande et al., 2011), and primes neutrophils for further 
NETosis (Garcia-Romo et al., 2011). Impaired DNase I-mediated NET degradation promotes 
complement activation and exacerbates disease (Hakkim et al., 2010, Leffler et al., 2012). NETs 
have been shown to stimulate the inflammasome in macrophages, which also drives 
proinflammatory responses (Kahlenberg et al., 2013). 
 Animal models also implicate NETosis in SLE pathology. Antibodies targeting NETs 
have been identified in NZM2328 lupus prone mice, which induce NETosis in vitro (Knight et 
al., 2013). Neutrophils infiltrate the kidneys of NZM2328 mice, where NETs directly impair 
endothelial function. Administration of Cl-amidine, an irreversible pan-PAD inhibitor, 
significantly reduced NETosis, complement activation and renal IC deposition in NZM2328 
mice. This group noted that whilst serum autoantibodies increased, most likely due to reduced 
renal deposition, endothelial function improved (Knight et al., 2013). 
When examining SLE peripheral blood mononuclear cells (PBMCs), Bennett et al. 
found a significant upregulation of granulocyte-specific gene expression (Bennett et al., 2003). 
Several studies have described an abnormal neutrophil subset in SLE patients (Hacbarth and 
Kajdacsy-Balla, 1986, Bennett et al., 2003, Denny et al., 2010, Leffler et al., 2012). Lower in 
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density than ‘conventional’ neutrophils, the subset was called low-density granulocytes (LDGs). 
LDGs express the same cell surface markers as mature neutrophils, however their nuclear 
morphology is more consistent with immature neutrophils. LDGs are therefore thought to have 
an immature neutrophil phenotype, instead of being activated neutrophils. This hypothesis is 
supported by increased expression of early granulopoiesis genes (Nakou et al., 2008). LDGs 
may represent an aberrant immature neutrophil subset that persists within the vasculature and 
tissues of SLE patients (Carmona-Rivera and Kaplan, 2013). 
LDGs are highly proinflammatory and secrete greater levels of TNF-α, type I and type 
II IFNs than conventional neutrophils (Denny et al., 2010, Carmona-Rivera and Kaplan, 2013). 
LDGs more readily undergo spontaneous NETosis (Denny et al., 2010) and express greater 
levels of various bactericidal proteins (Villanueva et al., 2011). Furthermore, LDGs have an 
increased capacity to kill ECs on contact and produce NETs on stimulation (Denny et al., 2010, 
Villanueva et al., 2011). NETosis in both SLE neutrophils and LDGs can be induced by SLE-
IgG (Carmona-Rivera et al., 2015). The combination of increased cytokine production, elevated 
NETosis and induction of EC death is central to the pathogenic contribution of LDGs.  
To conclude, there is a growing understanding of how neutrophils contribute to the 
pathogenesis of SLE. Through the aberrant activation of neutrophils, NETs are produced and 
cause endothelial damage. LDGs also contribute to the level of NETosis, whilst inducing EC 
death and dysfunction. Defective clearance of NETs facilitates immune activation, deposition of 
ICs and endothelial damage, all of which enhance pathology. 
 
1.6.3 Neutrophils in antiphospholipid syndrome 	  
Relatively less work has explored neutrophils in APS pathology. A C5a receptor-TF 
crosstalk has been described in neutrophils, whereby the in vitro aPL-mediated complement 
activation led to neutrophil C5a receptor engagement. This interaction subsequently induced TF 
expression and enhanced procoagulant activity (Ritis et al., 2006). 
This observation was replicated in vivo, with C5a generated by aPL inducing neutrophil 
TF expression in an aPL-induced pregnancy loss mouse model (Redecha et al., 2007). 
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Inflammation and pregnancy loss was reduced in TF knockout mice and wild-type mice 
administered TF blockade. Further immunohistochemical analysis found that TF expressed in 
neutrophils, but not trophoblasts, associated with foetal injury. Generation of myeloid-specific 
TF knockout mice found a significant reduction in ROS production following aPL treatment. 
Redecha et al. therefore proposed that aPL activated trophoblasts and initiated the complement 
cascade. C5a then bound neutrophils, which induced TF expression and oxidative burst, causing 
trophoblast injury, inflammation and foetal death (Redecha et al., 2007). 
 Redecha and colleagues subsequently explored the mechanisms by which TF 
contributed to neutrophil activation and trophoblast injury. Greater expression of protease-
activated receptor (PAR)-2 was observed in neutrophils of aPL-treated mice (Redecha et al., 
2008). ROS generation, phagocytosis and foetal loss were reduced in aPL-treated PAR-2 
knockout mice. Wild-type and Par2-/- neutrophils had similar respiratory burst and phagocytic 
responses following PMA stimulation in vitro (Redecha et al., 2008), suggesting that PAR-2 
signalling may modulate aPL-induced neutrophil activation. The authors also found that aPL-
induced activation was dependent on TF/Factor VIIa interactions (Redecha et al., 2008). These 
results could not be replicated by PAR-1 blockade, suggesting that TF/Factor VIIa/PAR-2 
signalling mediate neutrophil activation and foetal death in the aPL-induced pregnancy loss 
mouse model. 
A caveat of this model is the amount of purified IgG administered to mice. 10mg of 
human whole IgG was injected intraperitoneally at days 8 and 12 of pregnancy. For 
experimental procedures, 6-8 week old female C57BL/6 mice were used, weighing 15-20g. 
Given that C57BL/6 mice have approximately 58.5ml/kg of blood, 10mg of human IgG was 
injected into 0.87-1.17ml of blood at each administration. Whilst 10mg/ml roughly represents 
normal serum IgG levels in humans (Gonzalez-Quintela et al., 2008), serum IgG levels are 10-
fold lower in mice at 1.22mg/ml (Klein-Schneegans et al., 1989). As mice were administered at 
least 20mg of IgG over a 5-day period, it is possible that neutrophils are responding to the vast 
amount of human IgG. Experiments using physiologically representative IgG levels for mice 
would be interesting, but may give rise to more subtle differences that are harder to interpret. 
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Recent work has explored the effects of APS sera and IgG upon NETosis (Yalavarthi et 
al., 2015). APS-IgG induced significantly higher levels of NETs compared to HC-IgG, which 
was abrogated following depletion of β2GPI-specific IgG (Yalavarthi et al., 2015). In addition, 
ex vivo APS neutrophils were predisposed to produce NETs spontaneously. This group also 
found elevated NETs in the sera and plasma of primary APS patients compared to healthy 
volunteers. NETs have been shown to induce thrombosis in the absence of aPL both in vitro 
(Fuchs et al., 2010), and also promote deep vein thrombosis in mice (Brill et al., 2012), which 
may contribute to APS pathology. Therefore, APS-IgG, in particular anti-β2GPI antibodies, may 
prime neutrophils such that they more readily activate and release NETs to promote thrombosis.  
In summary, there is increasing interest in the contribution of neutrophils in APS 
pathology. Due to their ability to produce large quantities of ROS and NETs, both of which are 
known to cause cellular damage and are associated with increased thrombosis, neutrophils may 
promote APS pathogenesis. Table 1.3 summarises key publications that support the role of 
neutrophils in RA, SLE and APS. 
	  
1.7 Integrins in autoimmune rheumatic disease 	  
Defects in integrin regulation have been implicated in the immunopathology of several 
ARDs, with aberrant cellular interactions being reported in RA, SLE and APS. This section will 
explore the literature to evaluate the evidence for integrin involvement in RA, SLE and APS. 
	  
1.7.1 Integrins in rheumatoid arthritis 
 
The β1 integrins can regulate T cell cytokine production. ECM components have been 
shown to modulate IL-2 production in 2B4 T cells following stimulation with suboptimal doses 
of an anti-CD3 antibody (Takahashi et al., 1991). Cells stimulated in fibrinogen-, laminin- or 
collagen-coated or uncoated wells produced low levels of IL-2. In contrast, cells stimulated in 
fibronectin- or vitronectin-coated wells produced significantly higher IL-2 levels, which was 
reduced by β1 integrin blockade (Takahashi et al., 1991), implicating a β1 integrin-dependent 
mechanism of IL-2 production in 2B4 T cells. 
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Early studies found that SF T cell proliferation and IFN-γ production could be 
modulated through interactions with both native and denatured collagen (Ofosu-Appiah et al., 
1989a, Ofosu-Appiah et al., 1989b). Early work also reported elevated VLA-1 (CD49a/CD29, 
α1β1) expression in RA SF lymphocytes compared to peripheral blood lymphocytes (Hemler et 
al., 1986). The authors suggested that following recruitment to the synovium, T cells upregulate 
VLA-1 expression, which may contribute to disease. A limitation to this study is the lack of 
healthy or disease controls, meaning that whether this upregulation is RA-specific or a result of 
transmigration is unclear. Similar observations were made with VLA-4 expression on CD3+ T 
cells. Whilst there were no significant differences between RA and control peripheral blood T 
cells, matched peripheral blood and SF RA T cells highlighted that SF-derived T cells expressed 
significantly higher levels of VLA-4 (Laffon et al., 1991). 
Additional work observed upregulation of IL-1α, IL-1β, IFN-γ and TNF-α mRNA when 
RA PBMCs were cultured on fibronectin, laminin or collagen, but not bovine serum albumin 
(BSA), which was mitigated by β1 but not β2 integrin blockade (Miyake et al., 1993). The use of 
only 3 patients is a limitation to this study, however the data supports previous work by Ofosu-
Appiah and colleagues showing modulation of cytokine production by the presence of β1 
integrin ligands. Characterisation of larger RA and control cohorts are required, however these 
observations suggest that synovial T cells upregulate β1 integrins, which contributes to RA 
pathology through increased proinflammatory cytokine production. 
VLA-2 has also been implicated in both the antigen-induced arthritis (AIA) and human 
TNF-α transgenic mouse models (Peters et al., 2012). Itga2-/- mice do not express the α2 integrin 
subunit, therefore lack VLA-2 (α2β1), but still express the other β1 integrins. In both models, 
Itga2-/- mice had significantly reduced pannus formation, cartilage erosion and joint 
inflammation. VLA-2 deficient mice also had reduced MMP-3 expression and suppressed FLS 
proliferation and attachment to cartilage (Peters et al., 2012). This group therefore concluded 
that VLA-2 contributed to RA pathology by inducing MMP-3 expression and promoting FLS 
proliferation and attachment to ECM. Early work in keratinocytes found that VLA-2 ligation 
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upregulated MMP-1 expression (Pilcher et al., 1997), which may suggest that in RA, VLA-2 is 
able to upregulate expression of several MMPs. 
Integrin expression between RA FLS and control FLS has also been compared. 
Significantly higher expression of the α1-6, β1 and β4 integrin subunits was reported in RA FLS 
compared to controls (Rinaldi et al., 1997a), suggesting an upregulation of VLA-1 to -6 and 
α6β4. RA FLS also displayed increased adhesion to collagen, fibronectin, laminin and tenascin, 
all of which were inhibited by integrin-specific blockade. Further work found differential αVβ3 
regulation in FLS derived from OA patients and RA patients (Rinaldi et al., 1997b). Whilst 
similar basal αVβ3 expression was observed in RA and OA FLS, stimulation with IL-1β or TNF-
α increased expression in OA FLS but decreased expression in RA FLS, however the basis of 
this differential regulation remains unclear. 
RA synovial cells have been shown to express significantly higher levels of VLA-2, 
VLA-5 and αVβ3 compared to OA controls (Nakayamada et al., 2003). Moreover, crosslinking 
of β1 integrins induced ICAM-1 and Fas expression in RA synoviocytes but not in OA cells. 
Given the wealth of evidence, obtained from independent groups using various methodologies, 
the β1 integrins appear to contribute to the pathology of RA, by promoting cell adhesion, MMP 
production and proinflammatory cytokine secretion. 
 Early work found that β2 integrin blockade reduced acute arthritis and promoted the 
amelioration of chronic inflammation in an AIA rabbit model (Jasin et al., 1992). Early signs of 
inflammation were reduced in rabbits treated with an anti-β2 integrin antibody compared to 
saline control. The authors also noted a striking decease in infiltrating PMNs, suggesting that β2 
integrin blockade reduced the number of infiltrating neutrophils in the acute inflammatory phase 
of arthritis (Jasin et al., 1992).  
Immunohistochemical analysis of human RA synovial tissue sections found prominent 
ICAM-1 expression in the cells lining the synovium, believed to macrophages and fibroblasts 
(Lindsley et al., 1993). Given that ICAM-1 is a ligand for LFA-1 and the beneficial effects of β2 
integrin blockade, the rabbit AIA model was proposed to be LFA-1-dependent. This hypothesis 
was supported by studies using LFA-1 blockade and LFA-1 knockout mice, which highlighted 
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the importance of LFA-1 in the migration and recruitment of T cells, monocytes and neutrophils 
to sites of inflammation (Berlin-Rufenach et al., 1999, Ding et al., 1999, Mine et al., 2002). 
Moreover, LFA-1 blockade was also shown to reduce disease severity in the CIA and K/BxN 
serum transfer mouse models of arthritis (Kakimoto et al., 1992, Watts et al., 2005). 
Interestingly, β2 integrin deficient mice have been found to be resistant to the development of 
arthritis (Watts et al., 2005). 
These observations led to the development of a LFA-1 small molecule antagonist, 
BMS-587101, which was efficacious in in vitro and in vivo preclinical disease models (Suchard 
et al., 2010). BMS-587101 treatment in vitro inhibited human T cell proliferation, cytokine 
production and adhesion to ECs. In vivo administration of BMS-587101, in both AIA and CIA 
mouse models, significantly reduced disease severity either comparable to, or better than, 
treatment with an anti-LFA-1 antibody. AIA mice treated with BMS-587101 had lower levels of 
cytokine mRNA within the joints, whilst BMS-587101 treatment in the CIA model conferred a 
marked protection against inflammation and bone destruction (Suchard et al., 2010). LFA-1 
blockade in humans was trialled, using the monoclonal antibody efalizumab, but was withdrawn 
after some patients developed central nervous system infections including progressive 
multifocal leukoencephalopathy, caused by reactivation of latent JC virus (Major, 2010). 
Several reasons could account for the differences observed between mice and humans. 
A key difference is that experimental animals are immunologically naïve, whilst patients have 
been exposed to numerous pathogens. Therefore, it would have been impossible for mice to 
present with reactivation of JC virus, as reported in clinical studies. It is also worth 
consideration that LFA-1 also binds ICAM-3, an important interaction during antigen 
presentation (de Fougerolles and Springer, 1992). Efalizumab would therefore prevent LFA-1 
interactions with not only ICAM-1, but also ICAM-3, which may suppress the early stages of 
antigen presentation. Reports have found that efalizumab also inhibits VLA-4 (Guttman-Yassky 
et al., 2008). This integrin crosstalk may contribute to the T cell hypo-responsiveness observed 
in clinical trials (Major, 2010). Mac-1 has also been implicated in animal models. Interestingly, 
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administration of the small molecule Mac-1 agonist leukadherin-1 (LA-1) reduced inflammation 
and leukocyte extravasation in animal models, despite Mac-1 activation (Maiguel et al., 2011). 
In conclusion, increased β1 integrin expression in T cells and FLS enhances 
proinflammatory cytokines production within the RA joint. LFA-1 has also been implicated, 
however blockade was not beneficial in patients. Due to the importance of LFA-1 in immune 
homeostasis and the documented integrin crosstalk, LFA-1 may not be a suitable target in RA. 
Further investigation of other integrins and signalling pathways may highlight novel therapeutic 
targets. 
 
1.7.2 Integrins in systemic lupus erythematosus 
 
One of the strongest susceptibility risk loci for SLE is ITGAM, the gene encoding the 
αM subunit of Mac-1 (Nath et al., 2008, Hom et al., 2008, Harley et al., 2008, Yang et al., 2009, 
Han et al., 2009, Kim-Howard et al., 2010, Warchol et al., 2011). Multiple ITGAM gene 
variants have been identified, encoding point mutations in various domains of the αM subunit, 
the most studied being the rs1143679 variant. Examination of the rs1143679, rs1143638 and 
rs1143678 Mac-1 variants, encoding the amino acid changes R77H, A858V and P1146S 
respectively, found that Mac-1 function was altered (Zhou et al., 2013). Whilst there was no 
difference in surface expression between mutated and wild-type Mac-1, R77H neutrophils had 
reduced phagocytosis of IgG-opsonised sheep erythrocytes and adhesion to ICAM-1, P-selectin 
and TNF-α stimulated ECs (Zhou et al., 2013). These results support earlier work that found 
that the R77H mutation compromised phagocytosis of iC3b-opsonised sheep erythrocytes and 
adhesion to iC3b and ICAM-1 (MacPherson et al., 2011). 
Similar observations were made in monocytes and macrophages derived from SLE 
patients with the R77H mutation (Rhodes et al., 2012). In agreement with previous work, there 
was no difference in Mac-1 expression between wild-type and R77H cells. R77H variant 
monocytes and macrophages displayed reduced adhesion to immobilised fibrinogen, human 
serum albumin, ICAM-1, iC3b and an anti-Mac-1 antibody, as well as displaying defective 
phagocytosis of IgM-opsonised sheep erythrocytes (Rhodes et al., 2012). The R77H Mac-1 
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mutation has also been studied in SLE DCs, monocytes, macrophages and neutrophils. In this 
study, the group only found phagocytosis of iC3b-opsonised guinea pig erythrocytes to be 
defective in R77H cells, whilst Mac-1 expression, adhesion and transmigration were all 
unaffected (Fossati-Jimack et al., 2013).  
All groups agree that the R77H Mac-1 variant does not affect Mac-1 expression but 
leads to defective phagocytosis. There is disagreement over the effects on adhesion and 
transmigration. As integrin engagement of opsonised pathogens precedes phagocytosis, it is 
reasonable to suggest that adhesion and transmigration may also be defective in R77H cells.  
To better understand these observations, Rosetti and colleagues conducted various 
assays to interrogate Mac-1 function, including evaluating the kinetics of ligand binding, 
adhesion assays and neutrophil spreading and crawling experiments (Rosetti et al., 2015). The 
authors reported that the R77H Mac-1 variant had impaired affinity for ligands. This 
impairment was not due to a reduced ability to engage with ligands, but due to reduced bond 
stability. The group found that the wild-type variant allows the ‘force-induced’ allosteric bond 
stabilisation required for integrin binding, which was lost in the R77H Mac-1 variant. 
Taken together, substantial evidence indicates that point mutations in the αM chain 
contribute to the susceptibility of developing SLE. Several studies demonstrate an association 
between the rs1143679 Mac-1 variant and SLE in several populations (Nath et al., 2008, Hom 
et al., 2008, Harley et al., 2008, Yang et al., 2009, Han et al., 2009, Kim-Howard et al., 2010, 
Warchol et al., 2011). Recent work found that the R77H Mac-1 variant affects ligand affinity by 
reducing bond stability, thus conferring defective Mac-1 function to leukocytes.  
The αEβ7 integrin has also been implicated in SLE pathology. Expression of αEβ7 is 
largely restricted to mucosal CD8+ T cells (Cerf-Bensussan et al., 1987). Less than 2% of 
peripheral T cells express αEβ7 (Cerf-Bensussan et al., 1987), however expression can be 
induced following stimulation with antigens, cytokines, mitogens or phorbol esters 
(Schieferdecker et al., 1990, Parker et al., 1992). This observation suggests that the αEβ7 integrin 
may act as an activation marker. Examination of αEβ7 expression in healthy volunteers, SLE 
patients, Sjögren’s syndrome patients and polymyositis/dermatomyositis patients found similar 
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basal expression. Following phytohaemagglutinin (PHA) stimulation, αEβ7 expression was 
significantly higher in SLE lymphocytes compared to healthy and disease controls (Pang et al., 
1998). Within the SLE cohort, αEβ7 expression associated with oral ulcers and serositis, 
implicating αEβ7 in epithelial inflammation. 
Stimulation of β1 integrins induces ICAM-1 expression and Fas-mediated apoptosis in 
RA synovial cells (Nakayamada et al., 2003), as well as promoting T cell proliferation and IL-2 
production (Ennis et al., 1993, Kamiguchi et al., 1999). Given these observations, Nakayamada 
et al. explored β1 integrins in SLE. Peripheral CD3+ T cells from SLE patients had significantly 
higher levels of the common β1 integrin chain (CD29) compared to RA patients and healthy 
volunteers (Nakayamada et al., 2007). CD29 stimulation induced proliferation and CD40L 
expression in SLE T cells but not controls, which required crosslinking of CD29 and CD3. 
These results suggest that β1 integrin stimulation is sufficient to induce SLE T cell activation 
and proliferation, which may promote autoreactive T cell expansion. 
To conclude, both meta-analyses and experimental evidence associate defective Mac-1 
activity with SLE. There is also evidence for increased β1 integrin and αEβ7 expression and 
activity on T cells from patients with SLE, albeit in smaller studies that would require further 
work to validate findings. 
 
1.7.3 Integrins in antiphospholipid syndrome 
 
Increased arterial thrombotic risk in a cohort of Spanish APS patients was found to be 
associated with heterozygous polymorphisms in both platelet VLA-2 (glycoprotein Ia/IIa) and 
αIIbβ3 (glycoprotein IIb/IIIa) (Jimenez et al., 2008). The functional implications of these 
polymorphisms were not explored, however alterations in platelet integrin activity may 
contribution to thrombotic risk.  
Integrin expression was also examined in the cardiac endothelium of heart valves 
obtained from APS patients or controls (Afek et al., 1999). Immunohistochemical staining 
found VLA-3 expression in diseased APS valves, but not in the unaffected APS or control 
valves. Greater expression of collagen, fibronectin and laminin was observed in the endothelial 
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basement membrane of diseased APS valves. These observations suggest that altered integrin 
and ECM expression may contribute to cardiac disease in APS. 
Adhesion molecules are important in regulating trophoblast migration and invasion. 
Fibronectin, a constituent of the endometrial stroma, increases in concentration with 
decidualization during pregnancy (Aplin et al., 1988, Aplin et al., 1999). Attachment to 
fibronectin has been shown to induce differentiation of trophoblasts in vitro (Kao et al., 1988), 
with some evidence suggesting that adhesion to fibronectin inhibits trophoblast invasion 
(Damsky et al., 1994, Bischof et al., 1995). VLA-5 is an important trophoblast integrin, which is 
thought to be the main integrin mediating in vitro adhesion to fibronectin (Burrows et al., 1995) 
and regulating in vivo trophoblast invasion (Damsky et al., 1994, Bischof et al., 1995, Zeng et 
al., 2007). In normal placental development, trophoblasts orchestrate integrin expression to 
ensure successful invasion, by first upregulating VLA-5 (Coutifaris et al., 2005) but then 
switching to VLA-1 (Damsky et al., 1994, Zhao et al., 2012). 
APS-IgG has been shown to significantly reduce both gonadotropin secretion and 
trophoblast invasion compared to HC-IgG (Di Simone et al., 2000). Further investigation found 
that APS-IgG significantly increased mRNA and protein of the α5 subunit, whilst decreasing the 
α1 subunit compared to HC-IgG (Di Simone et al., 2002). These results suggest that APS-IgG 
upregulates VLA-5 and supresses VLA-1, such that trophoblast invasion is impaired. Integrin 
dysregulation may contribute to the pathogenesis underpinning pregnancy loss in APS patients, 
which is supported a study demonstrating that APS-IgG reduces trophoblast invasion compared 
to HC-IgG (Poulton et al., 2015).  
ICAM-1 expression is required for aPL-induced pregnancy loss in mice (Mo and 
Salmon, 2001). In this report, the authors examined foetal loss in a mouse model of pregnancy 
morbidity, in both wild-type and ICAM-1 knockout mice. Foetal loss was only observed in 
wild-type mice, suggesting that pregnancy morbidity is ICAM-1-dependent. Additional work is 
required to explore these observations, but given the restricted binding of ICAM-1, these results 
implicate β2 integrins in APS pathology. 
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In conclusion, there is evidence to suggest that dysregulated integrin expression, in 
particular the β1 integrins, contribute to APS pathology. Polymorphisms in VLA-2 have been 
reported in platelets, dysregulated expression of endothelial VLA-3 was observed in APS 
patients with cardiac valvulopathy, and there is differential regulation of VLA-1 and VLA-5 in 
trophoblasts exposed to APS-IgG. These observations suggest that β1 integrins may contribute 
to APS pathophysiology.  
 
1.8 Hypoxia and neutrophil biology 	  
Neutrophils circulate within the vasculature before migrating into infected and inflamed 
tissue, so are exposed to a wide range of oxygen levels. Atmospheric air contains 20.3% oxygen 
(154 mmHg), which is similar to the oxygen concentrations within the pulmonary vasculature, 
normally at 19.7% oxygen (150 mmHg) (Volkholz et al., 1984, Caldwell et al., 2001). Within 
the circulation, normal oxygen levels can range between 5.0-13.2% (38-100 mmHg) (Vaupel et 
al., 1973, Caldwell et al., 2001). Normal oxygen levels within tissues are even lower, ranging 
from 0.5-2.7% oxygen (4-20 mmHg) (Braun et al., 2001). Given that normal oxygen levels 
within circulation and tissues can be described as hypoxic, the effects of hypoxia are important 
and relevant to neutrophil function under physiological conditions and in disease states. 
  
1.8.1 Hypoxia and hypoxia-inducible factors 
 
 Hypoxia can be defined as a state where the oxygen supply to a tissue does not meet its 
demand. Hypoxia modulates gene expression in both unicellular and multicellular organisms 
(Bunn and Poyton, 1996). Studies of the haematopoietic growth factor, erythropoietin, 
highlighted the existence of a hypoxia-regulated transcription factor that upregulated 
erythropoietin expression (Semenza and Wang, 1992). Further analysis found that the oxygen-
sensing system regulating erythropoietin was widespread in mammalian cells and mediated 
other adaptive responses to hypoxia (Maxwell et al., 1993). This hypoxia-regulated transcription 
factor was demonstrated to be HIF-1 (Wang et al., 1995), founding the HIF family of 
transcription factors. To date, 3 HIF family members have been described, composed of one of 
the three α subunits (HIF-1α, HIF-2α or HIF-3α) and the common HIF-1β subunit, sometimes 
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referred to as aryl hydrocarbon receptor nuclear translocator protein (ARNT). HIF transcription 
factors bind conserved 5'-[A/G]CGTG-3' DNA sequences, referred to as hypoxia responsive 
elements (HREs) within the genome to modulate gene expression (Mole et al., 2009). 
HIF-1α was first described in 1995 as a transcription factor expressed in Hep3B human 
hepatoma cells when cultured at 1% oxygen, but not 20% oxygen, or by treatment with hypoxia 
mimetics (Wang et al., 1995). These observations implicated HIF-1α in the regulation of gene 
expression under hypoxia. Characterisation of HIF-1α structure highlighted four key regions: 
period circadian protein (PER), ARNT, and single-minded protein (SIM), which form a PER-
ARNT-SIM (PAS) domain, and a basic helix-loop-helix (bHLH) domain (Wang et al., 1995) 
(Figure 1.11). The bHLH-PAS motif is functionally important as it enables α subunit 
dimerisation with HIF-1β, which allows for transcriptional regulation (Kallio et al., 1997). 
Endothelial PAS domain protein-1 (EPAS-1) was described shortly after the discovery 
of HIF-1 (Tian et al., 1997). EPAS-1 was expressed by cells cultured under hypoxia or treated 
with the hypoxia mimetics cobalt chloride or desferrioxamine (Tian et al., 1997, Wiesener et al., 
1998). Due to high expression in ECs, EPAS-1 was hypothesised to regulate vascularisation by 
modulating endothelial gene expression under hypoxia. EPAS-1 exhibited high degrees of 
homology to HIF-1α, containing the same bHLH and PAS domains (Figure 1.11). Moreover, 
HIF-1α and EPAS-1 also displayed similar patterns of mRNA and protein expression in 
response to hypoxia and both facilitate transactivation of erythropoietin and vascular endothelial 
growth factor (VEGF) (Tian et al., 1997, Wiesener et al., 1998). EPAS-1 was independently 
identified by three other groups, reported as HIF-like factor (Ema et al., 1997), member of PAS 
superfamily 2 (Hogenesch et al., 1997) and HIF-related factor (Flamme et al., 1997). EPAS-1 
was therefore considered to belong to the HIF transcription factor family and was subsequently 
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HIF-2α was initially believed to modulate EC function in response to hypoxia, due to a 
perceived restricted expression to blood vessels (Tian et al., 1997, Wiesener et al., 1998), 
however HIF-2α was subsequently found to be expressed by multiple cell types (Wiesener et al., 
2003). There is a general consensus that HIF-1α mediates responses to acute hypoxia (under 24 
hours) and HIF-2α regulates expression under chronic hypoxic exposure (beyond 24 hours).  
The final member of the HIF superfamily, HIF-3α, was characterised in 1998 (Gu et al., 
1998). The precise function of HIF-3α is unclear and remains controversial. HIF-3α expresses 
both bHLH and PAS domains and can dimerise with HIF-1β (Gu et al., 1998). Whilst HIF-1α 
and HIF-2α both contain N-terminal and C-terminal transactivation domains (N-TAD and C-
TAD respectively), HIF-3α only possesses a N-TAD. HIF-3α has also contains evolutionary 
conserved motifs and domains not found in either HIF-1α or HIF-2α (Zhang et al., 2012). Due 
to alternative mRNA splicing, ten different human HIF-3α isoforms have been identified to 
date: HIF-3α1-10 (Maynard et al., 2003, Pasanen et al., 2010).  
Murine HIF-3α, inhibitory PAS domain protein (IPAS), enhances HRE-driven 
transcription in COS-7 cells co-transfected with both IPAS and HIF-1β (Gu et al., 1998). 
Studies in transfected COS-7 cells found that when HIF-3α and HIF-1β were co-transfected, 
HRE-driven transcription was enhanced (Hara et al., 2001). Interestingly when HIF-3α was co-
transfected with HIF-1α or HIF-2α, transactivation was suppressed (Hara et al., 2001). Similar 
observations were made in the hepatoma cell line, Hepa 1c1c7, whereby HIF-1α and HIF-2α 
driven transcription was suppressed when co-transfected with IPAS (Makino et al., 2001). IPAS 
also suppresses hypoxia-induced VEGF expression in primary mouse corneal epithelial cells 
(Makino et al., 2001). Mice implanted with IPAS-expressing hepatoma cells had significantly 
reduced tumour growth compared to control, suggesting IPAS could suppress hypoxia-driven 
tumour growth (Makino et al., 2001). An additional murine HIF-3α variant, neonatal and 
embryonic PAS protein (NEPAS) has been implicated in embryonic growth. Abnormal heart 
development and impaired lung remodelling was observed in NEPAS knockout mice, as well as 
increased expression of endothelin-1 and platelet-derived growth factor (PDGF)-β in pulmonary 
endothelium (Yamashita et al., 2008).  
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 Similar observations have been reported in human cells, with human HIF-3α4 shown to 
be a dominant negative regulator of HIF-1 signalling (Maynard et al., 2005). HIF-3α4 prevents 
HIF-1 binding to HREs, thus preventing HRE-driven transcription. Interestingly, hypoxia 
suppresses HIF-3α4 expression in both HepG2 hepatoma and HEK293A cells, suggesting that 
HIF-3α4 itself may be under hypoxic regulation (Maynard et al., 2005). Other groups also 
provide evidence that HIF-3α splice variants are regulated by HIF-1α (Pasanen et al., 2010). 
HIF-3α4 has also been shown to impair angiogenesis and proliferation in human hypervascular 
meningioma cell lines (Ando et al., 2013). Recent reports found that HIF-3α9 activates gene 
expression distinct from HIF-1α in zebrafish embryos, which was replicated in vitro using 
human U2 osteosarcoma and HEK293T cells transfected with HIF-3α9 (Zhang et al., 2014).  
HIF activity is regulated by the post-translational modification of the α subunit. Under 
normoxia the α subunit is targeted for degradation, whilst in hypoxia there is rapid cytosolic 
stabilisation of the α subunit (Kaelin and Ratcliffe, 2008, Majmundar et al., 2010). This 
regulation is achieved by the combined activity of prolyl-hydroxylases (PHDs) and factor 
inhibiting HIF-1α (FIH1). Under normoxia, PHDs hydroxylate conserved proline residues, 
Pro402 and Pro564, within the α subunit N-TAD (Ivan et al., 2001, Jaakkola et al., 2001, 
Masson et al., 2001, Yu et al., 2001). PHD-mediated hydroxylation is achieved via the coupling 
with the oxidative carboxylation of the tricarboxylic acid (TCA) cycle intermediate, 2-
oxoglutarate, into succinate and carbon dioxide in the presence of oxygen. The modified subunit 
is then recognised by the E3 ubiquitin ligase, von-Hippel-Lindau tumour suppressor, which is 
ubiquitinated and targeted for proteasomal degradation (Figure 1.12).  
In hypoxic environments, low levels of oxygen result in the accumulation of TCA cycle 
intermediates, other than 2-oxoglutarate, which inhibit the catalytic activity of PHDs (Selak et 
al., 2005). Studies suggest that when subjected to 1.5% oxygen (11.4 mmHg) or lower, 
mitochondria produce ROS that further suppress PHD activity (Klimova and Chandel, 2008). 
PHD inactivation prevents the ubiquitination and degradation of the HIF α subunit, enabling its 
stabilisation within the cytosol. The HIF α subunits are then trafficked to the nucleus and 
dimerise with HIF-1β. HIF transcription factors can then bind HREs and recruit transcriptional  
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co-activators, including p300-CREB-binding protein (CBP) to modulate gene expression.  
FIH1 is also dependent on 2-oxoglutarate and hydroxylates Asn803 on HIF-1α or 
Asn851 on HIF-2α, located within their C-TADs (Lando et al., 2002, McNeill et al., 2002) 
(Figure 1.12). Asparagine hydroxylation introduces a steric clash that prevents p300-CBP 
recruitment and suppresses transactivation (Hewitson et al., 2002). Reports found FIH1 remains 
active at higher oxygen levels than PHD, so may prevent HIF activity during milder levels of 
hypoxia (Dayan et al., 2006). HIF-1α is readily suppressed by FIH1, however HIF-2α displays a 
degree of resistance to FIH1-mediated inactivation (Bracken et al., 2006). 
It is important to consider the physiological oxygen gradient from the lungs to tissues. 
Jiang et al. examined HIF-1α and HIF-1β in nuclear extracts, as well as HIF-1 DNA-binding 
activity in HeLa S3 cells exposed to 0-20% oxygen (0-152 mmHg) (Jiang et al., 1996). 
Significant increases in HIF-1α protein and DNA-binding activity, thus HRE-driven 
transcription, in nuclear extracts were only observed when oxygen levels reached 5% (38 
mmHg) or lower. As oxygen levels can fall to 5% within the circulation and even lower in 
tissues, HIF signalling is an important factor in many cellular interactions. Furthermore, as 
hypoxia is a feature of several inflammatory diseases, the effects of hypoxia upon cell functions 
may contribute to pathophysiology. 
 
1.8.2 Neutrophil function and hypoxia 	  
A fine balance exists in the regulation of neutrophil survival. If neutrophil survival is 
prolonged, resolution of inflammation is delayed and there can be damage to surrounding cells 
and tissues, whilst if neutrophils undergo apoptosis too soon, they cannot mediate their 
antimicrobial functions (Savill, 1997, Rossi et al., 2006). As neutrophils migrate into tissues 
with hypoxic environments, it is important to consider the effects of hypoxia on neutrophil 
function. Hypoxia inhibits neutrophil apoptosis and promotes survival via HIF-1α-dependent 
NF-κB activation (Walmsley et al., 2005, Cross et al., 2006). As hypoxia drives neutrophil 
survival, the modulatory role of hypoxia upon other neutrophil functions is physiologically 
relevant and important in understanding disease pathology.  
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 The precise effect of hypoxia upon neutrophil function is not fully understood. 
Comparisons between published reports is made difficult by the fact these studies have 
employed different oxygen levels, experimental conditions and methods of neutrophil isolation. 
In neutrophil isolation, choice of anticoagulant affects both neutrophil yields and ex vivo 
function. For example, the highest yields of neutrophil isolation are achieved with EDTA-
treated blood, however responses to PMA are reduced in neutrophils isolated from EDTA-
treated blood compared to citrate- and heparin-treated blood (Haslett et al., 1985, Freitas et al., 
2008). Therefore, variations in the anticoagulant used between studies may influence functional 
readouts.  
Overall, reports suggest neutrophil function is generally enhanced under hypoxia. A 
study subjecting healthy volunteers to systemic hypoxaemia, defined by an arterial oxygen 
saturation of 68%, found that neutrophils from hypoxaemic volunteers had enhanced NE release 
on fMLP stimulation compared to normoxic volunteers (Tamura et al., 2002). In a similar study, 
healthy volunteers were exposed to oxygen concentrations ranging from 12-20% oxygen (91.2-
152 mmHg) for 2 hours and neutrophil function examined. Neutrophils isolated from the 
volunteers subjected to 12% oxygen had significantly enhanced chemotaxis, respiratory burst 
and phagocytosis compared to volunteers exposed to 20% oxygen (Wang and Liu, 2009).  
Evidence suggests that phagocytosis is elevated in hypoxia. Neutrophils isolated from 
hypoxaemic blood (5.0% oxygen, 38 mmHg) has significantly higher levels of phagocytosis 
compared to normoxic controls (Simms and D'Amico, 1994). Moreover, isolated neutrophils 
cultured under hypoxia (2.9% oxygen, 22 mmHg) display enhanced phagocytosis compared to 
normoxic controls (18.8% oxygen, 142.5 mmHg) (Walmsley et al., 2006).  
 Early reports found neutrophil migration was inhibited under hypoxia (3.9% oxygen, 30 
mmHg) compared to normoxia (20.0% oxygen, 152 mmHg) (Rotstein et al., 1988). More 
recently, Wang and Lui provided evidence that chemotaxis was enhanced by hypoxia (12.0% 
oxygen, 91.2 mmHg) (Wang and Liu, 2009). McGovern et al. however, found hypoxia (3.0% 
oxygen, 22.5 mmHg) had no effect on neutrophil transmigration (McGovern et al., 2011). These 
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discrepancies are likely to be due to a combination of differing isolation techniques, 
experimental oxygen levels and chemoattractants used.  
 Other studies have shown that hypoxia causes defective respiratory burst in neutrophils. 
McGovern et al. found that superoxide generation by both fMLP- and PMA-stimulated 
neutrophils was reduced under hypoxia (3% oxygen, 22.5 mmHg) compared to normoxia (20% 
oxygen, 152 mmHg), whilst NADPH oxidase expression, a key enzyme for respiratory burst, 
was not affected (McGovern et al., 2011). This observation may indicate that whilst expression 
of NADPH may not be oxygen sensitive, its activity may be regulated by hypoxia.  
 Conflicting evidence may arise due to the broad use of the term ‘hypoxia’ to describe 
oxygen levels below 20% oxygen. There are differences between cells cultured in 1% oxygen 
and those cultured in 12% oxygen, emphasised by work demonstrating that HRE-mediated 
binding is only detected at 5% oxygen and lower (Jiang et al., 1996). Variations in 
anticoagulation and isolation techniques also contribute to differences. Careful consideration 
should be taken when drawing conclusions of the effects of hypoxia upon neutrophil function. 
	  
1.8.3 Hypoxia and neutrophil extracellular trap formation 
 
 Relatively little work has examined the effects of hypoxia upon NETosis. McInturff et 
al. implicate HIF-1α as a regulator of NETosis (McInturff et al., 2012). This group found that 
both LPS and platelet-activating factor (PAF) activated mTOR, which induced HIF-1α 
stabilisation under normoxia and mediated NETosis. Inhibition of either HIF-1α, with 2-
methoxyestradiol, or mTORC1, with either rapamycin or the mTORC1 selective inhibitor torin-
1, reduced NETosis. These findings suggest that HIF-1α regulates NET production. 
Increased bactericidal capacity was also reported in phagocytes treated with the HIF-1α 
agonist mimosine (Zinkernagel et al., 2008). This group measured killing of Staphylococcus 
aureus by all phagocytes, isolated neutrophils and the human monocytic U937 cell line in the 
presence of varying concentrations of mimosine. Greater mimosine concentrations induced 
higher levels of HIF-1α and fewer surviving S. aureus, suggesting HIF-1 signalling may 
influence bacterial killing. Whilst the authors were unable to demonstrate differences in the 
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levels of NETs between untreated and mimosine-treated neutrophils, increased bactericidal 
activity was mitigated by DNase I treatment, implicating a NET-dependent mechanism.  
	  
1.9 Hypoxia in autoimmune rheumatic disease 
 
Hypoxia is a potent cell stimulus that induces transcriptional change and modulates 
protein expression. Hypoxia has been implicated to varying degrees in RA, SLE and APS 
pathogenesis. This section will evaluate the evidence relating to hypoxia in each disease. 
 
1.9.1 Hypoxia and rheumatoid arthritis 
  
Various methodologies have independently demonstrated that the RA synovial joint is 
hypoxic. Early investigations using microelectrodes found lower oxygen tensions in RA SF (3.5 
±2.5% oxygen, 26.5 ±19.3 mmHg) compared to control (8.3 ±2.5% oxygen, 63.0 ±19.2 mmHg) 
(Lund-Olesen, 1970). Additional groups have independently published results demonstrating 
the hypoxic nature of the RA synovial joint, finding increased carbon dioxide tensions 
(Richman et al., 1981, James et al., 1990), raised lactate (Goetzl et al., 1971, James et al., 1990), 
reduced glucose values (Richman et al., 1981) and acidosis (Geborek et al., 1989, James et al., 
1990) in RA joints compared to control. 
More recently, Sivakumar et al. replicated these findings by directly measuring the 
partial pressure of oxygen using microelectrodes in the joints of RA patients and non-RA 
controls undergoing hand surgery (Sivakumar et al., 2008). Intra-operative matched in vivo 
synovial measurements were made for both affected and unaffected joints. RA joints were 
significantly more hypoxic than controls, with an average reading of 26 mmHg (3.4% oxygen) 
and 74 mmHg (9.7% oxygen) respectively (Sivakumar et al., 2008). This group also suggested 
that disease activity affects oxygen tension. The mean oxygen tension for unaffected RA joint 
synovia was 46 mmHg (6.1% oxygen), however the oxygen tension of joints with evidence of 
synovitis was significantly lower, with a mean of 40 mmHg (5.3% oxygen) (Sivakumar et al., 
2008). Interestingly RA joints with severe synovitis, as determined by direct visualisation at 
surgery, were even more hypoxic, with a mean oxygen tension of 26 mmHg (3.4% oxygen) 
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(Sivakumar et al., 2008). Synovial hypoxia has been shown to promote VEGF expression, 
angiogenesis and cell migration (Sivakumar et al., 2008, Akhavani et al., 2009). 
Under the hypoxic environment of the synovial joint, mitochondria generate ROS 
(Klimova and Chandel, 2008). Early studies found that ROS activated osteoclasts and 
stimulated bone resorption both in vitro and in vivo (Garrett et al., 1990). Hydroxyl radicals are 
able to target and degrade hyaluronic acid (Grootveld et al., 1991), which decreases synovial 
lubrication and contributes to synovitis. Therefore, ROS generated under hypoxia drive 
hyaluronic acid degradation, which is supported by early reports demonstrating lower 
hyaluronic acid content in RA SF (1.15 ±0.37mg/ml) compared to controls (3.21 ±0.38mg/ml) 
(Decker et al., 1959). Hydroxyl radicals also modify amino acids, so may facilitate generation 
of autoantibodies targeting modified proteins (Bodamyali et al., 1998, Chandel et al., 2000).  
T cell function is affected by oxidative stress. Early work found that antioxidant 
depletion suppresses T cell proliferation, IL-2 secretion and IL-2 receptor expression (Chaudhri 
et al., 1988). Hypoxia also upregulates IL-1 and TNF-α, whilst suppressing IL-2 expression 
(Ghezzi et al., 1991), suggesting that hypoxia may modulate T cell function.  
Hypoxia and cellular stress have been shown to increase expression and activity of 
PAD-2 in astrocytes (Sambandam et al., 2004, Algeciras et al., 2008). A significant increase in 
PAD-2 mRNA was seen within 2 hours of hypoxic exposure (2% oxygen, 15.2 mmHg), 
translating to elevated PAD-2 protein by 8 hours of hypoxia (Sambandam et al., 2004). 
Increased glial fibrillary acidic protein citrullination was also reported, demonstrating increased 
PAD-2 activity (Sambandam et al., 2004). Given the importance of PAD-2 and PAD-4 in 
generating citrullinated proteins, pattern of expression and hypoxic regulation of PAD-2 in 
astrocytes, the hypoxic RA joint may favour the generation of citrullinated autoantigens through 
the activation of PAD-4.  
Hypoxia has also been found to increase the production of various inflammatory 
cytokines, MMPs and VEGF by synovial fibroblasts, which promoted recruitment of 
monocytes, B cells and T cells to the RA synovium (Hu et al., 2014). Interestingly, HIF-1α 
stabilisation was found to enhance synovial fibroblast-mediated expansion of Th1 and Th17 
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cells that lead to elevated levels of both IFN-γ and IL-17 (Hu et al., 2014), which contribute to 
the proinflammatory environment of the RA synovium. 
Taken together, hypoxia may contribute to RA pathology in a number of ways. Low 
oxygen levels promote the recruitment of inflammatory cells, skew T cell polarisation to favour 
TNF-α secretion, promote ROS generation that can induce post-translational modifications, 
which may facilitate the generation autoantigens. 
 
1.9.2 Hypoxia and systemic lupus erythematosus 
 
The role of hypoxia in SLE pathophysiology is not as well studied as in RA. HIF-1α 
signalling has been implicated in mesangial cell proliferation in patients with lupus nephritis. 
Using a renal pathology activity index defined to help refine prognosis for SLE patients with 
diffuse proliferative or membranoproliferative glomerulonephritis (Austin et al., 1984), greater 
levels of HIF-1α were found to associate with increased mesangial cell proliferation, more 
severe degrees of renal pathology and clinical manifestations (Deng et al., 2014). The enhanced 
mesangial cell proliferation observed in patient samples could be replicated in murine mesangial 
cells by treatment by the PHD inhibitor dimethyloxaloylglycine (DMOG) (Deng et al., 2014), 
implicating HIF-1α signalling in the pathology of lupus nephritis. 
 
1.9.3 Hypoxia and antiphospholipid syndrome 
 
APS is characterised by the persistent presence of aPL that induce a pro-thrombogenic 
state. These aPL exist within the circulation at 5.0-13.2% oxygen (38-100 mmHg) (Vaupel et 
al., 1973, Caldwell et al., 2001), without inducing any clinical thrombotic events, but require a 
second hit to elicit an effect. Therefore hypoxia in venous stasis or tissue surrounding an 
unstable plaque may enhance aPL-mediated effects.  
Hypoxia and HIF-mediated signalling regulate placental morphogenesis, angiogenesis 
and cell fate decisions (Adelman et al., 2000). Placental development is initiated when the 
blastocyst makes contact with the epithelial lining of the uterus following implantation. 
Placental villi subsequently develop, which consist of a mesenchymal core surrounded by a 
mononuclear villous cytotrophoblast stem cell monolayer. These stem cells either fuse to form 
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the overlying multinucleated syncytiotrophoblast or differentiate into extravillous trophoblasts, 
which grow out from the villous and spread laterally around the placenta (Irving et al., 1995). 
As extravillous trophoblasts migrate away from the placenta, they differentiate into an invasive 
phenotype in a process that is essential for successful placental development and pregnancy.  
Extravillous trophoblast invasion into the walls of the uterine spiral arteries is essential 
in adapting these vessels to become capable of delivering the increased blood supply required 
during the second and third trimesters of pregnancy (Brosens et al., 1967, Zhou et al., 1997). As 
these extravillous trophoblasts invade the spiral arteries in early pregnancy, they occlude the 
arteries and prevent maternal blood from entering the intervillious space, thereby creating an 
environment of physiological hypoxia (Jaffe et al., 1997, Burton et al., 1999). Direct 
measurements of oxygen tension also demonstrate the hypoxic nature of the early placenta. 
From 8-10 weeks of gestation, the partial pressure of oxygen within the placenta (17.9 mmHg, 
2.4% oxygen) was significantly lower than that of the endometrium (39.6 mmHg, 5.2% oxygen) 
(Rodesch et al., 1992).  
Studies examining murine placental cell fates found that HIF-1α and HIF-2α regulate 
trophoblast differentiation (Cowden Dahl et al., 2005). In this study, placentas from mice 
deficient of HIF-1α and HIF-2α or HIF-1β exhibited defective placental vascularisation and 
aberrant cell fate adaption. This group also showed that in the absence of either HIF-1α or HIF-
1β, trophoblast stem cell differentiation is also disrupted. Therefore, as trophoblast invasion and 
differentiation within the first trimester of pregnancy occur under physiological hypoxia, HIF 
signalling may contribute to obstetric complications associated with APS in early pregnancy. 
Clinical observations also implicate hypoxia in the pathogenesis of certain obstetric 
manifestations of APS (Branch, 1994, Galli and Barbui, 2003).  
Hypoxia is a feature in animal models of APS, in particular in vivo ischemia/reperfusion 
(I/R) experiments to model myocardial infarction or stroke. In a mouse model of mesenteric 
I/R-induced injury, CR2 deficiency conferred resistance to tissue damage, as reported in Cr2-/- 
mice (Fleming et al., 2004). In this experiment infusion of purified mouse or human aPL-IgG 
before I/R injury was administered, reconstituted I/R-induced intestinal and lung tissue damage 
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in Cr2-/- mice compared with control IgG, which lacked this effect. Similar observations were 
made in a rat model of I/R stroke injury, in which aPL-IgG exacerbated stroke severity post I/R 
injury and caused larger infarct compared to control IgG (Pericleous et al., 2014). These results 
demonstrate that circulating aPL may enhance cellular and tissue damage following the hypoxic 
insult caused by I/R injury. 
 
1.10 Introduction summary 	  
There is a growing awareness of the importance of neutrophils in ARD pathology, 
including RA, SLE and APS. Neutrophil integrin activation initiates numerous signalling 
cascades and mediates cell functions including transmigration, cytokine production, ROS 
generation and NETosis. Hypoxia is known to modulate several aspects of neutrophil biology 
and may also contribute to the pathology of RA, SLE and APS. The effects however, of hypoxia 
on neutrophil integrin activation and NETosis in these ARDs are not fully understood. In 
particular, although purified IgG from RA, SLE and APS patients have been shown to modulate 
aspects of neutrophil activation, their effects upon integrin activation, ROS generation and 
NETosis in hypoxia remains poorly characterised. 
 
1.11 Hypothesis and aims of this thesis 	  
My hypothesis is that hypoxia and purified IgG, from patients with ARDs, promote 
neutrophil integrin activation, ROS generation and NETosis. I have tested this hypothesis, with 
the following aims to examine: 
 
• The effects of hypoxia on integrin activation and neutrophil adhesion 
• The effects of hypoxia on ROS generation and NETosis 
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2.1 Materials 	  
2.1.1 General materials, equipment and buffers 	  
The general equipment and materials used for experimental procedures throughout this 
thesis are listed in appendix I. In addition, the formations of all experimental buffers are 
detailed in appendix II. 
 
2.1.2 Antibodies for ELISAs  	  
Optimised enzyme-linked immunosorbent assay (ELISA) antibodies dilutions can be 
found in Table 2.1. Capture antibodies were diluted in phosphate-buffered saline (PBS) and 
coated overnight at 4oC.  
 	  
2.1.3 Antibodies for flow cytometry 	  
Fluorochrome-conjugated antibodies were used at optimal dilutions in sodium HEPES 
buffer. Antibodies used for all flow cytometry experiments can be found in Table 2.2. 
Appropriate isotype controls were used from the same company for each antibody to determine 
background fluorescence. 
Table 2.1: Optimised antibody concentrations used for ELISA experiments. Detailed 
above are the immunogenic targets, host species and optimised working concentrations of all 
antibodies used for ELISA experiments throughout this thesis. 
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2.1.4 Antibodies for functional blocking 	  
Details of the integrin-specific functional blocking antibodies used in this thesis can be 
found in Table 2.3. Antibodies were titrated and used at optimal concentrations. 
	  
	  	  	  	  
Table 2.2: Fluorochrome-conjugated antibodies used for flow cytometry. Detailed above 
are the immunogenic targets, antibody isotypes, clones and conjugated fluorochromes of all 
antibodies used for flow cytometry throughout this thesis. 
Table 2.3: Functional blocking antibodies. Detailed above are the immunogenic targets, 
antibody isotypes and clones of all functional blocking antibodies used throughout this thesis. 
Chapter Two: Materials and Methods 
	   106	  
2.1.5 Antibodies for immunoblot  	  
All antibodies were diluted in 5% w/v skim milk/tris-buffered saline (TBS)/0.1% 
Tween-20 for immunoblot, using the dilutions stated in Table 2.4. Horseradish peroxidase 
(HRP)-conjugated secondary antibodies were also diluted in 5% w/v skim milk/TBS/0.1% 
Tween-20 using matched dilutions to respective primary antibodies. 
 
2.1.6 Primary human cells 	  
Human umbilical cord endothelial cells (HUVEC) from pooled donors were purchased 
from Lonza (Lonza Group Ltd., Switzerland). Cells were purchased at passage 2 (P-2) and 
Table 2.4: Optimised immunoblot antibody concentrations. Detailed above are the 
immunogenic targets, host species and optimised concentrations or dilutions of all antibodies 
used for immunoblot throughout this thesis. 
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cultured in endothelial basal media (EBM)-2 supplemented with 10% foetal calf serum (FCS) 
(Gibco, UK), 2mM L-glutamine (Gibco, UK) and growth factors provided in the endothelial 
growth media (EGM)-2 SingleQuot kit (Lonza Group Ltd., Switzerland). Cells were cultured in 
plastic 80cm2 nunclon-treated flasks (VWR International, UK) at a cell density of 2500-5000 
cells/cm2 and allowed to grow to confluency at 37oC in a humidified atmosphere of 5% CO2 in 
air. Once 70-80% confluent, the media was aspirated and the cells were washed twice with PBS 
(Thermo Scientific, UK). Warmed 0.05% trypsin/EDTA (Life Technologies, UK) was added to 
flasks and incubated for 3 minutes at 37oC, before addition of 10ml EGM-2 growth media to 
inactivate trypsin. A cell pellet was obtained by centrifugation at 170g for 5 minutes, which was 
resuspended in 10ml EGM-2 growth media. HUVEC were then seeded into either 80cm2 tissue 
culture flasks for further subculture or multi-dishes for experimentation. All HUVEC were used 
by P-5 for all experimental procedures. 
Human neutrophils were isolated from citrated venous blood obtained by informed 
consent from patients or healthy volunteers (UCL project ID: 13/LO/0900). Isolated neutrophils 
were resuspended in phenol-free Roswell Park Memorial Institute (RPMI) 1640 supplemented 
with 10% FCS (heat inactivated to 80oC) and 2mM L-glutamine and cultured at 37oC in a 
humidified atmosphere of 5% CO2 in air. All neutrophils were used within 24 hours of isolation. 
Human T cells were isolated from citrated venous blood obtained by informed consent 
from patients or healthy volunteers. T cells were resuspended in RPMI 1640 supplemented with 
10% FCS, 2mM L-glutamine and 20ng/ml IL-2 (Gibco, UK), which were cultured at 37oC in a 
humidified atmosphere of 5% CO2 in air. 
For all experiments exploring the effects of hypoxia, normoxia was defined as 21% 
oxygen (equivalent to 159.6 mmHg) and hypoxia as 1% oxygen (equivalent to 7.6 mmHg).  
 
2.1.7 Recombinant proteins 	  
Fibrinogen (1mg/ml; Sigma, UK), IL-2 (20µg/ml, Gibco, UK) LPS (1mg/ml; Sigma, 
UK) and TNF-α (10µg/ml; R&D Systems, UK) were purchased as lyophilised powders and 
reconstituted as suggested by the manufacturer to the concentrations stated. Proteins were 
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aliquoted and stored at -20oC until required. ICAM-1-Fc (3mg/ml) was given as a generous gift 
from Nancy Hogg (The Francis Crick Institute, London). Fibronectin (1mg/ml; Sigma, UK) was 
purchased as a 0.1% solution and stored at 4oC until required. 
 
2.1.8 Inhibitors, stimuli and other reagents 
 
2’, 7’-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-
AM) (1mM; Life Technologies, UK), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (5mg/ml; Sigma, UK) and PMA (2mM; Sigma, UK) were purchased as 
lyophilised powders and reconstituted to the concentrations stated. BCECF-AM and PMA were 
reconstituted using DMSO, whilst MTT was dissolved in distilled water and filter-sterilised. All 
compounds were aliquoted and stored at -20oC until required. Dextran (Sigma, UK) was 
purchased and dissolved as a 6% dextran solution in 0.9% sterile saline, which was filter-




2.2.1 Isolation of human peripheral blood cells 	  
Peripheral blood neutrophils and T cells were isolated from venous blood via density 
centrifugation. 50ml conical centrifuge tubes were layered with 10ml of 6% dextran/0.9% saline 
solution (at room temperature), to which 20ml PBS and 20ml citrated whole blood were then 
layered on top and the RBCs allowed to sediment for 45 minutes. The cell-rich plasma layer 
was transferred to a fresh centrifuge tube and PBS added to a total volume of 50ml. Following 
centrifugation at 300g for 5 minutes, supernatants were discarded and cells isolated by Percoll 
density separation, which separates neutrophils from PBMCs based upon their cellular density. 
To achieve the required Percoll gradient, 27ml of Percoll PLUS (Sigma, UK) was mixed with 
3ml of 10xPBS to obtain a 100% Percoll PLUS stock solution. This stock solution was used to 
prepare 55%, 67% and 81% Percoll PLUS in PBS solutions.  
A 4ml aliquot of the 67% Percoll PLUS solution was then carefully layered on top of 
4ml 81% Percoll PLUS solution in a 15ml conical centrifuge tube. The previous cell pellet was 
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resuspended in 4ml of the 55% Percoll PLUS solution. This cell suspension was then carefully 
layered on top of the Percoll gradient and allowed to separate by centrifugation at 700g for 30 




After separation, the PBMC layer between the 55% Percoll PLUS/67% Percoll PLUS 
interface was transferred to a fresh 50ml centrifuge tube and processed as described in 2.2.1.2. 
The neutrophil-enriched layer between the 67% Percoll/81% Percoll PLUS interface was 
transferred to a fresh 50ml centrifuge tube. The isolated cells were then washed with PBS.  If 
there was a visible RBC contamination, the pellet was resuspended in water for 30 seconds to 
allow for isotonic RBC lysis. Neutrophils were subjected to centrifugation at 300g for 5 minutes 
and resuspended for experimental procedures. All cells were used within 24 hours of isolation.  
	  
2.2.1.2 T cells 
 
Once transferred into a fresh 50ml centrifuge tube, PBMCs were washed twice with 
RPMI. PBMCs were resuspended in RPMI/10% FCS at 2.5x105 cells/ml. T cells were expanded 
by addition of PHA (Gibco, UK) to 1% v/v in RMPI/10% FCS for 72 hours. T cells were then 
washed and resuspended in RPMI/10% FCS supplemented with 20ng/ml IL-2 at 2.5x105 
cells/ml. Cells were allowed to grow until 1x106 cells/ml, at which point they were considered 
confluent and expanded. T cells were maintained for 1-2 weeks and used between days 10-14. 
	  
2.2.2 Determination of cell viability – MTT assay 
 
Cell viability was assessed via the colorimetric reaction of MTT, which is cleaved by 
mitochondrial succinate dehydrogenase to give a water-insoluble blue precipitate. The colour 
produced is dependent on cell number and metabolic activity, so only accounts for viable cells.  
For HUVEC, 1.5x105 cells were seeded into 96-well tissue culture plates. Stock MTT 
reagent was diluted to 1mg/ml in culture media and filter-sterilised. Following incubation, 
media was removed and 50µl of the 1mg/ml MTT working solution was added to wells. 
Following incubation for 1 hour at 37oC, MTT was removed and 100µl isopropanol was added  
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Figure 2.1: Percoll density separation of whole blood. Citrated whole blood was layered 
upon PBS and 6% dextran/0.9% saline, with red blood cells allowed to sediment for 45 
minutes. Cells were obtained by centrifugation of the cell-rich plasma and resuspended in 55% 
Percoll. This cell suspension was layered upon a Percoll gradient and subjected to 
centrifugation to allow for density separation. Cells were isolated and processed further. 
Abbreviations: PBMC, peripheral blood mononuclear cell; RBC, red blood cells. 
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to wells. The plate was incubated for 10 minutes at room temperature with gentle shaking to 
solubilise the blue precipitate. Absorbance was measured at 560nm using a Tecan GENios 
Spectra FLUOR plate reader (Tecan UK Ltd., UK).  
 For neutrophils, 3.5x105 cells were added to round-bottomed 96-well tissue culture 
plates. Following incubation, cells were subjected to centrifugation at 350g for 5 minutes. 
Media was removed and 50µl of the 1mg/ml MTT working solution added and incubated for a 
further hour at 37oC. After incubation, neutrophils were subjected to centrifugation at 350g for 5 
minutes, MTT was removed and 100µl isopropanol added to each well. Precipitates were 
allowed to solubilise for 10 minutes with gentle shaking and absorbance was read at 560nm. 
 
2.2.3 Neutrophil static adhesion assay 	  
Neutrophil adhesion to immobilised ligands and endothelial monolayers was assessed. 
To evaluate adhesion to immobilised integrin ligands, 96-well black MaxiSorp microplates 
(Thermo Scientific, UK) were coated overnight with either 4.5µg/ml ICAM-1-Fc, 200ng/ml 
fibrinogen or 20µg/ml fibronectin diluted in PBS. After coating, plates were washed three times 
with TBS/0.1% Tween-20 and blocked with 2% fish skin gelatin/TBS/0.1% Tween-20 for 1 
hour at 37oC. For adhesion to endothelial monolayers, HUVEC were grown to confluence in 96-
well black polystyrene TC-treated microplates (Corning, UK) that had been coated with 
attachment factor (Gibco, UK). To evaluate the effects of endothelial hypoxia on adhesion, 
HUVEC monolayers were incubated overnight in either normoxia or hypoxia. 
Neutrophils were isolated from whole blood, washed with a sodium HEPES buffer and 
resuspended at 1x106 neutrophils/ml. Cells were fluorescently labelled with 2.5µM BCECF-AM 
(Life Technologies, UK) for 30 minutes at 37oC in the dark, then washed with Hank’s balanced 
salt solution (HBSS) and resuspended to a cell density of 1x107 cells/ml. 
Assay plates were washed twice with HBSS and 50µl HBSS containing 100ng/ml LPS, 
10ng/ml TNF-α or 20nM PMA in the absence or presence of 200µg/ml purified IgG or 10µg/ml 
blocking antibodies was added to relevant wells. 50µl of the BCECF-AM labelled neutrophils 
were added, giving a final concentration of 5x105 neutrophils/well. Plates were centrifuged at 
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170g for 2 minutes and incubated at 37oC for 30 minutes. Following incubation, fluorescence 
was measured using a Tecan GENios Spectra FLUOR plate reader (Tecan UK Ltd., UK) with 
an emission wavelength of 535nm and an excitation wavelength of 490nm to determine total 
cell fluorescence. Plates were washed three times with HBSS and the fluorescence read again. 
The percentage of adherent neutrophils was calculated by comparing the fluorescence of 
washed wells to the initial total fluorescence. 
	  
2.2.4 Neutrophil trans-endothelial migration assay 	  
Neutrophil trans-endothelial migration was also measured. HUVEC were grown to 
confluence on 12mm trans-well inserts with 5µm pores (Millipore, UK). Once confluent, EC 
monolayers were cultured overnight under normoxia or hypoxia in the absence or presence of 
10ng/ml TNF-α. Neutrophils were isolated and resuspended to 1x106 cells/ml in serum-free 
medium-199 (M-199) and stained with 0.5µM CellTracker (Invitrogen, UK) for 20 minutes on 
ice. An unstained aliquot of neutrophils was kept aside. Following incubation, neutrophils were 
resuspended in M-199 supplemented with 1% FCS to a cell density of 5.5x106 neutrophils/ml.  
Wells were washed and 900µl of untreated M-199 or 150ng/ml IL-8 diluted in M-199 
was added to the lower chamber and 200µl of the neutrophil suspension added to the upper 
chamber and incubated for 90 minutes at 37oC. After incubation, the media from each of the 
lower chambers was collected and subjected to centrifugation at 300g for 5 minutes, which was 
then resuspended in 400µl 1% paraformaldehyde (PFA)/PBS. To this cell suspension, 50µl of 
CountBright™ absolute counting beads (Invitrogen, UK) was added and samples assessed on a 
FACSVerse (BD Biosciences, UK). Unlabelled cells were used to define experimental settings 
and cell gating strategies, based on the forward and side scatter properties of neutrophils. The 
CountBright™ absolute counting beads enabled the calculation of cell numbers in samples. 
Data was analysed using FlowJo (TreeStar Inc., UK).  
	  
2.2.5 Neutrophil integrin expression analysis 	  
Flow cytometry was used to quantify the expression of neutrophil β1 and β2 integrins. 
Neutrophils were isolated and incubated under normoxia or hypoxia. Cells were resuspended in 
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sodium HEPES buffer and 2x105 neutrophils incubated with fluorochrome-conjugated integrin-
specific or isotype control antibodies for 30 minutes at room temperature in the dark. A cell 
pellet was obtained by centrifugation at 350g for 5 minutes and washed twice in sodium HEPES 
buffer. After the final wash, cells were fixed with 200µl 1% PFA/PBS. Unstained cells were 
used to define gating strategies to analyse neutrophils. Stained cells were analysed, with 20,000 
gated events being assessed using a FACSVerse (BD Biosciences, UK). Data was analysed 
using FlowJo (TreeStar Inc., UK). 
 
2.2.6 Neutrophil nitrite generation analysis 
 
To measure nitrite generation the Griess test was performed on neutrophil supernatants. 
This assay depends on the production of diazonium salts by organic nitrites, facilitated by the 
sulphanilamide in the Griess reagent. The subsequent diazonium salt then interacts with the azo-
dye N-(1-napthyl)ethylenediamine, also in the Griess reagent,  to form a pink aqueous solution 
that can be measured by absorbance of light. 
Isolated neutrophils were stimulated for set time points, after which cell supernatants 
were obtained by centrifugation at 300g for 5 minutes. 100µl of either a nitrite standard (Sigma, 
UK) or cell supernatant was added in triplicate to a 96-well flat-bottomed plate. Following 
addition of 100µl Griess reagent (1% sulphanilamide, 0.1% N-(1-napthyl)ethylenediamine, 
2.1% phosphoric acid, made in ddH2O), plates were incubated for 10 minutes at room 
temperature and absorbance read at 560nm using a Tecan GENios Spectra FLUOR plate reader 
(Tecan UK Ltd., UK). Nitrite concentrations were calculated using the standard curve generated 
by the nitrite standards. 
	  
2.2.7 Neutrophil hydrogen peroxide generation analysis 	  
The effects of hypoxia and purified IgG upon hydrogen peroxide generation were 
evaluated using the Amplex UltraRed® assay. The assay reagent (10-acetyle-3,7-
dihydroxyphenoxazine) is a colourless HRP substrate, which in the presence of hydrogen 
peroxide, is rapidly converted into the fluorescent Amplex UltraRed® compound in a 1:1 
stoichiometry, thus allowing for the measurement of hydrogen peroxide production.  
Chapter Two: Materials and Methods 
	   114	  
Neutrophils were isolated and resuspended to 2x106 cells/ml. Neutrophil FcγRs were 
blocked by incubation with FcR block (Miltenyi Biotec, UK) for 20 minutes to exclude a non-
specific FcγR-mediated effects. Cells were preconditioned with either purified IgG or inhibitors 
for one hour at 37oC. Next, HRP (0.5U/ml) (Sigma, UK) was added to cell suspensions and then 
60nM Amplex® UltraRed (Invitrogen, UK). 200µl per well of the cell suspension was added in 
triplicate to a 96-well black microplate (Thermo Scientific, UK) and placed into a FLUOstar 
Omega microplate reader (BMG Labetech, Germany). Fluorescence was measured using an 
excitation wavelength of 544nm and emission wavelength of 590nm, with a gain of 1004. Basal 
levels of hydrogen peroxide generation were assessed between the 1st and 3rd cycles. 50nM 
PMA was added on the 4th cycle and fluorescence followed over time. Rates were determined 
using the Omega Mars Analysis software (BMG Labtech, Germany).  
	  
2.2.8 Immunofluorescence visualisation of neutrophil extracellular traps 	  
NETs were qualitatively evaluated by immunofluorescence microscopy. Assessment of 
co-localisation between DNA and proteins associated with NET structure was possible by 4’-6-
diamidino-2-phenylindole (DAPI) and indirect staining of histone H3.  
13mm glass coverslips (Fischer, UK) were sterilised with ethanol and air-dried in a 24-
well tissue culture plate. Once dry, coverslips were coated with 200µg/ml fibrinogen (Sigma, 
UK) in PBS overnight (400µl/well) at 4oC. Coverslips were washed for 5 minutes first with PBS 
and then RPMI. 5x105 neutrophils were added to coverslips and allowed to settle for 30 
minutes. Cells were then stimulated for 4 hours. Following incubation, coverslips were washed 
with ice-cold HBSS (Life Technologies, UK) and fixed for 15 minutes with 4% PFA/PBS at 
room temperature.  
Coverslips were blocked in 10% goat serum/1% BSA/2mM EDTA/HBSS/0.1% Tween-
2 (blocking buffer) overnight at 4oC with gentle agitation on an orbital shaker. Coverslips were 
washed once with HBSS and incubated with an anti-histone H3 antibody (Abcam, UK) diluted 
in blocking buffer for one hour at room temperature on an orbital shaker. Coverslips were 
washed twice with HBSS and incubated with an AlexaFluor® 488-conjugated secondary 
Chapter Two: Materials and Methods 
	   115	  
antibody (Life Technologies, UK) diluted 1:1000 in blocking buffer for a further hour at room 
temperature on an orbital shaker. After incubation, coverslips were washed twice for 5 minutes 
with HBSS and once with ddH2O before being mounted and sealed on microscope slides with a 
DAPI mounting medium. Slides were subsequently visualised using a Zeiss Axio Imager.A1 
inverted fluorescence microscope (Zeiss, Germany) and images analysed using Image J. 
	  
2.2.9 Neutrophil extracellular trap quantification – extracellular DNA quantification 	  
Measurement of cell-free dsDNA was conducted to provide a quantitative readout of 
NETosis. The Quanti-iT™ PicoGreen® dsDNA kit is widely used for this purpose and works 
by the PicoGreen® reagent integrating into extracellular dsDNA, but not single stranded DNA 
and extracellular RNA, allowing for specific and sensitive measurement of cell-free dsDNA. 
For assessment of NETosis, neutrophil supernatants were obtained by centrifugation at 350g for 
5 minutes following stimulation. Supernatants were stained using the Quanti-iT™ PicoGreen® 
dsDNA kit (Invitrogen, UK), and measured using a fluorescence plate reader. 
500µl of cell supernatants were added to microcentrifuge tubes and 500µl of Quanti-
iT™ PicoGreen® dsDNA reagent added (diluted 1:200 in 1xDNase-free TE buffer), mixed and 
incubated at room temperature for 3 minutes. To quantify NETs, a standard curve was generated 
using known concentrations of λ dsDNA ranging from 1µg/ml to 1ng/ml. Following incubation, 
300µl of dsDNA standard or sample was added in triplicate to the wells of a 96-well 
polystyrene TC-treated microplate. Fluorescence was read with an excitation wavelength of 
490nm and an emission wavelength of 535nm. Cell-free dsDNA concentrations were calculated 
using the dsDNA standard curve. 
	  
2.2.10 Neutrophil extracellular trap quantification – capture ELISA 	  
A capture ELISA was developed to quantify NETs, rather than extracellular dsDNA, by 
targeting two components of NET structure. Streptavidin-coated plates (Fisher Scientific, UK) 
were coated with 1µg/ml of a biotin-conjugated anti-MPO capture antibody (Abcam, UK) 
overnight at 4oC. Plates were washed three times with PBS/0.1% Tween-20 and blocked with 
0.5% BSA/PBS/0.1% Tween-20 for 1 hour at 37oC. Plates were then washed and incubated with 
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100µl of neutrophil supernatants for 2 hours at 37oC. Following incubation, wells were washed 
and 100µl of an anti-citrullinated histone H3 detection antibody (Abcam, UK), diluted to 
1µg/ml in 0.5% BSA/PBS/0.1% Tween-20, added and incubated for 1 hour at 37oC. Plates were 
washed and incubated with an HRP-conjugated secondary antibody (Dako, UK) for 1 hour at 
37oC. 100µl/well of room temperature SureBlue TMB Microwell Peroxidase Substrate (KPL, 
UK) was added and incubated in the dark at 37oC for 20 minutes. The reaction was then stopped 
by the addition of 100µl/well of TMB stop solution (KPL, UK). Absorbance was read at 450nm 
using a Tecan GENios Spectra FLUOR plate reader (Tecan UK Ltd., UK).  
 
2.2.11 Endothelial adhesion molecule expression analysis 	  
Endothelial adhesion molecules expression was evaluated, as they represent 
physiological integrin ligands. Levels of E-selectin, ICAM-1, ICAM-2 and VCAM-1 expression 
were assessed on HUVEC by flow cytometry. 5x105 HUVEC were seeded in 6-well tissue 
culture plates and allowed to grow to confluence. Cells were treated with 100ng/ml LPS, 
10ng/ml TNF-α or media alone under normoxia or hypoxia. After incubation, media was 
aspirated and cells washed twice with PBS. 0.5ml warmed cell dissociation buffer was added 
and incubated for 5 minutes at 37oC. HUVEC were transferred to polystyrene round-bottomed 
tubes (BD Falcon, UK) and subjected to centrifugation at 350g for 5 minutes. Cells were 
washed twice with sodium HEPES buffer and incubated with fluorophore-conjugated antibodies 
targeting endothelial adhesion molecules for 30 minutes at room temperature in the dark. 
Following incubation, cells were centrifuged at 350g for 5 minutes, washed twice with sodium 
HEPES buffer and fixed with 200µl 1% PFA/PBS. HUVEC were selected based on their 
forward and side scatter properties, with a gate being placed around cells of the correct size and 
granular properties. Stained HUVEC were analysed, with 20,000 gated events being assessed 
using a FACSVerse (BD Biosciences, UK). Data was analysed using FlowJo (TreeStar Inc.) 
 
2.2.12 Whole IgG purification  	  
Whole IgG fractions were purified from human sera using protein G agarose spin 
columns (Thermo Scientific, USA). Protein G selectively binds the Fc portion of IgG, thus 
Chapter Two: Materials and Methods 
	   117	  
allowing the separation from other Ig isotypes (IgA, IgM, IgD and IgE). Patient or healthy 
volunteer serum was selected and IgG purified by passing through a protein G column. Separate 
protein G spin columns were allocated for each group to prevent cross-contamination between 
IgG populations. Columns were allowed to reach room temperature before removal of the base 
and lid and allowing the storage solution (0.01% sodium azide/PBS) to run through. The 
column was then washed with 5ml binding buffer (0.1M phosphate buffer, pH 7.2) by gravity 
flow. Serum was diluted 1:1 with binding buffer and allowed to run through the protein G 
column. IgG-depleted serum was collected in conical centrifuge tubes and stored at -20oC. The 
column was washed three times with 5ml binding buffer. Bound IgG was eluted by 5ml elution 
buffer (0.1M glycine, pH 3.0) into conical centrifuge tubes containing 500µl of neutralisation 
buffer (1M Tris, pH 9.0).  
 
2.2.13 IgG concentration  	  
Eluted IgG was concentrated into PBS using 100kDa centrifugal filter units (Merck 
Millipore, Ireland). A 4ml aliquot of purified IgG was added to the filter unit and filtered by 
centrifugation at 2050g for 20 minutes. Then 2ml of the filtration waste was discarded and the 
remaining 1ml of the eluted purified IgG sample added to the filtration unit before repeating the 
centrifugation step. The sample was washed twice and dialysed by adding 2ml endotoxin-free 
PBS (Thermo, Scientific, USA) and subjecting to centrifugation for a further 20 minutes at 
2050g. Endotoxin-free PBS was used to make up the final concentrated sample to 1ml, which 
was then transferred to a sterile microcentrifuge tube. Protein concentration was then 
determined using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, USA). 
 
2.2.14 Endotoxin removal  	  
 Endotoxin was removed from purified and concentrated IgG by passage through a 
Detoxi-Gel endotoxin removal column (Thermo Scientific, USA) under laminar airflow. The 
column matrix contains immobilised polymyxin B beads that binds and removes LPS from 
samples. Columns were equilibrated at room temperature and the storage solution (25% 
ethanol) was removed by gravity flow. Columns were then washed sequentially with: 5ml of 
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1% sodium deoxycholate/endotoxin-free water (0.22µm filter-sterilised); 4ml endotoxin-free 
water; and 4ml sterile PBS. Purified IgG was then added and allowed to enter the column 
matrix. IgG was eluted by addition of 1.2ml sterile PBS, which was collected in a 
microcentrifuge tube. The protein concentration was re-tested using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, USA) to confirm the presence of purified IgG. The 
concentration of purified IgG was then determined using the IgG ELISA detailed in section 
2.2.16. All further use of purified IgG was always under laminar airflow to prevent endotoxin 
contamination. 
	  
2.2.15 Endotoxin quantification– Limulus Amoebocyte Lysate assay 	  
Once purified, IgG endotoxin content was determined using the Limulus Amoebocyte 
Lysate (LAL) test. For this assay, aqueous extracts from the horseshoe crab (Limulus 
polyphemus) was mixed with the purified IgG. When endotoxin is present, the LAL reacts to 
form a solid gel, which can be quantified by comparison with endotoxin standards run in 
tandem with the unknown samples. 
Endotoxin standards were made using LPS of known endotoxin units (EU). Stock LPS 
(Sigma, UK) containing 3,000,000 EU/ml of endotoxin was diluted to prepare 4, 2, 1, 0.5, 0.25, 
0.125, 0.06 and 0.03 EU/ml standards. All samples were prepared under laminar airflow, using 
sterile capped polystyrene 14ml sterile cell culture tubes and endotoxin-free water. Endotoxin 
standards were mixed by vortex (Scientific Industries Inc., USA) and used at the time of 
preparation. E-toxate test vial (Sigma, UK) was reconstituted in sterile endotoxin-free water, 
gently mixed and allowed to chill at 4oC immediately until required to test samples. Remaining 
E-toxate reagent was aliquoted and kept at -20oC. 
200µg IgG was diluted in endotoxin-free water to a final volume of 100µl in 10x75mm 
glass tubes. Endotoxin standards were added to separate 10x75mm glass tubes, with 100µl of 
endotoxin-free water as a negative control. Next, 100µl E-toxate was added to each tube and 
gently mixed. Tube mouths were covered with parafilm and then allowed to incubate 
undisturbed for 1 hour at 37oC. Samples positive for endotoxin formed a solid gel, whilst those 
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negative remain in the liquid phase. Samples testing positive at more than 0.25 EU/ml were re-
passed through the Detoxi-Gel endotoxin removal column as detailed in the previous section 
until sufficient endotoxin had been removed. 
	  
2.2.16 Purified IgG quantification  	  
Following endotoxin removal, concentrations of purified IgG were determined using an 
IgG capture ELISA. The test half of a MaxiSorp plate was coated with 400ng/ml of goat anti-
human IgG Fc antibody (I8885; Sigma, UK) in PBS overnight at 4oC, whilst the control half 
was coated with PBS alone to determine the relative backgrounds for each sample. Coated 
plates were washed twice with PBS/0.1% Tween-20 and blocked with 100µl of 2% BSA/PBS 
for 1 hour at 37oC. After blocking, plates were washed three times with PBS/0.1% Tween-20 
and serially diluted purified samples loaded (50µl/well) onto the plate alongside prepared IgG 
standards using IgG from human serum of known concentrations (I2511; Sigma, UK), which 
were allowed to incubate for 1 hour at room temperature. After incubation, plates were washed 
three times and a HRP-conjugated anti-human IgG (A6029; Sigma, UK) was added and 
incubated for a further hour at room temperature. Following three washes, 100µl of a HRP 
substrate was added and incubated for 15 minutes in the dark at room temperature before the 
reaction was stopped by addition of 100µl of stop solution. Absorbance was then read at 450nm 
using a Tecan GENios Spectra FLUOR plate reader (Tecan, UK Ltd., UK). The concentration 
of purified IgG samples was determined by comparison with the standard curve generated by 
the known concentrations of human IgG. 
 
2.2.17 Anti-citrullinated protein antibody ELISA 	  
To quantify the ACPA activity of purified IgG, samples were tested using the EDIA™ 
anti-CCP-2 kit (Euro Diagnostica, Sweden) as per instruction. In brief, 100µl of anti-CCP 
calibrators (human plasma of known CCP-2 activity) ranging from 0 U/ml to 300 U/ml and 
purified IgG diluted 1:101 in sample diluent (phosphate buffer/0.5% sodium azide) were added 
to 96-well plate strips in duplicate and incubated for 1 hour at room temperature. Wells were 
washed three times with diluted wash buffer (borate buffer/0.4% sodium azide) and 100µl of an 
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alkaline phosphatase-conjugated goat polyclonal anti-human IgG antibody was added to each 
well and then incubated for a further 30 minutes at room temperature. After washing, 100µl 
substrate solution (phenolphthalein monophosphate, Mg2+ buffer solution) was added to each 
well for 30 minutes at room temperature and the reaction was then stopped with 100µl of stop 
solution (sodium hydroxide in an EDTA/carbonate buffer, pH>10). Absorbance was read at 
560nm using a Tecan GENios Spectra FLUOR plate reader (Tecan, UK Ltd., UK) and the 
activity determined using a standard curve derived from the calibrators. 
	  
2.2.18 Anti-neutrophil cytoplasmic antibody ELISA 
 
To determine the ANCA positivity of purified IgG, samples were tested for PR3- and 
MPO-ANCA using the WIESLAB® ANCA screen kit (Euro Diagnostica, Sweden) as per 
instruction. In brief, purified IgG samples and human serum known to be positive or negative 
for PR3- and MPO-ANCA were diluted 1:4 in a dilution buffer and 100µl pipetted into either 
PR3- or MPO-coated wells. Samples were incubated at room temperature for 10 minutes on an 
orbital shaker. Wells were washed 4 times with diluted wash buffer then incubated with 100µl 
of an alkaline phosphatase-conjugated goat anti-human IgG antibody for a further 10 minutes at 
room temperature. Following incubation, wells were washed 4 times and 100µl of alkaline 
phosphatase substrate (para-Nitrophenylphophate) was added and allowed to incubate for 20 
minutes on an orbital shaker at room temperature. Absorbance was subsequently read at 405nm 
using a Tecan GENios Spectra FLUOR plate reader (Tecan, UK Ltd., UK) and ANCA 
positivity determined as an absorbance OD ratio relative to negative control. 
 
2.2.19 Protein extraction 	  
Both endothelial and neutrophil proteins were extracted using a T-SDS lysis buffer 
(0.66mM Tris-HCl pH 7.4, 2% SDS and complete mini protease and phosphatase inhibitor 
cocktail tablets [Roche]). HUVEC were grown in 6-well tissue culture plates (Thermo Fisher, 
UK) and treated following experimental protocol. Wells were washed with 1ml ice cold PBS 
and 50µl of T-SDS lysis buffer was added. Cells were immediately removed by scraping and 
transferred to microcentrifuge tubes by passage through a 25G needle. Neutrophils were 
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transferred to ice cold 1.5ml microcentrifuge tubes and centrifuged at 350g for 5 minutes at 4oC. 
Neutrophils were washed with 1ml ice cold PBS and then resuspended in 50µl of T-SDS lysis 
buffer, transferred to a fresh microcentrifuge tube by passage through a 25G needle and heated 
for 5 minutes at 95oC. Lysates were centrifuged at 16,100g for 5 minutes at 4oC to pellet cell 
debris. For some studies, fractional lysis was performed to obtain subcellular cell fractions 
using the ProteoExtract® subcellular proteome extraction kit (Millipore, Ireland). Gently and 
sequential cell lysis steps gave cytosolic, membrane and organelle, nuclear and cytoskeletal 
fractions. Lysate supernatants were then transferred to fresh microcentrifuge tubes and stored at 
-20oC for future analysis. 
	  
2.2.20 Estimation of protein concentration 	  
Protein concentrations of cell lysates were determined by bicinchoninic acid (BCA) 
protein assay (Thermo Scientific, UK). This assay relies on the reduction of copper ions by the 
peptide bonds in the lysates and the subsequent chelation of reduced copper ions by 
bicinchoninic acid, which induces a colorimetric change. Protein standards were made from 
dilutions of a 2mg/ml albumin solution to concentrations ranging from 2mg/ml to 25µg/ml. A 
working reagent was then prepared by mixing 50 parts of BCA reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) with 1 
part BCA reagent B (4% cupric acid). To each well the following agents were added in 
duplicate: 10µl of the albumin standard; 10µl of cell lysate supernatants; 10µl of T-SDS lysis 
buffer; and 10µl of PBS. Next 200µl of working reagent was added to each well and gently 
mixed. The plate was covered and incubated for 30 minutes at 37oC. Following incubation, 
absorbance was read at 560nm on a Tecan GENios microplate reader. Protein concentrations 
were then determined using the standard curve obtained by the albumin standards. 
 
2.2.21 Protein detection via immunoblot 	  
Cell lysates were diluted in lithium dodecyl sulphate (LDS) sample buffer (Life 
Technologies, UK) and heated to 70oC for 10 minutes, before being loaded into pre-cast bis-tris 
gels (Life Technologies, UK). MES [2-(N-morpholino)-ethanesulfonic acid] running buffer 
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(Life Technologies, UK) was added to the electrophoresis unit to cover the gel. A pre-stained 
full range protein marker ladder (New England BioLabs, UK) was added to the first lane and the 
prepared samples added to subsequent lanes. Proteins were resolved for 45 minutes at 165 volts.  
Resolved proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (GE 
Healthcare, UK), by placing the gel against the methanol-activated PVDF membrane between 
filter paper and sponges pre-soaked in transfer buffer. Gels were allowed to transfer for 1 hour 
at 10 volts in an electrophoresis rig containing transfer buffer (Life Technologies, UK).  
Membranes were then blocked for 1 hour in 5% skim milk/TBS/0.1% Tween-20 on an 
orbital shaker before overnight incubation with primary antibodies at 4oC. After overnight 
incubation, membranes were washed twice with TBS/0.1% Tween-20 for 15 minutes following 
which membranes were incubated with HRP-conjugated secondary antibodies for 1 hour at 
room temperature in blocking buffer. Membranes were then washed twice for 15 minutes and 
protein bands visualised using the Luminata Western HRP substrate system (Millipore, Ireland), 
allowing for the chemiluminescent detection of the HRP-conjugated secondary antibodies.  
	  
2.2.22 Statistical analysis 	  Data	  were	  evaluated	  using	  GraphPad	  Prism	  software. Experimental data was tested 
for normality using the Kolmogorov-Smirnov test. Data identified as normally distributed was 
assessed for statistical significance by means of a one-way analysis of variance (ANOVA) with 
a Bonferroni multiple comparison post-test analysis, or an unpaired t test depending on the 
nature of the experiment. If data was non-parametrically distributed, statistical significance was 
either tested using a Kruskal-Wallis test with a Dunn’s comparison post-test analysis or a Mann-
Whitney t test. For data comparing multiple parameters, a two-way ANOVA with a Bonferroni 
post-test analysis was conducted. If data represented matched observations, the appropriate 
paired statistical test was performed depending on the nature of data distribution. Experiments 
were conducted on three separate occasions, unless otherwise stated, with data being presented 
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3.1 Introduction and aims 
 
Early studies demonstrated enhanced neutrophil adhesion to ECs under hypoxia (Palluy 
et al., 1992, Rainger et al., 1995). Hypoxia has also been shown to increase neutrophil adhesion 
to epithelial cells (Beck-Schimmer et al., 2001), and promote trans-epithelial migration (Colgan 
et al., 1996). Increased mRNA and protein of the β2 integrin subunit (CD18) has been observed 
in murine and human leukocytes subjected to hypoxia, which promoted adhesion to ECs (Kong 
et al., 2004). Upregulation of β1 integrins has also been described under hypoxia (Blaschke et 
al., 2002, Keely et al., 2009, Lee et al., 2011). There are no reports however, on the effects of 
hypoxia on β1 integrins in neutrophils. Therefore, in this chapter, I determined the effects of 
hypoxia upon neutrophil β1 and β2 integrin expression, adhesion to immobilised integrin ligands 
and ECs, and trans-endothelial migration. 
  
3.2 Neutrophils express both β1 and β2 integrins 
 
Prior to examining the effects of hypoxia upon neutrophil integrins, I measured baseline 
integrin expression in unstimulated neutrophils from 5 healthy donors. All isolated neutrophils 
stained positive for CD15, which is expressed by mature neutrophils (Figure 3.1A).  
Integrin subunits α1 (CD49a), α4 (CD49d), α5 (CD49e), αL, (CD11a), αM (CD11b), αX 
(CD11c), β1 (CD29), and β2 (CD18) were assessed by flow cytometry. Neutrophils expressed 
varying levels of each of these integrin subunits (Figure 3.1B). Mean fluorescence intensity 
(MFI) data showed variable expression of all integrin subunits between donors. 
In addition, the number of neutrophils that expressed each integrin subunit was also 
examined (Table 3.1). Expression of αL, αM, αX and β2 was seen in 94%, 80%, 26% and 95% of 
neutrophils respectively. In contrast, α1, α4, α5 and, β1 expression was only observed on 1%, 5%, 
9% and 8% of neutrophils respectively. These results show that unstimulated neutrophils have 
high expression of β2 integrins and low levels of β1 integrins. 
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Figure 3.1: Freshly isolated neutrophils express varying levels of β1 and β2 integrins. 
Neutrophils were isolated and fluorescently stained for CD15 and various integrin subunits. 
(A) A representative flow cytometry plot of isolated neutrophils with the cell gate applied for 
further neutrophil analysis, based upon neutrophil side and forward scatter properties. Isolated 
cells were stained for CD15 (blue) or an isotype control (red). Gated cells were all found to be 
CD15+ neutrophils. (B) Baseline neutrophil integrin expression was assessed in 5 healthy 
donors. Neutrophils were found to express varying levels of all integrin subunits analysed. 
Data is presented as mean fluorescence intensity (MFI) ±SD of data obtained from all 5 
donors.  
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3.3 Expression of neutrophil β2 integrins, but not β1 integrins, is enhanced by 
hypoxia  
 
Having shown that neutrophils express β1 and β2 integrins, I then studied the effects of 
hypoxia upon integrin expression. To begin with, cell viability in response to hypoxia was 
assessed with MTT. Isolated neutrophils were cultured under hypoxia, which was confirmed by 
HIF-1α and HIF-2α expression by immunoblot (Figure 3.2A). Neutrophil viability was assessed 
at 4, 8 and 24 hours of culture under normoxia and hypoxia. Hypoxia did not significantly affect 
cell viability at 4 and 8 hours culture (Figure 3.2B). Optical density (OD) values decreased 
following 24 hours culture, indicating neutrophils were undergoing cell death, although these 
values were not significantly different between normoxia and hypoxia. 
 To determine the optimal time point to analyse integrin expression, a preliminary time 
course experiment was conducted with neutrophils isolated from one donor. Surface αL, αM and 
β2 expression was evaluated after 4, 6, 8 and 24 hours of culture under normoxia or hypoxia. 
Expression of αL did not vary between cells cultured up to 8 hours (Figure 3.3A). In contrast, 
culture under hypoxia for up to 8 hours enhanced αM expression, which decreased under 
normoxia (Figure 3.3B). Expression levels of β2 were also higher in neutrophils cultured under 
hypoxia compared to normoxia (Figure 3.3C). Integrin expression decreased following 24 hours 
culture under normoxia and hypoxia, probably as a result of cell death. For subsequent 
experiments, an 8-hour time point was chosen as neutrophil viability was not significantly 
affected and differences in αM and β2 expression were seen.   
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Figure 3.2: Hypoxia does not affect neutrophil viability. MTT assays were performed to 
assess neutrophil viability in response to hypoxia. (A) Hypoxia was confirmed by expression 
by HIF-1α and HIF-2α by immunoblot. Neutrophils were cultured for 1, 2, 3, 4, 6 or 24 hours 
under normoxia or hypoxia before lysis with a T-SDS lysis buffer. Resolved cell lysates were 
transferred to a PVDF membrane and probed for HIF-1α, HIF-2α and GAPDH. (B) 3.5x105 
neutrophils were cultured for 4, 8 or 24 hours under normoxia or hypoxia before cell viability 
was assessed. Hypoxia did not significantly affect neutrophil viability at 4 and 8 hours culture. 
Following 24 hours culture, OD values were 50-60% of earlier time points, indicative of cell 
death. Statistical analysis was tested by means of a two-way ANOVA with a Bonferroni’s post-
test. Data is presented as mean OD ±SD of two independent experiments. 
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Figure 3.3: Surface expression of αM increases with culture under hypoxia. A preliminary time 
course experiment was conducted to evaluate surface integrin expression. Neutrophils were isolated 
from one donor and cultured under normoxia or hypoxia for 4, 6, 8 or 24 hours and stained for αL 
(CD11a), αM (CD11b) and β2 (CD18). (A) Expression of αL did not vary between cells cultured 
under normoxia or hypoxia up until 8 hours culture. (B) Hypoxia increased αM expression up to 8 
hours culture. (C) Surface β2 expression was higher in cells cultured under hypoxia. Following 24 
hours culture under normoxia and hypoxia, decreased expression of all three integrin subunits was 
observed, most likely due to cell death. Data is presented as the mean fluorescence intensity (MFI) 
of 20,000 neutrophils 
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Neutrophils were isolated from 7 healthy donors and cultured for 8 hours under 
normoxia or hypoxia. Surface expression of the integrin subunits α1, α4, α5, αL, αM, αX, β1 and β2 
were assessed by flow cytometry. 
Surface expression of β1 integrins was not modulated by hypoxia (Figure 3.4A-D). 
Paired statistical tests did not find any differences in MFI of α1 (p=0.8750), α4 (p=0.2188), α5 
(p=0.1489) or β1 (p=0.1546). In addition, the number of neutrophils expressing each integrin 
subunit was not affected by hypoxia (Figure 3.4E-H). These results show that surface 
expression of VLA-1 (α1β1), VLA-4 (α4β1) and VLA-5 (α5β1) is not modulated by 8 hours 
hypoxic exposure. 
In contrast, β2 integrin expression was enhanced by hypoxia. Whilst there were no 
significant differences in MFI of αL (p=0.7645) and β2 (p=0.4688) between cells cultured under 
normoxia or hypoxia (Figure 3.5A, D), MFI for αM and αX significantly increased under hypoxia 
(p<0.001 and p=0.0038 respectively) (Figure 3.5B, C). Further analysis found that hypoxia 
significantly increased the number of neutrophils expressing αL (p=0.0156), αM (p=0.0001), αX 
(p=0.0179) and β2 (p=0.0313) (Figure 3.5E-H). Taken together, these results indicate that 
hypoxia induces greater numbers of neutrophils to express the β2 integrins LFA-1 (αLβ2), Mac-1 
(αMβ2) and p150,95 (αXβ2) following 8 hours hypoxic exposure. 	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3.4 Optimisation of neutrophil static adhesion assays  
 
Having found that hypoxia modulates neutrophil integrin expression, I then evaluated 
the effects of hypoxia upon neutrophil binding to immobilised integrin ligands. In this thesis, I 
assessed adhesion to three ligands: fibrinogen, fibronectin and ICAM-1. 
	  
3.4.1 Immobilised fibrinogen adhesion assay optimisation 
 
To examine Mac-1 activation, I optimised fibrinogen adhesion assays. Three fibrinogen 
concentrations were tested for optimal coating concentrations. Adhesion of PMA-stimulated 
neutrophils was comparable across all fibrinogen concentrations (Figure 3.6A). Given these 
results, 200µg/ml fibrinogen was chosen as the coating concentration for all further fibrinogen 
adhesion assays.  
Titration of the Mac-1-specific antibody, 2LPM19c, was performed (Figure 3.6B). 
Inhibition of neutrophil binding to immobilised fibrinogen was observed from 2.5µg/ml. To 
ensure saturation of the blocking antibody, 10µg/ml was selected for further experiments. 
Blockade using mAb44, an alternative Mac-1 blocking antibody, was also examined but mAb44 
was not found to block neutrophil adhesion to fibrinogen (data not shown). Adhesion to 
uncoated plastic wells was not blocked by treatment with 10µg/ml 2LPM19c (Figure 3.6C). 
Fibrinogen immobilisation was also tested using 50mM and 100mM 
bicarbonate/carbonate buffers, however no significant differences were observed between 
buffers (data not shown). Therefore, fibrinogen was diluted in PBS for all further experiments.  
 
3.4.2 Immobilised fibronectin adhesion assay optimisation 
  
To study the effects of hypoxia upon β1 integrin activation, I evaluated neutrophil 
adhesion to immobilised fibronectin. To optimise the coating concentration of fibronectin, T 
cells were used to remove potential Mac-1-mediated interactions. T cells were isolated from 
healthy donors and phenotypically characterised by flow cytometry to confirmed the isolation of 
CD3+ T cells (Figure 3.7A). T cells also expressed α4, αL, β1 and β2, but not αM, indicating the 
expression of LFA-1(αLβ2) and VLA-4 (α4β1), but not Mac-1 (αMβ2) (Figure 3.7B). 
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Figure 3.6: Optimisation of fibrinogen adhesion assay. Adhesion to immobilised 
fibrinogen was used to assess Mac-1 (αMβ2) activation. 5x105 fluorescently labelled 
neutrophils were added to fibrinogen-coated wells in the absence or presence of 20nM PMA 
for 30 minutes. (A) Fibrinogen was immobilised at concentrations of 20µg/ml, 200µg/ml and 
2mg/ml. PMA-stimulated neutrophil adhesion did not significantly vary between 
concentrations. (B) Neutrophil adhesion to fibrinogen was evaluated in the presence of the 
Mac-1 (αMβ2)-specific blocking antibody 2LPM19c. Adhesion was blocked from 2.5µg/ml 
2LPM19c. (C) Neutrophil binding to uncoated plastic well was assessed in the absence and 
presence of 10µg/ml 2LPM19c. PMA-stimulated neutrophil adhesion was not blocked by 
Mac-1 (αMβ2) blockade by 2LPM19c. Data presented as mean adhesion ±SD of three 
independent experiments. 
A 
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Figure 3.7: CD3+ T cells express LFA-1 and VLA-4, but do not express Mac-1. Isolated T cells 
were phenotypically characterised by flow cytometry. (A) Cultured lymphocytes were stained with 
the T cell markers CD3, CD4 and CD8. 90.4% of cells stained positive for CD3, which represents 
20,000 cells. Further characterisation of these gated CD3+ T cells found that the most were CD8+ T 
cells. (B) CD3+ T cells were found to express α4 (CD49d), αL (CD11a), β1 (CD29) and β2 (CD18), 
but not αM (CD11b). T cell characterisation was performed on three independent occasions, with 
representative plots and histograms shown above. 
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Fibronectin was immobilised at concentrations ranging between 10-100µg/ml and T cell 
adhesion evaluated. 5x105 fluorescently labelled T cells were added to wells in the absence or 
presence of PMA. PMA-stimulated T cell adhesion was observed with all coating 
concentrations of fibronectin (Figure 3.8A). For further experiments, 20µg/ml fibronectin was 
used to coat plates. Immobilisation using 50mM and 100mM bicarbonate/carbonate buffers was 
also tested, however no significant differences were observed (data not shown), and therefore 
PBS was used for subsequent experiments to dilute fibronectin. 
 Neutrophil adhesion to immobilised fibronectin was assessed in the presence of 1, 2, 5 
or 10µg/ml of the blocking antibody P5D2, which inhibits CD29 and therefore blocks adhesion 
mediated by all β1 integrins. A dose response was observed, with maximal inhibition of PMA-
induced neutrophil adhesion achieved with 10µg/ml P5D2 (Figure 3.8B).  
 
3.4.3 Immobilised ICAM-1 adhesion assay optimisation 
 
Finally, I optimised the coating concentration of Fc-conjugated recombinant ICAM-1 
(ICAM-1-Fc). T cells were used to remove potential Mac-1-mediated interactions. ICAM-1-Fc 
was titrated at concentrations ranging from 0.1-5µg/ml and T cell adhesion assessed in the 
absence or presence of PMA (Figure 3.9A). Increasing adhesion was observed between 3-
4µg/ml, which reached a plateau by 5µg/ml. Therefore, 4.5µg/ml ICAM-1-Fc was used to coat 
wells for further ICAM-1 adhesion assays. 
PMA-stimulated T cell adhesion to ICAM-1-Fc was shown to be LFA-1-dependent 
using: TS1/18, an anti-β2 antibody that blocks all β2 integrin adhesion (Figure 3.9B); and 
mAb38, an anti-αL antibody that specifically blocks LFA-1 (Figure 3.9C). A dose-dependent 
inhibitory effect was observed with TS1/18, whilst mAb38 potently inhibited PMA-stimulated 
T cell adhesion to ICAM-1-Fc.  
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Figure 3.8: Optimisation of fibronectin adhesion assay. Adhesion to immobilised fibronectin 
was used to evaluate β1 integrin activation. (A) 5x105 fluorescently labelled T cells were 
cultured in the absence or presence of 20nM PMA for 30 minutes. Adhesion was observed at all 
coating concentrations tested. 20µg/ml fibronectin was used for further experiments. (B) The 
pan-β1 integrin blocking antibody, P5D2, was titrated to determine β1 integrin specific adhesion. 
5x105 fluorescently labelled neutrophils were added to fibronectin-coated wells in the absence 
or presence of 20nM PMA and 1, 2, 5 or 10µg/ml P5D2. A dose-dependent inhibition of 
neutrophil adhesion was observed. Data is shown as mean adhesion ±SD of three independent 
experiments. 
A 
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Figure 3.9: Optimisation of ICAM-1 adhesion assay. Adhesion to immobilised ICAM-1-Fc was 
used to evaluate β2 integrin activation (A) 5x105 fluorescently labelled T cells were added to wells 
coated with ICAM-1-Fc ranging from 0.1-5µg/ml, in the absence or presence of 20nM PMA. 
Adhesion was observed in wells coated with at least 3µg/ml ICAM-1-Fc. Increasing adhesion 
reached a plateau by 4µg/ml ICAM-1-Fc. 4.5µg/ml ICAM-1-Fc was used for further experiments. 
(B) 5x105 fluorescently labelled T cells were added to wells in the absence or presence of 20nM 
PMA and 1-10µg/ml TS1/18, an anti-β2 (CD18) blocking antibody. A dose-dependent inhibition of 
T cell adhesion was observed. (C) PMA-stimulated T cell adhesion was also assessed in the 
presence of 1-10µg/ml mAb38, an anti-αL (CD11a) antibody. PMA-stimulated adhesion was 
inhibited from 1µg/ml mAb38. Data is presented as mean adhesion ±SD from three independent 
experiments. 
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3.5 Hypoxia reduces neutrophil adhesion to immobilised integrin ligands 
 
Having optimised coating concentrations, I subsequently evaluated the effects of 
hypoxia upon neutrophil adhesion to immobilised fibrinogen, fibronectin and ICAM-1-Fc 
following 30 minutes and 8 hours exposure to normoxia or hypoxia. 5x105 fluorescently 
labelled neutrophils were added to coated wells in the absence or presence of PMA and allowed 
to adhere for 30 minutes under normoxia or hypoxia. 30 minutes hypoxic exposure did not 
significantly affect neutrophil adhesion to immobilised fibrinogen, fibronectin or ICAM-1-Fc 
(Figure 3.10A-C). 
Neutrophil adhesion was also assessed following 8 hours culture under normoxia or 
hypoxia. Adhesion of 5x105 fluorescently labelled neutrophils in the absence or presence of 
PMA was evaluated. PMA-stimulated neutrophil adhesion following 8 hours culture under 
hypoxia was significantly reduced to immobilised fibrinogen (p<0.01), fibronectin (p<0.05) and 
ICAM-1-Fc (p<0.01) compared to normoxic controls (Figure 3.11A-C). 
	  
3.6 Hypoxia modulates endothelial adhesion molecule expression in response to 
LPS and TNF-α 
 
Having found reduced adhesion to immobilised fibrinogen, fibronectin and ICAM-1-Fc 
following 8 hours culture under hypoxia, I then studied neutrophil adhesion to HUVEC. 
HUVEC viability was first assessed in response to hypoxia, to ensure that any modulation of 
endothelial adhesion molecule expression was not a result of cell death. HUVEC were cultured 
under normoxia or hypoxia for up to 24 hours and HIF-1α or HIF-2α expression confirmed by 
immunoblot (Figure 3.12A). HUVEC viability was not significantly different at 4 and 8 hours 
culture under normoxia or hypoxia. Following 24 hours culture however, OD values were 
significantly higher in HUVEC cultured under normoxia, indicating cell proliferation that was 
not observed in cells cultured under hypoxia (p<0.05) (Figure 3.12B).  
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Figure 3.10: Neutrophil adhesion to immobilised integrin ligands is not affected by 30 
minutes hypoxia. The effects of 30 minutes hypoxia upon neutrophil adhesion to immobilised 
(A) fibrinogen (B) fibronectin and (C) ICAM-1-Fc were studied. 5x105 fluorescently labelled 
neutrophils were added to coated wells in the absence or presence of 20nM PMA and allowed 
to adhere for 30 minutes under normoxia or hypoxia. Hypoxia did not have a significant effect 
on neutrophil adhesion to immobilised integrin ligands, as determined by two-way ANOVA 
with Bonferroni’s post-test. Data is presented as mean adhesion ±SD of three independent 
experiments. 
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Figure 3.11: Neutrophils cultured under hypoxia for 8 hours have reduced adhesion to 
immobilised integrin ligands. The effects of hypoxia upon neutrophil firm adhesion to 
immobilised (A) fibrinogen (B) fibronectin and (C) ICAM-1-Fc following 8 hours culture were 
studied. Isolated neutrophils were cultured for 8 hours under normoxia or hypoxia. 5x105 
fluorescently labelled neutrophils were added to coated wells in the absence or presence of 
20nM PMA and adhesion assessed. Neutrophils cultured under hypoxia for 8 hours had 
significantly reduced PMA-stimulated adhesion to immobilised integrin ligands, as determined 
by a two-way ANOVA analysis with a Bonferroni’s post-test. Data is presented as mean 
adhesion ±SD of three independent experiments. *=p<0.05, **=p<0.01 
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Figure 3.12: Hypoxia suppresses endothelial proliferation. MTT assays were performed to 
assess endothelial viability in response to hypoxia. 1.5x104 HUVEC were cultured under 
normoxia or hypoxia for 4, 8 or 24 hours before being assessed for cell viability. OD values 
were not significantly different at 4 and 8 hours culture under normoxia or hypoxia. 
Following 24 hours, OD values obtained from HUVEC cultured under normoxia were 
significantly higher than cells cultured under hypoxia. Statistical analysis was determined by 
means of a two-way ANOVA with a Bonferroni’s post-test. Data is presented as mean OD 
±SD from three independent experiments. *=p<0.05 
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Prior to accessing neutrophil adhesion to HUVECs under hypoxia, I first examined the 
effects of hypoxia upon adhesion molecule expression in response to external stimuli. HUVEC 
were cultured in the absence or presence of LPS or TNF-α for 4, 8 and 24 hours under normoxia 
or hypoxia and accessed for surface expression of E-selectin, ICAM-1, ICAM-2 and VCAM-1 
by flow cytometry.  
 In untreated cells, only ICAM-1 varied over time (Figure 3.13A-D). Minimal E-selectin 
expression was seen under both normoxia and hypoxia at all time points studied (Figure 3.13A). 
Induction of ICAM-1 expression was observed in untreated cells under normoxia, which peaked 
at 8 hours (Figure 3.13B). ICAM-1 expression was significantly higher under normoxia at all 
time points studied (p<0.05 at 4 hours, p<0.001 at 8 hours and p<0.001 at 24 hours). Untreated 
HUVEC had high basal expression of ICAM-2 and low VCAM-1 expression. Neither ICAM-2 
nor VCAM-1 expression varied over time (Figure 3.13C, D). 
 LPS treatment induced E-selectin expression in HUVEC, which peaked at 4 hours 
stimulation (Figure 3.14A). E-selectin expression following 4 hours LPS stimulation was 
significantly lower in hypoxic cells (p<0.001). ICAM-1 and VCAM-1 expression was also 
induced by LPS, but there were no differences between HUVEC stimulated under normoxia and 
hypoxia (Figure 3.14B, D). LPS suppressed ICAM-2 expression under normoxia at all time 
points examined compared to baseline (Figure 3.14C). ICAM-2 expression was significantly 
higher in hypoxic HUVEC following 8 hours LPS stimulation (p<0.05) (Figure 3.14C). 
TNF-α treatment induced E-selectin expression under normoxia, which peaked at 8 
hours stimulation (Figure 3.15A). E-selectin expression was significantly lower in hypoxic 
HUVEC at all time points (p<0.05 at 4 hours, p<0.001 at 8 hours and p<0.05 at 24 hours). 
ICAM-1 expression was induced by TNF-α stimulation, which peaked at 8 hours under 
normoxia. Significantly higher levels of ICAM-1 expression however, were observed in 
HUVEC following 24 hours TNF-α stimulation under hypoxia compared to normoxia (p<0.001) 
(Figure 3.15B). ICAM-2 expression did not significantly vary between cells stimulated under 
normoxia and hypoxia (Figure 3.15C). There were no significant differences in TNF-α induced 
VCAM-1 expression between cells stimulated under normoxia and hypoxia (Figure 3.15D). 
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Figure 3.13: Hypoxia modulates ICAM-1 expression in untreated endothelial cells. To 
examine unstimulated endothelial responses to hypoxia, HUVEC were cultured under normoxia 
or hypoxia for 4, 8 or 24 hours and then examined for expression for E-selectin, ICAM-1, ICAM-
2 and VCAM-1. (A) Low baseline expression E-selectin expression was observed. Expression 
did not vary over time and there were no significant differences between normoxic and hypoxic 
HUCEC. (B) Induction of ICAM-1 expression was observed under normoxia. ICAM-1 induction 
was significantly lower in hypoxic HUVEC. (C) ICAM-2 expression did not significantly change 
over time and was not affected by hypoxia. (D) VCAM-1 expression did not vary over time and 
was not modulated by hypoxia. Data is presented as mean fluorescence intensity (MFI) ±SD of 
three independent experiments. Statistical significance was determined by two-way ANOVA 
with a Bonferroni’s post-test. *= p<0.05, ***= p<0.001 
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Figure 3.14: Hypoxia modulates E-selectin induction and ICAM-2 down regulation in LPS-
stimulated HUVEC. Endothelial responses to LPS were studied under normoxia and hypoxia. 
HUVEC were cultured for 4, 8 or 24 hours in the presence of 100ng/ml LPS under normoxia or 
hypoxia and then examined for expression of E-selectin, ICAM-1, ICAM-2 and VCAM-1. (A) LPS 
induced E-selectin expression in normoxic HUVEC, which was significantly lower under hypoxia. 
(B) LPS upregulated ICAM-1 expression under both normoxia and hypoxia. Hypoxia did not 
significantly modulate ICAM-1 expression. (C) LPS stimulation reduced ICAM-2 expression in 
normoxic cells. There was a trend to increased ICAM-2 expression under hypoxia, with expression 
levels being significantly higher under hypoxia following 8 hours LPS stimulation. (D) VCAM-1 
expression was observed in both normoxic and hypoxic cells treated with LPS. There were no 
significant differences between normoxia and hypoxia. Data is presented as mean fluorescence 
intensity (MFI) ±SD of three independent experiments. Statistical significance was determined by 
two-way ANOVA with a Bonferroni’s post-test. *= p<0.05, ***= p<0.001 
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Figure 3.15: Hypoxia reduces E-selectin expression but increases ICAM-1 expression in 
TNF-α treated endothelial cells. Endothelial responses to TNF-α under normoxia and hypoxia 
were studied. ECs were treated with 10ng/ml TNF-α for 4, 8 or 24 hours under normoxia or 
hypoxia and examined for expression of E-selectin, ICAM-1, ICAM-2 and VCAM-1. (A) TNF-α 
stimulation induced expression of E-selectin under normoxia. This upregulation was significantly 
suppressed by hypoxia. (B) TNF-α induced ICAM-1 expression in normoxic ECs. ICAM-1 
expression was modulated by hypoxia, with significantly higher expression at 24 hours 
stimulation. Moreover, whilst expression in normoxic HUVEC had begun to decrease at 24 hours, 
ICAM-1 expression in hypoxic cells was highest at 24 hours, suggesting a change in ICAM-1 
expression dynamics. (C) ICAM-2 expression was not significantly different between normoxia 
and hypoxia. (D) VCAM-1 upregulation was observed in both normoxic and hypoxic HUVEC, 
but differences were not significant. Data is presented as mean fluorescence intensity (MFI) ±SD 
of three independent experiments. Statistical significance was determined by two-way ANOVA 
with a Bonferroni’s post-test. *= p<0.05, ***= p<0.001 
Chapter Three: The Effects of Hypoxia on Neutrophil Integrin Activation 
	   147	  
3.7 Hypoxia promotes neutrophil adhesion to endothelial monolayers 
 
Having found a modulatory effect of hypoxia upon endothelial adhesion molecule 
expression in response to LPS and TNF-α, I then examined the effects of hypoxia upon 
neutrophil adhesion to ECs. HUVEC monolayers were cultured overnight under normoxia or 
hypoxia in the absence or presence of LPS or TNF-α. Neutrophils were isolated and also 
cultured under normoxia or hypoxia overnight. Following overnight cultures, neutrophils were 
fluorescently labelled and adhesion of 5x105 neutrophils to HUVEC was evaluated in response 
to PMA, LPS or TNF-α. Adhesion was assessed with normoxic neutrophils to normoxic 
HUVEC and hypoxic neutrophils to hypoxic HUVEC. 
Neutrophil adhesion to untreated HUVEC, in the absence of any stimuli, was 
significantly higher when both cells were cultured under hypoxia (p<0.01) (Figure 3.16). 
Hypoxia also significantly increased LPS-stimulated neutrophil adhesion to untreated HUVEC 
(p<0.001) (Figure 3.16). There were trends for increased neutrophil adhesion to HUVEC in 
response to PMA and TNF-α under hypoxia, however these differences did not reach 
significance (Figure 3.16).  
 Overnight culture of HUVEC and neutrophils under hypoxia did not have a significant 
effect upon unstimulated, LPS- or TNF-α-stimulated neutrophil adhesion to LPS-activated 
HUVEC (Figure 3.17). In contrast, PMA-stimulated neutrophil adhesion to endothelial 
monolayers stimulated with LPS overnight was significantly higher under hypoxia compared to 
normoxia (p<0.01) (Figure 3.17). 
 Hypoxia significantly increased both unstimulated and PMA-stimulated neutrophil 
adhesion to TNF-α-activated endothelial monolayers (p<0.05 and p<0.001 respectively) (Figure 
3.18). There were trends to higher LPS- and TNF-α-stimulated neutrophil adhesion under 
hypoxia, however these differences did not reach statistical significance (Figure 3.18). 	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Figure 3.16: Hypoxia enhances unstimulated and LPS-stimulated neutrophil adhesion to 
untreated endothelial monolayers. The effects of hypoxia upon neutrophil adhesion to resting 
HUVEC were examined. Endothelial monolayers were cultured under normoxia or hypoxia 
overnight. Neutrophils were isolated from whole blood and cultured overnight under normoxia 
or hypoxia. 5x105 fluorescently labelled neutrophils were added to endothelial monolayers in 
the absence or presence of 20nM PMA, 100ng/ml LPS or 10ng/ml TNF-α. Hypoxia 
significantly increased both unstimulated and LPS-stimulated neutrophil adhesion to resting 
HUVEC. Statistical significance was determined by means of a two-way ANOVA with a 
Bonferroni’s post-test. Data is presented as mean adhesion ±SD of four independent 
experiments. **=p<0.01, ***=p<0.001 
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Figure 3.17: Hypoxia increases PMA-stimulated neutrophil adhesion to LPS-activated 
endothelial monolayers. The effects of hypoxia upon neutrophil adhesion to LPS-stimulated 
HUVEC were also studied. Endothelial monolayers were treated with 100ng/ml LPS overnight 
under normoxia or hypoxia. Neutrophils were isolated from whole blood and cultured 
overnight. 5x105 fluorescently labelled neutrophils were added to endothelial monolayers in 
the absence or presence of 20nM PMA, 100ng/ml LPS or 10ng/ml TNF-α. Hypoxia 
significantly increased PMA-stimulated neutrophil adhesion to LPS-activated HUVEC. 
Statistical significance was determined by means of a two-way ANOVA with a Bonferroni’s 
post-test. Data is presented as mean adhesion ±SD of four independent experiments. 
**=p<0.01 
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Figure 3.18: Hypoxia enhances unstimulated and PMA-stimulated neutrophil adhesion to 
TNF-α activated endothelial monolayers. The effects of hypoxia upon neutrophil adhesion to 
TNF-α activated ECs were examined. HUVEC were treated overnight with 10ng/ml TNF-α 
under normoxia or hypoxia. Neutrophils were isolated from whole blood and cultured overnight 
under normoxia or hypoxia. 5x105 fluorescently labelled neutrophils were added to endothelial 
monolayers in the absence or presence of 20nM PMA, 100ng/ml LPS or 10ng/ml TNF-α. 
Unstimulated and PMA-stimulated neutrophil adhesion was significantly higher under hypoxia. 
Statistical significance was determined by means of a two-way ANOVA with a Bonferroni’s 
post-test. Data is presented as mean adhesion ±SD of four independent experiments. *=p<0.05, 
***=p<0.001 
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3.8 Hypoxia increases neutrophil trans-endothelial migration 
 
Having studied the effects of hypoxia on integrin expression and integrin-mediated 
adhesion, I subsequently examined trans-endothelial migration under hypoxia. Low levels of 
neutrophil transmigration were observed in the absence of a chemoattractant. Neutrophil 
transmigration across HUVEC monolayers was promoted by the presence of IL-8 (Figure 3.19). 
In addition, hypoxia significantly increased IL-8-induced neutrophil transmigration across 
resting endothelial monolayers (p<0.05) (Figure 3.19A).  
I also studied the effects of hypoxia upon neutrophil transmigration across activated 
ECs. HUVEC were cultured for 24 hours with TNF-α prior to transmigration. There was a trend 
to increased transmigration in the absence of a chemoattractant, however this difference did not 
reach statistical significance. Hypoxia significantly increased IL-8-induced neutrophil migration 
across TNF-α activated HUVEC (p<0.05) (Figure 3.19B). 
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Figure 3.19: Hypoxia increases IL-8-induced neutrophil trans-endothelial migration. To 
examine the effects of hypoxia on trans-endothelial migration, neutrophil migration in response 
to IL-8 was studied. HUVEC were cultured overnight under normoxia or hypoxia in the absence 
or presence of 10ng/ml TNF-α. 1.1x106 fluorescently labelled neutrophils were added to the 
apical side of HUVEC in the upper chamber and allowed to transmigrate for 90 minutes under 
normoxia or hypoxia. (A) Neutrophil migration towards IL-8 across resting HUVEC was 
significantly higher under hypoxia. (B) Greater migration was observed across TNF-α activated 
HUVEC. Hypoxia significantly increased neutrophil trans-endothelial migration towards IL-8 
across TNF-α activated HUVEC. Statistical significance was determined by means of a two-way 
ANOVA with a Bonferroni’s post-test. Data is presented as mean transmigration ±SD of three 
independent experiments. *=p<0.05 
Chapter Three: The Effects of Hypoxia on Neutrophil Integrin Activation 
	   153	  
3.9 Discussion 
 
In this chapter, I have shown that neutrophils express β1 and β2 integrins. Moreover, 
whilst β1 integrin expression was not modulated by hypoxia, surface expression of LFA-1 
(αLβ2), Mac-1 (αMβ2) and p150,95 (αXβ2) increased under hypoxia. Hypoxia modulated adhesion 
molecule expression in stimulated HUVEC by reducing E-selectin and enhancing ICAM-1 
expression. Neutrophil adhesion to immobilised integrin ligands was reduced under hypoxia, 
but adhesion to HUVEC was increased by hypoxia. In addition, neutrophil trans-endothelial 
migration was enhanced under hypoxia. This section will discuss my results in context of 
published studies and highlight possible avenues for future work. 
 
3.9.1 Effects of hypoxia upon neutrophil integrin expression 
 
 Published reports have documented the upregulation of β1 integrins under hypoxia 
(Blaschke et al., 2002, Keely et al., 2009, Lee et al., 2011), however this effect was not 
replicated in my experimental data. Published studies demonstrated upregulation of β1 integrins 
in embryonic stem cells, fibroblasts and smooth muscles cells cultured in hypoxia. In contrast, 
my work examined β1 integrin expression in isolated neutrophils, which may not be subject to 
the same hypoxic regulation. 
 Studies have also shown increased β2 expression under hypoxia (Kong et al., 2004). 
Whilst I did not find increased MFI, more neutrophils expressed the β2 subunit under hypoxia. 
Key experimental differences may account for these discrepant results. Elevated β2 expression 
was found in whole blood leukocytes cultured at 5% oxygen for 24 hours (Kong et al., 2004). 
Given that data was obtained from all leukocytes, the relative contribution from individual cell 
types cannot be determined. In contrast, my work examined integrin expression in isolated 
neutrophils cultured in 1% oxygen for 8 hours. Kong and colleagues also found that β2 subunits 
associated with CD11 (Kong et al., 2004), however the precise α subunit was not determined. 
My experimental data show that the MFI for αM and αX, but not αL, increased following 8 hours 
culture under hypoxia, which may indicate that hypoxia increases expression of Mac-1 (αMβ2) 
and p150,95 (αXβ2). Therefore, differences in cells studied, oxygen levels utilised and duration 
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of incubation, render comparisons between my own and published studies difficult and may 
account for discrepant results.  
 
3.9.2 Effects of hypoxia upon neutrophil adhesion 
 
There is conflicting evidence regarding the effects of hypoxia upon EC adhesion 
molecule expression. An early report found that LPS- and TNF-α-stimulated ECs under hypoxia 
had higher E-selectin expression (Zund et al., 1996). A more recent study found reduced E-
selectin expression in ECs stimulated under hypoxia (Maurus et al., 2003). Several differences 
however, exist between these studies including origin of ECs, oxygen levels and assay to 
measure adhesion molecule expression. Zund and colleagues used bovine aortic ECs, whilst 
Maurus et al. examined human aortic ECs. Different oxygen levels were used between studies, 
with Zund et al. culturing cells at 2% oxygen whilst Maurus and colleagues subjected cells to 
1% oxygen. In addition, Maurus et al. evaluated adhesion molecule expression by flow 
cytometry, whilst Zund et al. quantified E-selectin expression by cell ELISA. Therefore, a 
combination of species variation, differences in oxygen levels and techniques may explain the 
contrasting conclusions.  
My observations are consistent with work published by Maurus and colleagues. I 
cultured human umbilical cord vein ECs at 1% oxygen and evaluated E-selectin expression by 
flow cytometry, which found reduced E-selectin expression in ECs stimulated under hypoxia. 
Whilst Maurus et al. examined arterial-derived ECs and I used venous-derived ECs, results are 
consistent between studies. Taken together, the evidence suggests that human ECs express 
lower levels of E-selectin on stimulation at 1% oxygen. 
Published data show increased adhesion under hypoxia (Palluy et al., 1992, Rainger et 
al., 1995). Consistent with these reports, I found that hypoxia promoted neutrophil adhesion to 
HUVEC. Given my results from neutrophil integrin and endothelial adhesion molecule 
expression studies, increased neutrophil adhesion HUVEC under hypoxia may be attributed to 
enhanced interactions between Mac-1 and ICAM-1.  
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Interestingly, whilst neutrophil adhesion to HUVEC was enhanced under hypoxia, I 
found adhesion to immobilised fibrinogen, fibronectin and ICAM-1 was reduced. This 
observation may indicate that cellular crosstalk is required to promote adhesion under hypoxia. 
Alternatively, several integrin-ligand interactions may simultaneously be required for firm 
adhesion under hypoxia, which cannot be replicated when studying adhesion to single 
immobilised ligands. 
 
3.9.3 Effects of hypoxia upon neutrophil transmigration 
 
Early reports found that hypoxia promoted neutrophil trans-epithelial migration (Colgan 
et al., 1996). More recent evidence found neutrophil trans-endothelial migration was unaffected 
by hypoxia (McGovern et al., 2011), whilst other reports found increased chemotaxis under 
hypoxia (Wang and Liu, 2009). These differences arose due to differences in methodologies and 
chemoattractants used between studies. I found IL-8-induced neutrophil trans-endothelial 
migration across both resting and TNF-α-activated HUVEC was enhanced under hypoxia. 
Taken together, my data suggest that increased neutrophil integrin and EC adhesion molecule 
expression under hypoxia not only facilitate adhesion, but also promote transmigration.  
 
3.9.4 Future work 
 
With regards to integrin expression, examining integrin subunit mRNA levels in 
response to hypoxia would complement my cell surface expression data. Neutrophil adhesion 
studies could be expanded to include additional immobilised ligands, including ICAM-2 and 
VCAM-1. Adhesion to a combination of immobilised ligands could be examined to determine 
whether integrin crosstalk promotes adhesion under hypoxia. Endothelial adhesion assays could 
also be expanded to include functional blocking antibodies, targeting both neutrophil integrins 
and endothelial adhesion molecules, to dissect the molecular interactions mediating neutrophil 
adhesion. A similar approach would be beneficial in transmigration experiments, which would 
determine the cellular interactions promoting neutrophil trans-endothelial migration under 
hypoxia. Finally, having conducted static adhesion assays, it would be interesting to examine 
the effect of hypoxia upon neutrophil adhesion and transmigration under flow. 
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In this chapter, I observed differences in neutrophil integrin expression, adhesion and 
transmigration under hypoxia. Given that integrin activation not only mediates adhesion, but 
also promotes numerous cellular functions, in the next chapter, I examined the effects of 
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4.1 Introduction and aims 	   	  
Investigations of the effects of hypoxia on ROS generation in neutrophils are limited 
and conflicting. Whilst one report has shown hypoxia increases ROS (Wang and Liu, 2009), 
another study found that GM-CSF primed neutrophils stimulated with fMLP or PMA produced 
lower levels of superoxide anions under hypoxia (McGovern et al., 2011). Similarly, limited 
studies have examined the effects of hypoxia upon NETosis. Increased bactericidal killing was 
reported in neutrophils treated with a HIF-1α agonist, which was mitigated by DNase treatment 
(Zinkernagel et al., 2008). Pharmacological stabilisation of HIF-1α has also been shown to 
promote NETosis (McInturff et al., 2012). Neither study however, examined NETosis cultured 
neutrophils under hypoxia. Therefore, I explored the effects of hypoxia upon neutrophil reactive 
nitrogen species generation, ROS production and NETosis.  
	  
4.2 Neutrophils do not produce detectable levels of reactive nitrogen species 
 
Neutrophils were cultured for either 8 or 12 hours in the absence or presence of IFN-γ, a 
cytokine known to induce nitrite generation. Monocytes treated with IFN-γ for 12 hours were 
used as a positive control for nitrite production. Following incubation, cell supernatants were 
assessed for the presence of nitrites. 
IFN-γ stimulation of 2x106, 5x106 and 1x107 neutrophils did not produce detectable 
levels of nitrites (Figure 4.1A-C). 2x107 neutrophils secreted nanomolar concentrations of 
nitrites following IFN-γ stimulation (Figure 4.1D). These results show that either the Griess 
assay is not sensitive enough to accurately measure nitrites produced by neutrophils or that 
neutrophils do not secrete nitrites on IFN-γ stimulation. Given these results, I did not explore 
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4.3 Neutrophils produce reactive oxygen species on PMA stimulation 
 
 Given the impractically large number of neutrophils required to study reactive nitrogen 
species, I examined ROS generation. A preliminary titration was performed with neutrophils 
isolated from two donors, which were stimulated with PMA concentrations ranging from 0-
400nM. Hydrogen peroxide generation was assessed using the Amplex® UltraRed assay. A 
dose-dependent response was observed in both donors (Figure 4.2). Further experiments 
examining ROS generation were performed using 50nM PMA to ensure that both increased and 
decreased hydrogen peroxide production could be detected. 
  
4.4 Hypoxia does not modulate hydrogen peroxide production by neutrophils 	  
 To examine the effects of hypoxia upon ROS generation, neutrophils were isolated from 
8 healthy donors and cultured for 1 hour under normoxia or hypoxia. HRP and Amplex® 
UltraRed were added and rates of hydrogen peroxide generation measured in the absence or 
presence of PMA. 
 Unstimulated neutrophils produced minimal rates of hydrogen peroxide (Figure 4.3A). 
Unstimulated ROS generation was not altered under hypoxia (p=0.5781). Stimulation with 
PMA induced rapid hydrogen peroxide production. PMA-induced hydrogen peroxide 
generation was not affected by hypoxia (p=0.2136) (Figure 4.3B). 
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Figure 4.2: PMA-stimulated neutrophils produce hydrogen peroxide in a dose-
dependent manner. Isolated neutrophils were cultured for 1 hour under normoxia before the 
addition of 0.5U/ml HRP and 60nM Amplex® UltraRed. 4x105 neutrophils were treated with 
PMA at concentrations varying from 0-400nM and hydrogen peroxide generation assessed. 
(A) Individual rates of hydrogen peroxide from two donors. (B) Average rates obtained from 
both donors. Both donors show a dose-dependent response to PMA.  Data is shown as mean 
rate ±SD of three independent experiments. 
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Figure 4.3: Hypoxia does not modulate neutrophil hydrogen peroxide generation. Neutrophils 
were isolated from whole blood donated from 8 different donors. Cells were cultured for 1 hour 
under either normoxia or hypoxia before the addition of 0.5U/ml HRP and 60nM Amplex® 
UltraRed. 4x105 neutrophils were then treated with 50nM PMA and hydrogen peroxide generation 
evaluated. Rates of hydrogen peroxide production were determined using the Omega software 
package. (A) Minimal hydrogen peroxide was produced by unstimulated neutrophils. There were 
no significant differences between cells cultured under normoxia and those under hypoxia 
(p=0.5781, Wilcoxon matched pairs test). (B) Stimulation with 50nM PMA induced hydrogen 
peroxide production. Statistical analysis did not find a significant difference between normoxic and 
hypoxic neutrophils (p=0.2136, paired t test). Data presented as box plots of all eight matched 
observations. 
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4.5 Integrin blockade does not significantly affect rates of hydrogen peroxide 
generation under normoxia and hypoxia 	  
Next, I assessed hydrogen peroxide generation in the presence of integrin blockade to 
determine whether integrins regulate ROS production. Neutrophils were isolated from 4 healthy 
individuals. Neutrophils were incubated for 1 hour in the absence or presence of 2LPM19c 
(Mac-1-specific blockade), mAb38 (LFA-1-specific blockade), P5D2 (β1 integrin blockade) or 
mAb1976 (αVβ3-specific blockade). HRP and Amplex® UltraRed were added and hydrogen 
peroxide generation measured in response to PMA. Unstimulated neutrophils produced low 
rates of hydrogen peroxide production, whilst PMA-stimulated neutrophils in the absence of 
integrin blockade rapidly produced hydrogen peroxide (Figure 4.4). There was a trend for 
decreased hydrogen peroxide generation following Mac-1 blockade with 2LPM19c, but this 
difference was not significant (p=0.0542). 
In addition, I examined the effects of hypoxia upon hydrogen peroxide generation 
following integrin blockade in 3 healthy donors. Neutrophils were cultured for 1 hour in the 
absence or presence of 2LPM19c, mAb38, P5D2 or mAb1976 under normoxia or hypoxia. HRP 
and Amplex UltraRed® were subsequently added and rates of hydrogen peroxide generation 
measured in response to PMA. There was a trend for decreased rates of hydrogen peroxide 
generation under hypoxia in the absence of integrin blockade (Figure 4.5A). This trend was 
more apparent in neutrophils subjected to integrin blockade (Figure 4.5B-E), however given the 
small number of donors tested, significance was not reached for any of the experimental 
conditions (p=0.2500). 	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Figure 4.4: Integrin blockade does not significantly affect hydrogen peroxide generation. 
Neutrophils were isolated from 4 healthy donors. 2x106 cells were cultured in the absence or 
presence of 10µg/ml 2LPM19c (Mac-1/αMβ2-specific blockade), mAb38 (LFA-1/αLβ2-specific 
blockade), P5D2 (β1 integrin blockade) or mAb1976 (αVβ3-specific blockade) for 1 hour under 
normoxia. Following incubation, 0.5U/ml HRP and 60nM Amplex® UltraRed were added. 
4x105 neutrophils treated with 50nM PMA and hydrogen peroxide generation was assessed. 
Unstimulated neutrophils produced minimal hydrogen peroxide, whilst neutrophils treated with 
50nM PMA rapidly produced hydrogen peroxide. Integrin blockade did not significantly affect 
rates of hydrogen peroxide generation (p=0.0542, Friedman test). Data is presented as the mean 
rate of hydrogen peroxide generation ±SD of all 4 donors. 
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Figure 4.5: Hypoxia does not significantly affect integrin-mediated hydrogen peroxide generation. 
Neutrophils were isolated from 3 healthy donors. 2x106 cells were cultured under normoxia or hypoxia 
for 1 hour in presence of (A) no blockade, (B) 2LPM19c (Mac-1/αMβ2-specific blockade), (C) mAb38 
(LFA-1/αLβ2-specific blockade), (D) P5D2 (β1 integrin blockade) or (E) mAb1976 (αVβ3-specific 
blockade). Following incubation, 0.5U/ml HRP and 60nM Amplex® UltraRed were added. 4x105 
neutrophils were then treated with 50nM PMA and hydrogen peroxide generation was assessed. None 
of the results were statistically significant (p=0.2500, Wilcoxon matched pairs test). Data is presented as 
the mean rate of hydrogen peroxide generation ±SD of all 3 different donors. 
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4.6 PMA stimulation induces neutrophil extracellular trap release 
 
 Having found no effect on hydrogen peroxide production, I examined the effects of 
hypoxia upon NETosis. Immunofluorescence microscopy was used to verify whether 4 hours 
stimulation with PMA was sufficient to induce NETosis. Immunofluorescence imaging using 
uncoated coverslips was unsuccessful as neutrophils failed to adhere to the glass coverslips 
(data not shown). Similarly, coating coverslips with poly-l-lysine produced high background 
and in some cases induced NETosis in unstimulated neutrophils (data not shown).  
Fibrinogen-coated coverslips allowed neutrophils to adhere without inducing NETosis. 
Neutrophils were added to coverslips in the absence or presence of PMA for 4 hours. Cells were 
fixed and stained for histone H3 and mounted onto microscope slides with a DAPI mounting 
medium to stain DNA. Unstimulated cells had a punctate staining pattern, indicating nuclear 
localisation of both DNA and histone H3 (Figure 4.6). PMA stimulation induced the 
externalisation of both DNA and histone H3 (Figure 4.6), indicative of NETosis. 
Having qualitatively demonstrated PMA-induced NETosis, quantitative measurement 
of NETosis was performed. The PicoGreen® dsDNA quantification kit is widely used to 
quantify NETs, as the PicoGreen® reagent fluorescently stains dsDNA. I also developed and 
optimised a capture ELISA to specifically measure NETs. Streptavidin-coated wells were 
coated with a biotin-conjugated anti-MPO capture antibody before incubation with PMA-
stimulated neutrophil supernatants. NETs were detected by an anti-citrullinated histone H3 
antibody followed by a HRP-conjugated secondary antibody. Titrations of all antibodies were 
conducted for optimal concentrations for the detection of NETs (data not shown). 
Following optimisation of the NET capture ELISA, I compared the optimised capture 
ELISA with the PicoGreen® dsDNA quantification kit. Neutrophils were cultured in the 
absence or presence of PMA for 4 or 24 hours. Cell supernatants tested for the presence of 
NETs in both the NET capture ELISA and PicoGreen® dsDNA quantification kit. 
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Figure 4.6: Neutrophils release NETs following PMA stimulation. 5x105 neutrophils were 
added to fibrinogen-coated coverslips and cultured in the absence or presence of 40nM PMA for 4 
hours. Cells were fixed and stained for histone H3 (green) and sealed with a DAPI mounting 
medium (blue). This was repeated with three different donors. Representative images can be seen 
for (A) donor 1 and (B) donor 2. PMA stimulation induced the externalisation of histone H3 and 
DNA, indicative of NETosis and was not seen in untreated cells. Images were taken at 20x 
magnification. 
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Neutrophil supernatants following PMA stimulation for 4 or 24 hours had significantly 
higher OD values compared to untreated neutrophils in the NET capture ELISA (p<0.05 and 
p<0.01 respectively) (Figure 4.7A). Supernatants assessed using the PicoGreen® dsDNA 
quantification kit displayed a similar pattern, however only 24 hours PMA stimulation produced 
significantly higher RFU values (p<0.05) (Figure 4.7B). 
 
4.7 Hypoxia enhances PMA-stimulated NETosis 	  
 Having determined a quantitative method to evaluate NETs, I then studied the effects of 
hypoxia upon NETosis. Neutrophils were isolated and cultured overnight under normoxia or 
hypoxia. Following overnight incubation, cells were cultured in the absence or presence of 
PMA for 4 hours, after which supernatants were assessed for NETs.  
Cell supernatants from PMA-stimulated neutrophils had significantly higher OD values 
compared to untreated cells. OD values from both untreated and PMA-stimulated neutrophil 
supernatants were significantly increased in hypoxia compared to normoxia (p<0.05 and 
p<0.001 respectively) (Figure 4.8).  
 
4.8 NETosis is a cation-dependent process 
 
Next, I conducted a preliminary study to determine whether NETosis is integrin-
dependent. Immunofluorescence staining was performed in the absence or presence of EDTA, 
which chelates divalent cations that are essential for integrin function. 
Untreated neutrophils had a punctate DAPI and histone H3 staining pattern (Figure 
4.9A), whilst PMA stimulation externalised nuclear stains (Figure 4.9B). Neutrophils treated 
with PMA and EDTA also had a punctate staining pattern (Figure 4.9C), demonstrating a 
requirement for cations in NETosis. Manganese cations are able to activate cellular integrins. 
Neutrophils treated with manganese chloride had extracellular DAPI and histone H3 staining 
(Figure 4.9D), which was not observed in neutrophils treated with manganese chloride and 
EDTA (Figure 4.9E). 
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Figure 4.7: Similar results are obtained from a NET capture ELISA and PicoGreen® dsDNA 
quantification kit. 2x106 neutrophils were cultured in the absence or presence of 40nM PMA for 4 
or 24 hours. Cell supernatants were tested for presence of NETs using the (A) NET capture ELISA or 
(B) PicoGreen® dsDNA quantification kit. Readouts were significantly higher in the supernatant of 
neutrophils stimulated with 40nM PMA. Similar patterns were observed between assays. Statistics 
significance was tested using a 2-way ANOVA with a Bonferroni post-test analysis. Data is 
presented as mean ±SD of 3 independent experiments. ns = no significance, * = p<0.05, ** = p<0.01 
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Figure 4.8: Hypoxia enhances NETosis of PMA-stimulated neutrophils. Neutrophils were 
isolated and incubated overnight under either normoxia or hypoxia. Cells were cultured for a 
further 4 hours in the absence or presence of 40nM PMA. Neutrophil supernatants were tested 
for the presence of NETs by capture ELISA.  OD values were significantly higher in untreated 
and PMA-stimulated neutrophils supernatants under hypoxia. Statistical significance was 
tested by two-way ANOVA with a Bonferroni post-test analysis. Data is presented as the mean 
OD ±SD of three independent experiments *=p<0.05, *** = p<0.001 
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Figure 4.9: NETosis is inhibited by EDTA treatment and stimulated by manganese cations. 5x105 
neutrophils were added to fibrinogen-coated coverslips and incubated for 4 hours with (A) untreated 
media, (B) 40nM PMA, (C) 40nM PMA and 5mM EDTA, (D) 0.5mM manganese chloride or (E) 0.5mM 
manganese chloride and 5mM EDTA. Cells were fixed and stained for histone H3 (green) and sealed with 
a DAPI mounting medium (blue). Externalisation of nuclear stains was observed in PMA and manganese 
chloride treated cells, but not those treated with 5mM EDTA. Representative images from each slide are 
shown above. Images were taken at 20x magnification. 
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4.9 Mac-1 activation induces NETosis 	  
 Having shown NETosis is cation-dependent and can be induced with manganese 
cations, thus implicating integrin involvement, I subsequently studied the effects of Mac-1 
activation on NETosis. Leukadherin-1 (LA-1) is a small molecule agonist, which specifically 
activates Mac-1 (Celik et al., 2013). Titrations of LA-1 induced neutrophil adhesion to 
immobilised fibrinogen in a dose-dependent manner (Figure 4.10).  
 Immunofluorescence studies were then conducted to study the effects of LA-1 treatment 
on NETosis. Neutrophils were treated with 10, 25, 100 or 200µM LA-1 for 4 hours and stained 
for NETs. Untreated and 10µM LA-1-treated cells displayed punctate staining (Figure 4.11A, 
B), however neutrophils treated with 25, 100 or 200µM LA-1 demonstrated evidence of 
NETosis (Figure 4.11C-E) similar to that of cells stimulated with 40nM PMA (Figure 4.11F). 	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Figure 4.10: Leukadherin-1 promotes neutrophil adhesion to immobilised fibrinogen. 
Neutrophils were isolated from whole blood and fluorescently labelled with BCECF-AM. 
Neutrophil adhesion to immobilised fibrinogen was then measured in response to several 
concentrations of the small molecule Mac-1 agonist leukadherin-1 (LA-1). Increased adhesion 
compared to DMSO vehicle controls was observed from 15µM, which increased with greater 
LA-1 concentrations. Data is presented as mean adhesion ±SD of three independent 
experiments. 
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Figure 4.11: Mac-1 activation induces NETosis. 5x105 neutrophils were added to fibrinogen-coated 
coverslips and incubated for 4 hours with (A) untreated media, (B) 10µM leukadherin-1 (LA-1), (C) 
25µM LA-1, (D) 100µM LA-1, (E) 200µM LA-1, or (F) 40nM PMA. Cells were fixed and stained for 
histone H3 (green) and sealed with a DAPI mounting medium (blue). Externalisation of nuclear stains 
was observed in neutrophils cultured with LA-1 concentrations of 25µM and greater. PMA stimulation 
also induced extracellular histone H3 and DAPI staining. Representative images from each slide are 
shown above of 2 independent experiments. Images were taken at 20x magnification. 
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4.10 Endothelial co-culture may modulate neutrophil responses to PMA 
 
As integrin activation induced NETosis, I next examined neutrophil responses during 
endothelial co-culture. A preliminary experiment was conducted to explore the effects of 
neutrophil-endothelial interactions upon ROS generation under normoxia. HUVEC were seeded 
into 96-well plates and grown to confluence. Prior to experimentation, cells were cultured 
overnight in the absence or presence of TNF-α. Neutrophils were isolated and treated with HRP 
and Amplex® UltraRed before addition of neutrophils to empty wells or wells containing 
resting or TNF-α-activated endothelial monolayers.  
PMA-induced hydrogen peroxide production was reduced in neutrophils stimulated in 
the presence of resting HUVEC monolayers compared to empty wells (Figure 4.12). 
Interestingly, rates of hydrogen peroxide generation were higher in neutrophils stimulated in the 
presence of TNF-α-activated endothelial monolayers compared to resting HUVEC, similar to 
rates obtained from empty wells (Figure 4.12). Integrin blockade also had greater effects in 
wells containing HUVEC. Whilst each condition was tested in triplicate, the experiment was 
only conducted once so statistical significance cannot be determined. 
 I also studied the contribution of endothelial monolayers to NETosis. Neutrophils were 
added to empty wells or wells containing endothelial monolayers. Neutrophils were cultured in 
the absence or presence of PMA for 4 hours, following which, cell supernatants were assessed 
for NETs by capture ELISA. NETs were detected in the supernatants of PMA-stimulated 
neutrophils, but not HUVEC (Figure 4.13). Neutrophils stimulated in the presence of HUVEC 
had significantly higher levels of NETs compared to neutrophils stimulated in the absence of 
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Figure 4.12: The effects of endothelial co-culture on neutrophil ROS generation. HUVEC 
were grown to confluence. Prior to experimentation, EC monolayers were cultured for 24 hours 
in the absence or presence of 10ng/ml TNF-α. Neutrophils were isolated and cultured in the 
absence or presence of 10µg/ml 2LPM19c (Mac-1/αMβ2-specific blockade), mAb38 (LFA-
1/αLβ2-specific blockade), P5D2 (β1 integrin blockade) or mAb1976 (αVβ3-specific blockade) for 
1 hour under normoxia, after which 0.5U/ml HRP and 60nM Amplex® UltraRed were added. 
4x105 neutrophils were added to empty wells, resting HUVEC monolayers or activated HUVEC 
monolayers. Cells were treated with 50nM PMA and hydrogen peroxide generation was then 
assessed. Neutrophils stimulated in the presence of resting ECs had lower rates of hydrogen 
peroxide generation, compared to empty wells and wells containing TNF-α-activated ECs. 
Integrin blockade had greater effects in the presence of EC monolayers. Statistical significance 
could not be determined as this preliminary experiment was only conducted once. Data is 
presented as the mean rate of hydrogen peroxide generation ±SD of triplicate wells. 
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Figure 4.13: Endothelial co-culture enhances NETosis. HUVEC were grown to confluence 
into endothelial monolayers. Neutrophils were isolated and 2x106 cells were added to either 
empty wells or wells containing EC monolayers. Cells were then cultured for 4 hours in the 
absence or presence of 40nM PMA. Following incubation, cell supernatants were tested for the 
presence of NETs by capture ELISA. Only PMA-stimulated neutrophil supernatants tested 
positive for NETs. Neutrophils stimulated in the presence of endothelial monolayers had 
significantly higher levels of NETs compared to neutrophils stimulated alone. Statistical 
significance was determined by two-way ANOVA with a Bonferroni post-test analysis. Data is 
presented as the mean OD ±SD of three independent experiments. ns= no significance, 
**=p<0.01, *** = p<0.001 
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4.11 Hypoxia alters protein expression in neutrophils 
 
 Having found functional effects of hypoxia upon neutrophil activation, I began to 
explore the mechanisms underpinning neutrophil activation. Given the importance of MPO and 
PAD-4 in NETosis, preliminary experiments were conducted to determine the expression and 
intracellular localisation of both proteins in response to hypoxia and PMA stimulation.  
Neutrophils were cultured under normoxia or hypoxia for 4 hours in the absence or 
presence of PMA. Following incubation, cells were lysed using a ProteoExtract® subcellular 
proteome extraction kit (Millipore, Ireland), to obtain cytosolic, membrane, nuclear and 
cytoskeletal cell lysate fractions. Cell lysates from each fraction were resolved by gel 
electrophoresis and transferred to a PVDF membrane, which was probed for MPO, PAD-4 and 
GAPDH by immunoblot (Figure 4.14A).  
MPO was predominately found in nuclear cell fractions. Unstimulated neutrophils 
cultured under normoxia had greater MPO expression than unstimulated hypoxic cells (Figure 
4.14B). In contrast, greater MPO expression in PMA-stimulated neutrophils was seen under 
hypoxia compared to normoxia (Figure 4.14C).  
PAD-4 expression was only seen in cytosolic cell fractions. Unstimulated hypoxic 
neutrophils had twice as much PAD-4 expression compared to normoxic cells (Figure 4.14D). 
PMA stimulation increased expression in normoxic cells, however expression was still higher in 
hypoxic cells (Figure 4.14E). 	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Figure 4.14: Hypoxia alters intracellular expression of PAD-4 and MPO in neutrophils. 
Neutrophils cultured under normoxia or hypoxia in the absence or presence of 40nM PMA for 4 hours, 
after which cells were subjected to fractional lysis. (A) Resolved proteins were transferred to a PVDF 
membrane, which were probed for MPO and PAD-4, which were normalised to GAPDH. (B) 
Unstimulated hypoxic neutrophils had lower MPO levels. (C) Greater MPO levels were observed in 
PMA-stimulated neutrophils under hypoxia. (D) PAD-4 levels were higher in unstimulated hypoxic 
neutrophils. (E) Hypoxic stimulated neutrophils had lower levels than unstimulated cells, but had 
higher levels than normoxic counterparts. Cy= cytosolic, M= membrane, N= nuclear, CSk=cytoskeletal 
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4.12 Inhibition of p38 MAPK, but not mTOR, reduces PMA-induced NETosis 	  
Before determining whether hypoxia modulates signalling pathways regulating 
NETosis, I conducted preliminary experiments to highlight the key pathways involved in PMA-
induced NETosis. Given that p38 MAPK signalling has been implicated in PMA-induced 
NETosis (Riyapa et al., 2012) as well as the importance of mTOR and HIF-1α in the regulation 
of NET release (McInturff et al., 2012), I studied the effects of mTOR and p38 MAPK 
inhibition on NETosis. 
Neutrophils were incubated with varying concentrations of rapamycin or SB203580, 
which inhibit mTOR and p38 MAPK signalling respectively, for 2 hours and then treated with 
PMA for a further 4 hours. Following incubation, supernatants were assessed for the presence of 
NETs. There was a trend for decreased NETosis with increasing concentrations of rapamycin, 
but these differences did not reach significance (Figure 4.15A). In contrast, a significant dose-
dependent reduction in NETosis was observed in neutrophils treated with 10µM and 20µM 
SB203580 (Figure 4.15B). 
 
4.13 Hypoxia induces transient endothelial PAD-4 expression and activity 	  
In addition to studying the effects of hypoxia upon neutrophil protein expression, I also 
examined the endothelial PAD-4 and citrullinated histone H3 expression. A preliminary time 
course experiment was conducted in which HUVEC were exposed to hypoxia for up to 24 
hours, before cells were lysed and proteins resolved by gel electrophoresis. Resolved proteins 
were transferred to a membrane and probed for HIF-1α, PAD-4, citrullinated histone H3 and β-
tubulin (Figure 4.16A). HIF-1 α protein levels increased by 3.1 fold compared to baseline 
following 4 hours in hypoxia, before declining back to baseline (Figure 4.16B). PAD-4 
expression increased by 1.2 fold following 4 hours of hypoxic culture (Figure 4.16C). Levels of 
citrullinated histone H3 also rapidly increased by 15 fold above baseline after 4 hours 
incubation in hypoxia (Figure 4.16D). As this experiment was only conducted once, statistical 
significance could not be determined. 
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Figure 4.15: Inhibition of p38 MAPK, but not mTOR signalling significantly reduces 
NETosis. Neutrophils were isolated and treated with varying concentrations of rapamycin or 
SB203580 for 2 hours and then stimulated with 40nM PMA for 4 hours and supernatants assessed 
for NETs by capture ELISA. (A) A marginal decrease was observed with increasing rapamycin 
concentrations, however this difference was not significant. (B) PMA-stimulated NETosis 
significantly decreased with increasing concentrations of SB203580. Statistical significance was 
tested by one-way ANOVA with a Bonferroni multiple comparison test. Data is presented as the 
mean OD ±SD of two independent experiments. ns= no significance, *=p<0.05, ** = p<0.01 
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4.14 Discussion 
 
 In this chapter, I have shown that PMA induces neutrophil hydrogen peroxide 
production, which is neither modulated by hypoxia nor integrin blockade. PMA stimulation 
induces NETosis, which is enhanced under hypoxia and is cation-dependent. Preliminary work 
has implicated Mac-1 activation in the generation of NETs. Co-culture of neutrophils with ECs 
appears to modulate neutrophil responses, however further work is required to validate 
preliminary findings. Hypoxia increases PAD-4 expression in neutrophils, with increased PAD-
4 and citrullinated histone H3 also being observed in HUVEC. In this section I will discuss my 
findings within the context of published reports, evaluate limitations of my work and explore 
avenues of future work. 
	  
4.14.1 Effects of hypoxia upon ROS generation 	  
There is conflicting evidence regarding the effects of hypoxia on neutrophil ROS 
generation. Whilst Wang and Lui reported increased ROS production when neutrophils were 
exposed to 12% oxygen (Wang and Liu, 2009), McGovern et al. found defective ROS 
production when neutrophils primed with GM-CSF were stimulated under 3% oxygen 
(McGovern et al., 2011). The latter study is most similar to my work, but I cultured neutrophils 
at 1% oxygen and did not prime cells prior to treatment. I did not find a significant difference in 
hydrogen peroxide production by neutrophils stimulated under normoxia and hypoxia.  
Conflicting evidence may be explained by considering the cellular effects of the varying 
oxygen levels. Jiang and colleagues had previously demonstrated that HIF-1α protein 
expression and DNA-binding activity was only seen in HeLa S3 nuclear extracts when exposed 
to 5% oxygen or lower (Jiang et al., 1996). It is therefore possible that the neutrophils exposed 
to 12% oxygen by Wang and Lui lacked HIF-mediated signalling. In contrast, as both my own 
work and that of McGovern et al. had cultured neutrophils below 5% oxygen, responses are 
likely to be mediated by HRE-mediated transcription. Given the discrepant findings and 
variations in experimental conditions, further work is required to determine the precise effects 
of hypoxia upon ROS generation in neutrophils.  
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4.14.2 Effects of hypoxia upon NETosis 
 
Two studies have examined the role of HIF-1α in NETosis, both of which implicate 
HIF-1α signalling with enhanced NETosis. Neither study subjected neutrophils to hypoxia, but 
instead treated cells with hypoxia mimetics. Neutrophils treated with the HIF-1α agonist 
mimosine displayed increased bactericidal killing, which was mitigated by the degradation of 
extracellular DNA via DNase treatment (Zinkernagel et al., 2008). In addition, mTOR-
dependent HIF-1α stabilisation promoted NETosis, whilst inhibition of either mTOR or HIF-1α 
reduced NETosis (McInturff et al., 2012). My work conducted under low oxygen levels is 
consistent with these published reports using hypoxia mimetics. Whilst these studies show that 
pharmacological stabilisation of HIF-1α enhances NET release, my results demonstrate that 
culture under hypoxia, which stabilises HIF-1α expression, promotes NETosis in human 
neutrophils. Therefore, an important factor in NETosis is the stabilisation of HIF-1α. 
	  
4.14.3 Molecular mechanisms and cell signalling underlying neutrophil activation 
 
 Conflicting evidence exists regarding the molecular and signalling events regulating 
neutrophil activation under hypoxia. Several studies have shown Mac-1 blockade reduces 
NETosis (Neeli et al., 2009, Raftery et al., 2014, Rossaint et al., 2014, Yalavarthi et al., 2015), 
but did not dissect integrin involvement further. Similar observations have been reported with β1 
integrin blockade (Lavigne et al., 2007, Gillenius and Urban, 2015). My preliminary data shows 
that NETosis is cation-dependent, which indirectly supports these published reports. Moreover, 
my data showing LA-1, which specifically activates Mac-1 via allosteric conformational 
changes (Celik et al., 2013), induces NETosis complements the findings of published reports 
showing reduced NETosis following Mac-1 inhibition.	  
 My preliminary data show that endothelial co-culture, particularly with activated ECs, 
may modulate neutrophil hydrogen peroxide generation. NETosis was also elevated in 
neutrophils cultured with resting ECs. Published reports demonstrate that activated ECs can 
induce NETosis (Gupta et al., 2010), therefore cellular interactions with ECs may promote NET 
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production and release. Further work evaluating NETosis in the presence of activated ECs may 
provide data more consistent with published reports.  
I found increased PAD-4 expression in neutrophils following 4 hours culture under 
hypoxia. There was also an increase in PAD-4 expression in HUVEC exposed to hypoxia, 
however as there were no EC normoxic comparisons, it is impossible to say whether this finding 
represents increased expression in response to hypoxia. A published report has documented 
increased PAD-2 expression and activity in astrocytes exposed to hypoxia (Sambandam et al., 
2004), however the effects of hypoxia upon PAD-4 expression have not been studied. My novel 
finding demonstrates that PAD-4 expression is also under hypoxic regulation. Increased 
citrullinated histone H3 under hypoxia was noted in ECs, which indicates enhanced PAD-4 
activity, however due to the lack of normoxic controls, this observation cannot be conclusively 
attributed to the effects of hypoxia. 
There is conflicting evidence regarding the contribution of mTOR in NETosis. In one 
report, mTOR signalling promotes NETosis via HIF-1α stabilisation (McInturff et al., 2012), 
whilst in another publication, mTOR inhibited NETosis through suppression of autophagy 
(Itakura and McCarty, 2013). My preliminary data found that mTOR inhibition with rapamycin 
did not significantly affect PMA-induced NETosis. In these published reports, neutrophils were 
stimulated with either LPS or fMLP, whilst in my work neutrophils were stimulated with PMA. 
Therefore, it is possible that mTOR does not regulate NETosis in response to PMA stimulation. 
In contrast, treatment with the p38 MAPK inhibitor SB203580 significantly reduced NET 
release in PMA-stimulated neutrophils. This observation is consistent with published reports, 
which have also found that PMA-induced NETosis was reduced following p38 MAPK 
inhibition (Riyapa et al., 2012). 
	  
4.14.4 Future work 	  
 There are many avenues in which my work could be expanded. With regards to 
hydrogen peroxide generation, as my work only examined the effects of hypoxia after 1 hour 
exposure, additional time points up until 8 hours could be studied to explore the effects of 
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longer culture under hypoxia upon ROS generation. Additional experiments could also be 
conducted to examine the effects of integrin blockade on hydrogen peroxide generation by 
neutrophils in the presence of immobilised ligands. Further investigation is required to expand 
on my preliminary data exploring the effects of endothelial co-culture upon neutrophil ROS 
generation. In addition, whilst the Amplex® UltraRed assay is a robust assay, it may be useful 
to assess ROS generation using flow cytometry-based assays that allow for the identification of 
several species of both reactive oxygen and nitrogen species, which would provide a better 
understanding of how hypoxia affects neutrophil activation. 
 I would have also liked to conduct further endothelial co-culture experiments. Studying 
NETosis in co-culture with resting and activated endothelium would validate and expand upon 
my preliminary data. Inclusion of functional blocking antibodies against both neutrophil 
integrins and endothelial adhesion molecules would build upon published studies and identify 
the cellular interactions that promote NETosis in co-culture. Examining the effects of hypoxia 
on cellular interactions and how they modulate NETosis would provide further insight into 
neutrophil biology. 
 Further work is also required to complete studies examining the effects of hypoxia upon 
protein expression and subcellular localisation in both neutrophil and ECs. Earlier time points 
would highlight the dynamics of protein expression and subcellular localisation, which may 
indicate how hypoxia affects protein trafficking. Given that the proteins examined are integral 
to NET structure and function, assessing cell supernatants for MPO, citrullinated histone H3, 
and even PAD-4 (Spengler et al., 2015), would contribute to our understanding of the kinetics 
and dynamics of NETosis under hypoxia, from protein synthesis to release within NETs. 
 Finally, further dissection of the signalling pathways involved may highlight important 
signalling molecules important to NETosis during hypoxia. For example, as p38 MAPK 
inhibition exhibited a dose-dependent inhibitory effect in NETosis, it would be interesting to 
examine the effects of hypoxia upon p38 MAPK expression and activity. Having explored the 
effects of hypoxia upon neutrophil activation, in the next chapter, I will evaluate the modulatory 
role of IgG upon neutrophil function. 
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5.1 Introduction and aims 	  
 Neutrophil dysfunction has been implicated in the pathology of RA, SLE and APS, but 
few studies have examined the effects of purified IgG upon neutrophil adhesion and activation. 
SLE- and APS-IgG enhance monocyte adhesion to ECs (Simantov et al., 1995, Del Papa et al., 
1999), but the effects upon adhesion of other leukocytes have not been explored. RA-IgG has 
been found to modulate in vitro NETosis (Khandpur et al., 2013), with a similar effect being 
observed with SLE-IgG in mouse models (Knight et al., 2013). Recent studies have also shown 
that APS-IgG enhances NETosis (Yalavarthi et al., 2015). Therefore, I carried out work in this 
chapter to examine how purified IgG affects neutrophil adhesion, ROS generation and NETosis. 
 
5.2 IgG purification from the serum of patients with RA, SLE and APS  
 
 To examine the effects of IgG upon neutrophil activation, I first purified whole IgG 
fractions from the sera of HCs and patients with RA, SLE or APS. Demographic details of these 
IgG samples are listed in Table 5.1. 
 The RA cohort had a mean age of 51 ±13.4 years, which was significantly older than 
SLE, APS and HC cohorts (p<0.05). All 9 RA patients had inflammatory arthritis, 1 patient was 
hypertensive, 1 had ILD and 1 had rheumatoid nodules. There was a range of 
immunomodulatory medications within the RA cohort: 5 patients were prescribed HCQ; 3 
patients received methotrexate; 1 patient was prescribed prednisolone; and 1 patient was 
prescribed sulfasalazine. In addition, 2 patients had been administered rituximab and 1 patient 
had stopped humira between 3-6 months before the time of serum preparation. 
 The SLE cohort had a mean age of 32 ±7.4 years. Within the cohort, 2 patients had 
arthralgia, 4 had nephritis and 2 had a lupus-associated rash. SLE patients were also prescribed 
a range of immunomodulatory treatments: 5 patients were prescribed mycophenolate mofetil; 5 
patients were prescribed prednisolone; 4 patients were taking HCQ; and 1 patient was 
prescribed tacrolimus. Three patients were also prescribed aspirin. 
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 The APS cohort had a mean age of 39 ±10.1 years. 7 patients had venous thrombotic 
clinical events, whilst the remaining 2 had pregnancy morbidity. 1 patient was prescribed 
prednisolone. All 9 patients were taking warfarin and 1 was prescribed aspirin as 
thromboprophylaxis. 
 The HC cohort had a mean age of 39 ±4.5 years. None of these subjects had any clinical 
complications and were not taking any prescribed medications. 
ACPA and ANCA titres were determined by ELISA, with positivity defined as ACPA 
titres of 5 U/ml or greater and ANCA ratios greater than 4.0, as determined by manufacturer 
protocol. 8 of 9 RA-IgG samples were ACPA positive (20.46-299.3 U/ml) and one was ACPA 
negative (1.57 U/ml). All other IgG samples were ACPA negative: SLE-IgG (2.04-2.99 U/ml); 
APS-IgG (2.03-2.40 U/ml); and HC-IgG (2.00-2.32 U/ml). All IgG samples were negative for 
both PR3- and MPO-ANCA: RA-IgG (PR3-ANCA: 0.66-0.90; MPO-ANCA: 0.67-0.90); SLE-
IgG (PR3-ANCA: 0.69-0.79; MPO-ANCA: 0.70-0.76); APS-IgG (PR3-ANCA: 0.69-0.83; 
MPO-ANCA: 0.72-0.81); and HC-IgG (PR3-ANCA: 0.69-1.18; MPO-ANCA: 0.70-0.82). 
	  
5.3 APS-IgG enhances PMA-induced neutrophil adhesion to fibronectin 
 
 To examine the effects of IgG upon integrin activation, I assessed neutrophil adhesion 
to immobilised integrin ligands in the presence of purified IgG. First the effects of IgG upon β1 
integrin activation were investigated by examining neutrophil adhesion to immobilised 
fibronectin. Neutrophils were allowed to adhere to immobilised fibronectin in the absence or 
presence of PMA and purified IgG.  
Unstimulated neutrophils displayed a 1.5 to 2.5 fold increase in adhesion to fibronectin 
in the presence of IgG, however increased adhesion was not significant compared to no IgG 
controls (Figure 5.1A). Stimulation with PMA increased neutrophil adhesion in the presence 
and absence of IgG. Neutrophils treated with HC-IgG had similar binding to no IgG controls 
(Figure 5.B). APS-IgG significantly increased PMA-stimulated adhesion to immobilised 
fibronectin compared to HC-IgG (p<0.05). Although there was a trend for increased adhesion in  
 
Chapter Five: The Effects of Purified Immunoglobulin G on Neutrophil Function 
	   191	   
Figure 5.1: APS-IgG significantly enhances PMA-stimulated neutrophil adhesion to immobilised 
fibronectin. To examine the modulatory effects of IgG upon β1 integrin activation, neutrophil 
adhesion to immobilised fibronectin in the presence of IgG was studied. 5x105 fluorescently labelled 
neutrophils were added to fibronectin-coated wells in the absence or presence of 20nM PMA and 
200µg/ml of purified RA-IgG (n=7), SLE-IgG (n=4), APS-IgG (n=6) or HC-IgG (n=6). (A) The 
presence of purified IgG increased adhesion, however this increase was not significant compared to no 
IgG (B) APS-IgG significantly increased PMA-induced adhesion to fibronectin compared to HC-IgG. 
Statistical significance was determined by a Kruskal-Wallis test with a Dunn’s multiple comparison 
test. Data is presented as box plots, with averaged results for each IgG samples from three independent 
experiments. Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, systemic lupus 
erythematosus; APS, antiphospholipid syndrome. ns= no significance *=p<0.05 
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PMA-stimulated neutrophils treated with RA- and SLE-IgG, these differences failed to reach 
statistical significance. 
To determine whether the increased PMA-stimulated adhesion to fibronectin was β1 
integrin-dependent, adhesion assays were conducted in the absence or presence of P5D2, which 
specifically inhibits β1 integrin-mediated adhesion. For all IgG groups, incubation with P5D2 
significantly reduced adhesion, demonstrating that the adhesion observed in the presence of IgG 
was mediated by β1 integrin activation (Figure 5.2A-D). 
 
5.4 RA- and SLE-IgG enhance Mac-1-mediated neutrophil adhesion  	  
 Having found differential β1 integrin activation by APS-IgG, I then studied the effects 
of purified IgG upon β2 integrin-mediated adhesion. To interrogate activation of Mac-1, rather 
than LFA-1, neutrophil adhesion to immobilised fibrinogen was examined. Neutrophils were 
added to fibrinogen-coated wells and adhesion assessed in the absence or presence of PMA and 
HC-, RA-, SLE- or APS-IgG. 
Low binding to fibrinogen was observed by unstimulated neutrophils. Adhesion was 
increased by the presence of purified IgG, however these differences were not significant 
(Figure 5.3A). In contrast, PMA stimulation significantly increased neutrophil adhesion to 
fibrinogen, which was further modulated by the presence of certain ARD-IgG (Figure 5.3B). 
HC-IgG did not significantly alter adhesion compared to no IgG controls. Significant increases 
in neutrophil adhesion to immobilised fibrinogen were observed in the presence of RA-IgG 
(p<0.05) and SLE-IgG (p<0.01) but not APS-IgG (p>0.05) compared to HC-IgG. 
To determine whether the increased PMA-stimulated adhesion observed was Mac-1-
dependent, neutrophil adhesion was also examined in the absence or presence of the Mac-1-
specific blocking antibody 2LPM19c. For all IgG groups, PMA-induced neutrophil adhesion 
was significantly reduced by the presence of 2LPM19c (Figure 5.4A-D). Therefore, RA- and 
SLE-IgG modulate PMA-stimulated neutrophil adhesion to fibrinogen by promoting Mac-1 
activation. 
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Figure 5.2: Increased PMA-stimulated neutrophil adhesion to fibronectin is inhibited by β1 
integrin blockade. To assess whether increased adhesion to fibronectin was integrin mediated, 
adhesion assays were performed in the absence or presence of 10µg/ml of the pan-β1 integrin 
inhibitor P5D2. 5x105 fluorescently labelled neutrophils were allowed to adhere to immobilised 
fibronectin with 20nM PMA and 200µg/ml of (A) HC-IgG (n=6) (B) RA-IgG (n=7) (C) SLE-IgG 
(n=4) or (D) APS-IgG (n=6). P5D2 significantly reduced adhesion for all groups by Wilcoxon 
matched pairs tests. Data is presented as matched observations with averaged results from three 
independent experiments. Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; APS, antiphospholipid syndrome. 
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Figure 5.3: RA- and SLE-IgG enhance PMA-stimulated neutrophil adhesion to immobilised 
fibrinogen. To examine the effects of IgG upon β2 integrin activation, neutrophil adhesion to 
immobilised fibrinogen in the presence of IgG was assessed. 5x105 fluorescently labelled neutrophils 
were added to fibrinogen-coated wells in the absence or presence of 20nM PMA and 200µg/ml of 
purified RA-IgG (n=7), SLE-IgG (n=4), APS-IgG (n=6) or HC-IgG (n=6). (A) The presence of IgG 
did not significantly increase neutrophil adhesion in the absence of PMA (B) Significant increases in 
adhesion in the presence of PMA was observed in the presence of RA-IgG and SLE-IgG. Statistical 
significance was determined by a Kruskal-Wallis test with a Dunn’s multiple comparison test. Data is 
presented as box plots, with averaged results for each IgG samples from three independent 
experiments. Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, systemic lupus 
erythematosus; APS, antiphospholipid syndrome. ns= no significance *=p<0.05, ***=p<0.001 
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Figure 5.4: Enhanced PMA-induced neutrophil adhesion to fibrinogen is inhibited by Mac-
1 blockade. To determine whether adhesion to fibrinogen was integrin mediated, assays were 
performed in the absence or presence of 10µg/ml of the Mac-1 (αMβ2) inhibitor 2LPM19C. 
5x105 fluorescently labelled neutrophils were allowed to adhere to immobilised fibrinogen with 
20nM PMA and 200µg/ml of (A) HC-IgG (n=6) (B) RA-IgG (n=7) (C) SLE-IgG (n=4) or (D) 
APS-IgG (n=6). Paired t tests found significant decreases in adhesion with 2LPM19C treatment 
in panels A and B. Wilcoxon matched pairs tests found 2LPM19C significantly reduced 
adhesion in panels C and D. Data is presented as matched observations with averaged results 
from three independent experiments. Abbreviations: HC, healthy control; RA, rheumatoid 
arthritis; SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome.  
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5.5 RA-, SLE- and APS-IgG bind neutrophils  	  
Having found an effect of purified IgG upon neutrophil adhesion to immobilised 
integrin ligands, I examined whether purified IgG bound neutrophils. To exclude non-specific 
effects of FcR binding, neutrophils were cultured in the absence or presence of a FcR blocking 
reagent (Miltenyi, UK) with IgG pooled from either healthy volunteers or patients with RA, 
SLE or APS characterised in Table 5.1. Following incubation, neutrophils were fixed and 
stained for CD15 and human IgG, to determine the extent to which purified IgG bound 
neutrophils. 
CD15+ neutrophils incubated with either no IgG or HC-IgG had low positivity for 
human IgG (Figure 5.5A), demonstrating low binding to neutrophils. Significantly higher levels 
of CD15+IgG+ neutrophils were observed when cells were incubated with RA-, SLE or APS-
IgG (Figure 5.5A), indicating increased binding of ARD-IgG to neutrophils. Furthermore, 
neutrophils incubated with RA-, SLE- or APS-IgG in the absence of FcγR blockade had 
significantly higher binding compared to cells treated with HC-IgG (p<0.01) (Figure 5.5B). 
Interestingly in the presence of FcγR blockade, significantly more neutrophils bound RA-IgG 
(p<0.001) and APS-IgG (p<0.05) compared to HC-IgG (Figure 5.5C). Incubation with SLE-IgG 
however, failed to produce significantly higher numbers of IgG+ neutrophils compared to HC-
IgG (Figure 5.5C). 
Binding of pooled IgG was also compared in the absence or presence of FcγR blockade 
(Figure 5.6). Binding of HC-, RA- and APS-IgG was not significantly affected by FcγR 
blockade (Figure 5.6A, B, D), however significantly lower numbers of neutrophils were positive 
for human IgG when cultured with SLE-IgG in the presence of FcγR blockade (Figure 5.6C). 
Having shown that purified IgG can directly bind neutrophils and modulate neutrophil adhesion 
to fibronectin and fibrinogen, I then examined the effects of purified IgG upon other aspects of 
neutrophil activation.  	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Figure 5.6: Binding of SLE-, but not HC-, RA- or APS-IgG to neutrophils is reduced by FcγR 
blockade. IgG binding was compared in the absence or presence of FcγR blockade. 2x105 neutrophils 
from 9 donors were cultured for 2 hours with 200µg/ml pooled HC-, RA-, SLE- or APS-IgG (IgG 
pools were comprised of 5 IgG samples previously characterised in Table 5.1). After incubation, cells 
were stained for CD15 and human IgG and then analysed by flow cytometry. (A) Binding of HC-IgG 
was not significantly affected by FcγR blockade (Wilcoxon matched pairs test). (B) RA-IgG binding 
was not affected by the presence of FcγR blockade (paired t test). (C) Binding of SLE-IgG was 
significantly lower in the presence of FcγR blockade (paired t test). (D) APS-IgG was not significantly 
affected by FcγR blockade (Wilcoxon matched pairs test). Abbreviations: HC, healthy control; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome 
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5.6 SLE patient-derived neutrophils have lower rates of hydrogen peroxide 
generation  
 
To explore the effects of purified IgG upon neutrophil activation, I began by examining 
the effects of IgG upon neutrophil hydrogen peroxide generation. First, to determine whether 
there were intrinsic differences in ROS production between control and patient populations, I 
compared hydrogen peroxide generation in neutrophils isolated from separate cohorts of HC 
and patients with RA, SLE or APS, demographics shown in Table 5.2.  
 RA patients had a mean age of 62 ±4.1 years, which was significantly older than SLE 
(p<0.05), APS (p<0.05) and HC cohorts (p<0.001). All 7 RA patients had inflammatory 
arthritis, 1 patient was hypertensive, 3 had ILD and 1 had rheumatoid nodules. There was a 
range of immunomodulatory medications within the RA cohort: 5 patients were prescribed 
HCQ; 1 patient received methotrexate; and, 1 patient was prescribed prednisolone. In addition, 
1 patient had received rituximab 6 months prior to blood donation. 
 The SLE cohort had a mean age of 40 ±4.5 years. Within the cohort, 3 patients had 
arthralgia, 6 had nephritis, 2 had ILD and 2 had a lupus-associated rash. SLE patients were also 
prescribed a range of immunomodulatory treatments: 12 patients were prescribed 
mycophenolate mofetil; 12 patients were prescribed prednisolone; 8 patients were taking HCQ; 
and 2 patients were prescribed tacrolimus. Five patients with SLE were also prescribed aspirin.  
 APS patients had a mean age of 44 ±13.7 years. 5 patients had venous thrombotic 
clinical events, 2 patients had pregnancy morbidity and 3 had both thrombotic and pregnancy 
manifestations. At the time of blood donation, 3 patients were prescribed prednisolone. Five 
patients were taking warfarin and 8 were taking aspirin as thromboprophylaxis. 
The HC cohort had a mean age of 36 ±8.2 years. None of the subjects had any clinical 
complications and were not taking any prescribed medications at the time of blood donation. 
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Neutrophils were isolated from patients with RA (n=7), SLE (n=12) or APS (n=10) and 
HC (n=12). Rates of hydrogen peroxide were assessed in the absence or presence of PMA. Low 
levels of hydrogen peroxide were seen in unstimulated neutrophils, which were not significantly 
different between patient and control populations (Figure 5.7A). PMA stimulation induced 
hydrogen peroxide generation in all groups, however rates of production were significantly 
lower in SLE-derived neutrophils compared to neutrophils isolated from patients with RA 
(p<0.05), APS (p<0.001) and HC (p<0.05) (Figure 5.7B). There was a trend to faster rates of 
hydrogen peroxide production by neutrophils derived from APS patients compared to HC, 
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Figure 5.7: Neutrophils isolated from SLE patients display slower rates of hydrogen 
peroxide generation. To examine whether there were differences in reactive oxygen species 
generation between patient and control populations, neutrophils were isolated patients with RA 
(n=7), SLE (n=12) or APS (n=10) and healthy volunteers (n=12) and rates of hydrogen 
peroxide production from 4x105 neutrophils were assessed in the absence or presence of 50nM 
PMA. (A) Neutrophils produce low rates of hydrogen peroxide production in the absence of 
PMA. Rates were similar across all groups. (B) SLE-derived neutrophils has slower rates of 
PMA-stimulated hydrogen peroxide generation compared to RA, APS and HC. Statistical 
significance was determined by one-way ANOVA with a Bonferroni’s multiple comparison 
test. Data is presented as box and whisker plots from averaged observations from each patient. 
Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, systemic lupus 
erythematosus; APS, antiphospholipid syndrome. *=p<0.05, ***=p<0.001 
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5.7 RA- and SLE-IgG elevate rates of hydrogen peroxide generation 
 
Having found reduced rates of hydrogen peroxide in neutrophils of patients with SLE, I 
then examined the effects of purified IgG upon ROS production by HC neutrophils. A 
preliminary experiment was conducted to determine whether incubation of neutrophils with IgG 
induced FcR-mediated modulation of neutrophil activation. HC neutrophils were isolated and 
incubated with HC-IgG (n=6) or RA-IgG (n=9) in the absence or presence of a FcR blocking 
reagent (Miltenyi, UK). Rates of hydrogen peroxide generation were then measured in response 
to PMA (Figure 5.8A). In the absence of FcγR blockade, rates of hydrogen peroxide generation 
were not significantly different between neutrophils incubated with HC- and RA-IgG 
(p=0.0813). In contrast, RA-IgG significantly increased hydrogen peroxide generation 
compared to HC-IgG in the presence of FcγR blockade (p=0.0008). FcγR blockade significantly 
reduced hydrogen peroxide production rates in neutrophils incubated with HC-IgG (p=0.0169) 
(Figure 5.8B). In contrast, no significance difference was observed in RA-IgG treated cells in 
the absence or presence of FcγR blockade (p=0.2348) (Figure 5.8C). Given these observations, 
FcγR blockade was used for all further functional neutrophil activation assays. 
To examine the effects of purified IgG upon ROS generation, HC neutrophils were pre-
incubated with HC-IgG (n=9), RA-IgG (n=9), SLE-IgG (n=4) or APS-IgG (n=9) for 1 hour. 
Following incubation, rates of hydrogen peroxide production were measured in the absence or 
presence of PMA. Unstimulated neutrophils produced low levels of hydrogen peroxide, which 
were similar across all IgG groups (data not shown). PMA stimulation induced hydrogen 
peroxide generation, with ARD-IgG conferring a modulatory effect. Pre-incubation with HC-
IgG did not significantly affect rates of PMA-induced hydrogen peroxide production compared 
to no IgG controls (Figure 5.9). Rates of hydrogen peroxide generation were significantly 
increased following pre-incubation with RA-IgG (p<0.01) and SLE-IgG (p<0.001) compared to 
HC-IgG. A trend for increased hydrogen peroxide generation was observed following pre-
incubation with APS-IgG, but differences failed to reach statistical significance.  
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Figure 5.8: FcγR blockade reduces hydrogen peroxide generation in the presence of HC-IgG but 
not RA-IgG. Hydrogen peroxide generation by 4x105 neutrophils was measured in the absence or 
presence of FcγR blockade and 200µg/ml HC-IgG (n=6) or RA-IgG (n=9) in response to 50nM PMA. 
(A) HC-IgG produced similar rates of hydrogen peroxide generation as no IgG controls. In the absence 
of FcγR blockade, HC- and RA-IgG were not significantly different (p=0.0813, unpaired t test), whereas 
in the presence of FcγR blockade, differences were significantly different (p=0.0008, unpaired t test). 
(B) FcγR blockade significantly reduced hydrogen peroxide production in the presence of HC-IgG 
(p=0.0169, paired t test). (C) FcγR blockade did not significantly affect hydrogen peroxide generation in 
the presence of RA-IgG (p=0.2348, paired t test). Data is presented as box and whisker plots or matched 
observations from each IgG sample. Abbreviations: HC, healthy control; RA, rheumatoid arthritis 
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Figure 5.9: Neutrophils treated with RA- or SLE-IgG display elevated rates of hydrogen 
peroxide generation. Healthy control neutrophils were isolated and treated with FcγR 
blockade. Cells were then incubated for 1 hour with 200µg/ml purified RA-IgG (n=9), SLE-
IgG (n=4), APS-IgG (n=9) or HC-IgG (n=9). Following incubation, 4x105 neutrophils were 
added to the wells of a 96-well black tissue culture plate and rates of hydrogen peroxide 
generation evaluated in response to 50nM PMA. Significantly higher rates of hydrogen 
peroxide production were observed in neutrophils incubated with RA- or SLE-IgG compared 
to HC-IgG. Statistical significance was determined by a Kruskal-Wallis test with a Dunn’s 
multiple comparison test. Data is presented as box and whisker plots from averaged 
observations made in three independent experiments. Abbreviations: HC, healthy control: RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome. 
ns= no significance, **=p<0.01, ***=p<0.001 
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5.8 RA- and SLE-IgG modulate NETosis in control neutrophils 
 
 Having demonstrated a modulatory effect of purified ARD-IgG upon neutrophil 
adhesion and ROS generation, I subsequently explored the effects of purified IgG upon 
NETosis.  
HC neutrophils were isolated and pre-incubated with purified HC-IgG (n=5), RA-IgG 
(n=5), SLE-IgG (n=5) or APS-IgG (n=5) for 1 hour in the presence of FcγR blockade. To 
examine spontaneous NETosis, following pre-incubation cells were incubated for a further 4 
hours. Some neutrophils were treated with PMA or LPS for 4 hours to examine whether IgG 
modulates PMA-induced or LPS-induced NETosis. Following incubation, neutrophil 
supernatants were obtained by centrifugation and assessed for the presence of NETs using the 
Quanti-iT™ PicoGreen® dsDNA kit. 
Unstimulated neutrophils cultured with HC-IgG had similar levels of NETs compared 
to no IgG controls. Significant increases in cell-free DNA were observed in neutrophils cultured 
with RA-IgG (p<0.05) and SLE-IgG (p<0.01) (Figure 5.10). APS-IgG did not significantly 
increase spontaneous NETosis in HC neutrophils compared to HC-IgG. 
Addition of PMA stimulation increased cell-free DNA in all neutrophils (Figure 5.11). 
HC-IgG did not significantly modulate PMA-induced NETosis further, compared with 
neutrophils stimulated in the absence of purified IgG. Pre-incubation with RA-IgG, prior to 
PMA stimulation significantly increased NETosis compared to HC-IgG (p<0.01) (Figure 5.11). 
Pre-incubation with SLE- or APS-IgG did not significantly affect PMA-induced NETosis 
compared to HC-IgG.  
A similar pattern was obtained with LPS treatment that also increased cell-free DNA 
(Figure 5.12). Pre-incubation with HC-IgG produced similar results as neutrophils stimulated 
with LPS in the absence of IgG. Significant increases in cell-free DNA however, were observed 
in neutrophils cultured with both RA-IgG (p<0.05) and SLE-IgG (p<0.01) (Figure 5.12). APS-
IgG did not significantly increase LPS-induced NETosis compared to HC-IgG. 
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Figure 5.10: RA- and SLE-IgG induce greater levels of spontaneous NETosis compared to 
HC-IgG. Control neutrophils were isolated and treated with FcγR blockade. Cells were then 
incubated for 1 hour with 200µg/ml purified RA-IgG (n=5), SLE-IgG (n=5), APS-IgG (n=5) or 
HC-IgG (n=5). Neutrophils were incubated for a further 4 hours in the absence of additional 
stimuli. Cell supernatants were assessed for the presence of NETs using the Quanti-iT™ 
PicoGreen® dsDNA kit. Significantly higher levels of cell-free DNA were found in 
supernatants from neutrophils incubated with RA- or SLE-IgG compared to HC-IgG. Statistical 
significance was determined by one-way ANOVA with a Tukey post-test analysis. Data is 
presented as box and whisker plots from averaged observations from each IgG sample in two 
independent experiments. Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; APS, antiphospholipid syndrome. ns= no significance, *=p<0.05, 
**=p<0.01 
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Figure 5.11: RA-IgG elevates PMA-induced NETosis compared to healthy control-IgG. 
Control neutrophils were isolated and treated with FcγR blockade. Cells were then incubated 
for 1 hour with 200µg/ml purified RA-IgG (n=5), SLE-IgG (n=5), APS-IgG (n=5) or HC-IgG 
(n=5). Following incubation, neutrophils were treated with 40nM PMA for a further 4 hours. 
Cell supernatants were assessed for the presence of NETs using the Quanti-iT™ PicoGreen® 
dsDNA kit. Significantly higher levels of cell-free DNA were found in supernatants from 
neutrophils incubated with RA-IgG compared to HC-IgG. Statistical significance was 
determined by one-way ANOVA with a Tukey post-test analysis. Data is presented as box and 
whisker plots from averaged observations from each IgG sample in two independent 
experiments. Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, systemic 
lupus erythematosus; APS, antiphospholipid syndrome. ns= no significance, **=p<0.01 	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Figure 5.12: RA- and SLE-IgG enhance LPS-induced NETosis compared to healthy 
control-IgG. Control neutrophils were isolated and treated with FcγR blockade. Cells were then 
incubated for 1 hour with 200µg/ml purified RA-IgG (n=5), SLE-IgG (n=5), APS-IgG (n=5) or 
HC-IgG (n=5). Neutrophils were treated with 100ng/ml LPS for a further 4 hours. Cell 
supernatants were assessed for the presence of NETs using the Quanti-iT™ PicoGreen® dsDNA 
kit. Significantly higher levels of cell-free DNA were found in supernatants from neutrophils 
incubated with RA- or SLE-IgG compared to HC-IgG. Statistical significance was determined by 
a Kruskal-Wallis test with a Dunn’s multiple comparison test. Data is presented as box and 
whisker plots from averaged observations from each IgG sample in two independent 
experiments. Abbreviations: HC, healthy control; RA, rheumatoid arthritis; SLE, systemic lupus 
erythematosus; APS, antiphospholipid syndrome. ns= no significance, *=p<0.05, **=p<0.01 	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5.9 Discussion 	  
In this chapter, I have shown that RA-, SLE- and APS-IgG bind neutrophils. Moreover, 
I observed a differential effect of IgG upon neutrophil integrin activation, with APS-IgG 
enhancing PMA-stimulated neutrophil adhesion to fibronectin, whilst RA- and SLE-IgG 
augmented PMA-stimulated adhesion to fibrinogen. RA-, SLE- and APS-IgG were found to 
bind neutrophils however, determining the precise antigenic target was outside the scope of this 
PhD thesis. Given my data showing that RA- and APS-IgG binding was not affected by FcγR 
blockade, I hypothesise that these IgG samples are binding via antigen-specific interactions. In 
contrast, SLE-IgG binding was reduced following FcγR blockade, suggesting that SLE-IgG 
binds neutrophils via both Fab- and Fc-mediated interactions. Ex vivo neutrophils isolated from 
SLE patients had significantly lower rates of hydrogen peroxide production compared to RA, 
APS and HC neutrophils. Furthermore, RA- and SLE-IgG significantly increased hydrogen 
peroxide generation by HC neutrophils. Finally, RA- and SLE-IgG were also found to enhance 
spontaneous, PMA-induced and LPS-induced NETosis. This section will discuss my findings 
within the context of published reports, evaluate the limitations of my work and highlight areas 
in which my work could expand. 
 
5.9.1 The effects of IgG upon neutrophil adhesion  
 
The effects of purified IgG upon neutrophil integrin activation and adhesion have not 
been previously studied. Early reports found that SLE- and APS-IgG increased monocyte 
adhesion to ECs (Simantov et al., 1995, Del Papa et al., 1999). Both studies however, cultured 
HUVEC with 100µg/ml SLE- or APS-IgG before the adhesion of monocytic cell lines was 
assessed. Therefore, these reports examined the effects of IgG upon EC adhesion molecule 
expression and not leukocyte integrin activation.  
My data show that ARD-IgG differentially regulate neutrophil integrin activation. APS-
IgG enhanced PMA-stimulated neutrophil adhesion to fibronectin compared to HC-IgG. 
Conversely, RA- and SLE-IgG increased PMA-stimulated adhesion to fibrinogen. Insights to 
this differential response may be gained by consideration of the nature of the different ARDs. 
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RA and SLE are both characterised by chronic inflammation and endothelial 
dysfunction (Piper et al., 2007, Totoson et al., 2014). Although the biology of fibrinogen is 
complex, increased fibrinogen levels have been associated with inflammatory conditions 
(Kamath and Lip, 2003). It is therefore interesting that RA- and SLE-IgG promote Mac-1-
mediated adhesion to fibrinogen. Further experiments would be required to determine the 
precise molecular interactions underlying my observations. 
In contrast, APS can be characterised by cellular (including endothelial) activation 
(Pierangeli et al., 2008). Under resting physiological conditions, the endothelium displays 
polarised fibronectin expression, primarily forming a constituent of the sub-endothelial matrix 
within the basement membrane (Peters et al., 1990). Activated endothelial monolayers have 
been shown to deposit fibronectin at both apical and basal cell membranes (Kowalczyk et al., 
1990). Therefore, persistent EC activation leads to increased fibronectin deposition within the 
vasculature. My observation that APS-IgG enhances neutrophil adhesion to immobilised 
fibronectin may indicate that APS-IgG promote neutrophil adhesion to ECM proteins expressed 
on the vessel wall by activated ECs. A potential limitation of this work however, is that 
adhesion assays were performed in the absence of FcγR blockade. Additional experiments 
would be required to conclusively determine whether my observations arise via antigen-specific 
or FcγR-mediated interactions. 
 
5.9.2 The effects of IgG upon neutrophil ROS generation  
 
  Several groups have documented the dysregulation of NETosis in RA, SLE and APS 
(Garcia-Romo et al., 2011, Sur Chowdhury et al., 2014, Yalavarthi et al., 2015). These studies 
show that IgG-induced NETosis is dependent on ROS generation. Therefore, I tested the 
hypothesis that ARD-IgG can modulate ROS production. Through comparisons of neutrophil 
hydrogen peroxide generation, I found that SLE-derived neutrophils had significantly lower 
rates of hydrogen peroxide generation compared to neutrophils isolated from healthy volunteers 
and patients with RA and APS. Possible explanations for this observation are that SLE-derived 
neutrophils have defective in vitro hydrogen peroxide generation or due to persistent systemic 
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activation, ex vivo responses of SLE-derived neutrophils are blunted. The uptake of circulating 
nucleosomes has been reported to induce the systemic activation of neutrophils in SLE patients 
(Ronnefarth et al., 2006). Therefore, it is possible that the reduced hydrogen peroxide 
generation observed represents a form of neutrophil senescence arising from persistent cellular 
stimulation. Given these results, I examined the effects of purified IgG upon ROS generation of 
control neutrophils. Both RA- and SLE-IgG significantly increased hydrogen peroxide 
generation. The observation that SLE-IgG increases hydrogen peroxide generation of ex vivo 
control neutrophils adds to my hypothesis that SLE-derived neutrophils had lower rates of ROS 
generation due to the persistent activation by factors such as circulating nucleosomes and IgG. 
Given that SLE-IgG had reduced binding in the presence of FcγR blockade, it would be 
interesting in future work to test whether an enhanced response occurs in the absence of FcγR 
blockade. 
A further limitation to these experiments is the significantly older RA cohorts. At the 
time of serum donation, my RA cohort had a mean age of 51 years whilst HC, SLE and APS 
cohorts had mean ages of 30, 32 and 39 respectively. This age difference was also seen in 
patients who donated whole blood. The RA cohort had a mean age of 62 years, whilst HC, SLE 
and APS cohorts had mean ages of 36, 40 and 44 years respectively. In the future, to acquire 
better age-matched controls for RA patients, patient relatives or non-ARD patients may have to 
be recruited. Whilst an older HC cohort would benefit comparisons with the RA cohort, both 
SLE and APS patients were significantly younger than RA patients and were similar in age to 
the HC cohort. This age difference between ARD patients complicates the recruitment of 
healthy volunteers. If healthy volunteers were recruited to satisfy RA, SLE and APS patients, 
large standard deviations in age would then exist within the HC cohort. Alternatively, two HC 
groups of different ages would be required to match either RA or SLE and APS patients. 
 
5.9.3 The effects of IgG upon NETosis  
 
 Several reports have demonstrated increased NETosis following culture with RA-, SLE- 
or APS-IgG (Garcia-Romo et al., 2011, Khandpur et al., 2013, Knight et al., 2013, Sur 
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Chowdhury et al., 2014, Yalavarthi et al., 2015). I found incubation with RA- and SLE-IgG 
significantly increased spontaneous NETosis, which is consistent with published data 
(Carmona-Rivera and Kaplan, 2013, Khandpur et al., 2013). I also found that incubation with 
RA- or SLE-IgG enhanced LPS-stimulated NETosis. Given that LPS and TLR-4 signalling 
have been implicated in NETosis (Clark et al., 2007, Remijsen et al., 2011a), my data indirectly 
support involvement of TLR-4 in RA- and SLE-IgG induced NETosis. Only RA-IgG 
augmented PMA-induced NETosis, which may indicate differential signalling pathway 
induction by purified IgG. Published reports have shown APS-IgG induces spontaneous 
NETosis (Yalavarthi et al., 2015). There are differences between this study and my own work 
that may explain the conflicting results. I stimulated neutrophils with 200µg/ml whole IgG 
purified from APS serum, however in work by Yalavarthi and colleagues, neutrophils were 
stimulated with 10µg/ml of either whole IgG or affinity-purified anti-β2GPI antibodies purified 
from APS serum. In addition, given that my work consisted of purified RA-, SLE and APS-IgG 
statistical analysis was performed using multiple comparison tests, whereas Yalavarthi et al. 
compared APS- and HC-IgG using unpaired t tests. These differences may account for the 
discrepant results of statistical significance between published reports and my own data. If 
unpaired t tests are performed on my data, the differences between APS-IgG and HC-IgG 
become significant however, given my experimental design comparing IgG purified from three 
patient cohorts, multiple comparison tests are the most appropriate statistical analysis to apply. 
The identity of the antigenic targets bound by purified IgG remains unknown. For this 
thesis, FcγR blockade was achieved using an FcR blocking reagent (Miltenyi, UK), which is a 
human serum IgG preparation. A limitation of using this FcR blocking reagent is that whilst the 
high-affinity FcγRI is readily blocked, the lower affinity FcγRIIA and FcγRIIIB may not be as 
efficiently blocked. FcγRIIA and FcγRIIIB function synergistically to activate neutrophils 
(Zhou et al., 1995). FcγRIIA activation by soluble ICs has been shown to induce NETosis 
(Chen et al., 2012). Immobilised ICs can also activate FcγRIIIB and Mac-1, which induce 
NETosis (Behnen et al., 2014). Therefore, it is possible that whilst the FcR blocking reagent 
Chapter Five: The Effects of Purified Immunoglobulin G on Neutrophil Function 
	   214	  
efficiently blocks the high-affinity FcγRI, it is less efficient at FcγRIIA and FcγRIIIB blockade 
thus promoting neutrophil activation by IC engagement. 
Many groups have tried to determine the antigenic targets that mediate IgG-induced 
NETosis, without a clear answer. Given the evidence demonstrating that aPL bind β2GPI, APS-
IgG may bind and crosslink β2GPI with TLR-4 to induce intracellular signalling (Raschi et al., 
2003, Mulla et al., 2009), which has been implicated in NETosis (Clark et al., 2007, Remijsen et 
al., 2011a). Evidence to support this hypothesis is provided by Yalavarthi and colleagues who 
demonstrate that NETosis induced by APS-IgG can be suppressed by depletion of anti-β2GPI 
antibodies (Yalavarthi et al., 2015). This group also showed the induction of NETosis following 
incubation of affinity-purified anti-β2GPI antibodies, which further supports this hypothesis. 
Multiple autoantigens have been identified in RA and SLE, such as citrullinated antigens in RA 
and nuclear contents in SLE, which make defining the precise antigenic targets on neutrophils 
difficult. 
 
5.9.4 Future work  
 
Whilst statistical significance was achieved in experiments using purified IgG, given 
more time I would have liked to expand on the number of samples in my SLE group. 
Furthermore, ANCA positivity was only characterised for the classical ANCA antigens PR3 and 
MPO. Additional non-classical ANCA antigens have been implicated in inflammatory 
conditions, including α-enolase, azurocidin, bactericidal permeability increasing protein, 
cathespin G, elastase, high mobility group box (HMGB)-1, HMGB-2, lactoferrin and lysozyme 
(Halbwachs-Mecarelli et al., 1992, Coremans et al., 1993, Peen et al., 1993, Skogh and Peen, 
1993, Tervaert et al., 1993, Zhao et al., 1995, Zhao and Lockwood, 1996). Many of these 
additional antigens are also associated with NET formation and structure. Therefore, it would be 
interesting to examine ANCA positivity for non-classical ANCA antigens. 
Several approaches could be applied to determine the mechanisms underlying IgG-
mediated neutrophil activation. Fab or F(ab')2 fragments could be generated by papain or pepsin 
digestion respectively, to determine whether neutrophil activation is mediated by IgG variable 
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regions rather than Fc-mediated. Purified IgG could also be subjected to ultracentrifugation to 
remove serum-induced complexes and functional responses assessed. ICs could be produced 
from HC-IgG by heat aggregation and the effects on neutrophil activation evaluated. 
Alternatively, specific blockade of FcγRI, FcγRIIA or FcγRIIIB would highlight whether my 
observations are Fc mediated and if so, which of the FcγRs mediate the response.  
I would also like to explore the effects of IgG upon neutrophil adhesion to additional 
integrin ligands such as: ICAM-1, which is upregulated on cell activation and therefore 
physiologically relevant; VCAM-1, which is also upregulated by activated ECs; and collagen, 
which is expressed in arthritic joints.  
 Another model would be to examine the effects of purified IgG on neutrophil adhesion 
to ECs, fibroblasts, FLS and synoviocytes. These cell types would provide a better 
understanding of neutrophil interactions within tissues during and following extravasation, 
which may hold pathological relevance for RA, SLE and APS. Examination of the effects of 
IgG upon neutrophil adhesion to platelets may provide further insight to the mechanisms 
underlying thrombosis in APS patients. Adhesion assays could also be conducted under flow, 
which would also examine the effects of IgG upon neutrophil attachment and rolling. 
Transmigration assays could also be performed to examine whether IgG also affects neutrophil 
migration across the endothelium. 
 Various studies have shown that ROS are important in NETosis, however reactive 
nitrogen intermediates have also been implicated (Patel et al., 2010, Keshari et al., 2012). As 
RA- and SLE-IgG modulated neutrophil hydrogen peroxide generation, it would be interesting 
to examine reactive nitrogen intermediates production. The Griess test was not sensitive enough 
to detect nitrites produced by IFN-γ-stimulated neutrophils, however flow cytometry-based 
assays are able to examine reactive nitrogen intermediates. These experiments would give a 
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6.1 Key findings 
 
Key findings obtained in this thesis can be found summarised in Table 6.1 below. 	  
	  	  
Table 6.1: Key findings obtained in this thesis. Listed above are the key observations made 
throughout my PhD. 
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6.2 Overall discussion 	  
The underlying premise of all the experiments described in this thesis was that cellular 
environments can affect neutrophil function. The molecular mechanisms regulating neutrophil 
adhesion and ROS generation have been extensively studied. With regards to NETs, most 
published reports focus on elucidating NET structure and mechanisms regulating NETosis. My 
work adds to current literature by examining the effects of hypoxia upon integrin expression, 
integrin activation, ROS generation and NETosis. Many studies conduct experiments under 
atmospheric oxygen levels. Given that oxygen levels within the vasculature are far lower than 
atmospheric levels, examining neutrophil function under hypoxia is physiologically relevant.  
In addition, the effects of purified RA-, SLE- and APS-IgG upon cellular function has 
also been examined in numerous cell types. The contribution of neutrophils however is less 
studied. Emerging work has begun to study the effects of ARD-IgG upon neutrophil activation. 
Data from this thesis has been consistent with published reports and builds upon current work. 
Differences in statistical significance between my own and published data can be attributed to 
my use of the more statistically stringent multiple comparison tests rather than the unpaired t 
tests, of other reports.  
Overall, this thesis has shown that hypoxia does not affect surface expression of 
neutrophil β1 integrins, but increases αM and αX expression. Therefore, under hypoxia there is 
increased expression of Mac-1 (αMβ2) and p150,95 (αXβ2). Given that Mac-1 and p150,95 are 
also complement receptors (CR3 and CR4 respectively), my data hints that CR-mediated 
adhesion and function may be enhanced under hypoxia. Neutrophil adhesion to ECs and trans-
endothelial migration was also enhanced under hypoxia. Examination of EC adhesion molecule 
expression found increased ICAM-1 expression under hypoxia. Based on this observation and 
the elevated expression of Mac-1 and p150,95 on neutrophils, increased adhesion and 
transmigration under hypoxia may be mediated by interactions between Mac-1 and ICAM-1. 
NETosis was enhanced when neutrophils were stimulated in the presence of ECs, which may 
also be a result of increased cellular interactions between neutrophils and ECs. My work also 
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shows for the first time that hypoxia increases PAD-4 expression in neutrophils. Whilst this has 
not been previously described, published data demonstrates that hypoxia upregulates PAD-2 
expression in astrocytes (Sambandam et al., 2004). HRE consensus sequences were also 
identified in within evolutionary conserved regions upstream of the PAD-4 coding gene, using 
the publically available software ECR browser (http://ecrbrowser.dcode.org). These conserved 
regions are likely to represent promoter regions, which indicate that PAD-4 may be regulated by 
HIF signalling. My experimental data confirms that PAD-4 is also upregulated under hypoxia. 
This observation may provide an insight to the mechanisms enhancing NETosis under hypoxia. 
With regards to the effects of purified IgG, this thesis identified that ARD-IgG had 
differential effects upon neutrophil integrin activation and modulated both ROS production and 
NETosis. In particular, APS-IgG enhanced PMA-stimulated neutrophil adhesion to fibronectin 
via a β1 integrin-dependent manner, whilst RA- and SLE-IgG increased PMA-stimulated 
adhesion to fibrinogen via Mac-1 activation. RA- and SLE-IgG increased rates of hydrogen 
peroxide generation in control neutrophils. NETosis was also modulated by the presence of 
purified IgG, with increased levels of spontaneous, PMA- and LPS-induced NETosis in 
neutrophils cultured with RA-IgG. SLE-IgG also increased spontaneous and LPS-induced 
NETosis. My data examining the effects of RA- and SLE-IgG upon NETosis was consistent 
with published data (Carmona-Rivera and Kaplan, 2013, Khandpur et al., 2013, Knight et al., 
2013), however I did not find significant effects of APS-IgG upon ROS production or NETosis 
as described in published reports (Yalavarthi et al., 2015). This discrepancy can be explained by 
differences in statistical analysis. Whilst published reports demonstrated statistical significance 
using an unpaired t test, my experimental data failed to reproduce this significance using a 
multiple comparison test. Interestingly, performing unpaired t tests between HC- and APS-IgG 
groups in my data found statistical significance, demonstrating similar trends that were masked 
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6.3 Future directions 
 
 In order to take these findings forward, there are several points I would consider. 
Having examined the effects of hypoxia and purified IgG upon neutrophil function separately, it 
would be important to study the combined effects of hypoxia and purified IgG to determine 
whether there is an additive effect upon neutrophil adhesion, ROS generation and NETosis. 
 Preliminary work in this thesis supports published reports and found that p38 MAPK 
inhibition significantly reduced PMA-stimulated NETosis (Riyapa et al., 2012). Further 
experiments to determine p38 MAPK expression and phosphorylation could be performed to 
dissect the signalling pathways involved in NETosis under hypoxia in the absence or presence 
of purified IgG and PMA. These experiments may highlight signalling pathways and molecules 
that could serve as novel therapeutic targets, which is interesting given that p38 MAPK 
inhibitors are currently in development for the treatment of RA. Pre-clinical studies in animal 
models demonstrated that p38 MAPK inhibition reduced both synovial inflammation and the 
destruction of bone and cartilage (Nishikawa et al., 2003, Zwerina et al., 2006). The benefits of 
p38 MAPK inhibition in RA have not translated into humans, with several p38 MAPK 
inhibitors having been trialled and discontinued due to adverse effects, such as infection or 
neurological effects (Weisman, 2002, Cohen et al., 2009, Damjanov et al., 2009, Alten et al., 
2010). The lack of efficacy of p38 MAPK inhibition in RA patients may be due to inadequate 
dosing, which is limited by toxicity (Hammaker and Firestein, 2010) or by compensatory 
mechanism that appear to overcome the inhibition of p38 MAP kinase after several weeks 
(Genovese et al., 2008, Bonilla-Hernan et al., 2011). Losmapimod, a novel and potent p38 
MAPK inhibitor, has also produced positive data in patients with non-ST-segment elevation 
myocardial infarction and was well tolerated by patients (Newby et al., 2014), which is now 
being trialled in RA patients.  
Neutrophil activation was examined in this thesis by studying ROS generation and 
NETosis. An additional form of neutrophil activation is the generation of microparticles. 
Published reports have shown neutrophil microparticles to have a wide range of biological 
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effects, including causing endothelial damage (Pitanga et al., 2014) and promoting thrombosis 
(Kambas et al., 2014, Huang et al., 2015). A recent study found that a subpopulation of CD66b+ 
neutrophil microparticles containing annexin A1 protected mice from inflammatory arthritis 
(Headland et al., 2015). This study also found elevated neutrophil-derived microparticles, as 
well as monocyte- and T cell-derived microparticles, in patients with RA. Given that oxygen 
levels in the vasculature are lower than atmospheric oxygen, studying the effects of hypoxia 
upon neutrophil microparticles populations would be relevant. In addition, examining the 
effects of purified IgG upon neutrophil microparticle generation would also be interesting. 
Given the evidence demonstrating the contributions of neutrophils to pathology, this field of 
work would be relevant to RA, SLE and APS. 
 All of the experiments conducted in this thesis used neutrophils isolated from peripheral 
blood. Given the evidence showing differential integrin expression in T cells isolated from 
peripheral blood and SF (Hemler et al., 1986, Laffon et al., 1991), and the importance of 
NETosis to mucosal immunology (Mohanty et al., 2015), examination of neutrophils isolated 
from BAL fluid or sputum may also be of interest.  A limitation to these experiments however, 
is that whilst samples may be readily obtained from patient populations, examination of healthy 
control samples may prove difficult. These experiments would examine neutrophils within the 
context of mucosal immunity, as cells would have migrated out of the vasculature. Given its 
importance to mucosal immunology, it would become physiologically relevant to examine the 
effects of purified IgA, which is enriched within mucosal membranes. Similarly, examining the 
difference in neutrophil function in SF-derived neutrophils may provide an insight to the 
contribution of neutrophils to disease pathophysiology. 
The contribution of neutrophils to ARD pathology is becoming increasing recognised, 
with studies beginning to explore the effects of purified IgG upon neutrophil activation. The 
effects of hypoxia have been studied within the context of cell biology, but few reports have 
examined hypoxia within the context of ARD. The work produced in this thesis has hopefully 




 ABRAHAMS,	  V.	  M.	  2009.	  Mechanisms	  of	  antiphospholipid	  antibody-­‐associated	  pregnancy	  complications.	  Thromb	  Res,	  124,	  521-­‐5.	  ABRAMSON,	   S.	   B.,	   GIVEN,	   W.	   P.,	   EDELSON,	   H.	   S.	   &	   WEISSMANN,	   G.	   1983.	   Neutrophil	  aggregation	   induced	   by	   sera	   from	   patients	   with	   active	   systemic	   lupus	  erythematosus.	  Arthritis	  Rheum,	  26,	  630-­‐6.	  ADELMAN,	   D.	   M.,	   GERTSENSTEIN,	   M.,	   NAGY,	   A.,	   SIMON,	   M.	   C.	   &	   MALTEPE,	   E.	   2000.	  Placental	  cell	  fates	  are	  regulated	  in	  vivo	  by	  HIF-­‐mediated	  hypoxia	  responses.	  Genes	  
Dev,	  14,	  3191-­‐203.	  AFEK,	   A.,	   SHOENFELD,	   Y.,	   MANOR,	   R.,	   GOLDBERG,	   I.,	   ZIPOREN,	   L.,	   GEORGE,	   J.,	   POLAK-­‐CHARCON,	  S.,	  AMIGO,	  M.	  C.,	  GARCIA-­‐TORRES,	  R.,	  SEGAL,	  R.	  &	  KOPOLOVIC,	  J.	  1999.	  Increased	   endothelial	   cell	   expression	   of	   alpha3beta1	   integrin	   in	   cardiac	  valvulopathy	  in	  the	  primary	  (Hughes)	  and	  secondary	  antiphospholipid	  syndrome.	  
Lupus,	  8,	  502-­‐7.	  AFSHAR-­‐KHARGHAN,	  V.,	  DIZ-­‐KUCUKKAYA,	  R.,	  LUDWIG,	  E.	  H.,	  MARIAN,	  A.	  J.	  &	  LOPEZ,	  J.	  A.	  2001.	   Human	   polymorphism	   of	   P-­‐selectin	   glycoprotein	   ligand	   1	   attributable	   to	  variable	  numbers	  of	  tandem	  decameric	  repeats	  in	  the	  mucinlike	  region.	  Blood,	  97,	  3306-­‐7.	  AGARWAL,	   A.,	   SALEM,	   P.	   &	   ROBBINS,	   K.	   C.	   1993.	   Involvement	   of	   p72syk,	   a	   protein-­‐tyrosine	  kinase,	  in	  Fc	  gamma	  receptor	  signaling.	  J	  Biol	  Chem,	  268,	  15900-­‐5.	  AGGARWAL,	   A.,	   SHARMA,	   A.	   &	   BHATNAGAR,	   A.	   2014.	   Role	   of	   cytolytic	   impairment	   of	  natural	   killer	   and	   natural	   killer	   T-­‐cell	   populations	   in	   rheumatoid	   arthritis.	   Clin	  
Rheumatol,	  33,	  1067-­‐78.	  AGNELLO,	   V.,	   DE	   BRACCO,	  M.	  M.	   &	   KUNKEL,	   H.	   G.	   1972.	   Hereditary	   C2	   deficiency	  with	  some	  manifestations	  of	  systemic	  lupus	  erythematosus.	  J	  Immunol,	  108,	  837-­‐40.	  AGOSTINIS,	  C.,	  BIFFI,	  S.,	  GARROVO,	  C.,	  DURIGUTTO,	  P.,	  LORENZON,	  A.,	  BEK,	  A.,	  BULLA,	  R.,	  GROSSI,	  C.,	  BORGHI,	  M.	  O.,	  MERONI,	  P.	  &	  TEDESCO,	  F.	  2011.	  In	  vivo	  distribution	  of	  beta2	  glycoprotein	  I	  under	  various	  pathophysiologic	  conditions.	  Blood,	  118,	  4231-­‐8.	  AGOSTINIS,	   C.,	   DURIGUTTO,	   P.,	   SBLATTERO,	   D.,	   BORGHI,	   M.	   O.,	   GROSSI,	   C.,	   GUIDA,	   F.,	  BULLA,	  R.,	  MACOR,	  P.,	  PREGNOLATO,	  F.,	  MERONI,	  P.	  L.	  &	  TEDESCO,	  F.	  2014.	  A	  non-­‐complement-­‐fixing	   antibody	   to	   beta2	   glycoprotein	   I	   as	   a	   novel	   therapy	   for	  antiphospholipid	  syndrome.	  Blood,	  123,	  3478-­‐87.	  AKHAVANI,	  M.	  A.,	  MADDEN,	  L.,	  BUYSSCHAERT,	  I.,	  SIVAKUMAR,	  B.,	  KANG,	  N.	  &	  PALEOLOG,	  E.	   M.	   2009.	   Hypoxia	   upregulates	   angiogenesis	   and	   synovial	   cell	   migration	   in	  rheumatoid	  arthritis.	  Arthritis	  Res	  Ther,	  11,	  R64.	  ALARCON,	   G.	   S.,	   MCGWIN,	   G.,	   JR.,	   PETRI,	   M.,	   REVEILLE,	   J.	   D.,	   RAMSEY-­‐GOLDMAN,	   R.	   &	  KIMBERLY,	   R.	   P.	   2002.	   Baseline	   characteristics	   of	   a	   multiethnic	   lupus	   cohort:	  PROFILE.	  Lupus,	  11,	  95-­‐101.	  ALETAHA,	  D.,	  NEOGI,	  T.,	  SILMAN,	  A.	  J.,	  FUNOVITS,	  J.,	  FELSON,	  D.	  T.,	  BINGHAM,	  C.	  O.,	  3RD,	  BIRNBAUM,	   N.	   S.,	   BURMESTER,	   G.	   R.,	   BYKERK,	   V.	   P.,	   COHEN,	   M.	   D.,	   COMBE,	   B.,	  COSTENBADER,	  K.	  H.,	  DOUGADOS,	  M.,	   EMERY,	  P.,	   FERRACCIOLI,	  G.,	  HAZES,	   J.	  M.,	  HOBBS,	   K.,	   HUIZINGA,	   T.	   W.,	   KAVANAUGH,	   A.,	   KAY,	   J.,	   KVIEN,	   T.	   K.,	   LAING,	   T.,	  MEASE,	  P.,	  MENARD,	  H.	  A.,	  MORELAND,	  L.	  W.,	  NADEN,	  R.	  L.,	  PINCUS,	  T.,	  SMOLEN,	  J.	  S.,	   STANISLAWSKA-­‐BIERNAT,	   E.,	   SYMMONS,	   D.,	   TAK,	   P.	   P.,	   UPCHURCH,	   K.	   S.,	  VENCOVSKY,	   J.,	   WOLFE,	   F.	   &	   HAWKER,	   G.	   2010.	   2010	   rheumatoid	   arthritis	  classification	   criteria:	   an	   American	   College	   of	   Rheumatology/European	   League	  Against	  Rheumatism	  collaborative	  initiative.	  Ann	  Rheum	  Dis,	  69,	  1580-­‐8.	  ALGECIRAS,	  M.	   E.,	   TAKAHARA,	  H.	  &	  BHATTACHARYA,	   S.	   K.	   2008.	  Mechanical	   stretching	  elevates	  peptidyl	  arginine	  deiminase	  2	  expression	   in	  astrocytes.	  Curr	  Eye	  Res,	  33,	  994-­‐1001.	  
References 
	   223	  
ALLEN,	  L.	  A.	  &	  ADEREM,	  A.	  1996a.	  Mechanisms	  of	  phagocytosis.	  Curr	  Opin	  Immunol,	  8,	  36-­‐40.	  ALLEN,	  L.	  A.	  &	  ADEREM,	  A.	  1996b.	  Molecular	  definition	  of	  distinct	  cytoskeletal	  structures	  involved	  in	  complement-­‐	  and	  Fc	  receptor-­‐mediated	  phagocytosis	  in	  macrophages.	  
J	  Exp	  Med,	  184,	  627-­‐37.	  ALON,	  R.,	  KASSNER,	  P.	  D.,	  CARR,	  M.	  W.,	  FINGER,	  E.	  B.,	  HEMLER,	  M.	  E.	  &	  SPRINGER,	  T.	  A.	  1995.	  The	  integrin	  VLA-­‐4	  supports	  tethering	  and	  rolling	  in	  flow	  on	  VCAM-­‐1.	  J	  Cell	  
Biol,	  128,	  1243-­‐53.	  ALTEN,	  R.	   E.,	   ZERBINI,	   C.,	   JEKA,	   S.,	   IRAZOQUE,	   F.,	   KHATIB,	   F.,	   EMERY,	   P.,	   BERTASSO,	  A.,	  RABBIA,	  M.	  &	  CAULFIELD,	  J.	  P.	  2010.	  Efficacy	  and	  safety	  of	  pamapimod	  in	  patients	  with	   active	   rheumatoid	   arthritis	   receiving	   stable	   methotrexate	   therapy.	   Ann	  
Rheum	  Dis,	  69,	  364-­‐7.	  ALVARADO-­‐SANCHEZ,	   B.,	  HERNANDEZ-­‐CASTRO,	  B.,	   PORTALES-­‐PEREZ,	  D.,	   BARANDA,	   L.,	  LAYSECA-­‐ESPINOSA,	   E.,	   ABUD-­‐MENDOZA,	   C.,	   CUBILLAS-­‐TEJEDA,	   A.	   C.	   &	  GONZALEZ-­‐AMARO,	   R.	   2006.	   Regulatory	   T	   cells	   in	   patients	   with	   systemic	   lupus	  erythematosus.	  J	  Autoimmun,	  27,	  110-­‐8.	  ANDO,	  H.,	  NATSUME,	  A.,	   IWAMI,	  K.,	  OHKA,	  F.,	  KUCHIMARU,	  T.,	  KIZAKA-­‐KONDOH,	  S.,	   ITO,	  K.,	   SAITO,	   K.,	   SUGITA,	   S.,	   HOSHINO,	   T.	   &	   WAKABAYASHI,	   T.	   2013.	   A	   hypoxia-­‐inducible	  factor	  (HIF)-­‐3alpha	  splicing	  variant,	  HIF-­‐3alpha4	  impairs	  angiogenesis	  in	  hypervascular	  malignant	  meningiomas	  with	   epigenetically	   silenced	   HIF-­‐3alpha4.	  
Biochem	  Biophys	  Res	  Commun,	  433,	  139-­‐44.	  ANDREOLI,	  L.,	  CHIGHIZOLA,	  C.	  B.,	  NALLI,	  C.,	  GEROSA,	  M.,	  BORGHI,	  M.	  O.,	  PREGNOLATO,	  F.,	  GROSSI,	  C.,	  ZANOLA,	  A.,	  ALLEGRI,	  F.,	  NORMAN,	  G.	  L.,	  MAHLER,	  M.,	  MERONI,	  P.	  L.	  &	  TINCANI,	   A.	   2015.	   Clinical	   characterization	   of	   antiphospholipid	   syndrome	   by	  detection	   of	   IgG	   antibodies	   against	   beta2	   -­‐glycoprotein	   i	   domain	   1	   and	   domain	  4/5:	   ratio	   of	   anti-­‐domain	   1	   to	   anti-­‐domain	   4/5	   as	   a	   useful	   new	   biomarker	   for	  antiphospholipid	  syndrome.	  Arthritis	  Rheumatol,	  67,	  2196-­‐204.	  ANTHIS,	  N.	   J.	  &	  CAMPBELL,	  I.	  D.	  2011.	  The	  tail	  of	   integrin	  activation.	  Trends	  Biochem	  Sci,	  36,	  191-­‐8.	  APLIN,	  J.	  D.,	  CHARLTON,	  A.	  K.	  &	  AYAD,	  S.	  1988.	  An	  immunohistochemical	  study	  of	  human	  endometrial	  extracellular	  matrix	  during	  the	  menstrual	  cycle	  and	  first	  trimester	  of	  pregnancy.	  Cell	  Tissue	  Res,	  253,	  231-­‐40.	  APLIN,	   J.	   D.,	   HAIGH,	   T.,	   JONES,	   C.	   J.,	   CHURCH,	  H.	   J.	   &	  VICOVAC,	   L.	   1999.	  Development	   of	  cytotrophoblast	  columns	  from	  explanted	  first-­‐trimester	  human	  placental	  villi:	  role	  of	  fibronectin	  and	  integrin	  alpha5beta1.	  Biol	  Reprod,	  60,	  828-­‐38.	  ARATANI,	   Y.,	   KOYAMA,	   H.,	   NYUI,	   S.,	   SUZUKI,	   K.,	   KURA,	   F.	   &	   MAEDA,	   N.	   1999.	   Severe	  impairment	   in	   early	   host	   defense	   against	   Candida	   albicans	   in	   mice	   deficient	   in	  myeloperoxidase.	  Infect	  Immun,	  67,	  1828-­‐36.	  ARBOUR,	  N.	  C.,	  LORENZ,	  E.,	  SCHUTTE,	  B.	  C.,	  ZABNER,	  J.,	  KLINE,	  J.	  N.,	  JONES,	  M.,	  FREES,	  K.,	  WATT,	   J.	   L.	   &	   SCHWARTZ,	   D.	   A.	   2000.	   TLR4	   mutations	   are	   associated	   with	  endotoxin	  hyporesponsiveness	  in	  humans.	  Nat	  Genet,	  25,	  187-­‐91.	  ARMSTRONG,	   D.	   J.,	   CROCKARD,	   A.	   D.,	  WISDOM,	   B.	   G.,	  WHITEHEAD,	   E.	   M.	   &	   BELL,	   A.	   L.	  2006.	  Accelerated	  apoptosis	  in	  SLE	  neutrophils	  cultured	  with	  anti-­‐dsDNA	  antibody	  isolated	  from	  SLE	  patient	  serum:	  a	  pilot	  study.	  Rheumatol	  Int,	  27,	  153-­‐6.	  ARNETT,	   F.	   C.,	   THIAGARAJAN,	   P.,	   AHN,	   C.	   &	   REVEILLE,	   J.	   D.	   1999.	   Associations	   of	   anti-­‐beta2-­‐glycoprotein	   I	   autoantibodies	   with	   HLA	   class	   II	   alleles	   in	   three	   ethnic	  groups.	  Arthritis	  Rheum,	  42,	  268-­‐74.	  ARNOUT,	  J.	  2001.	  Antiphospholipid	  syndrome:	  diagnostic	  aspects	  of	  lupus	  anticoagulants.	  
Thromb	  Haemost,	  86,	  83-­‐91.	  ASHERSON,	  R.	  A.,	   CERVERA,	  R.,	  DE	  GROOT,	  P.	  G.,	   ERKAN,	  D.,	  BOFFA,	  M.	  C.,	   PIETTE,	   J.	   C.,	  KHAMASHTA,	   M.	   A.	   &	   SHOENFELD,	   Y.	   2003.	   Catastrophic	   antiphospholipid	  syndrome:	   international	   consensus	   statement	   on	   classification	   criteria	   and	  treatment	  guidelines.	  Lupus,	  12,	  530-­‐4.	  
References 
	   224	  
AUSTIN,	  H.	  A.,	  3RD,	  MUENZ,	  L.	  R.,	  JOYCE,	  K.	  M.,	  ANTONOVYCH,	  T.	  T.	  &	  BALOW,	  J.	  E.	  1984.	  Diffuse	  proliferative	   lupus	  nephritis:	   identification	  of	   specific	  pathologic	   features	  affecting	  renal	  outcome.	  Kidney	  Int,	  25,	  689-­‐95.	  AYHAN-­‐ARDIC,	   F.	   F.,	   OKEN,	   O.,	   YORGANCIOGLU,	   Z.	   R.,	   USTUN,	   N.	   &	   GOKHARMAN,	   F.	   D.	  2006.	   Pulmonary	   involvement	   in	   lifelong	  non-­‐smoking	  patients	  with	   rheumatoid	  arthritis	   and	   ankylosing	   spondylitis	   without	   respiratory	   symptoms.	   Clin	  
Rheumatol,	  25,	  213-­‐8.	  BAKKALOGLU,	   A.,	   TOPALOGLU,	   R.,	   SAATCI,	   U.,	   OZDEMIR,	   S.,	   OZEN,	   S.,	   BASSOY,	   Y.	   &	  BESBAS,	   N.	   1998.	   Antineutrophil	   cytoplasmic	   antibodies	   in	   childhood	   systemic	  lupus	  erythematosus.	  Clin	  Rheumatol,	  17,	  265-­‐7.	  BALADA,	  E.,	  CASTRO-­‐MARRERO,	  J.,	  FELIP,	  L.,	  ORDI-­‐ROS,	  J.	  &	  VILARDELL-­‐TARRES,	  M.	  2014.	  Clinical	   and	   serological	   findings	   associated	   with	   the	   expression	   of	   ITGAL,	   PRF1,	  and	  CD70	  in	  systemic	  lupus	  erythematosus.	  Clin	  Exp	  Rheumatol,	  32,	  113-­‐6.	  BARGATZE,	   R.	   F.,	   JUTILA,	  M.	   A.	   &	   BUTCHER,	   E.	   C.	   1995.	   Distinct	   roles	   of	   L-­‐selectin	   and	  integrins	  alpha	  4	  beta	  7	  and	  LFA-­‐1	  in	  lymphocyte	  homing	  to	  Peyer's	  patch-­‐HEV	  in	  situ:	  the	  multistep	  model	  confirmed	  and	  refined.	  Immunity,	  3,	  99-­‐108.	  BARNHART,	  M.	  I.,	  RIDDLE,	  J.	  M.	  &	  BLUHM,	  G.	  B.	  1967.	  Immunocytology	  in	  arthritic	  joints.	  
Ann	  Rheum	  Dis,	  26,	  281-­‐96.	  BARRAT,	  F.	  J.,	  MEEKER,	  T.,	  GREGORIO,	  J.,	  CHAN,	  J.	  H.,	  UEMATSU,	  S.,	  AKIRA,	  S.,	  CHANG,	  B.,	  DURAMAD,	  O.	  &	  COFFMAN,	  R.	  L.	  2005.	  Nucleic	  acids	  of	  mammalian	  origin	  can	  act	  as	   endogenous	   ligands	   for	   Toll-­‐like	   receptors	   and	   may	   promote	   systemic	   lupus	  erythematosus.	  J	  Exp	  Med,	  202,	  1131-­‐9.	  BARREIRO,	   O.,	   YANEZ-­‐MO,	   M.,	   SERRADOR,	   J.	   M.,	   MONTOYA,	   M.	   C.,	   VICENTE-­‐MANZANARES,	  M.,	   TEJEDOR,	   R.,	   FURTHMAYR,	   H.	   &	   SANCHEZ-­‐MADRID,	   F.	   2002.	  Dynamic	   interaction	   of	   VCAM-­‐1	   and	   ICAM-­‐1	   with	   moesin	   and	   ezrin	   in	   a	   novel	  endothelial	  docking	  structure	  for	  adherent	  leukocytes.	  J	  Cell	  Biol,	  157,	  1233-­‐45.	  BARTON,	  A.,	  BOWES,	  J.,	  EYRE,	  S.,	  SPRECKLEY,	  K.,	  HINKS,	  A.,	  JOHN,	  S.	  &	  WORTHINGTON,	  J.	  2004.	   A	   functional	   haplotype	   of	   the	   PADI4	   gene	   associated	   with	   rheumatoid	  arthritis	   in	   a	   Japanese	   population	   is	   not	   associated	   in	   a	   United	   Kingdom	  population.	  Arthritis	  Rheum,	  50,	  1117-­‐21.	  BAS,	   S.,	   PERNEGER,	   T.	   V.,	   SEITZ,	  M.,	   TIERCY,	   J.	  M.,	   ROUX-­‐LOMBARD,	   P.	  &	  GUERNE,	   P.	   A.	  2002.	   Diagnostic	   tests	   for	   rheumatoid	   arthritis:	   comparison	   of	   anti-­‐cyclic	  citrullinated	   peptide	   antibodies,	   anti-­‐keratin	   antibodies	   and	   IgM	   rheumatoid	  factors.	  Rheumatology	  (Oxford),	  41,	  809-­‐14.	  BATES,	   S.	   M.,	   GREER,	   I.	   A.,	   PABINGER,	   I.,	   SOFAER,	   S.	   &	   HIRSH,	   J.	   2008.	   Venous	  thromboembolism,	   thrombophilia,	   antithrombotic	   therapy,	   and	   pregnancy:	  American	  College	  of	  Chest	  Physicians	  Evidence-­‐Based	  Clinical	  Practice	  Guidelines	  (8th	  Edition).	  Chest,	  133,	  844S-­‐886S.	  BECK-­‐SCHIMMER,	   B.,	   SCHIMMER,	   R.	   C.,	   MADJDPOUR,	   C.,	   BONVINI,	   J.	   M.,	   PASCH,	   T.	   &	  WARD,	   P.	   A.	   2001.	   Hypoxia	   mediates	   increased	   neutrophil	   and	   macrophage	  adhesiveness	  to	  alveolar	  epithelial	  cells.	  Am	  J	  Respir	  Cell	  Mol	  Biol,	  25,	  780-­‐7.	  BEHNEN,	   M.,	   LESCHCZYK,	   C.,	   MOLLER,	   S.,	   BATEL,	   T.,	   KLINGER,	   M.,	   SOLBACH,	   W.	   &	  LASKAY,	  T.	  2014.	  Immobilized	  immune	  complexes	  induce	  neutrophil	  extracellular	  trap	   release	   by	   human	   neutrophil	   granulocytes	   via	   FcgammaRIIIB	   and	   Mac-­‐1.	   J	  
Immunol,	  193,	  1954-­‐65.	  BEHRENS,	   F.,	   HIMSEL,	   A.,	   REHART,	   S.,	   STANCZYK,	   J.,	   BEUTEL,	   B.,	   ZIMMERMANN,	   S.	   Y.,	  KOEHL,	   U.,	   MOLLER,	   B.,	   GAY,	   S.,	   KALTWASSER,	   J.	   P.,	   PFEILSCHIFTER,	   J.	   M.	   &	  RADEKE,	  H.	  H.	  2007.	  Imbalance	  in	  distribution	  of	  functional	  autologous	  regulatory	  T	  cells	  in	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  66,	  1151-­‐6.	  BELAAOUAJ,	   A.,	   MCCARTHY,	   R.,	   BAUMANN,	   M.,	   GAO,	   Z.,	   LEY,	   T.	   J.,	   ABRAHAM,	   S.	   N.	   &	  SHAPIRO,	  S.	  D.	  1998.	  Mice	  lacking	  neutrophil	  elastase	  reveal	  impaired	  host	  defense	  against	  gram	  negative	  bacterial	  sepsis.	  Nat	  Med,	  4,	  615-­‐8.	  BELCHER,	  C.,	  DOHERTY,	  M.	  &	  CROUCH,	  S.	  P.	  2002.	  Synovial	  fluid	  neutrophil	  function	  in	  RA:	  the	  effect	  of	  pregnancy	  associated	  proteins.	  Ann	  Rheum	  Dis,	  61,	  379-­‐80.	  
References 
	   225	  
BENNETT,	   L.,	   PALUCKA,	   A.	   K.,	   ARCE,	   E.,	   CANTRELL,	   V.,	   BORVAK,	   J.,	   BANCHEREAU,	   J.	   &	  PASCUAL,	   V.	   2003.	   Interferon	   and	   granulopoiesis	   signatures	   in	   systemic	   lupus	  erythematosus	  blood.	  J	  Exp	  Med,	  197,	  711-­‐23.	  BERLIN-­‐RUFENACH,	  C.,	  OTTO,	  F.,	  MATHIES,	  M.,	  WESTERMANN,	  J.,	  OWEN,	  M.	  J.,	  HAMANN,	  A.	   &	   HOGG,	   N.	   1999.	   Lymphocyte	   migration	   in	   lymphocyte	   function-­‐associated	  antigen	  (LFA)-­‐1-­‐deficient	  mice.	  J	  Exp	  Med,	  189,	  1467-­‐78.	  BERLIN,	  C.,	  BARGATZE,	  R.	  F.,	  CAMPBELL,	  J.	  J.,	  VON	  ANDRIAN,	  U.	  H.,	  SZABO,	  M.	  C.,	  HASSLEN,	  S.	  R.,	  NELSON,	  R.	  D.,	  BERG,	  E.	  L.,	  ERLANDSEN,	  S.	  L.	  &	  BUTCHER,	  E.	  C.	  1995.	  alpha	  4	  integrins	  mediate	  lymphocyte	  attachment	  and	  rolling	  under	  physiologic	  flow.	  Cell,	  80,	  413-­‐22.	  BERLIN,	   C.,	   BERG,	   E.	   L.,	   BRISKIN,	  M.	   J.,	   ANDREW,	   D.	   P.,	   KILSHAW,	   P.	   J.,	   HOLZMANN,	   B.,	  WEISSMAN,	   I.	   L.,	   HAMANN,	   A.	   &	   BUTCHER,	   E.	   C.	   1993.	   Alpha	   4	   beta	   7	   integrin	  mediates	   lymphocyte	  binding	  to	  the	  mucosal	  vascular	  addressin	  MAdCAM-­‐1.	  Cell,	  74,	  185-­‐95.	  BERMAN,	   M.	   E.	   &	   MULLER,	   W.	   A.	   1995.	   Ligation	   of	   platelet/endothelial	   cell	   adhesion	  molecule	   1	   (PECAM-­‐1/CD31)	   on	   monocytes	   and	   neutrophils	   increases	   binding	  capacity	  of	  leukocyte	  CR3	  (CD11b/CD18).	  J	  Immunol,	  154,	  299-­‐307.	  BERMAN,	  M.	  E.,	  XIE,	  Y.	  &	  MULLER,	  W.	  A.	  1996.	  Roles	  of	  platelet/endothelial	  cell	  adhesion	  molecule-­‐1	  (PECAM-­‐1,	  CD31)	  in	  natural	  killer	  cell	  transendothelial	  migration	  and	  beta	  2	  integrin	  activation.	  J	  Immunol,	  156,	  1515-­‐24.	  BERTSIAS,	  G.	  &	  BOUMPAS,	  D.	  T.	  2008.	  Update	  on	  the	  management	  of	   lupus	  nephritis:	   let	  the	  treatment	  fit	  the	  patient.	  Nat	  Clin	  Pract	  Rheumatol,	  4,	  464-­‐72.	  BEVILACQUA,	  M.	   P.,	   STENGELIN,	   S.,	   GIMBRONE,	  M.	   A.,	   JR.	   &	   SEED,	   B.	   1989.	   Endothelial	  leukocyte	   adhesion	  molecule	   1:	   an	   inducible	   receptor	   for	   neutrophils	   related	   to	  complement	  regulatory	  proteins	  and	  lectins.	  Science,	  243,	  1160-­‐5.	  BILSLAND,	  C.	  A.,	  DIAMOND,	  M.	  S.	  &	  SPRINGER,	  T.	  A.	  1994.	  The	  leukocyte	  integrin	  p150,95	  (CD11c/CD18)	   as	   a	   receptor	   for	   iC3b.	   Activation	   by	   a	   heterologous	   beta	   subunit	  and	  localization	  of	  a	  ligand	  recognition	  site	  to	  the	  I	  domain.	  J	  Immunol,	  152,	  4582-­‐9.	  BISCHOF,	   P.,	   HAENGGELI,	   L.	   &	   CAMPANA,	   A.	   1995.	   Gelatinase	   and	   oncofetal	   fibronectin	  secretion	   is	   dependent	   on	   integrin	   expression	   on	   human	   cytotrophoblasts.	  Hum	  
Reprod,	  10,	  734-­‐42.	  BLAIR,	   P.	   A.,	   NORENA,	   L.	   Y.,	   FLORES-­‐BORJA,	   F.,	   RAWLINGS,	   D.	   J.,	   ISENBERG,	   D.	   A.,	  EHRENSTEIN,	  M.	  R.	  &	  MAURI,	   C.	   2010.	  CD19(+)CD24(hi)CD38(hi)	  B	   cells	   exhibit	  regulatory	   capacity	   in	   healthy	   individuals	   but	   are	   functionally	   impaired	   in	  systemic	  Lupus	  Erythematosus	  patients.	  Immunity,	  32,	  129-­‐40.	  BLANK,	  M.,	  KRAUSE,	  I.,	  FRIDKIN,	  M.,	  KELLER,	  N.,	  KOPOLOVIC,	  J.,	  GOLDBERG,	  I.,	  TOBAR,	  A.	  &	   SHOENFELD,	   Y.	   2002.	   Bacterial	   induction	   of	   autoantibodies	   to	   beta2-­‐glycoprotein-­‐I	  accounts	  for	  the	  infectious	  etiology	  of	  antiphospholipid	  syndrome.	  J	  
Clin	  Invest,	  109,	  797-­‐804.	  BLASCHKE,	  F.,	  STAWOWY,	  P.,	  GOETZE,	  S.,	  HINTZ,	  O.,	  GRAFE,	  M.,	  KINTSCHER,	  U.,	  FLECK,	  E.	  &	   GRAF,	   K.	   2002.	   Hypoxia	   activates	   beta(1)-­‐integrin	   via	   ERK	   1/2	   and	   p38	  MAP	  kinase	  in	  human	  vascular	  smooth	  muscle	  cells.	  Biochem	  Biophys	  Res	  Commun,	  296,	  890-­‐6.	  BLOMBERG,	  S.,	  ELORANTA,	  M.	  L.,	  CEDERBLAD,	  B.,	  NORDLIN,	  K.,	  ALM,	  G.	  V.	  &	  RONNBLOM,	  L.	   2001.	   Presence	   of	   cutaneous	   interferon-­‐alpha	   producing	   cells	   in	   patients	  with	  systemic	  lupus	  erythematosus.	  Lupus,	  10,	  484-­‐90.	  BODAMYALI,	   T.,	   STEVENS,	   C.	   R.,	   BILLINGHAM,	   M.	   E.,	   OHTA,	   S.	   &	   BLAKE,	   D.	   R.	   1998.	  Influence	  of	  hypoxia	  in	  inflammatory	  synovitis.	  Ann	  Rheum	  Dis,	  57,	  703-­‐10.	  BOGEN,	  S.,	  PAK,	  J.,	  GARIFALLOU,	  M.,	  DENG,	  X.	  &	  MULLER,	  W.	  A.	  1994.	  Monoclonal	  antibody	  to	   murine	   PECAM-­‐1	   (CD31)	   blocks	   acute	   inflammation	   in	   vivo.	   J	   Exp	  Med,	   179,	  1059-­‐64.	  BONELLI,	  M.,	  SAVITSKAYA,	  A.,	  VON	  DALWIGK,	  K.,	  STEINER,	  C.	  W.,	  ALETAHA,	  D.,	  SMOLEN,	  J.	   S.	   &	   SCHEINECKER,	   C.	   2008.	   Quantitative	   and	   qualitative	   deficiencies	   of	  
References 
	   226	  
regulatory	   T	   cells	   in	   patients	   with	   systemic	   lupus	   erythematosus	   (SLE).	   Int	  
Immunol,	  20,	  861-­‐8.	  BONFANTI,	   R.,	   FURIE,	   B.	   C.,	   FURIE,	   B.	   &	  WAGNER,	   D.	   D.	   1989.	   PADGEM	   (GMP140)	   is	   a	  component	   of	  Weibel-­‐Palade	  bodies	   of	   human	  endothelial	   cells.	  Blood,	   73,	   1109-­‐12.	  BONILLA-­‐HERNAN,	  M.	  G.,	  MIRANDA-­‐CARUS,	  M.	  E.	  &	  MARTIN-­‐MOLA,	  E.	  2011.	  New	  drugs	  beyond	   biologics	   in	   rheumatoid	   arthritis:	   the	   kinase	   inhibitors.	   Rheumatology	  
(Oxford),	  50,	  1542-­‐50.	  BORREGAARD,	  N.,	  KJELDSEN,	  L.,	  RYGAARD,	  K.,	  BASTHOLM,	  L.,	  NIELSEN,	  M.	  H.,	  SENGELOV,	  H.,	   BJERRUM,	   O.	   W.	   &	   JOHNSEN,	   A.	   H.	   1992.	   Stimulus-­‐dependent	   secretion	   of	  plasma	  proteins	  from	  human	  neutrophils.	  J	  Clin	  Invest,	  90,	  86-­‐96.	  BORREGAARD,	   N.,	   KJELDSEN,	   L.,	   SENGELOV,	   H.,	   DIAMOND,	   M.	   S.,	   SPRINGER,	   T.	   A.,	  ANDERSON,	  H.	  C.,	  KISHIMOTO,	  T.	  K.	  &	  BAINTON,	  D.	  F.	  1994.	  Changes	  in	  subcellular	  localization	  and	  surface	  expression	  of	  L-­‐selectin,	  alkaline	  phosphatase,	  and	  Mac-­‐1	  in	   human	   neutrophils	   during	   stimulation	  with	   inflammatory	  mediators.	   J	  Leukoc	  
Biol,	  56,	  80-­‐7.	  BRACKEN,	  C.	  P.,	  FEDELE,	  A.	  O.,	  LINKE,	  S.,	  BALRAK,	  W.,	  LISY,	  K.,	  WHITELAW,	  M.	  L.	  &	  PEET,	  D.	   J.	   2006.	   Cell-­‐specific	   regulation	   of	   hypoxia-­‐inducible	   factor	   (HIF)-­‐1alpha	   and	  HIF-­‐2alpha	   stabilization	   and	   transactivation	   in	   a	   graded	   oxygen	   environment.	   J	  
Biol	  Chem,	  281,	  22575-­‐85.	  BRANCH,	  D.	  W.	  1994.	  Thoughts	  on	  the	  mechanism	  of	  pregnancy	   loss	  associated	  with	  the	  antiphospholipid	  syndrome.	  Lupus,	  3,	  275-­‐80.	  BRANDT,	   L.	   &	   HEDBERG,	   H.	   1969.	   Impaired	   phagocytosis	   by	   peripheral	   blood	  granulocytes	  in	  systemic	  lupus	  erythematosus.	  Scand	  J	  Haematol,	  6,	  348-­‐53.	  BRANZK,	  N.,	  LUBOJEMSKA,	  A.,	  HARDISON,	  S.	  E.,	  WANG,	  Q.,	  GUTIERREZ,	  M.	  G.,	  BROWN,	  G.	  D.	  &	  PAPAYANNOPOULOS,	  V.	  2014.	  Neutrophils	  sense	  microbe	  size	  and	  selectively	  release	  neutrophil	  extracellular	  traps	  in	  response	  to	  large	  pathogens.	  Nat	  Immunol,	  15,	  1017-­‐25.	  BRAUN,	  R.	  D.,	  LANZEN,	  J.	  L.,	  SNYDER,	  S.	  A.	  &	  DEWHIRST,	  M.	  W.	  2001.	  Comparison	  of	  tumor	  and	  normal	  tissue	  oxygen	  tension	  measurements	  using	  OxyLite	  or	  microelectrodes	  in	  rodents.	  Am	  J	  Physiol	  Heart	  Circ	  Physiol,	  280,	  H2533-­‐44.	  BRENNAN,	  F.	  M.,	  ZACHARIAE,	  C.	  O.,	  CHANTRY,	  D.,	  LARSEN,	  C.	  G.,	  TURNER,	  M.,	  MAINI,	  R.	  N.,	  MATSUSHIMA,	   K.	   &	   FELDMANN,	   M.	   1990.	   Detection	   of	   interleukin	   8	   biological	  activity	  in	  synovial	  fluids	  from	  patients	  with	  rheumatoid	  arthritis	  and	  production	  of	  interleukin	  8	  mRNA	  by	  isolated	  synovial	  cells.	  Eur	  J	  Immunol,	  20,	  2141-­‐4.	  BRENNAN,	  P.	  J.,	  ZIGMOND,	  S.	  H.,	  SCHREIBER,	  A.	  D.,	  SMITH,	  E.	  R.	  &	  SOUTHWICK,	  F.	  S.	  1991.	  Binding	  of	   IgG	  containing	   immune	  complexes	  to	  human	  neutrophil	  Fc	  gamma	  RII	  and	   Fc	   gamma	  RIII	   induces	   actin	   polymerization	   by	   a	   pertussis	   toxin-­‐insensitive	  transduction	  pathway.	  J	  Immunol,	  146,	  4282-­‐8.	  BRILL,	  A.,	  FUCHS,	  T.	  A.,	  SAVCHENKO,	  A.	  S.,	  THOMAS,	  G.	  M.,	  MARTINOD,	  K.,	  DE	  MEYER,	  S.	  F.,	  BHANDARI,	  A.	  A.	  &	  WAGNER,	  D.	  D.	  2012.	  Neutrophil	  extracellular	   traps	  promote	  deep	  vein	  thrombosis	  in	  mice.	  J	  Thromb	  Haemost,	  10,	  136-­‐44.	  BRINKMANN,	  V.,	  REICHARD,	  U.,	  GOOSMANN,	  C.,	  FAULER,	  B.,	  UHLEMANN,	  Y.,	  WEISS,	  D.	  S.,	  WEINRAUCH,	   Y.	   &	   ZYCHLINSKY,	   A.	   2004.	   Neutrophil	   extracellular	   traps	   kill	  bacteria.	  Science,	  303,	  1532-­‐1535.	  BROSENS,	   I.,	  ROBERTSON,	  W.	  B.	  &	  DIXON,	  H.	  G.	  1967.	  The	  physiological	   response	  of	   the	  vessels	  of	  the	  placental	  bed	  to	  normal	  pregnancy.	  J	  Pathol	  Bacteriol,	  93,	  569-­‐79.	  BROWN,	  E.	  E.,	  EDBERG,	  J.	  C.	  &	  KIMBERLY,	  R.	  P.	  2007.	  Fc	  receptor	  genes	  and	  the	  systemic	  lupus	  erythematosus	  diathesis.	  Autoimmunity,	  40,	  567-­‐81.	  BROWN,	  E.	  J.	  1991.	  Complement	  receptors	  and	  phagocytosis.	  Curr	  Opin	  Immunol,	  3,	  76-­‐82.	  BRUEHL,	   R.	   E.,	   MOORE,	   K.	   L.,	   LORANT,	   D.	   E.,	   BORREGAARD,	   N.,	   ZIMMERMAN,	   G.	   A.,	  MCEVER,	   R.	   P.	   &	   BAINTON,	   D.	   F.	   1997.	   Leukocyte	   activation	   induces	   surface	  redistribution	  of	  P-­‐selectin	  glycoprotein	  ligand-­‐1.	  J	  Leukoc	  Biol,	  61,	  489-­‐99.	  
References 
	   227	  
BRUHNS,	  P.	  2012.	  Properties	  of	  mouse	  and	  human	  IgG	  receptors	  and	  their	  contribution	  to	  disease	  models.	  Blood,	  119,	  5640-­‐9.	  BRUSCA,	   S.	   B.,	   ABRAMSON,	   S.	   B.	   &	   SCHER,	   J.	   U.	   2014.	   Microbiome	   and	   mucosal	  inflammation	   as	   extra-­‐articular	   triggers	   for	   rheumatoid	   arthritis	   and	  autoimmunity.	  Curr	  Opin	  Rheumatol,	  26,	  101-­‐7.	  BUCCIARELLI,	   S.,	   ESPINOSA,	   G.	  &	   CERVERA,	   R.	   2009.	   The	   CAPS	  Registry:	  morbidity	   and	  mortality	  of	  the	  catastrophic	  antiphospholipid	  syndrome.	  Lupus,	  18,	  905-­‐12.	  BUNN,	  H.	  F.	  &	  POYTON,	  R.	  O.	  1996.	  Oxygen	  sensing	  and	  molecular	  adaptation	  to	  hypoxia.	  
Physiol	  Rev,	  76,	  839-­‐85.	  BURR,	  M.	   L.,	   NASEEM,	   H.,	   HINKS,	   A.,	   EYRE,	   S.,	   GIBBONS,	   L.	   J.,	   BOWES,	   J.,	  WILSON,	   A.	   G.,	  MAXWELL,	   J.,	   MORGAN,	   A.	   W.,	   EMERY,	   P.,	   STEER,	   S.,	   HOCKING,	   L.,	   REID,	   D.	   M.,	  WORDSWORTH,	  P.,	  HARRISON,	  P.,	  THOMSON,	  W.,	  WORTHINGTON,	   J.	  &	  BARTON,	  A.	  2010.	  PADI4	  genotype	  is	  not	  associated	  with	  rheumatoid	  arthritis	  in	  a	  large	  UK	  Caucasian	  population.	  Ann	  Rheum	  Dis,	  69,	  666-­‐70.	  BURROWS,	  T.	  D.,	  KING,	  A.,	  SMITH,	  S.	  K.	  &	  LOKE,	  Y.	  W.	  1995.	  Human	  trophoblast	  adhesion	  to	  matrix	  proteins:	  inhibition	  and	  signal	  transduction.	  Hum	  Reprod,	  10,	  2489-­‐500.	  BURTON,	  G.	   J.,	   JAUNIAUX,	  E.	  &	  WATSON,	  A.	  L.	  1999.	  Maternal	  arterial	  connections	  to	  the	  placental	   intervillous	   space	   during	   the	   first	   trimester	   of	   human	   pregnancy:	   the	  Boyd	  collection	  revisited.	  Am	  J	  Obstet	  Gynecol,	  181,	  718-­‐24.	  BYRD,	  A.	   S.,	  O'BRIEN,	  X.	  M.,	   JOHNSON,	  C.	  M.,	   LAVIGNE,	  L.	  M.	  &	  REICHNER,	   J.	   S.	  2013.	  An	  extracellular	   matrix-­‐based	   mechanism	   of	   rapid	   neutrophil	   extracellular	   trap	  formation	  in	  response	  to	  Candida	  albicans.	  J	  Immunol,	  190,	  4136-­‐48.	  CALDWELL,	  C.	  C.,	  KOJIMA,	  H.,	  LUKASHEV,	  D.,	  ARMSTRONG,	  J.,	  FARBER,	  M.,	  APASOV,	  S.	  G.	  &	  SITKOVSKY,	   M.	   V.	   2001.	   Differential	   effects	   of	   physiologically	   relevant	   hypoxic	  conditions	  on	  T	   lymphocyte	  development	  and	  effector	   functions.	   J	  Immunol,	   167,	  6140-­‐9.	  CALIZ,	  R.,	  ATSUMI,	  T.,	  KONDEATIS,	  E.,	  AMENGUAL,	  O.,	  KHAMASHTA,	  M.	  A.,	  VAUGHAN,	  R.	  W.,	  LANCHBURY,	  J.	  S.	  &	  HUGHES,	  G.	  R.	  2001.	  HLA	  class	  II	  gene	  polymorphisms	  in	  antiphospholipid	   syndrome:	   haplotype	   analysis	   in	   83	   Caucasoid	   patients.	  
Rheumatology	  (Oxford),	  40,	  31-­‐6.	  CAPONI,	   L.,	   PETIT-­‐TEIXEIRA,	   E.,	   SEBBAG,	  M.,	   BONGIORNI,	   F.,	  MOSCATO,	   S.,	   PRATESI,	   F.,	  PIERLOT,	  C.,	  OSORIO,	  J.,	  CHAPUY-­‐REGAUD,	  S.,	  GUERRIN,	  M.,	  CORNELIS,	  F.,	  SERRE,	  G.	   &	   MIGLIORINI,	   P.	   2005.	   A	   family	   based	   study	   shows	   no	   association	   between	  rheumatoid	  arthritis	  and	  the	  PADI4	  gene	  in	  a	  white	  French	  population.	  Ann	  Rheum	  
Dis,	  64,	  587-­‐93.	  CARICCHIO,	  R.,	  MCPHIE,	  L.	  &	  COHEN,	  P.	  L.	  2003.	  Ultraviolet	  B	  radiation-­‐induced	  cell	  death:	  critical	   role	   of	   ultraviolet	   dose	   in	   inflammation	   and	   lupus	   autoantigen	  redistribution.	  J	  Immunol,	  171,	  5778-­‐86.	  CARMAN,	  C.	  V.	  &	  SPRINGER,	  T.	  A.	  2004.	  A	  transmigratory	  cup	  in	  leukocyte	  diapedesis	  both	  through	   individual	   vascular	   endothelial	   cells	   and	   between	   them.	   J	   Cell	  Biol,	   167,	  377-­‐88.	  CARMONA-­‐RIVERA,	  C.	  &	  KAPLAN,	  M.	  J.	  2013.	  Low-­‐density	  granulocytes:	  a	  distinct	  class	  of	  neutrophils	  in	  systemic	  autoimmunity.	  Semin	  Immunopathol,	  35,	  455-­‐63.	  CARMONA-­‐RIVERA,	   C.,	   ZHAO,	   W.,	   YALAVARTHI,	   S.	   &	   KAPLAN,	   M.	   J.	   2015.	   Neutrophil	  extracellular	   traps	   induce	   endothelial	   dysfunction	   in	   systemic	   lupus	  erythematosus	   through	   the	   activation	   of	  matrix	  metalloproteinase-­‐2.	  Ann	  Rheum	  
Dis,	  74,	  1417-­‐24.	  CARMONA,	  F.,	  FONT,	  J.,	  AZULAY,	  M.,	  CREUS,	  M.,	  FABREGUES,	  F.,	  CERVERA,	  R.,	  PUERTO,	  B.	  &	   BALASCH,	   J.	   2001.	   Risk	   factors	   associated	   with	   fetal	   losses	   in	   treated	  antiphospholipid	   syndrome	   pregnancies:	   a	   multivariate	   analysis.	   Am	   J	   Reprod	  
Immunol,	  46,	  274-­‐9.	  CARON,	   E.	   &	   HALL,	   A.	   1998.	   Identification	   of	   two	   distinct	   mechanisms	   of	   phagocytosis	  controlled	  by	  different	  Rho	  GTPases.	  Science,	  282,	  1717-­‐21.	  
References 
	   228	  
CARTER,	  T.	  D.,	  HALLAM,	  T.	  J.	  &	  PEARSON,	  J.	  D.	  1989.	  Protein	  kinase	  C	  activation	  alters	  the	  sensitivity	   of	   agonist-­‐stimulated	   endothelial-­‐cell	   prostacyclin	   production	   to	  intracellular	  Ca2+.	  Biochem	  J,	  262,	  431-­‐7.	  CEDENO,	   S.,	   CIFARELLI,	   D.	   F.,	   BLASINI,	   A.	   M.,	   PARIS,	   M.,	   PLACERES,	   F.,	   ALONSO,	   G.	   &	  RODRIGUEZ,	  M.	  A.	  2003.	  Defective	  activity	  of	  ERK-­‐1	  and	  ERK-­‐2	  mitogen-­‐activated	  protein	   kinases	   in	   peripheral	   blood	   T	   lymphocytes	   from	   patients	   with	   systemic	  lupus	  erythematosus:	  potential	  role	  of	  altered	  coupling	  of	  Ras	  guanine	  nucleotide	  exchange	  factor	  hSos	  to	  adapter	  protein	  Grb2	  in	   lupus	  T	  cells.	  Clin	  Immunol,	  106,	  41-­‐9.	  CELIK,	   E.,	   FARIDI,	   M.	   H.,	   KUMAR,	   V.,	   DEEP,	   S.,	   MOY,	   V.	   T.	   &	   GUPTA,	   V.	   2013.	   Agonist	  leukadherin-­‐1	  increases	  CD11b/CD18-­‐dependent	  adhesion	  via	  membrane	  tethers.	  
Biophys	  J,	  105,	  2517-­‐27.	  CERF-­‐BENSUSSAN,	  N.,	   JARRY,	  A.,	  BROUSSE,	  N.,	  LISOWSKA-­‐GROSPIERRE,	  B.,	  GUY-­‐GRAND,	  D.	   &	   GRISCELLI,	   C.	   1987.	   A	   monoclonal	   antibody	   (HML-­‐1)	   defining	   a	   novel	  membrane	  molecule	  present	  on	  human	  intestinal	  lymphocytes.	  Eur	  J	  Immunol,	  17,	  1279-­‐85.	  CERVERA,	  R.,	  ASHERSON,	  R.	  A.,	  ACEVEDO,	  M.	  L.,	  GOMEZ-­‐PUERTA,	   J.	  A.,	  ESPINOSA,	  G.,	  DE	  LA	   RED,	   G.,	   GIL,	   V.,	   RAMOS-­‐CASALS,	  M.,	   GARCIA-­‐CARRASCO,	  M.,	   INGELMO,	  M.	   &	  FONT,	  J.	  2004.	  Antiphospholipid	  syndrome	  associated	  with	  infections:	  clinical	  and	  microbiological	  characteristics	  of	  100	  patients.	  Ann	  Rheum	  Dis,	  63,	  1312-­‐7.	  CERVERA,	   R.,	   BOFFA,	   M.	   C.,	   KHAMASHTA,	   M.	   A.	   &	   HUGHES,	   G.	   R.	   2009a.	   The	   Euro-­‐Phospholipid	  project:	  epidemiology	  of	   the	  antiphospholipid	  syndrome	   in	  Europe.	  
Lupus,	  18,	  889-­‐93.	  CERVERA,	   R.,	   BUCCIARELLI,	   S.,	   PLASIN,	   M.	   A.,	   GOMEZ-­‐PUERTA,	   J.	   A.,	   PLAZA,	   J.,	   PONS-­‐ESTEL,	   G.,	   SHOENFELD,	   Y.,	   INGELMO,	   M.	   &	   ESPINOS,	   G.	   2009b.	   Catastrophic	  antiphospholipid	  syndrome	  (CAPS):	  descriptive	  analysis	  of	  a	  series	  of	  280	  patients	  from	  the	  "CAPS	  Registry".	  J	  Autoimmun,	  32,	  240-­‐5.	  CERVERA,	  R.,	  FONT,	   J.,	  GOMEZ-­‐PUERTA,	   J.	  A.,	  ESPINOSA,	  G.,	  CUCHO,	  M.,	  BUCCIARELLI,	  S.,	  RAMOS-­‐CASALS,	  M.,	  INGELMO,	  M.,	  PIETTE,	  J.	  C.,	  SHOENFELD,	  Y.	  &	  ASHERSON,	  R.	  A.	  2005.	   Validation	   of	   the	   preliminary	   criteria	   for	   the	   classification	   of	   catastrophic	  antiphospholipid	  syndrome.	  Ann	  Rheum	  Dis,	  64,	  1205-­‐9.	  CERVERA,	   R.,	   KHAMASHTA,	   M.	   A.	   &	   HUGHES,	   G.	   R.	   2009c.	   The	   Euro-­‐lupus	   project:	  epidemiology	  of	  systemic	  lupus	  erythematosus	  in	  Europe.	  Lupus,	  18,	  869-­‐74.	  CERVERA,	   R.,	   PIETTE,	   J.	   C.,	   FONT,	   J.,	   KHAMASHTA,	  M.	   A.,	   SHOENFELD,	   Y.,	   CAMPS,	  M.	   T.,	  JACOBSEN,	   S.,	   LAKOS,	   G.,	   TINCANI,	   A.,	   KONTOPOULOU-­‐GRIVA,	   I.,	   GALEAZZI,	   M.,	  MERONI,	  P.	  L.,	  DERKSEN,	  R.	  H.,	  DE	  GROOT,	  P.	  G.,	  GROMNICA-­‐IHLE,	  E.,	  BALEVA,	  M.,	  MOSCA,	  M.,	  BOMBARDIERI,	  S.,	  HOUSSIAU,	  F.,	  GRIS,	   J.	  C.,	  QUERE,	  I.,	  HACHULLA,	  E.,	  VASCONCELOS,	  C.,	  ROCH,	  B.,	  FERNANDEZ-­‐NEBRO,	  A.,	  BOFFA,	  M.	  C.,	  HUGHES,	  G.	  R.	  &	   INGELMO,	   M.	   2002.	   Antiphospholipid	   syndrome:	   clinical	   and	   immunologic	  manifestations	   and	   patterns	   of	   disease	   expression	   in	   a	   cohort	   of	   1,000	   patients.	  
Arthritis	  Rheum,	  46,	  1019-­‐27.	  CHABAUD,	  M.,	  FOSSIEZ,	  F.,	  TAUPIN,	  J.	  L.	  &	  MIOSSEC,	  P.	  1998.	  Enhancing	  effect	  of	  IL-­‐17	  on	  IL-­‐1-­‐induced	   IL-­‐6	   and	   leukemia	   inhibitory	   factor	   production	   by	   rheumatoid	  arthritis	  synoviocytes	  and	  its	  regulation	  by	  Th2	  cytokines.	  J	  Immunol,	  161,	  409-­‐14.	  CHAKRAVARTI,	  A.,	  RAQUIL,	  M.	  A.,	  TESSIER,	  P.	  &	  POUBELLE,	  P.	  E.	  2009.	  Surface	  RANKL	  of	  Toll-­‐like	   receptor	   4-­‐stimulated	   human	   neutrophils	   activates	   osteoclastic	   bone	  resorption.	  Blood,	  114,	  1633-­‐44.	  CHAN,	  B.	  M.,	  ELICES,	  M.	   J.,	  MURPHY,	  E.	  &	  HEMLER,	  M.	  E.	  1992.	  Adhesion	  to	  vascular	  cell	  adhesion	  molecule	  1	   and	   fibronectin.	   Comparison	  of	   alpha	  4	  beta	  1	   (VLA-­‐4)	   and	  alpha	  4	  beta	  7	  on	  the	  human	  B	  cell	  line	  JY.	  J	  Biol	  Chem,	  267,	  8366-­‐70.	  CHANDEL,	  N.	  S.,	  TRZYNA,	  W.	  C.,	  MCCLINTOCK,	  D.	  S.	  &	  SCHUMACKER,	  P.	  T.	  2000.	  Role	  of	  oxidants	   in	  NF-­‐kappa	   B	   activation	   and	   TNF-­‐alpha	   gene	   transcription	   induced	   by	  hypoxia	  and	  endotoxin.	  J	  Immunol,	  165,	  1013-­‐21.	  
References 
	   229	  
CHATHAM,	  W.	  W.,	  HECK,	  L.	  W.	  &	  BLACKBURN,	  W.	  D.,	  JR.	  1990.	  Lysis	  of	  fibrillar	  collagen	  by	  neutrophils	   in	  synovial	   fluid.	  A	  role	   for	  surface-­‐bound	  immunoglobulins.	  Arthritis	  
Rheum,	  33,	  1333-­‐9.	  CHAUDHRI,	   G.,	   HUNT,	   N.	   H.,	   CLARK,	   I.	   A.	   &	   CEREDIG,	   R.	   1988.	   Antioxidants	   inhibit	  proliferation	   and	   cell	   surface	   expression	   of	   receptors	   for	   interleukin-­‐2	   and	  transferrin	   in	   T	   lymphocytes	   stimulated	   with	   phorbol	   myristate	   acetate	   and	  ionomycin.	  Cell	  Immunol,	  115,	  204-­‐13.	  CHAVAKIS,	   T.,	   KEIPER,	   T.,	   MATZ-­‐WESTPHAL,	   R.,	   HERSEMEYER,	   K.,	   SACHS,	   U.	   J.,	  NAWROTH,	  P.	  P.,	  PREISSNER,	  K.	  T.	  &	  SANTOSO,	  S.	  2004.	  The	   junctional	  adhesion	  molecule-­‐C	  promotes	  neutrophil	  transendothelial	  migration	  in	  vitro	  and	  in	  vivo.	  J	  
Biol	  Chem,	  279,	  55602-­‐8.	  CHEN,	   K.,	   NISHI,	   H.,	   TRAVERS,	   R.,	   TSUBOI,	   N.,	  MARTINOD,	   K.,	  WAGNER,	   D.	   D.,	   STAN,	   R.,	  CROCE,	   K.	   &	   MAYADAS,	   T.	   N.	   2012.	   Endocytosis	   of	   soluble	   immune	   complexes	  leads	   to	   their	   clearance	   by	   FcgammaRIIIB	   but	   induces	   neutrophil	   extracellular	  traps	  via	  FcgammaRIIA	  in	  vivo.	  Blood,	  120,	  4421-­‐31.	  CHENG,	  J.,	  ZHANG,	  H.,	  ZHUANG,	  C.	  &	  LIU,	  R.	  2012.	  Peptidylarginine	  deiminase	  type	  4	  and	  methyl-­‐CpG	   binding	   domain	   4	   polymorphisms	   in	   Chinese	   patients	   with	  rheumatoid	  arthritis.	  J	  Rheumatol,	  39,	  1159-­‐65.	  CHENG,	  M.,	  LI,	  J.,	  NEGRI,	  A.	  &	  COLLER,	  B.	  S.	  2013.	  Swing-­‐out	  of	  the	  beta3	  hybrid	  domain	  is	  required	   for	   alphaIIbbeta3	   priming	   and	   normal	   cytoskeletal	   reorganization,	   but	  not	  adhesion	  to	  immobilized	  fibrinogen.	  PLoS	  One,	  8,	  e81609.	  CHIBA,	  R.,	  NAKAGAWA,	  N.,	  KURASAWA,	  K.,	   TANAKA,	  Y.,	   SAITO,	  Y.	  &	   IWAMOTO,	   I.	   1999.	  Ligation	   of	   CD31	   (PECAM-­‐1)	   on	   endothelial	   cells	   increases	   adhesive	   function	   of	  alphavbeta3	   integrin	   and	   enhances	   beta1	   integrin-­‐mediated	   adhesion	   of	  eosinophils	  to	  endothelial	  cells.	  Blood,	  94,	  1319-­‐29.	  CHIU,	  J.	   J.,	  LEE,	  P.	  L.,	  CHEN,	  C.	  N.,	  LEE,	  C.	   I.,	  CHANG,	  S.	  F.,	  CHEN,	  L.	   J.,	  LIEN,	  S.	  C.,	  KO,	  Y.	  C.,	  USAMI,	  S.	  &	  CHIEN,	  S.	  2004.	  Shear	  stress	  increases	  ICAM-­‐1	  and	  decreases	  VCAM-­‐1	  and	  E-­‐selectin	  expressions	  induced	  by	  tumor	  necrosis	  factor-­‐[alpha]	  in	  endothelial	  cells.	  Arterioscler	  Thromb	  Vasc	  Biol,	  24,	  73-­‐9.	  CICCO,	  N.	  A.,	  LINDEMANN,	  A.,	  CONTENT,	  J.,	  VANDENBUSSCHE,	  P.,	  LUBBERT,	  M.,	  GAUSS,	  J.,	  MERTELSMANN,	  R.	  &	  HERRMANN,	  F.	  1990.	  Inducible	  production	  of	   interleukin-­‐6	  by	   human	   polymorphonuclear	   neutrophils:	   role	   of	   granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  and	  tumor	  necrosis	  factor-­‐alpha.	  Blood,	  75,	  2049-­‐52.	  CLARK,	   S.	   R.,	   MA,	   A.	   C.,	   TAVENER,	   S.	   A.,	   MCDONALD,	   B.,	   GOODARZI,	   Z.,	   KELLY,	   M.	   M.,	  PATEL,	  K.	  D.,	  CHAKRABARTI,	  S.,	  MCAVOY,	  E.,	  SINCLAIR,	  G.	  D.,	  KEYS,	  E.	  M.,	  ALLEN-­‐VERCOE,	   E.,	   DEVINNEY,	   R.,	   DOIG,	   C.	   J.,	   GREEN,	   F.	   H.	   &	   KUBES,	   P.	   2007.	   Platelet	  TLR4	  activates	  neutrophil	   extracellular	   traps	   to	  ensnare	  bacteria	   in	   septic	  blood.	  
Nat	  Med,	  13,	  463-­‐9.	  COHEN,	   S.	   B.,	   CHENG,	   T.	   T.,	   CHINDALORE,	   V.,	   DAMJANOV,	   N.,	   BURGOS-­‐VARGAS,	   R.,	  DELORA,	  P.,	  ZIMANY,	  K.,	  TRAVERS,	  H.	  &	  CAULFIELD,	   J.	  P.	  2009.	  Evaluation	  of	   the	  efficacy	  and	  safety	  of	  pamapimod,	  a	  p38	  MAP	  kinase	   inhibitor,	   in	  a	  double-­‐blind,	  methotrexate-­‐controlled	   study	   of	   patients	   with	   active	   rheumatoid	   arthritis.	  
Arthritis	  Rheum,	  60,	  335-­‐44.	  COJOCARU,	  M.,	   COJOCARU,	   I.	  M.,	   SILOSI,	   I.,	   VRABIE,	   C.	   D.	  &	  TANASESCU,	   R.	   2010.	   Extra-­‐articular	  Manifestations	  in	  Rheumatoid	  Arthritis.	  Maedica	  (Buchar),	  5,	  286-­‐91.	  COLASANTI,	   T.,	   MASELLI,	   A.,	   CONTI,	   F.,	   SANCHEZ,	   M.,	   ALESSANDRI,	   C.,	   BARBATI,	   C.,	  VACIRCA,	   D.,	   TINARI,	   A.,	   CHIAROTTI,	   F.,	   GIOVANNETTI,	   A.,	   FRANCONI,	   F.,	  VALESINI,	   G.,	   MALORNI,	   W.,	   PIERDOMINICI,	   M.	   &	   ORTONA,	   E.	   2012.	  Autoantibodies	   to	   estrogen	   receptor	   alpha	   interfere	   with	   T	   lymphocyte	  homeostasis	   and	   are	   associated	   with	   disease	   activity	   in	   systemic	   lupus	  erythematosus.	  Arthritis	  Rheum,	  64,	  778-­‐87.	  COLGAN,	  S.	  P.,	  DZUS,	  A.	  L.	  &	  PARKOS,	  C.	  A.	  1996.	  Epithelial	  exposure	  to	  hypoxia	  modulates	  neutrophil	  transepithelial	  migration.	  J	  Exp	  Med,	  184,	  1003-­‐15.	  
References 
	   230	  
COREMANS,	  I.	  E.,	  HAGEN,	  E.	  C.,	  VAN	  DER	  VOORT,	  E.	  A.,	  VAN	  DER	  WOUDE,	  F.	  J.,	  DAHA,	  M.	  R.	  &	  BREEDVELD,	   F.	   C.	   1993.	  Autoantibodies	   to	   neutrophil	   cytoplasmic	   enzymes	   in	  Felty's	  syndrome.	  Clin	  Exp	  Rheumatol,	  11,	  255-­‐62.	  CORTET,	  B.,	  FLIPO,	  R.	  M.,	  REMY-­‐JARDIN,	  M.,	  COQUERELLE,	  P.,	  DUQUESNOY,	  B.,	  REMY,	  J.	  &	  DELCAMBRE,	  B.	  1995.	  Use	  of	  high	  resolution	  computed	  tomography	  of	  the	  lungs	  in	  patients	  with	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  54,	  815-­‐9.	  COUTIFARIS,	   C.,	   OMIGBODUN,	   A.	   &	   COUKOS,	   G.	   2005.	   The	   fibronectin	   receptor	   alpha5	  integrin	   subunit	   is	   upregulated	   by	   cell-­‐cell	   adhesion	   via	   a	   cyclic	   AMP-­‐dependent	  mechanism:	   implications	   for	   human	   trophoblast	   migration.	   Am	   J	   Obstet	   Gynecol,	  192,	  1240-­‐53;	  discussion	  1253-­‐5.	  COWDEN	   DAHL,	   K.	   D.,	   FRYER,	   B.	   H.,	   MACK,	   F.	   A.,	   COMPERNOLLE,	   V.,	   MALTEPE,	   E.,	  ADELMAN,	  D.	  M.,	  CARMELIET,	  P.	  &	  SIMON,	  M.	  C.	  2005.	  Hypoxia-­‐inducible	   factors	  1alpha	  and	  2alpha	  regulate	  trophoblast	  differentiation.	  Mol	  Cell	  Biol,	  25,	  10479-­‐91.	  COXON,	   A.,	   CULLERE,	   X.,	   KNIGHT,	   S.,	   SETHI,	   S.,	   WAKELIN,	   M.	   W.,	   STAVRAKIS,	   G.,	  LUSCINSKAS,	   F.	  W.	  &	  MAYADAS,	   T.	  N.	   2001.	   Fc	   gamma	  RIII	  mediates	   neutrophil	  recruitment	   to	   immune	   complexes.	   a	  mechanism	   for	   neutrophil	   accumulation	   in	  immune-­‐mediated	  inflammation.	  Immunity,	  14,	  693-­‐704.	  CRIBBS,	  A.	  P.,	  KENNEDY,	  A.,	  PENN,	  H.,	  READ,	  J.	  E.,	  AMJADI,	  P.,	  GREEN,	  P.,	  SYED,	  K.,	  MANKA,	  S.	  W.,	  BRENNAN,	  F.	  M.,	  GREGORY,	  B.	  &	  WILLIAMS,	  R.	  O.	  2014.	  Treg	  cell	  function	  in	  rheumatoid	  arthritis	  is	  compromised	  by	  ctla-­‐4	  promoter	  methylation	  resulting	  in	  a	  failure	  to	  activate	  the	   indoleamine	  2,3-­‐dioxygenase	  pathway.	  Arthritis	  Rheumatol,	  66,	  2344-­‐54.	  CROSS,	  A.,	  BARNES,	  T.,	  BUCKNALL,	  R.	  C.,	  EDWARDS,	  S.	  W.	  &	  MOOTS,	  R.	  J.	  2006.	  Neutrophil	  apoptosis	   in	   rheumatoid	   arthritis	   is	   regulated	   by	   local	   oxygen	   tensions	   within	  joints.	  J	  Leukoc	  Biol,	  80,	  521-­‐8.	  CROWLEY,	  M.	  T.,	  COSTELLO,	  P.	  S.,	  FITZER-­‐ATTAS,	  C.	  J.,	  TURNER,	  M.,	  MENG,	  F.,	  LOWELL,	  C.,	  TYBULEWICZ,	   V.	   L.	   &	   DEFRANCO,	   A.	   L.	   1997.	   A	   critical	   role	   for	   Syk	   in	   signal	  transduction	  and	  phagocytosis	  mediated	  by	  Fcgamma	  receptors	  on	  macrophages.	  J	  
Exp	  Med,	  186,	  1027-­‐39.	  CUTOLO,	  M.,	  BRIZZOLARA,	  R.,	  ATZENI,	  F.,	  CAPELLINO,	  S.,	  STRAUB,	  R.	  H.	  &	  PUTTINI,	  P.	  C.	  2010.	  The	  immunomodulatory	  effects	  of	  estrogens:	  clinical	  relevance	  in	   immune-­‐mediated	  rheumatic	  diseases.	  Ann	  N	  Y	  Acad	  Sci,	  1193,	  36-­‐42.	  DAIEN,	  C.	   I.,	  GAILHAC,	  S.,	  MURA,	  T.,	  AUDO,	  R.,	  COMBE,	  B.,	  HAHNE,	  M.	  &	  MOREL,	   J.	  2014.	  Regulatory	  B10	  cells	  are	  decreased	   in	  patients	  with	  rheumatoid	  arthritis	  and	  are	  inversely	  correlated	  with	  disease	  activity.	  Arthritis	  Rheumatol,	  66,	  2037-­‐46.	  DAMJANOV,	   N.,	   KAUFFMAN,	   R.	   S.	   &	   SPENCER-­‐GREEN,	   G.	   T.	   2009.	   Efficacy,	  pharmacodynamics,	   and	   safety	   of	   VX-­‐702,	   a	   novel	   p38	   MAPK	   inhibitor,	   in	  rheumatoid	  arthritis:	  results	  of	  two	  randomized,	  double-­‐blind,	  placebo-­‐controlled	  clinical	  studies.	  Arthritis	  Rheum,	  60,	  1232-­‐41.	  DAMSKY,	  C.	  H.,	  LIBRACH,	  C.,	  LIM,	  K.	  H.,	  FITZGERALD,	  M.	  L.,	  MCMASTER,	  M.	  T.,	  JANATPOUR,	  M.,	  ZHOU,	  Y.,	  LOGAN,	  S.	  K.	  &	  FISHER,	  S.	  J.	  1994.	  Integrin	  switching	  regulates	  normal	  trophoblast	  invasion.	  Development,	  120,	  3657-­‐66.	  DARBY,	   C.,	   GEAHLEN,	   R.	   L.	   &	   SCHREIBER,	   A.	   D.	   1994.	   Stimulation	   of	   macrophage	   Fc	  gamma	   RIIIA	   activates	   the	   receptor-­‐associated	   protein	   tyrosine	   kinase	   Syk	   and	  induces	   phosphorylation	   of	   multiple	   proteins	   including	   p95Vav	   and	   p62/GAP-­‐associated	  protein.	  J	  Immunol,	  152,	  5429-­‐37.	  DASGUPTA,	  B.,	  DUFOUR,	  E.,	  MAMDOUH,	  Z.	  &	  MULLER,	  W.	  A.	  2009.	  A	  novel	  and	  critical	  role	  for	   tyrosine	   663	   in	   platelet	   endothelial	   cell	   adhesion	  molecule-­‐1	   trafficking	   and	  transendothelial	  migration.	  J	  Immunol,	  182,	  5041-­‐51.	  DAYAN,	  F.,	  ROUX,	  D.,	  BRAHIMI-­‐HORN,	  M.	  C.,	  POUYSSEGUR,	  J.	  &	  MAZURE,	  N.	  M.	  2006.	  The	  oxygen	   sensor	   factor-­‐inhibiting	  hypoxia-­‐inducible	   factor-­‐1	   controls	   expression	  of	  distinct	   genes	   through	   the	   bifunctional	   transcriptional	   character	   of	   hypoxia-­‐inducible	  factor-­‐1alpha.	  Cancer	  Res,	  66,	  3688-­‐98.	  
References 
	   231	  
DE	  FOUGEROLLES,	  A.	  R.	  &	  SPRINGER,	  T.	  A.	  1992.	  Intercellular	  adhesion	  molecule	  3,	  a	  third	  adhesion	   counter-­‐receptor	   for	   lymphocyte	   function-­‐associated	   molecule	   1	   on	  resting	  lymphocytes.	  J	  Exp	  Med,	  175,	  185-­‐90.	  DE	   FOUGEROLLES,	   A.	   R.,	   STACKER,	   S.	   A.,	   SCHWARTING,	   R.	   &	   SPRINGER,	   T.	   A.	   1991.	  Characterization	  of	  ICAM-­‐2	  and	  evidence	  for	  a	  third	  counter-­‐receptor	  for	  LFA-­‐1.	  J	  
Exp	  Med,	  174,	  253-­‐67.	  DE	   GROOT,	   P.	   G.	   &	   DERKSEN,	   R.	   H.	   2005.	   Pathophysiology	   of	   the	   antiphospholipid	  syndrome.	  J	  Thromb	  Haemost,	  3,	  1854-­‐60.	  DE	   JESUS,	   G.	   R.,	   AGMON-­‐LEVIN,	   N.,	   ANDRADE,	   C.	   A.,	   ANDREOLI,	   L.,	   CHIGHIZOLA,	   C.	   B.,	  PORTER,	  T.	  F.,	  SALMON,	  J.,	  SILVER,	  R.	  M.,	  TINCANI,	  A.	  &	  BRANCH,	  D.	  W.	  2014.	  14th	  International	   Congress	   on	   Antiphospholipid	   Antibodies	   Task	   Force	   report	   on	  obstetric	  antiphospholipid	  syndrome.	  Autoimmun	  Rev,	  13,	  795-­‐813.	  DE	  LAAT,	  B.,	  DERKSEN,	  R.	  H.,	  VAN	  LUMMEL,	  M.,	  PENNINGS,	  M.	  T.	  &	  DE	  GROOT,	  P.	  G.	  2006.	  Pathogenic	   anti-­‐beta2-­‐glycoprotein	   I	   antibodies	   recognize	   domain	   I	   of	   beta2-­‐glycoprotein	  I	  only	  after	  a	  conformational	  change.	  Blood,	  107,	  1916-­‐24.	  DE	   LAAT,	   B.,	   MERTENS,	   K.	   &	   DE	   GROOT,	   P.	   G.	   2008.	   Mechanisms	   of	   disease:	  antiphospholipid	   antibodies-­‐from	   clinical	   association	   to	   pathologic	   mechanism.	  
Nat	  Clin	  Pract	  Rheumatol,	  4,	  192-­‐9.	  DECKER,	  B.,	  MC,	  G.	  W.,	  MC,	  K.	  B.	  &	  SLOCUMB,	  C.	  H.	  1959.	  Concentration	  of	  hyaluronic	  acid	  in	  synovial	  fluid.	  Clin	  Chem,	  5,	  465-­‐9.	  DEL	   PAPA,	   N.,	   RASCHI,	   E.,	   MORONI,	   G.,	   PANZERI,	   P.,	   BORGHI,	   M.	   O.,	   PONTICELLI,	   C.,	  TINCANI,	   A.,	   BALESTRIERI,	   G.	   &	   MERONI,	   P.	   L.	   1999.	   Anti-­‐endothelial	   cell	   IgG	  fractions	   from	  systemic	   lupus	  erythematosus	  patients	  bind	   to	  human	  endothelial	  cells	  and	  induce	  a	  pro-­‐adhesive	  and	  a	  pro-­‐inflammatory	  phenotype	  in	  vitro.	  Lupus,	  8,	  423-­‐9.	  DELVES,	  P.	   J.	  &	  ROITT,	   I.	  M.	  2000.	  The	   immune	  system.	  First	  of	   two	  parts.	  N	  Engl	  J	  Med,	  343,	  37-­‐49.	  DEMIR,	   R.,	   BODUR,	   H.,	   TOKOGLU,	   F.,	   OLCAY,	   I.,	   UCAN,	   H.	   &	   BORMAN,	   P.	   1999.	   High	  resolution	   computed	   tomography	   of	   the	   lungs	   in	   patients	   with	   rheumatoid	  arthritis.	  Rheumatol	  Int,	  19,	  19-­‐22.	  DEN	  BROEDER,	  A.	  A.,	  WANTEN,	  G.	  J.,	  OYEN,	  W.	  J.,	  NABER,	  T.,	  VAN	  RIEL,	  P.	  L.	  &	  BARRERA,	  P.	  2003.	   Neutrophil	   migration	   and	   production	   of	   reactive	   oxygen	   species	   during	  treatment	   with	   a	   fully	   human	   anti-­‐tumor	   necrosis	   factor-­‐alpha	   monoclonal	  antibody	  in	  patients	  with	  rheumatoid	  arthritis.	  J	  Rheumatol,	  30,	  232-­‐7.	  DENG,	  W.,	  REN,	  Y.,	  FENG,	  X.,	  YAO,	  G.,	  CHEN,	  W.,	  SUN,	  Y.,	  WANG,	  H.,	  GAO,	  X.	  &	  SUN,	  L.	  2014.	  Hypoxia	   inducible	   factor-­‐1	   alpha	   promotes	   mesangial	   cell	   proliferation	   in	   lupus	  nephritis.	  Am	  J	  Nephrol,	  40,	  507-­‐15.	  DENNY,	  M.	  F.,	  YALAVARTHI,	  S.,	  ZHAO,	  W.,	  THACKER,	  S.	  G.,	  ANDERSON,	  M.,	   SANDY,	  A.	  R.,	  MCCUNE,	   W.	   J.	   &	   KAPLAN,	   M.	   J.	   2010.	   A	   distinct	   subset	   of	   proinflammatory	  neutrophils	   isolated	   from	   patients	   with	   systemic	   lupus	   erythematosus	   induces	  vascular	  damage	  and	  synthesizes	  type	  I	  IFNs.	  J	  Immunol,	  184,	  3284-­‐97.	  DETMERS,	  P.	  A.,	   ZHOU,	  D.,	  POWELL,	  D.,	   LICHENSTEIN,	  H.,	  KELLEY,	  M.	  &	  PIRONKOVA,	  R.	  1995.	   Endotoxin	   receptors	   (CD14)	   are	   found	   with	   CD16	   (Fc	   gamma	   RIII)	   in	   an	  intracellular	   compartment	   of	   neutrophils	   that	   contains	   alkaline	   phosphatase.	   J	  
Immunol,	  155,	  2085-­‐95.	  DEYOUNG,	  M.	  P.,	  HORAK,	  P.,	  SOFER,	  A.,	  SGROI,	  D.	  &	  ELLISEN,	  L.	  W.	  2008.	  Hypoxia	  regulates	  TSC1/2-­‐mTOR	  signaling	  and	  tumor	  suppression	  through	  REDD1-­‐mediated	  14-­‐3-­‐3	  shuttling.	  Genes	  Dev,	  22,	  239-­‐51.	  DI	   SIMONE,	   N.,	   CASTELLANI,	   R.,	   CALIANDRO,	   D.	   &	   CARUSO,	   A.	   2002.	   Antiphospholid	  antibodies	   regulate	   the	   expression	   of	   trophoblast	   cell	   adhesion	  molecules.	   Fertil	  
Steril,	  77,	  805-­‐11.	  DI	  SIMONE,	  N.,	  MERONI,	  P.	  L.,	  DE	  PAPA,	  N.,	  RASCHI,	  E.,	  CALIANDRO,	  D.,	  DE	  CAROLIS,	  C.	  S.,	  KHAMASHTA,	   M.	   A.,	   ATSUMI,	   T.,	   HUGHES,	   G.	   R.,	   BALESTRIERI,	   G.,	   TINCANI,	   A.,	  CASALI,	   P.	   &	   CARUSO,	   A.	   2000.	   Antiphospholipid	   antibodies	   affect	   trophoblast	  
References 
	   232	  
gonadotropin	  secretion	  and	  invasiveness	  by	  binding	  directly	  and	  through	  adhered	  beta2-­‐glycoprotein	  I.	  Arthritis	  Rheum,	  43,	  140-­‐50.	  DIACOVO,	   T.	   G.,	   DEFOUGEROLLES,	   A.	   R.,	   BAINTON,	   D.	   F.	   &	   SPRINGER,	   T.	   A.	   1994.	   A	  functional	   integrin	   ligand	   on	   the	   surface	   of	   platelets:	   intercellular	   adhesion	  molecule-­‐2.	  J	  Clin	  Invest,	  94,	  1243-­‐51.	  DIAMOND,	  M.	  S.,	  STAUNTON,	  D.	  E.,	  MARLIN,	  S.	  D.	  &	  SPRINGER,	  T.	  A.	  1991.	  Binding	  of	  the	  integrin	  Mac-­‐1	  (CD11b/CD18)	  to	  the	  third	  immunoglobulin-­‐like	  domain	  of	  ICAM-­‐1	  (CD54)	  and	  its	  regulation	  by	  glycosylation.	  Cell,	  65,	  961-­‐71.	  DING,	  Z.	  M.,	  BABENSEE,	  J.	  E.,	  SIMON,	  S.	  I.,	  LU,	  H.,	  PERRARD,	  J.	  L.,	  BULLARD,	  D.	  C.,	  DAI,	  X.	  Y.,	  BROMLEY,	  S.	  K.,	  DUSTIN,	  M.	  L.,	  ENTMAN,	  M.	  L.,	  SMITH,	  C.	  W.	  &	  BALLANTYNE,	  C.	  M.	  1999.	   Relative	   contribution	   of	   LFA-­‐1	   and	   Mac-­‐1	   to	   neutrophil	   adhesion	   and	  migration.	  J	  Immunol,	  163,	  5029-­‐38.	  DIZ-­‐KUCUKKAYA,	   R.,	   INANC,	   M.,	   AFSHAR-­‐KHARGHAN,	   V.,	   ZHANG,	   Q.	   E.,	   LOPEZ,	   J.	   A.	   &	  PEKCELEN,	   Y.	   2007.	   P-­‐selectin	   glycoprotein	   ligand-­‐1	   VNTR	   polymorphisms	   and	  risk	  of	  thrombosis	  in	  the	  antiphospholipid	  syndrome.	  Ann	  Rheum	  Dis,	  66,	  1378-­‐80.	  DJEU,	  J.	  Y.,	  SERBOUSEK,	  D.	  &	  BLANCHARD,	  D.	  K.	  1990.	  Release	  of	  tumor	  necrosis	  factor	  by	  human	  polymorphonuclear	  leukocytes.	  Blood,	  76,	  1405-­‐9.	  DOMINICAL,	  V.	  M.,	  BERTOLO,	  M.	  B.,	  ALMEIDA,	  C.	  B.,	  GARRIDO,	  V.	  T.,	  MIGUEL,	  L.	  I.,	  COSTA,	  F.	  F.	  &	  CONRAN,	  N.	  2011.	  Neutrophils	  of	  rheumatoid	  arthritis	  patients	  on	  anti-­‐TNF-­‐alpha	   therapy	   and	   in	   disease	   remission	   present	   reduced	   adhesive	   functions	   in	  association	   with	   decreased	   circulating	   neutrophil-­‐attractant	   chemokine	   levels.	  
Scand	  J	  Immunol,	  73,	  309-­‐18.	  DONNELLY,	  S.,	  ROAKE,	  W.,	  BROWN,	  S.,	  YOUNG,	  P.,	  NAIK,	  H.,	  WORDSWORTH,	  P.,	  ISENBERG,	  D.	   A.,	   REID,	   K.	   B.	   &	   EGGLETON,	   P.	   2006.	   Impaired	   recognition	   of	   apoptotic	  neutrophils	   by	   the	   C1q/calreticulin	   and	   CD91	   pathway	   in	   systemic	   lupus	  erythematosus.	  Arthritis	  Rheum,	  54,	  1543-­‐56.	  DORNER,	  T.,	  GIESECKE,	  C.	  &	  LIPSKY,	  P.	  E.	  2011.	  Mechanisms	  of	  B	  cell	  autoimmunity	  in	  SLE.	  
Arthritis	  Res	  Ther,	  13,	  243.	  DOUDA,	  D.	  N.,	  YIP,	  L.,	  KHAN,	  M.	  A.,	  GRASEMANN,	  H.	  &	  PALANIYAR,	  N.	  2014.	  Akt	  is	  essential	  to	   induce	   NADPH-­‐dependent	   NETosis	   and	   to	   switch	   the	   neutrophil	   death	   to	  apoptosis.	  Blood,	  123,	  597-­‐600.	  DRANSFIELD,	  I.,	  CABANAS,	  C.,	  CRAIG,	  A.	  &	  HOGG,	  N.	  1992.	  Divalent	  cation	  regulation	  of	  the	  function	  of	  the	  leukocyte	  integrin	  LFA-­‐1.	  J	  Cell	  Biol,	  116,	  219-­‐26.	  DUBRAVEC,	   D.	   B.,	   SPRIGGS,	   D.	   R.,	   MANNICK,	   J.	   A.	   &	   RODRICK,	   M.	   L.	   1990.	   Circulating	  human	   peripheral	   blood	   granulocytes	   synthesize	   and	   secrete	   tumor	   necrosis	  factor	  alpha.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  87,	  6758-­‐61.	  DULARAY,	   B.,	   BADESHA,	   J.	   S.,	   DIEPPE,	   P.	   A.	   &	   ELSON,	   C.	   J.	   1990.	   Oxidative	   response	   of	  polymorphonuclear	   leucocytes	   to	   synovial	   fluids	   from	   patients	   with	   rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  49,	  661-­‐4.	  DULARAY,	   B.,	   ELSON,	   C.	   J.	   &	   DIEPPE,	   P.	   A.	   1988.	   Enhanced	   oxidative	   response	   of	  polymorphonuclear	   leukocytes	   from	   synovial	   fluids	   of	   patients	  with	   rheumatoid	  arthritis.	  Autoimmunity,	  1,	  159-­‐69.	  DYETT,	   D.	   E.,	   MALAWISTA,	   S.	   E.,	   VAN	   BLARICOM,	   G.,	   MELNICK,	   D.	   A.	   &	   MALECH,	   H.	   L.	  1985.	   Functional	   integrity	   of	   cytokineplasts:	   specific	   chemotactic	   and	   capping	  responses.	  J	  Immunol,	  135,	  2090-­‐4.	  EDELMAN,	  G.	  M.	  1973.	  Antibody	  structure	  and	  molecular	  immunology.	  Science,	  180,	  830-­‐40.	  EDWARDS,	   J.	   C.,	   SZCZEPANSKI,	   L.,	   SZECHINSKI,	   J.,	   FILIPOWICZ-­‐SOSNOWSKA,	  A.,	   EMERY,	  P.,	   CLOSE,	   D.	   R.,	   STEVENS,	   R.	   M.	   &	   SHAW,	   T.	   2004.	   Efficacy	   of	   B-­‐cell-­‐targeted	  therapy	  with	   rituximab	   in	   patients	  with	   rheumatoid	   arthritis.	  N	  Engl	   J	  Med,	   350,	  2572-­‐81.	  EDWARDS,	   L.	   J.,	   MIZUI,	   M.	   &	   KYTTARIS,	   V.	   2015.	   Signal	   transducer	   and	   activator	   of	  transcription	   (STAT)	  3	   inhibition	  delays	   the	   onset	   of	   lupus	  nephritis	   in	  MRL/lpr	  mice.	  Clin	  Immunol,	  158,	  221-­‐30.	  
References 
	   233	  
EDWARDS,	  S.	  W.,	  HUGHES,	  V.,	  BARLOW,	  J.	  &	  BUCKNALL,	  R.	  1988.	  Immunological	  detection	  of	   myeloperoxidase	   in	   synovial	   fluid	   from	   patients	   with	   rheumatoid	   arthritis.	  
Biochem	  J,	  250,	  81-­‐5.	  EGERER,	   K.,	   FEIST,	   E.,	   ROHR,	   U.,	   PRUSS,	   A.,	   BURMESTER,	   G.	   R.	   &	   DORNER,	   T.	   2000.	  Increased	   serum	   soluble	   CD14,	   ICAM-­‐1	   and	   E-­‐selectin	   correlate	   with	   disease	  activity	  and	  prognosis	  in	  systemic	  lupus	  erythematosus.	  Lupus,	  9,	  614-­‐21.	  EGESTEN,	   A.,	   BRETON-­‐GORIUS,	   J.,	   GUICHARD,	   J.,	   GULLBERG,	   U.	   &	   OLSSON,	   I.	   1994.	   The	  heterogeneity	   of	   azurophil	   granules	   in	   neutrophil	   promyelocytes:	   immunogold	  localization	   of	   myeloperoxidase,	   cathepsin	   G,	   elastase,	   proteinase	   3,	   and	  bactericidal/permeability	  increasing	  protein.	  Blood,	  83,	  2985-­‐94.	  EISENBERG,	  R.	  2005.	  Update	  on	  rituximab.	  Ann	  Rheum	  Dis,	  64	  Suppl	  4,	  iv55-­‐7.	  ELICES,	  M.	  J.,	  OSBORN,	  L.,	  TAKADA,	  Y.,	  CROUSE,	  C.,	  LUHOWSKYJ,	  S.,	  HEMLER,	  M.	  E.	  &	  LOBB,	  R.	  R.	  1990.	  VCAM-­‐1	  on	  activated	  endothelium	  interacts	  with	  the	  leukocyte	  integrin	  VLA-­‐4	  at	  a	  site	  distinct	  from	  the	  VLA-­‐4/fibronectin	  binding	  site.	  Cell,	  60,	  577-­‐84.	  ELLMEIER,	   W.,	   SAWADA,	   S.	   &	   LITTMAN,	   D.	   R.	   1999.	   The	   regulation	   of	   CD4	   and	   CD8	  coreceptor	   gene	   expression	   during	   T	   cell	   development.	   Annu	   Rev	   Immunol,	   17,	  523-­‐54.	  EMA,	  M.,	  TAYA,	  S.,	  YOKOTANI,	  N.,	  SOGAWA,	  K.,	  MATSUDA,	  Y.	  &	  FUJII-­‐KURIYAMA,	  Y.	  1997.	  A	   novel	   bHLH-­‐PAS	   factor	   with	   close	   sequence	   similarity	   to	   hypoxia-­‐inducible	  factor	  1alpha	  regulates	  the	  VEGF	  expression	  and	  is	  potentially	  involved	  in	  lung	  and	  vascular	  development.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  94,	  4273-­‐8.	  EMERY,	  P.,	  LOPEZ,	  A.	  F.,	  BURNS,	  G.	  F.	  &	  VADAS,	  M.	  A.	  1988.	  Synovial	   fluid	  neutrophils	  of	  patients	   with	   rheumatoid	   arthritis	   have	   membrane	   antigen	   changes	   that	   reflect	  activation.	  Ann	  Rheum	  Dis,	  47,	  34-­‐9.	  EMSLEY,	   J.,	   KNIGHT,	   C.	   G.,	   FARNDALE,	   R.	  W.,	   BARNES,	  M.	   J.	   &	   LIDDINGTON,	   R.	   C.	   2000.	  Structural	  basis	  of	  collagen	  recognition	  by	  integrin	  alpha2beta1.	  Cell,	  101,	  47-­‐56.	  ENNIS,	  E.,	  ISBERG,	  R.	  R.	  &	  SHIMIZU,	  Y.	  1993.	  Very	  late	  antigen	  4-­‐dependent	  adhesion	  and	  costimulation	   of	   resting	   human	   T	   cells	   by	   the	   bacterial	   beta	   1	   integrin	   ligand	  invasin.	  J	  Exp	  Med,	  177,	  207-­‐12.	  ERKELLER-­‐YUKSEL,	   F.	  M.,	   LYDYARD,	   P.	  M.	  &	   ISENBERG,	  D.	   A.	   1997.	   Lack	   of	  NK	   cells	   in	  lupus	  patients	  with	  renal	  involvement.	  Lupus,	  6,	  708-­‐12.	  ERRIDGE,	   C.,	   STEWART,	   J.	   &	   POXTON,	   I.	   R.	   2003.	   Monocytes	   heterozygous	   for	   the	  Asp299Gly	   and	   Thr399Ile	   mutations	   in	   the	   Toll-­‐like	   receptor	   4	   gene	   show	   no	  deficit	  in	  lipopolysaccharide	  signalling.	  J	  Exp	  Med,	  197,	  1787-­‐91.	  ESAGUY,	   N.,	   AGUAS,	   A.	   P.,	   VILANOVA,	   M.	   &	   SILVA,	   M.	   T.	   1991.	   Activation	   of	   human	  neutrophils	   by	   phorbol	   ester	   decreases	   the	   cytoplasm	   compactness	   and	   the	  lactoferrin	  content	  of	  the	  granulocytes.	  J	  Leukoc	  Biol,	  50,	  444-­‐52.	  ESPINOLA,	  R.	  G.,	  LIU,	  X.,	  COLDEN-­‐STANFIELD,	  M.,	  HALL,	  J.,	  HARRIS,	  E.	  N.	  &	  PIERANGELI,	  S.	  S.	   2003.	   E-­‐Selectin	  mediates	   pathogenic	   effects	   of	   antiphospholipid	   antibodies.	   J	  
Thromb	  Haemost,	  1,	  843-­‐8.	  ESTRADA-­‐CAPETILLO,	   L.,	   HERNANDEZ-­‐CASTRO,	   B.,	   MONSIVAIS-­‐URENDA,	   A.,	   ALVAREZ-­‐QUIROGA,	   C.,	   LAYSECA-­‐ESPINOSA,	   E.,	   ABUD-­‐MENDOZA,	   C.,	   BARANDA,	   L.,	  URZAINQUI,	  A.,	  SANCHEZ-­‐MADRID,	  F.	  &	  GONZALEZ-­‐AMARO,	  R.	  2013.	  Induction	  of	  Th17	   lymphocytes	  and	  Treg	  cells	  by	  monocyte-­‐derived	  dendritic	  cells	   in	  patients	  with	   rheumatoid	   arthritis	   and	   systemic	   lupus	   erythematosus.	   Clin	  Dev	   Immunol,	  2013,	  584303.	  ETULAIN,	  J.,	  MARTINOD,	  K.,	  WONG,	  S.	  L.,	  CIFUNI,	  S.	  M.,	  SCHATTNER,	  M.	  &	  WAGNER,	  D.	  D.	  2015.	  P-­‐selectin	  promotes	  neutrophil	  extracellular	   trap	   formation	   in	  mice.	  Blood,	  126,	  242-­‐6.	  EYLES,	   J.	  L.,	  HICKEY,	  M.	   J.,	  NORMAN,	  M.	  U.,	  CROKER,	  B.	  A.,	  ROBERTS,	  A.	  W.,	  DRAKE,	  S.	  F.,	  JAMES,	  W.	  G.,	  METCALF,	  D.,	  CAMPBELL,	  I.	  K.	  &	  WICKS,	  I.	  P.	  2008.	  A	  key	  role	  for	  G-­‐CSF-­‐induced	  neutrophil	  production	  and	   trafficking	  during	   inflammatory	  arthritis.	  
Blood,	  112,	  5193-­‐201.	  
References 
	   234	  
FAGERAS	  BOTTCHER,	  M.,	  HMANI-­‐AIFA,	  M.,	   LINDSTROM,	  A.,	   JENMALM,	  M.	  C.,	  MAI,	  X.	  M.,	  NILSSON,	  L.,	  ZDOLSEK,	  H.	  A.,	  BJORKSTEN,	  B.,	  SODERKVIST,	  P.	  &	  VAARALA,	  O.	  2004.	  A	  TLR4	  polymorphism	  is	  associated	  with	  asthma	  and	  reduced	  lipopolysaccharide-­‐induced	   interleukin-­‐12(p70)	   responses	   in	   Swedish	   children.	   J	   Allergy	   Clin	  
Immunol,	  114,	  561-­‐7.	  FALLMAN,	   M.,	   ANDERSSON,	   R.	   &	   ANDERSSON,	   T.	   1993.	   Signaling	   properties	   of	   CR3	  (CD11b/CD18)	   and	   CR1	   (CD35)	   in	   relation	   to	   phagocytosis	   of	   complement-­‐opsonized	  particles.	  J	  Immunol,	  151,	  330-­‐8.	  FARKAS,	   L.,	   BEISKE,	   K.,	   LUND-­‐JOHANSEN,	   F.,	   BRANDTZAEG,	   P.	   &	   JAHNSEN,	   F.	   L.	   2001.	  Plasmacytoid	   dendritic	   cells	   (natural	   interferon-­‐	   alpha/beta-­‐producing	   cells)	  accumulate	  in	  cutaneous	  lupus	  erythematosus	  lesions.	  Am	  J	  Pathol,	  159,	  237-­‐43.	  FARQUHARSON,	  D.,	  BUTCHER,	   J.	  P.	  &	  CULSHAW,	  S.	  2012.	  Periodontitis,	  Porphyromonas,	  and	  the	  pathogenesis	  of	  rheumatoid	  arthritis.	  Mucosal	  Immunol,	  5,	  112-­‐20.	  FAURSCHOU,	  M.	  &	  BORREGAARD,	  N.	  2003.	  Neutrophil	  granules	  and	  secretory	  vesicles	  in	  inflammation.	  Microbes	  Infect,	  5,	  1317-­‐27.	  FERNANDO,	  M.	  M.,	  STEVENS,	  C.	  R.,	  SABETI,	  P.	  C.,	  WALSH,	  E.	  C.,	  MCWHINNIE,	  A.	  J.,	  SHAH,	  A.,	  GREEN,	  T.,	  RIOUX,	   J.	  D.	  &	  VYSE,	  T.	   J.	  2007.	   Identification	  of	   two	   independent	  risk	  factors	  for	  lupus	  within	  the	  MHC	  in	  United	  Kingdom	  families.	  PLoS	  Genet,	  3,	  e192.	  FIGUEROA-­‐VEGA,	  N.,	  GALINDO-­‐RODRIGUEZ,	  G.,	  BAJANA,	  S.,	  PORTALES-­‐PEREZ,	  D.,	  ABUD-­‐MENDOZA,	   C.,	   SANCHEZ-­‐TORRES,	   C.	   &	   GONZALEZ-­‐AMARO,	   R.	   2006.	   Phenotypic	  analysis	   of	   IL-­‐10-­‐treated,	   monocyte-­‐derived	   dendritic	   cells	   in	   patients	   with	  systemic	  lupus	  erythematosus.	  Scand	  J	  Immunol,	  64,	  668-­‐76.	  FILLATREAU,	  S.,	  SWEENIE,	  C.	  H.,	  MCGEACHY,	  M.	  J.,	  GRAY,	  D.	  &	  ANDERTON,	  S.	  M.	  2002.	  B	  cells	  regulate	  autoimmunity	  by	  provision	  of	  IL-­‐10.	  Nat	  Immunol,	  3,	  944-­‐50.	  FIORE,	   N.,	   CASTELLANO,	   G.,	   BLASI,	   A.,	   CAPOBIANCO,	   C.,	   LOVERRE,	   A.,	   MONTINARO,	   V.,	  NETTI,	  S.,	  TORRES,	  D.,	  MANNO,	  C.,	  GRANDALIANO,	  G.,	  RANIERI,	  E.,	  SCHENA,	  F.	  P.	  &	  GESUALDO,	  L.	  2008.	  Immature	  myeloid	  and	  plasmacytoid	  dendritic	  cells	  infiltrate	  renal	  tubulointerstitium	  in	  patients	  with	  lupus	  nephritis.	  Mol	  Immunol,	  45,	  259-­‐65.	  FISCHETTI,	   F.,	   DURIGUTTO,	   P.,	   PELLIS,	   V.,	   DEBEUS,	   A.,	  MACOR,	   P.,	   BULLA,	   R.,	   BOSSI,	   F.,	  ZILLER,	  F.,	  SBLATTERO,	  D.,	  MERONI,	  P.	  &	  TEDESCO,	  F.	  2005.	  Thrombus	  formation	  induced	   by	   antibodies	   to	   beta2-­‐glycoprotein	   I	   is	   complement	   dependent	   and	  requires	  a	  priming	  factor.	  Blood,	  106,	  2340-­‐6.	  FITZER-­‐ATTAS,	  C.	  J.,	  LOWRY,	  M.,	  CROWLEY,	  M.	  T.,	  FINN,	  A.	  J.,	  MENG,	  F.,	  DEFRANCO,	  A.	  L.	  &	  LOWELL,	   C.	   A.	   2000.	   Fcgamma	   receptor-­‐mediated	   phagocytosis	   in	   macrophages	  lacking	  the	  Src	  family	  tyrosine	  kinases	  Hck,	  Fgr,	  and	  Lyn.	  J	  Exp	  Med,	  191,	  669-­‐82.	  FLAMME,	  I.,	  FROHLICH,	  T.,	  VON	  REUTERN,	  M.,	  KAPPEL,	  A.,	  DAMERT,	  A.	  &	  RISAU,	  W.	  1997.	  HRF,	   a	   putative	   basic	   helix-­‐loop-­‐helix-­‐PAS-­‐domain	   transcription	   factor	   is	   closely	  related	   to	   hypoxia-­‐inducible	   factor-­‐1	   alpha	   and	   developmentally	   expressed	   in	  blood	  vessels.	  Mech	  Dev,	  63,	  51-­‐60.	  FLEMING,	  S.	  D.,	  EGAN,	  R.	  P.,	  CHAI,	  C.,	  GIRARDI,	  G.,	  HOLERS,	  V.	  M.,	  SALMON,	  J.,	  MONESTIER,	  M.	   &	   TSOKOS,	   G.	   C.	   2004.	   Anti-­‐phospholipid	   antibodies	   restore	   mesenteric	  ischemia/reperfusion-­‐induced	   injury	   in	   complement	   receptor	   2/complement	  receptor	  1-­‐deficient	  mice.	  J	  Immunol,	  173,	  7055-­‐61.	  FOSSATI-­‐JIMACK,	  L.,	  LING,	  G.	  S.,	  CORTINI,	  A.,	  SZAJNA,	  M.,	  MALIK,	  T.	  H.,	  MCDONALD,	   J.	  U.,	  PICKERING,	  M.	  C.,	  COOK,	  H.	  T.,	  TAYLOR,	  P.	  R.	  &	  BOTTO,	  M.	  2013.	  Phagocytosis	   is	  the	  main	  CR3-­‐mediated	  function	  affected	  by	  the	  lupus-­‐associated	  variant	  of	  CD11b	  in	  human	  myeloid	  cells.	  PLoS	  One,	  8,	  e57082.	  FREITAS,	   M.,	   PORTO,	   G.,	   LIMA,	   J.	   L.	   &	   FERNANDES,	   E.	   2008.	   Isolation	   and	   activation	   of	  human	   neutrophils	   in	   vitro.	   The	   importance	   of	   the	   anticoagulant	   used	   during	  blood	  collection.	  Clin	  Biochem,	  41,	  570-­‐5.	  FROSCH,	   M.,	   VOGL,	   T.,	   WALDHERR,	   R.,	   SORG,	   C.,	   SUNDERKOTTER,	   C.	   &	   ROTH,	   J.	   2004.	  Expression	  of	  MRP8	  and	  MRP14	  by	  macrophages	  is	  a	  marker	  for	  severe	  forms	  of	  glomerulonephritis.	  J	  Leukoc	  Biol,	  75,	  198-­‐206.	  
References 
	   235	  
FUCHS,	  T.	  A.,	  ABED,	  U.,	  GOOSMANN,	  C.,	  HURWITZ,	  R.,	  SCHULZE,	  I.,	  WAHN,	  V.,	  WEINRAUCH,	  Y.,	   BRINKMANN,	   V.	   &	   ZYCHLINSKY,	   A.	   2007.	   Novel	   cell	   death	   program	   leads	   to	  neutrophil	  extracellular	  traps.	  J	  Cell	  Biol,	  176,	  231-­‐41.	  FUCHS,	  T.	  A.,	  BRILL,	  A.,	  DUERSCHMIED,	  D.,	  SCHATZBERG,	  D.,	  MONESTIER,	  M.,	  MYERS,	  D.	  D.,	   JR.,	  WROBLESKI,	   S.	   K.,	  WAKEFIELD,	   T.	  W.,	   HARTWIG,	   J.	   H.	   &	  WAGNER,	   D.	   D.	  2010.	  Extracellular	  DNA	  traps	  promote	  thrombosis.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  107,	  15880-­‐5.	  FUJISHIMA,	  S.,	  HOFFMAN,	  A.	  R.,	  VU,	  T.,	  KIM,	  K.	  J.,	  ZHENG,	  H.,	  DANIEL,	  D.,	  KIM,	  Y.,	  WALLACE,	  E.	  F.,	  LARRICK,	   J.	  W.	  &	  RAFFIN,	  T.	  A.	  1993.	  Regulation	  of	  neutrophil	   interleukin	  8	  gene	   expression	   and	   protein	   secretion	   by	   LPS,	   TNF-­‐alpha,	   and	   IL-­‐1	   beta.	   J	   Cell	  
Physiol,	  154,	  478-­‐85.	  FUNAUCHI,	   M.,	   OHNO,	   M.,	   MINODA,	   M.	   &	   HORIUCHI,	   A.	   1993.	   Abnormal	   expression	   of	  intercellular	   adhesion	   molecule-­‐1	   on	   peripheral	   blood	   mononuclear	   cells	   from	  patients	  with	  systemic	  lupus	  erythematosus.	  J	  Clin	  Lab	  Immunol,	  40,	  115-­‐24.	  GABBAY,	   E.,	   TARALA,	   R.,	  WILL,	   R.,	   CARROLL,	   G.,	   ADLER,	   B.,	   CAMERON,	  D.	  &	   LAKE,	   F.	   R.	  1997.	  Interstitial	  lung	  disease	  in	  recent	  onset	  rheumatoid	  arthritis.	  Am	  J	  Respir	  Crit	  
Care	  Med,	  156,	  528-­‐35.	  GAL,	  I.,	  BAJNOK,	  E.,	  SZANTO,	  S.,	  SARRAJ,	  B.,	  GLANT,	  T.	  T.	  &	  MIKECZ,	  K.	  2005.	  Visualization	  and	   in	   situ	   analysis	   of	   leukocyte	   trafficking	   into	   the	   ankle	   joint	   in	   a	   systemic	  murine	  model	  of	  rheumatoid	  arthritis.	  Arthritis	  Rheum,	  52,	  3269-­‐78.	  GALEAZZI,	   M.,	   SEBASTIANI,	   G.	   D.,	   TINCANI,	   A.,	   PIETTE,	   J.	   C.,	   ALLEGRI,	   F.,	   MOROZZI,	   G.,	  BELLISAI,	   F.,	   SCORZA,	   R.,	   FERRARA,	   G.	   B.,	   CARCASSI,	   C.,	   FONT,	   J.,	   PASSIU,	   G.,	  SMOLEN,	  J.,	  PAPASTERIADES,	  C.,	  HOUSSIAU,	  F.,	  NEBRO,	  A.	  F.,	  RAMON	  GARRIDO,	  E.	  D.,	  JEDRYKA-­‐GORAL,	  A.	  &	  MARCOLONGO,	  R.	  2000.	  HLA	  class	  II	  alleles	  associations	  of	   anticardiolipin	   and	   anti-­‐beta2GPI	   antibodies	   in	   a	   large	   series	   of	   European	  patients	  with	  systemic	  lupus	  erythematosus.	  Lupus,	  9,	  47-­‐55.	  GALLATIN,	   W.	   M.,	   WEISSMAN,	   I.	   L.	   &	   BUTCHER,	   E.	   C.	   1983.	   A	   cell-­‐surface	   molecule	  involved	  in	  organ-­‐specific	  homing	  of	  lymphocytes.	  Nature,	  304,	  30-­‐4.	  GALLI,	   M.	   &	   BARBUI,	   T.	   2003.	   Antiphospholipid	   syndrome:	   definition	   and	   treatment.	  
Semin	  Thromb	  Hemost,	  29,	  195-­‐204.	  GALLI,	  M.,	   COMFURIUS,	   P.,	  MAASSEN,	  C.,	  HEMKER,	  H.	   C.,	  DE	  BAETS,	  M.	  H.,	   VAN	  BREDA-­‐VRIESMAN,	  P.	   J.,	  BARBUI,	  T.,	  ZWAAL,	  R.	  F.	  &	  BEVERS,	  E.	  M.	  1990.	  Anticardiolipin	  antibodies	   (ACA)	   directed	   not	   to	   cardiolipin	   but	   to	   a	   plasma	   protein	   cofactor.	  
Lancet,	  335,	  1544-­‐7.	  GARCIA-­‐ROMO,	  G.	  S.,	  CAIELLI,	  S.,	  VEGA,	  B.,	  CONNOLLY,	  J.,	  ALLANTAZ,	  F.,	  XU,	  Z.,	  PUNARO,	  M.,	   BAISCH,	   J.,	   GUIDUCCI,	   C.,	   COFFMAN,	   R.	   L.,	   BARRAT,	   F.	   J.,	   BANCHEREAU,	   J.	   &	  PASCUAL,	  V.	  2011.	  Netting	  neutrophils	  are	  major	  inducers	  of	  type	  I	  IFN	  production	  in	  pediatric	  systemic	  lupus	  erythematosus.	  Sci	  Transl	  Med,	  3,	  73ra20.	  GARCIA,	  R.	  C.,	  PETERSON,	  C.	  G.,	  SEGAL,	  A.	  W.	  &	  VENGE,	  P.	  1985.	  Elastase	   in	  the	  different	  primary	   granules	   of	   the	   human	   neutrophil.	   Biochem	   Biophys	   Res	   Commun,	   132,	  1130-­‐6.	  GARRETT,	   I.	   R.,	   BOYCE,	   B.	   F.,	   OREFFO,	   R.	   O.,	   BONEWALD,	   L.,	   POSER,	   J.	   &	  MUNDY,	   G.	   R.	  1990.	   Oxygen-­‐derived	   free	   radicals	   stimulate	   osteoclastic	   bone	   resorption	   in	  rodent	  bone	  in	  vitro	  and	  in	  vivo.	  J	  Clin	  Invest,	  85,	  632-­‐9.	  GEBOREK,	  P.,	  SAXNE,	  T.,	  PETTERSSON,	  H.	  &	  WOLLHEIM,	  F.	  A.	  1989.	  Synovial	  fluid	  acidosis	  correlates	  with	  radiological	  joint	  destruction	  in	  rheumatoid	  arthritis	  knee	  joints.	  J	  
Rheumatol,	  16,	  468-­‐72.	  GENOVESE,	  M.	  C.,	  COHEN,	  S.	  B.,	  WOFSY,	  D.,	  WEINBLATT,	  M.	  E.,	  FIRESTEIN,	  G.	  S.,	  BRAHN,	  E.,	  STRAND,	   V.,	   BAKER,	   D.	   G.	   &	   TONG,	   S.	   E.	   2008.	   A	   randomized,	   double-­‐blind,	  placebo-­‐controlled	  phase	  2	  study	  of	  an	  oral	  p38	  alpha	  MAPK	  inhibitor,	  SCIO-­‐469,	  in	  patients	  with	  active	  rheumatoid	  arthritis.	  Arthritis	  Rheum,	  58,	  S431-­‐S432.	  GEORGE,	  J.,	  GILBURD,	  B.,	  HOJNIK,	  M.,	  LEVY,	  Y.,	  LANGEVITZ,	  P.,	  MATSUURA,	  E.,	  KOIKE,	  T.	  &	  SHOENFELD,	   Y.	   1998.	   Target	   recognition	   of	   beta2-­‐glycoprotein	   I	   (beta2GPI)-­‐
References 
	   236	  
dependent	   anticardiolipin	   antibodies:	   evidence	   for	   involvement	   of	   the	   fourth	  domain	  of	  beta2GPI	  in	  antibody	  binding.	  J	  Immunol,	  160,	  3917-­‐23.	  GEORGIADIS,	  A.	  N.,	  METAFRATZI,	  Z.	  M.	  &	  DROSOS,	  A.	  A.	  2009.	  Pulmonary	  abnormalities	  in	  patients	  with	  early	  and	  longstanding	  rheumatoid	  arthritis.	  J	  Rheumatol,	  36,	  444-­‐5;	  author	  reply	  445-­‐6.	  GHAZIZADEH,	   S.,	   BOLEN,	   J.	   B.	   &	   FLEIT,	   H.	   B.	   1995.	   Tyrosine	   phosphorylation	   and	  association	  of	  Syk	  with	  Fc	  gamma	  RII	  in	  monocytic	  THP-­‐1	  cells.	  Biochem	  J,	  305	  (	  Pt	  2),	  669-­‐74.	  GHEZZI,	  P.,	  DINARELLO,	  C.	  A.,	  BIANCHI,	  M.,	  ROSANDICH,	  M.	  E.,	  REPINE,	  J.	  E.	  &	  WHITE,	  C.	  W.	  1991.	  Hypoxia	  increases	  production	  of	  interleukin-­‐1	  and	  tumor	  necrosis	  factor	  by	  human	  mononuclear	  cells.	  Cytokine,	  3,	  189-­‐94.	  GIANNAKOPOULOS,	  B.	  &	  KRILIS,	  S.	  A.	  2009.	  How	  I	   treat	   the	  antiphospholipid	  syndrome.	  
Blood,	  114,	  2020-­‐30.	  GILLENIUS,	   E.	   &	   URBAN,	   C.	   F.	   2015.	   The	   adhesive	   protein	   invasin	   of	   Yersinia	  pseudotuberculosis	   induces	   neutrophil	   extracellular	   traps	   via	   beta1	   integrins.	  
Microbes	  Infect,	  17,	  327-­‐36.	  GINSBERG,	  M.	  H.,	  LIGHTSEY,	  A.,	  KUNICKI,	  T.	  J.,	  KAUFMANN,	  A.,	  MARGUERIE,	  G.	  &	  PLOW,	  E.	  F.	  1986.	  Divalent	  cation	  regulation	  of	  the	  surface	  orientation	  of	  platelet	  membrane	  glycoprotein	   IIb.	  Correlation	  with	   fibrinogen	  binding	   function	  and	  definition	  of	   a	  novel	  variant	  of	  Glanzmann's	  thrombasthenia.	  J	  Clin	  Invest,	  78,	  1103-­‐11.	  GINSBURG,	   K.	   S.,	   LIANG,	   M.	   H.,	   NEWCOMER,	   L.,	   GOLDHABER,	   S.	   Z.,	   SCHUR,	   P.	   H.,	  HENNEKENS,	  C.	  H.	  &	  STAMPFER,	  M.	  J.	  1992.	  Anticardiolipin	  antibodies	  and	  the	  risk	  for	  ischemic	  stroke	  and	  venous	  thrombosis.	  Ann	  Intern	  Med,	  117,	  997-­‐1002.	  GIRARDI,	   G.,	   BERMAN,	   J.,	   REDECHA,	   P.,	   SPRUCE,	   L.,	   THURMAN,	   J.	   M.,	   KRAUS,	   D.,	  HOLLMANN,	   T.	   J.,	   CASALI,	   P.,	   CAROLL,	   M.	   C.,	   WETSEL,	   R.	   A.,	   LAMBRIS,	   J.	   D.,	  HOLERS,	  V.	  M.	  &	  SALMON,	  J.	  E.	  2003.	  Complement	  C5a	  receptors	  and	  neutrophils	  mediate	  fetal	  injury	  in	  the	  antiphospholipid	  syndrome.	  J	  Clin	  Invest,	  112,	  1644-­‐54.	  GOETZL,	  E.	  J.,	  FALCHUK,	  K.	  H.,	  ZEIGER,	  L.	  S.,	  SULLIVAN,	  A.	  L.,	  HEBERT,	  C.	  L.,	  ADAMS,	  J.	  P.	  &	  DECKER,	  J.	  L.	  1971.	  A	  physiological	  approach	  to	  the	  assessment	  of	  disease	  activity	  in	  rheumatoid	  arthritis.	  J	  Clin	  Invest,	  50,	  1167-­‐80.	  GOLDBERG,	   S.	   N.,	   CONTI-­‐KELLY,	   A.	   M.	   &	   GRECO,	   T.	   P.	   1995.	   A	   family	   study	   of	  anticardiolipin	  antibodies	  and	  associated	  clinical	  conditions.	  Am	  J	  Med,	  99,	  473-­‐9.	  GOLDSBY,	  R.	  A.,	  KINDT,	  T.	   J.,	  OSBORNE,	  B.	  A.	  &	  KUBY,	   J.	   2003.	   Immunology.	  5th	  ed.	  New	  York:	  W.H.	  Freeman	  and	  Company.	  GONG,	   H.,	   SHEN,	   B.,	   FLEVARIS,	   P.,	   CHOW,	   C.,	   LAM,	   S.	   C.,	   VOYNO-­‐YASENETSKAYA,	   T.	   A.,	  KOZASA,	   T.	   &	   DU,	   X.	   2010.	   G	   protein	   subunit	   Galpha13	   binds	   to	   integrin	  alphaIIbbeta3	  and	  mediates	  integrin	  "outside-­‐in"	  signaling.	  Science,	  327,	  340-­‐3.	  GONZALEZ-­‐QUINTELA,	   A.,	   ALENDE,	   R.,	   GUDE,	   F.,	   CAMPOS,	   J.,	   REY,	   J.,	   MEIJIDE,	   L.	   M.,	  FERNANDEZ-­‐MERINO,	  C.	  &	  VIDAL,	  C.	  2008.	  Serum	  levels	  of	  immunoglobulins	  (IgG,	  IgA,	   IgM)	   in	   a	   general	   adult	   population	   and	   their	   relationship	   with	   alcohol	  consumption,	   smoking	   and	   common	  metabolic	   abnormalities.	   Clin	   Exp	   Immunol,	  151,	  42-­‐50.	  GOOD,	  D.	  W.,	  GEORGE,	  T.	  &	  WATTS,	  B.	  A.,	  3RD	  2012.	  Toll-­‐like	   receptor	  2	   is	   required	   for	  LPS-­‐induced	  Toll-­‐like	  receptor	  4	  signaling	  and	  inhibition	  of	  ion	  transport	  in	  renal	  thick	  ascending	  limb.	  J	  Biol	  Chem,	  287,	  20208-­‐20.	  GOODSON,	  N.	  &	  SYMMONS,	  D.	  2002.	  Rheumatoid	  arthritis	  in	  women:	  still	  associated	  with	  an	  increased	  mortality.	  Ann	  Rheum	  Dis,	  61,	  955-­‐6.	  GORDON,	  D.	  L.,	  JOHNSON,	  G.	  M.	  &	  HOSTETTER,	  M.	  K.	  1987.	  Characteristics	  of	  iC3b	  binding	  to	  human	  polymorphonuclear	  leucocytes.	  Immunology,	  60,	  553-­‐8.	  GORMAN,	  J.	  D.,	  LUM,	  R.	  F.,	  CHEN,	  J.	  J.,	  SUAREZ-­‐ALMAZOR,	  M.	  E.,	  THOMSON,	  G.	  &	  CRISWELL,	  L.	  A.	  2004.	  Impact	  of	  shared	  epitope	  genotype	  and	  ethnicity	  on	  erosive	  disease:	  a	  meta-­‐analysis	  of	  3,240	  rheumatoid	  arthritis	  patients.	  Arthritis	  Rheum,	  50,	  400-­‐12.	  GRAHAM,	   R.	   R.,	   ORTMANN,	   W.,	   RODINE,	   P.,	   ESPE,	   K.,	   LANGEFELD,	   C.,	   LANGE,	   E.,	  WILLIAMS,	  A.,	  BECK,	  S.,	  KYOGOKU,	  C.,	  MOSER,	  K.,	  GAFFNEY,	  P.,	  GREGERSEN,	  P.	  K.,	  
References 
	   237	  
CRISWELL,	  L.	  A.,	  HARLEY,	   J.	  B.	  &	  BEHRENS,	  T.	  W.	  2007.	  Specific	   combinations	  of	  HLA-­‐DR2	   and	   DR3	   class	   II	   haplotypes	   contribute	   graded	   risk	   for	   disease	  susceptibility	  and	  autoantibodies	  in	  human	  SLE.	  Eur	  J	  Hum	  Genet,	  15,	  823-­‐30.	  GRANADOS,	   J.,	   VARGAS-­‐ALARCON,	  G.,	  DRENKARD,	   C.,	   ANDRADE,	   F.,	  MELIN-­‐ALDANA,	  H.,	  ALCOCER-­‐VARELA,	   J.	   &	   ALARCON-­‐SEGOVIA,	   D.	   1997.	   Relationship	   of	  anticardiolipin	  antibodies	  and	  antiphospholipid	  syndrome	  to	  HLA-­‐DR7	  in	  Mexican	  patients	  with	  systemic	  lupus	  erythematosus	  (SLE).	  Lupus,	  6,	  57-­‐62.	  GREENBERG,	   S.,	   CHANG,	   P.	  &	   SILVERSTEIN,	   S.	   C.	   1994.	   Tyrosine	   phosphorylation	   of	   the	  gamma	   subunit	   of	   Fc	   gamma	   receptors,	   p72syk,	   and	  paxillin	  during	  Fc	   receptor-­‐mediated	  phagocytosis	  in	  macrophages.	  J	  Biol	  Chem,	  269,	  3897-­‐902.	  GRIFFITHS,	  R.	  J.,	  PETTIPHER,	  E.	  R.,	  KOCH,	  K.,	  FARRELL,	  C.	  A.,	  BRESLOW,	  R.,	  CONKLYN,	  M.	  J.,	   SMITH,	  M.	   A.,	   HACKMAN,	   B.	   C.,	  WIMBERLY,	   D.	   J.,	   MILICI,	   A.	   J.	   &	   ET	   AL.	   1995.	  Leukotriene	   B4	   plays	   a	   critical	   role	   in	   the	   progression	   of	   collagen-­‐induced	  arthritis.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  92,	  517-­‐21.	  GRILLO-­‐LOPEZ,	  A.	  J.,	  WHITE,	  C.	  A.,	  VARNS,	  C.,	  SHEN,	  D.,	  WEI,	  A.,	  MCCLURE,	  A.	  &	  DALLAIRE,	  B.	   K.	   1999.	   Overview	   of	   the	   clinical	   development	   of	   rituximab:	   first	   monoclonal	  antibody	  approved	  for	  the	  treatment	  of	  lymphoma.	  Semin	  Oncol,	  26,	  66-­‐73.	  GROOTVELD,	   M.,	   HENDERSON,	   E.	   B.,	   FARRELL,	   A.,	   BLAKE,	   D.	   R.,	   PARKES,	   H.	   G.	   &	  HAYCOCK,	  P.	  1991.	  Oxidative	  damage	  to	  hyaluronate	  and	  glucose	  in	  synovial	  fluid	  during	   exercise	   of	   the	   inflamed	   rheumatoid	   joint.	   Detection	   of	   abnormal	   low-­‐molecular-­‐mass	  metabolites	   by	  proton-­‐n.m.r.	   spectroscopy.	  Biochem	  J,	   273(Pt	  2),	  459-­‐67.	  GROTENDORST,	  G.	  R.,	  SMALE,	  G.	  &	  PENCEV,	  D.	  1989.	  Production	  of	  transforming	  growth	  factor	  beta	  by	  human	  peripheral	  blood	  monocytes	  and	  neutrophils.	   J	  Cell	  Physiol,	  140,	  396-­‐402.	  GRUMET,	   F.	   C.,	   COUKELL,	   A.,	   BODMER,	   J.	   G.,	   BODMER,	   W.	   F.	   &	   MCDEVITT,	   H.	   O.	   1971.	  Histocompatibility	  (HL-­‐A)	  antigens	  associated	  with	  systemic	  lupus	  erythematosus.	  A	  possible	  genetic	  predisposition	  to	  disease.	  N	  Engl	  J	  Med,	  285,	  193-­‐6.	  GU,	   Y.	   Z.,	   MORAN,	   S.	   M.,	   HOGENESCH,	   J.	   B.,	   WARTMAN,	   L.	   &	   BRADFIELD,	   C.	   A.	   1998.	  Molecular	   characterization	   and	   chromosomal	   localization	   of	   a	   third	   alpha-­‐class	  hypoxia	  inducible	  factor	  subunit,	  HIF3alpha.	  Gene	  Expr,	  7,	  205-­‐13.	  GUPTA,	  A.	  K.,	  JOSHI,	  M.	  B.,	  PHILIPPOVA,	  M.,	  ERNE,	  P.,	  HASLER,	  P.,	  HAHN,	  S.	  &	  RESINK,	  T.	  J.	  2010.	   Activated	   endothelial	   cells	   induce	   neutrophil	   extracellular	   traps	   and	   are	  susceptible	  to	  NETosis-­‐mediated	  cell	  death.	  FEBS	  Lett,	  584,	  3193-­‐7.	  GUTOWSKA-­‐OWSIAK,	  D.,	  BIRCHALL,	  M.	  A.,	  MOOTS,	  R.	  J.,	  CHRISTMAS,	  S.	  E.	  &	  PAZMANY,	  L.	  2014.	   Proliferatory	   defect	   of	   invariant	   population	   and	   accumulation	   of	   non-­‐invariant	   CD1d-­‐restricted	   natural	   killer	   T	   cells	   in	   the	   joints	   of	   RA	   patients.	  Mod	  
Rheumatol,	  24,	  434-­‐42.	  GUTTMAN-­‐YASSKY,	  E.,	  VUGMEYSTER,	  Y.,	  LOWES,	  M.	  A.,	  CHAMIAN,	  F.,	  KIKUCHI,	  T.,	  KAGEN,	  M.,	  GILLEAUDEAU,	  P.,	  LEE,	  E.,	  HUNTE,	  B.,	  HOWELL,	  K.,	  DUMMER,	  W.,	  BODARY,	  S.	  C.	  &	   KRUEGER,	   J.	   G.	   2008.	   Blockade	   of	   CD11a	   by	   efalizumab	   in	   psoriasis	   patients	  induces	  a	  unique	  state	  of	  T-­‐cell	  hyporesponsiveness.	  J	  Invest	  Dermatol,	  128,	  1182-­‐91.	  GUYRE,	   P.	  M.,	   CAMPBELL,	   A.	   S.,	   KNIFFIN,	  W.	  D.	  &	   FANGER,	  M.	  W.	   1990.	  Monocytes	   and	  polymorphonuclear	  neutrophils	  of	  patients	  with	  streptococcal	  pharyngitis	  express	  increased	  numbers	  of	  type	  I	  IgG	  Fc	  receptors.	  J	  Clin	  Invest,	  86,	  1892-­‐6.	  HACBARTH,	   E.	   &	   KAJDACSY-­‐BALLA,	   A.	   1986.	   Low	   density	   neutrophils	   in	   patients	   with	  systemic	   lupus	   erythematosus,	   rheumatoid	   arthritis,	   and	   acute	   rheumatic	   fever.	  
Arthritis	  Rheum,	  29,	  1334-­‐42.	  HAGBERG,	  N.,	  THEORELL,	  J.,	  HJORTON,	  K.,	  SPEE,	  P.,	  ELORANTA,	  M.	  L.,	  BRYCESON,	  Y.	  T.	  &	  RONNBLOM,	   L.	   2015.	   Functional	   anti-­‐CD94/NKG2A	   and	   anti-­‐CD94/NKG2C	  autoantibodies	   in	   patients	   with	   systemic	   lupus	   erythematosus.	   Arthritis	  
Rheumatol,	  67,	  1000-­‐11.	  
References 
	   238	  
HAKKIM,	   A.,	   FUCHS,	   T.	   A.,	   MARTINEZ,	   N.	   E.,	   HESS,	   S.,	   PRINZ,	   H.,	   ZYCHLINSKY,	   A.	   &	  WALDMANN,	   H.	   2011.	   Activation	   of	   the	   Raf-­‐MEK-­‐ERK	   pathway	   is	   required	   for	  neutrophil	  extracellular	  trap	  formation.	  Nat	  Chem	  Biol,	  7,	  75-­‐7.	  HAKKIM,	   A.,	   FURNROHR,	   B.	   G.,	   AMANN,	   K.,	   LAUBE,	   B.,	   ABED,	   U.	   A.,	   BRINKMANN,	   V.,	  HERRMANN,	   M.,	   VOLL,	   R.	   E.	   &	   ZYCHLINSKY,	   A.	   2010.	   Impairment	   of	   neutrophil	  extracellular	   trap	   degradation	   is	   associated	  with	   lupus	   nephritis.	  Proc	  Natl	  Acad	  
Sci	  U	  S	  A,	  107,	  9813-­‐8.	  HALBWACHS-­‐MECARELLI,	   L.,	   NUSBAUM,	   P.,	   NOEL,	   L.	   H.,	   REUMAUX,	   D.,	   ERLINGER,	   S.,	  GRUNFELD,	   J.	   P.	   &	   LESAVRE,	   P.	   1992.	   Antineutrophil	   cytoplasmic	   antibodies	  (ANCA)	   directed	   against	   cathepsin	   G	   in	   ulcerative	   colitis,	   Crohn's	   disease	   and	  primary	  sclerosing	  cholangitis.	  Clin	  Exp	  Immunol,	  90,	  79-­‐84.	  HAMMAKER,	  D.	  &	  FIRESTEIN,	  G.	  S.	  2010.	  "Go	  upstream,	  young	  man":	  lessons	  learned	  from	  the	  p38	  saga.	  Ann	  Rheum	  Dis,	  69	  Suppl	  1,	  i77-­‐82.	  HAN,	   S.,	   KIM-­‐HOWARD,	   X.,	   DESHMUKH,	   H.,	   KAMATANI,	   Y.,	   VISWANATHAN,	   P.,	  GUTHRIDGE,	  J.	  M.,	  THOMAS,	  K.,	  KAUFMAN,	  K.	  M.,	  OJWANG,	  J.,	  ROJAS-­‐VILLARRAGA,	  A.,	  BACA,	  V.,	  OROZCO,	  L.,	  RHODES,	  B.,	  CHOI,	  C.	  B.,	  GREGERSEN,	  P.	  K.,	  MERRILL,	  J.	  T.,	  JAMES,	  J.	  A.,	  GAFFNEY,	  P.	  M.,	  MOSER,	  K.	  L.,	  JACOB,	  C.	  O.,	  KIMBERLY,	  R.	  P.,	  HARLEY,	  J.	  B.,	  BAE,	  S.	  C.,	  ANAYA,	  J.	  M.,	  ALARCON-­‐RIQUELME,	  M.	  E.,	  MATSUDA,	  K.,	  VYSE,	  T.	  J.	  &	  NATH,	  S.	  K.	  2009.	  Evaluation	  of	  imputation-­‐based	  association	  in	  and	  around	  the	  integrin-­‐alpha-­‐M	   (ITGAM)	   gene	   and	   replication	   of	   robust	   association	   between	   a	  non-­‐synonymous	   functional	   variant	   within	   ITGAM	   and	   systemic	   lupus	  erythematosus	  (SLE).	  Hum	  Mol	  Genet,	  18,	  1171-­‐80.	  HARA,	   S.,	   HAMADA,	   J.,	   KOBAYASHI,	   C.,	   KONDO,	   Y.	   &	   IMURA,	   N.	   2001.	   Expression	   and	  characterization	   of	   hypoxia-­‐inducible	   factor	   (HIF)-­‐3alpha	   in	   human	   kidney:	  suppression	  of	  HIF-­‐mediated	  gene	  expression	  by	  HIF-­‐3alpha.	  Biochem	  Biophys	  Res	  
Commun,	  287,	  808-­‐13.	  HARADA,	  T.,	  KYTTARIS,	  V.,	  LI,	  Y.,	  JUANG,	  Y.	  T.,	  WANG,	  Y.	  &	  TSOKOS,	  G.	  C.	  2007.	  Increased	  expression	  of	  STAT3	  in	  SLE	  T	  cells	  contributes	  to	  enhanced	  chemokine-­‐mediated	  cell	  migration.	  Autoimmunity,	  40,	  1-­‐8.	  HARINGMAN,	   J.	   J.,	   GERLAG,	   D.	   M.,	   ZWINDERMAN,	   A.	   H.,	   SMEETS,	   T.	   J.,	   KRAAN,	   M.	   C.,	  BAETEN,	   D.,	   MCINNES,	   I.	   B.,	   BRESNIHAN,	   B.	   &	   TAK,	   P.	   P.	   2005.	   Synovial	   tissue	  macrophages:	   a	   sensitive	   biomarker	   for	   response	   to	   treatment	   in	   patients	   with	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  64,	  834-­‐8.	  HARLEY,	  J.	  B.,	  ALARCON-­‐RIQUELME,	  M.	  E.,	  CRISWELL,	  L.	  A.,	  JACOB,	  C.	  O.,	  KIMBERLY,	  R.	  P.,	  MOSER,	  K.	  L.,	  TSAO,	  B.	  P.,	  VYSE,	  T.	  J.,	  LANGEFELD,	  C.	  D.,	  NATH,	  S.	  K.,	  GUTHRIDGE,	  J.	  M.,	  COBB,	  B.	  L.,	  MIREL,	  D.	  B.,	  MARION,	  M.	  C.,	  WILLIAMS,	  A.	  H.,	  DIVERS,	  J.,	  WANG,	  W.,	  FRANK,	  S.	  G.,	  NAMJOU,	  B.,	  GABRIEL,	  S.	  B.,	  LEE,	  A.	  T.,	  GREGERSEN,	  P.	  K.,	  BEHRENS,	  T.	  W.,	  TAYLOR,	  K.	  E.,	  FERNANDO,	  M.,	  ZIDOVETZKI,	  R.,	  GAFFNEY,	  P.	  M.,	  EDBERG,	  J.	  C.,	  RIOUX,	  J.	  D.,	  OJWANG,	  J.	  O.,	  JAMES,	  J.	  A.,	  MERRILL,	  J.	  T.,	  GILKESON,	  G.	  S.,	  SELDIN,	  M.	   F.,	   YIN,	   H.,	   BAECHLER,	   E.	   C.,	   LI,	   Q.	   Z.,	   WAKELAND,	   E.	   K.,	   BRUNER,	   G.	   R.,	  KAUFMAN,	   K.	   M.	   &	   KELLY,	   J.	   A.	   2008.	   Genome-­‐wide	   association	   scan	   in	   women	  with	   systemic	   lupus	   erythematosus	   identifies	   susceptibility	   variants	   in	   ITGAM,	  PXK,	  KIAA1542	  and	  other	  loci.	  Nat	  Genet,	  40,	  204-­‐10.	  HARTUNG,	  K.,	  COLDEWEY,	  R.,	  CORVETTA,	  A.,	  DEICHER,	  H.,	  KALDEN,	  J.	  R.,	  KRAPF,	  F.,	  LANG,	  B.,	   LAKOMEK,	   H.	   J.,	   LIEDVOGEL,	   B.,	   PETER,	   H.	   H.	   &	   ET	   AL.	   1992.	   MHC	   gene	  products	  and	  anticardiolipin	  antibodies	  in	  systemic	  lupus	  erythematosus	  results	  of	  a	  multicenter	  study.	  SLE	  Study	  Group.	  Autoimmunity,	  13,	  95-­‐9.	  HASLETT,	   C.,	   GUTHRIE,	   L.	   A.,	   KOPANIAK,	   M.	   M.,	   JOHNSTON,	   R.	   B.,	   JR.	   &	   HENSON,	   P.	   M.	  1985.	   Modulation	   of	   multiple	   neutrophil	   functions	   by	   preparative	   methods	   or	  trace	  concentrations	  of	  bacterial	  lipopolysaccharide.	  Am	  J	  Pathol,	  119,	  101-­‐10.	  HEADLAND,	  S.	  E.,	  JONES,	  H.	  R.,	  NORLING,	  L.	  V.,	  KIM,	  A.,	  SOUZA,	  P.	  R.,	  CORSIERO,	  E.,	  GIL,	  C.	  D.,	   NERVIANI,	   A.,	   DELL'ACCIO,	   F.,	   PITZALIS,	   C.,	   OLIANI,	   S.	   M.,	   JAN,	   L.	   Y.	   &	  PERRETTI,	  M.	  2015.	  Neutrophil-­‐derived	  microvesicles	  enter	  cartilage	  and	  protect	  the	  joint	  in	  inflammatory	  arthritis.	  Sci	  Transl	  Med,	  7,	  315ra190.	  
References 
	   239	  
HEMLER,	   M.	   E.,	   GLASS,	   D.,	   COBLYN,	   J.	   S.	   &	   JACOBSON,	   J.	   G.	   1986.	   Very	   late	   activation	  antigens	  on	  rheumatoid	  synovial	  fluid	  T	  lymphocytes.	  Association	  with	  stages	  of	  T	  cell	  activation.	  J	  Clin	  Invest,	  78,	  696-­‐702.	  HERMAND,	  P.,	  GANE,	  P.,	  HUET,	  M.,	  JALLU,	  V.,	  KAPLAN,	  C.,	  SONNEBORN,	  H.	  H.,	  CARTRON,	  J.	  P.	  &	  BAILLY,	  P.	  2003.	  Red	  cell	  ICAM-­‐4	  is	  a	  novel	  ligand	  for	  platelet-­‐activated	  alpha	  IIbbeta	  3	  integrin.	  J	  Biol	  Chem,	  278,	  4892-­‐8.	  HERVIER,	   B.,	   BEZIAT,	   V.,	   HAROCHE,	   J.,	   MATHIAN,	   A.,	   LEBON,	   P.,	   GHILLANI-­‐DALBIN,	   P.,	  MUSSET,	  L.,	  DEBRE,	  P.,	  AMOURA,	  Z.	  &	  VIEILLARD,	  V.	  2011.	  Phenotype	  and	  function	  of	   natural	   killer	   cells	   in	   systemic	   lupus	   erythematosus:	   excess	   interferon-­‐gamma	  production	  in	  patients	  with	  active	  disease.	  Arthritis	  Rheum,	  63,	  1698-­‐706.	  HEWITSON,	  K.	  S.,	  MCNEILL,	  L.	  A.,	  RIORDAN,	  M.	  V.,	  TIAN,	  Y.	  M.,	  BULLOCK,	  A.	  N.,	  WELFORD,	  R.	   W.,	   ELKINS,	   J.	   M.,	   OLDHAM,	   N.	   J.,	   BHATTACHARYA,	   S.,	   GLEADLE,	   J.	   M.,	  RATCLIFFE,	   P.	   J.,	   PUGH,	   C.	  W.	  &	   SCHOFIELD,	   C.	   J.	   2002.	  Hypoxia-­‐inducible	   factor	  (HIF)	   asparagine	   hydroxylase	   is	   identical	   to	   factor	   inhibiting	   HIF	   (FIH)	   and	   is	  related	  to	  the	  cupin	  structural	  family.	  J	  Biol	  Chem,	  277,	  26351-­‐5.	  HINKS,	   A.,	   BARTON,	   A.,	   JOHN,	   S.,	   BRUCE,	   I.,	   HAWKINS,	   C.,	   GRIFFITHS,	   C.	   E.,	   DONN,	   R.,	  THOMSON,	  W.,	   SILMAN,	   A.	   &	  WORTHINGTON,	   J.	   2005.	   Association	   between	   the	  PTPN22	   gene	   and	   rheumatoid	   arthritis	   and	   juvenile	   idiopathic	   arthritis	   in	   a	   UK	  population:	   further	   support	   that	   PTPN22	   is	   an	   autoimmunity	   gene.	   Arthritis	  
Rheum,	  52,	  1694-­‐9.	  HIRAOKA,	  N.,	  PETRYNIAK,	  B.,	  NAKAYAMA,	  J.,	  TSUBOI,	  S.,	  SUZUKI,	  M.,	  YEH,	  J.	  C.,	  IZAWA,	  D.,	  TANAKA,	   T.,	   MIYASAKA,	   M.,	   LOWE,	   J.	   B.	   &	   FUKUDA,	   M.	   1999.	   A	   novel,	   high	  endothelial	  venule-­‐specific	  sulfotransferase	  expresses	  6-­‐sulfo	  sialyl	  Lewis(x),	  an	  L-­‐selectin	  ligand	  displayed	  by	  CD34.	  Immunity,	  11,	  79-­‐89.	  HIROSE,	  N.,	  WILLIAMS,	  R.,	  ALBERTS,	  A.	  R.,	  FURIE,	  R.	  A.,	  CHARTASH,	  E.	  K.,	  JAIN,	  R.	  I.,	  SISON,	  C.,	  LAHITA,	  R.	  G.,	  MERRILL,	  J.	  T.,	  CUCURULL,	  E.,	  GHARAVI,	  A.	  E.,	  SAMMARITANO,	  L.	  R.,	   SALMON,	   J.	   E.,	   HASHIMOTO,	   S.,	   SAWADA,	   T.,	   CHU,	   C.	   C.,	   GREGERSEN,	   P.	   K.	   &	  CHIORAZZI,	   N.	   1999.	   A	   role	   for	   the	   polymorphism	   at	   position	   247	   of	   the	   beta2-­‐glycoprotein	  I	  gene	  in	  the	  generation	  of	  anti-­‐beta2-­‐glycoprotein	  I	  antibodies	  in	  the	  antiphospholipid	  syndrome.	  Arthritis	  Rheum,	  42,	  1655-­‐61.	  HOGENESCH,	   J.	  B.,	  CHAN,	  W.	  K.,	   JACKIW,	  V.	  H.,	  BROWN,	  R.	  C.,	  GU,	  Y.	  Z.,	  PRAY-­‐GRANT,	  M.,	  PERDEW,	  G.	  H.	  &	  BRADFIELD,	  C.	  A.	  1997.	  Characterization	  of	  a	  subset	  of	  the	  basic-­‐helix-­‐loop-­‐helix-­‐PAS	   superfamily	   that	   interacts	   with	   components	   of	   the	   dioxin	  signaling	  pathway.	  J	  Biol	  Chem,	  272,	  8581-­‐93.	  HOLERS,	   V.	   M.,	   GIRARDI,	   G.,	   MO,	   L.,	   GUTHRIDGE,	   J.	   M.,	   MOLINA,	   H.,	   PIERANGELI,	   S.	   S.,	  ESPINOLA,	  R.,	   XIAOWEI,	   L.	   E.,	  MAO,	  D.,	   VIALPANDO,	   C.	   G.	  &	   SALMON,	   J.	   E.	   2002.	  Complement	  C3	  activation	  is	  required	  for	  antiphospholipid	  antibody-­‐induced	  fetal	  loss.	  J	  Exp	  Med,	  195,	  211-­‐20.	  HOM,	  G.,	  GRAHAM,	  R.	  R.,	  MODREK,	  B.,	  TAYLOR,	  K.	  E.,	  ORTMANN,	  W.,	  GARNIER,	  S.,	  LEE,	  A.	  T.,	   CHUNG,	   S.	   A.,	   FERREIRA,	   R.	   C.,	   PANT,	   P.	   V.,	   BALLINGER,	   D.	   G.,	   KOSOY,	   R.,	  DEMIRCI,	  F.	  Y.,	  KAMBOH,	  M.	  I.,	  KAO,	  A.	  H.,	  TIAN,	  C.,	  GUNNARSSON,	  I.,	  BENGTSSON,	  A.	  A.,	  RANTAPAA-­‐DAHLQVIST,	  S.,	  PETRI,	  M.,	  MANZI,	  S.,	  SELDIN,	  M.	  F.,	  RONNBLOM,	  L.,	   SYVANEN,	  A.	   C.,	   CRISWELL,	   L.	   A.,	   GREGERSEN,	   P.	   K.	  &	  BEHRENS,	   T.	  W.	   2008.	  Association	   of	   systemic	   lupus	   erythematosus	   with	   C8orf13-­‐BLK	   and	   ITGAM-­‐ITGAX.	  N	  Engl	  J	  Med,	  358,	  900-­‐9.	  HOPPE,	  B.,	  HAUPL,	  T.,	  GRUBER,	  R.,	  KIESEWETTER,	  H.,	  BURMESTER,	  G.	  R.,	   SALAMA,	  A.	  &	  DORNER,	   T.	   2006.	   Detailed	   analysis	   of	   the	   variability	   of	   peptidylarginine	  deiminase	   type	   4	   in	   German	   patients	   with	   rheumatoid	   arthritis:	   a	   case-­‐control	  study.	  Arthritis	  Res	  Ther,	  8,	  R34.	  HORTELANO,	  S.,	  LOPEZ-­‐FONTAL,	  R.,	  TRAVES,	  P.	  G.,	  VILLA,	  N.,	  GRASHOFF,	  C.,	  BOSCA,	  L.	  &	  LUQUE,	  A.	  2010.	  ILK	  mediates	  LPS-­‐induced	  vascular	  adhesion	  receptor	  expression	  and	  subsequent	  leucocyte	  trans-­‐endothelial	  migration.	  Cardiovasc	  Res,	  86,	  283-­‐92.	  HSIEH,	  S.	  C.,	  WU,	  T.	  H.,	  TSAI,	  C.	  Y.,	  LI,	  K.	  J.,	  LU,	  M.	  C.,	  WU,	  C.	  H.	  &	  YU,	  C.	  L.	  2008.	  Abnormal	  in	  vitro	   CXCR2	   modulation	   and	   defective	   cationic	   ion	   transporter	   expression	   on	  
References 
	   240	  
polymorphonuclear	   neutrophils	   responsible	   for	   hyporesponsiveness	   to	   IL-­‐8	  stimulation	   in	   patients	  with	   active	   systemic	   lupus	   erythematosus.	  Rheumatology	  
(Oxford),	  47,	  150-­‐7.	  HSU-­‐LIN,	   S.,	   BERMAN,	   C.	   L.,	   FURIE,	   B.	   C.,	   AUGUST,	   D.	   &	   FURIE,	   B.	   1984.	   A	   platelet	  membrane	   protein	   expressed	   during	   platelet	   activation	   and	   secretion.	   Studies	  using	  a	  monoclonal	  antibody	  specific	  for	  thrombin-­‐activated	  platelets.	  J	  Biol	  Chem,	  259,	  9121-­‐6.	  HSU,	  H.	  C.,	  YANG,	  P.,	  WANG,	  J.,	  WU,	  Q.,	  MYERS,	  R.,	  CHEN,	  J.,	  YI,	  J.,	  GUENTERT,	  T.,	  TOUSSON,	  A.,	   STANUS,	   A.	   L.,	   LE,	   T.	   V.,	   LORENZ,	   R.	   G.,	   XU,	   H.,	   KOLLS,	   J.	   K.,	   CARTER,	   R.	   H.,	  CHAPLIN,	  D.	  D.,	  WILLIAMS,	  R.	  W.	  &	  MOUNTZ,	  J.	  D.	  2008.	  Interleukin	  17-­‐producing	  T	   helper	   cells	   and	   interleukin	   17	   orchestrate	   autoreactive	   germinal	   center	  development	  in	  autoimmune	  BXD2	  mice.	  Nat	  Immunol,	  9,	  166-­‐75.	  HU,	  D.	  D.,	  HOYER,	  J.	  R.	  &	  SMITH,	  J.	  W.	  1995.	  Ca2+	  suppresses	  cell	  adhesion	  to	  osteopontin	  by	  attenuating	  binding	  affinity	  for	  integrin	  alpha	  v	  beta	  3.	  J	  Biol	  Chem,	  270,	  9917-­‐25.	  HU,	  F.,	  MU,	  R.,	  ZHU,	  J.,	  SHI,	  L.,	  LI,	  Y.,	  LIU,	  X.,	  SHAO,	  W.,	  LI,	  G.,	  LI,	  M.,	  SU,	  Y.,	  COHEN,	  P.	  L.,	  QIU,	  X.	   &	   LI,	   Z.	   2014.	   Hypoxia	   and	   hypoxia-­‐inducible	   factor-­‐1alpha	   provoke	   toll-­‐like	  receptor	  signalling-­‐induced	  inflammation	  in	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  73,	  928-­‐36.	  HUANG,	  A.	  J.,	  SILVERSTEIN,	  S.	  C.	  &	  MALAWISTA,	  S.	  E.	  1991.	  Cryopreserved	  cytoplasts	  from	  human	   neutrophils	   migrate	   across	   monolayers	   of	   human	   endothelial	   cells	   in	  response	  to	  a	  chemoattractant	  gradient.	  J	  Leukoc	  Biol,	  50,	  624-­‐7.	  HUANG,	  C.,	  ZANG,	  Q.,	  TAKAGI,	  J.	  &	  SPRINGER,	  T.	  A.	  2000.	  Structural	  and	  functional	  studies	  with	  antibodies	  to	  the	  integrin	  beta	  2	  subunit.	  A	  model	  for	  the	  I-­‐like	  domain.	  J	  Biol	  
Chem,	  275,	  21514-­‐24.	  HUANG,	  J.,	  DIBBLE,	  C.	  C.,	  MATSUZAKI,	  M.	  &	  MANNING,	  B.	  D.	  2008.	  The	  TSC1-­‐TSC2	  complex	  is	  required	  for	  proper	  activation	  of	  mTOR	  complex	  2.	  Mol	  Cell	  Biol,	  28,	  4104-­‐15.	  HUANG,	  M.	  T.,	  LARBI,	  K.	  Y.,	  SCHEIERMANN,	  C.,	  WOODFIN,	  A.,	  GERWIN,	  N.,	  HASKARD,	  D.	  O.	  &	   NOURSHARGH,	   S.	   2006.	   ICAM-­‐2	   mediates	   neutrophil	   transmigration	   in	   vivo:	  evidence	   for	   stimulus	   specificity	   and	   a	   role	   in	   PECAM-­‐1-­‐independent	  transmigration.	  Blood,	  107,	  4721-­‐7.	  HUANG,	   Y.	   M.,	   WANG,	   H.,	   WANG,	   C.,	   CHEN,	   M.	   &	   ZHAO,	   M.	   H.	   2015.	   Promotion	   of	  hypercoagulability	  in	  antineutrophil	  cytoplasmic	  antibody-­‐associated	  vasculitis	  by	  C5a-­‐induced	   tissue	   factor-­‐expressing	  microparticles	   and	   neutrophil	   extracellular	  traps.	  Arthritis	  Rheumatol,	  67,	  2780-­‐90.	  HUANG,	  Z.,	  FU,	  B.,	  ZHENG,	  S.	  G.,	  LI,	  X.,	  SUN,	  R.,	  TIAN,	  Z.	  &	  WEI,	  H.	  2011a.	   Involvement	  of	  CD226+	   NK	   cells	   in	   immunopathogenesis	   of	   systemic	   lupus	   erythematosus.	   J	  
Immunol,	  186,	  3421-­‐31.	  HUANG,	  Z.	  Y.,	  HUNTER,	  S.,	  CHIEN,	  P.,	  KIM,	  M.	  K.,	  HAN-­‐KIM,	  T.	  H.,	  INDIK,	  Z.	  K.	  &	  SCHREIBER,	  A.	   D.	   2011b.	   Interaction	   of	   two	   phagocytic	   host	   defense	   systems:	   Fcgamma	  receptors	  and	  complement	  receptor	  3.	  J	  Biol	  Chem,	  286,	  160-­‐8.	  HUGHES,	  G.	  R.	  1983.	  Thrombosis,	  abortion,	  cerebral	  disease,	  and	  the	  lupus	  anticoagulant.	  
Br	  Med	  J	  (Clin	  Res	  Ed),	  287,	  1088-­‐9.	  HUGHES,	  G.	  R.	  1993.	  The	  antiphospholipid	  syndrome:	  ten	  years	  on.	  Lancet,	  342,	  341-­‐4.	  HUGHES,	   J.	   R.,	   ERHARDT,	   C.	   C.	   &	   CLEMENT,	   M.	   1995.	   Neutrophilic	   dermatosis	   in	  association	  with	  rheumatoid	  arthritis.	  Clin	  Exp	  Dermatol,	  20,	  168-­‐70.	  HUMPHREYS,	   J.	   H.,	   VERSTAPPEN,	   S.	  M.,	   HYRICH,	   K.	   L.,	   CHIPPING,	   J.	   R.,	  MARSHALL,	   T.	  &	  SYMMONS,	   D.	   P.	   2013.	   The	   incidence	   of	   rheumatoid	   arthritis	   in	   the	   UK:	  comparisons	  using	  the	  2010	  ACR/EULAR	  classification	  criteria	  and	  the	  1987	  ACR	  classification	  criteria.	  Results	   from	  the	  Norfolk	  Arthritis	  Register.	  Ann	  Rheum	  Dis,	  72,	  1315-­‐20.	  HYNES,	  R.	  O.	  2002.	  Integrins:	  bidirectional,	  allosteric	  signaling	  machines.	  Cell,	  110,	  673-­‐87.	  
References 
	   241	  
ICHIKAWA,	  K.,	  KHAMASHTA,	  M.	  A.,	  KOIKE,	  T.,	  MATSUURA,	  E.	  &	  HUGHES,	  G.	  R.	  1994.	  beta	  2-­‐Glycoprotein	  I	  reactivity	  of	  monoclonal	  anticardiolipin	  antibodies	  from	  patients	  with	  the	  antiphospholipid	  syndrome.	  Arthritis	  Rheum,	  37,	  1453-­‐61.	  IHANUS,	   E.,	   UOTILA,	   L.	  M.,	   TOIVANEN,	   A.,	   VARIS,	  M.	  &	   GAHMBERG,	   C.	   G.	   2007.	   Red-­‐cell	  ICAM-­‐4	   is	   a	   ligand	   for	   the	   monocyte/macrophage	   integrin	   CD11c/CD18:	  characterization	  of	  the	  binding	  sites	  on	  ICAM-­‐4.	  Blood,	  109,	  802-­‐10.	  IKEMATSU,	   W.,	   LUAN,	   F.	   L.,	   LA	   ROSA,	   L.,	   BELTRAMI,	   B.,	   NICOLETTI,	   F.,	   BUYON,	   J.	   P.,	  MERONI,	   P.	   L.,	   BALESTRIERI,	   G.	   &	   CASALI,	   P.	   1998.	   Human	   anticardiolipin	  monoclonal	  autoantibodies	  cause	  placental	  necrosis	  and	  fetal	  loss	  in	  BALB/c	  mice.	  
Arthritis	  Rheum,	  41,	  1026-­‐39.	  IKEZUMI,	  Y.,	  SUZUKI,	  T.,	  HAYAFUJI,	  S.,	  OKUBO,	  S.,	  NIKOLIC-­‐PATERSON,	  D.	  J.,	  KAWACHI,	  H.,	  SHIMIZU,	   F.	   &	   UCHIYAMA,	   M.	   2005.	   The	   sialoadhesin	   (CD169)	   expressing	   a	  macrophage	   subset	   in	   human	   proliferative	   glomerulonephritis.	   Nephrol	   Dial	  
Transplant,	  20,	  2704-­‐13.	  IMAI,	  Y.,	   SINGER,	  M.	   S.,	   FENNIE,	  C.,	   LASKY,	  L.	  A.	  &	  ROSEN,	   S.	  D.	  1991.	   Identification	  of	   a	  carbohydrate-­‐based	   endothelial	   ligand	   for	   a	   lymphocyte	   homing	   receptor.	   J	   Cell	  
Biol,	  113,	  1213-­‐21.	  INOUE,	  O.,	  SUZUKI-­‐INOUE,	  K.,	  DEAN,	  W.	  L.,	  FRAMPTON,	  J.	  &	  WATSON,	  S.	  P.	  2003.	  Integrin	  alpha2beta1	   mediates	   outside-­‐in	   regulation	   of	   platelet	   spreading	   on	   collagen	  through	  activation	  of	  Src	  kinases	  and	  PLCgamma2.	  J	  Cell	  Biol,	  160,	  769-­‐80.	  IOANNOU,	  Y.,	  PERICLEOUS,	  C.,	  GILES,	  I.,	  LATCHMAN,	  D.	  S.,	  ISENBERG,	  D.	  A.	  &	  RAHMAN,	  A.	  2007.	  Binding	  of	  antiphospholipid	  antibodies	  to	  discontinuous	  epitopes	  on	  domain	  I	  of	  human	  beta(2)-­‐glycoprotein	  I:	  mutation	  studies	  including	  residues	  R39	  to	  R43.	  
Arthritis	  Rheum,	  56,	  280-­‐90.	  IRVING,	   J.	   A.,	   LYSIAK,	   J.	   J.,	   GRAHAM,	   C.	   H.,	   HEARN,	   S.,	   HAN,	   V.	   K.	   &	   LALA,	   P.	   K.	   1995.	  Characteristics	  of	   trophoblast	  cells	  migrating	   from	  first	   trimester	  chorionic	  villus	  explants	  and	  propagated	  in	  culture.	  Placenta,	  16,	  413-­‐33.	  ITAKURA,	  A.	  &	  MCCARTY,	  O.	  J.	  2013.	  Pivotal	  role	  for	  the	  mTOR	  pathway	  in	  the	  formation	  of	   neutrophil	   extracellular	   traps	   via	   regulation	   of	   autophagy.	   Am	   J	   Physiol	   Cell	  
Physiol,	  305,	  C348-­‐54.	  IVAN,	  M.,	   KONDO,	  K.,	   YANG,	  H.,	   KIM,	  W.,	   VALIANDO,	   J.,	   OHH,	  M.,	   SALIC,	  A.,	   ASARA,	   J.	  M.,	  LANE,	   W.	   S.	   &	   KAELIN,	   W.	   G.,	   JR.	   2001.	   HIFalpha	   targeted	   for	   VHL-­‐mediated	  destruction	   by	   proline	   hydroxylation:	   implications	   for	   O2	   sensing.	   Science,	   292,	  464-­‐8.	  IVERSON,	   G.	   M.,	   VICTORIA,	   E.	   J.	   &	   MARQUIS,	   D.	   M.	   1998.	   Anti-­‐beta2	   glycoprotein	   I	  (beta2GPI)	   autoantibodies	   recognize	   an	   epitope	  on	   the	   first	   domain	  of	   beta2GPI.	  
Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  95,	  15542-­‐6.	  IWAMOTO,	   T.,	   IKARI,	   K.,	   NAKAMURA,	   T.,	   KUWAHARA,	   M.,	   TOYAMA,	   Y.,	   TOMATSU,	   T.,	  MOMOHARA,	   S.	   &	   KAMATANI,	   N.	   2006.	   Association	   between	   PADI4	   and	  rheumatoid	  arthritis:	  a	  meta-­‐analysis.	  Rheumatology	  (Oxford),	  45,	  804-­‐7.	  JAAKKOLA,	  P.,	  MOLE,	  D.	  R.,	  TIAN,	  Y.	  M.,	  WILSON,	  M.	   I.,	  GIELBERT,	   J.,	  GASKELL,	  S.	   J.,	  VON	  KRIEGSHEIM,	  A.,	  HEBESTREIT,	  H.	  F.,	  MUKHERJI,	  M.,	  SCHOFIELD,	  C.	  J.,	  MAXWELL,	  P.	  H.,	  PUGH,	  C.	  W.	  &	  RATCLIFFE,	  P.	  J.	  2001.	  Targeting	  of	  HIF-­‐alpha	  to	  the	  von	  Hippel-­‐Lindau	  ubiquitylation	  complex	  by	  O2-­‐regulated	  prolyl	  hydroxylation.	  Science,	  292,	  468-­‐72.	  JAFFE,	   R.,	   JAUNIAUX,	   E.	   &	   HUSTIN,	   J.	   1997.	   Maternal	   circulation	   in	   the	   first-­‐trimester	  human	  placenta-­‐-­‐myth	  or	  reality?	  Am	  J	  Obstet	  Gynecol,	  176,	  695-­‐705.	  JAKUS,	  Z.,	  NEMETH,	  T.,	  VERBEEK,	  J.	  S.	  &	  MOCSAI,	  A.	  2008.	  Critical	  but	  overlapping	  role	  of	  FcgammaRIII	  and	  FcgammaRIV	  in	  activation	  of	  murine	  neutrophils	  by	  immobilized	  immune	  complexes.	  J	  Immunol,	  180,	  618-­‐29.	  JAMES,	  M.	  J.,	  CLELAND,	  L.	  G.,	  ROFE,	  A.	  M.	  &	  LESLIE,	  A.	  L.	  1990.	  Intraarticular	  pressure	  and	  the	  relationship	  between	  synovial	  perfusion	  and	  metabolic	  demand.	   J	  Rheumatol,	  17,	  521-­‐7.	  JANEWAY,	  C.	  A.,	  JR.	  1993.	  How	  the	  immune	  system	  recognizes	  invaders.	  Sci	  Am,	  269,	  72-­‐9.	  
References 
	   242	  
JASIN,	  H.	  E.,	  LIGHTFOOT,	  E.,	  DAVIS,	  L.	  S.,	  ROTHLEIN,	  R.,	  FAANES,	  R.	  B.	  &	  LIPSKY,	  P.	  E.	  1992.	  Amelioration	   of	   antigen-­‐induced	   arthritis	   in	   rabbits	   treated	   with	   monoclonal	  antibodies	  to	  leukocyte	  adhesion	  molecules.	  Arthritis	  Rheum,	  35,	  541-­‐9.	  JIANG,	  B.	  H.,	  SEMENZA,	  G.	  L.,	  BAUER,	  C.	  &	  MARTI,	  H.	  H.	  1996.	  Hypoxia-­‐inducible	   factor	  1	  levels	  vary	  exponentially	  over	  a	  physiologically	  relevant	  range	  of	  O2	  tension.	  Am	  J	  
Physiol,	  271,	  C1172-­‐80.	  JIMENEZ,	  S.,	  TASSIES,	  D.,	  ESPINOSA,	  G.,	  GARCIA-­‐CRIADO,	  A.,	  PLAZA,	   J.,	  MONTEAGUDO,	   J.,	  CERVERA,	  R.	  &	  REVERTER,	   J.	   C.	   2008.	  Double	  heterozygosity	  polymorphisms	   for	  platelet	   glycoproteins	   Ia/IIa	   and	   IIb/IIIa	   increases	   arterial	   thrombosis	   and	  arteriosclerosis	   in	  patients	  with	  the	  antiphospholipid	  syndrome	  or	  with	  systemic	  lupus	  erythematosus.	  Ann	  Rheum	  Dis,	  67,	  835-­‐40.	  JIN,	  O.,	  KAVIKONDALA,	  S.,	  MOK,	  M.	  Y.,	  SUN,	  L.,	  GU,	  J.,	  FU,	  R.,	  CHAN,	  A.,	  YEUNG,	  J.,	  NIE,	  Y.	  &	  LAU,	   C.	   S.	   2010.	   Abnormalities	   in	   circulating	   plasmacytoid	   dendritic	   cells	   in	  patients	  with	  systemic	  lupus	  erythematosus.	  Arthritis	  Res	  Ther,	  12,	  R137.	  JIN,	   O.,	   SUN,	   L.	   Y.,	   ZHOU,	   K.	   X.,	   ZHANG,	   X.	   S.,	   FENG,	   X.	   B.,	  MOK,	  M.	   Y.	   &	   LAU,	   C.	   S.	   2005.	  Lymphocyte	  apoptosis	  and	  macrophage	  function:	  correlation	  with	  disease	  activity	  in	  systemic	  lupus	  erythematosus.	  Clin	  Rheumatol,	  24,	  107-­‐10.	  JOHNSON-­‐LEGER,	  C.	  A.,	  AURRAND-­‐LIONS,	  M.,	  BELTRAMINELLI,	  N.,	  FASEL,	  N.	  &	  IMHOF,	  B.	  A.	   2002.	   Junctional	   adhesion	   molecule-­‐2	   (JAM-­‐2)	   promotes	   lymphocyte	  transendothelial	  migration.	  Blood,	  100,	  2479-­‐86.	  JURY,	   E.	   C.,	   FLORES-­‐BORJA,	   F.,	   KALSI,	   H.	   S.,	   LAZARUS,	  M.,	   ISENBERG,	  D.	   A.,	  MAURI,	   C.	   &	  EHRENSTEIN,	  M.	  R.	  2010.	  Abnormal	  CTLA-­‐4	  function	  in	  T	  cells	  from	  patients	  with	  systemic	  lupus	  erythematosus.	  Eur	  J	  Immunol,	  40,	  569-­‐78.	  KAELIN,	  W.	  G.,	  JR.	  &	  RATCLIFFE,	  P.	  J.	  2008.	  Oxygen	  sensing	  by	  metazoans:	  the	  central	  role	  of	  the	  HIF	  hydroxylase	  pathway.	  Mol	  Cell,	  30,	  393-­‐402.	  KAHLENBERG,	  J.	  M.,	  CARMONA-­‐RIVERA,	  C.,	  SMITH,	  C.	  K.	  &	  KAPLAN,	  M.	  J.	  2013.	  Neutrophil	  extracellular	   trap-­‐associated	   protein	   activation	   of	   the	   NLRP3	   inflammasome	   is	  enhanced	  in	  lupus	  macrophages.	  J	  Immunol,	  190,	  1217-­‐26.	  KAKIMOTO,	  K.,	  NAKAMURA,	  T.,	  ISHII,	  K.,	  TAKASHI,	  T.,	  IIGOU,	  H.,	  YAGITA,	  H.,	  OKUMURA,	  K.	  &	   ONOUE,	   K.	   1992.	   The	   effect	   of	   anti-­‐adhesion	   molecule	   antibody	   on	   the	  development	  of	  collagen-­‐induced	  arthritis.	  Cell	  Immunol,	  142,	  326-­‐37.	  KALLIO,	  P.	  J.,	  PONGRATZ,	  I.,	  GRADIN,	  K.,	  MCGUIRE,	  J.	  &	  POELLINGER,	  L.	  1997.	  Activation	  of	  hypoxia-­‐inducible	   factor	   1alpha:	   posttranscriptional	   regulation	   and	  conformational	   change	  by	   recruitment	  of	   the	  Arnt	   transcription	   factor.	  Proc	  Natl	  
Acad	  Sci	  U	  S	  A,	  94,	  5667-­‐72.	  KAMATA,	   T.	   &	   TAKADA,	   Y.	   1994.	   Direct	   binding	   of	   collagen	   to	   the	   I	   domain	   of	   integrin	  alpha	  2	  beta	  1	   (VLA-­‐2,	  CD49b/CD29)	   in	  a	  divalent	   cation-­‐independent	  manner.	   J	  
Biol	  Chem,	  269,	  26006-­‐10.	  KAMATH,	  S.	  &	  LIP,	  G.	  Y.	  2003.	  Fibrinogen:	  biochemistry,	  epidemiology	  and	  determinants.	  
QJM,	  96,	  711-­‐29.	  KAMBAS,	   K.,	   CHRYSANTHOPOULOU,	   A.,	   VASSILOPOULOS,	   D.,	   APOSTOLIDOU,	   E.,	  SKENDROS,	   P.,	   GIROD,	   A.,	   ARELAKI,	   S.,	   FROUDARAKIS,	   M.,	   NAKOPOULOU,	   L.,	  GIATROMANOLAKI,	  A.,	  SIDIROPOULOS,	  P.,	  KOFFA,	  M.,	  BOUMPAS,	  D.	  T.,	  RITIS,	  K.	  &	  MITROULIS,	  I.	  2014.	  Tissue	  factor	  expression	  in	  neutrophil	  extracellular	  traps	  and	  neutrophil	   derived	   microparticles	   in	   antineutrophil	   cytoplasmic	   antibody	  associated	   vasculitis	   may	   promote	   thromboinflammation	   and	   the	   thrombophilic	  state	  associated	  with	  the	  disease.	  Ann	  Rheum	  Dis,	  73,	  1854-­‐63.	  KAMIGUCHI,	   K.,	   TACHIBANA,	   K.,	   IWATA,	   S.,	   OHASHI,	   Y.	   &	  MORIMOTO,	   C.	   1999.	   Cas-­‐L	   is	  required	   for	   beta	   1	   integrin-­‐mediated	   costimulation	   in	   human	  Tcells.	   J	   Immunol,	  163,	  563-­‐8.	  KANDA,	   N.,	   TSUCHIDA,	   T.	   &	   TAMAKI,	   K.	   1999.	   Estrogen	   enhancement	   of	   anti-­‐double-­‐stranded	   DNA	   antibody	   and	   immunoglobulin	   G	   production	   in	   peripheral	   blood	  mononuclear	   cells	   from	   patients	   with	   systemic	   lupus	   erythematosus.	   Arthritis	  
Rheum,	  42,	  328-­‐37.	  
References 
	   243	  
KANG,	  C.	  P.,	  LEE,	  H.	  S.,	  JU,	  H.,	  CHO,	  H.,	  KANG,	  C.	  &	  BAE,	  S.	  C.	  2006.	  A	  functional	  haplotype	  of	  the	   PADI4	   gene	   associated	   with	   increased	   rheumatoid	   arthritis	   susceptibility	   in	  Koreans.	  Arthritis	  Rheum,	  54,	  90-­‐6.	  KAO,	  L.	  C.,	  CALTABIANO,	  S.,	  WU,	  S.,	  STRAUSS,	  J.	  F.,	  3RD	  &	  KLIMAN,	  H.	  J.	  1988.	  The	  human	  villous	  cytotrophoblast:	  interactions	  with	  extracellular	  matrix	  proteins,	  endocrine	  function,	   and	   cytoplasmic	   differentiation	   in	   the	   absence	   of	   syncytium	   formation.	  
Dev	  Biol,	  130,	  693-­‐702.	  KARASSA,	  F.	  B.,	  TRIKALINOS,	  T.	  A.	  &	  IOANNIDIS,	  J.	  P.	  2002.	  Role	  of	  the	  Fcgamma	  receptor	  IIa	   polymorphism	   in	   susceptibility	   to	   systemic	   lupus	   erythematosus	   and	   lupus	  nephritis:	  a	  meta-­‐analysis.	  Arthritis	  Rheum,	  46,	  1563-­‐71.	  KARASSA,	   F.	   B.,	   TRIKALINOS,	   T.	   A.	   &	   IOANNIDIS,	   J.	   P.	   2003.	   The	   Fc	   gamma	   RIIIA-­‐F158	  allele	   is	   a	   risk	   factor	   for	   the	   development	   of	   lupus	   nephritis:	   a	   meta-­‐analysis.	  
Kidney	  Int,	  63,	  1475-­‐82.	  KEELY,	  S.,	  GLOVER,	  L.	  E.,	  MACMANUS,	  C.	  F.,	  CAMPBELL,	  E.	  L.,	  SCULLY,	  M.	  M.,	  FURUTA,	  G.	  T.	  &	  COLGAN,	  S.	  P.	  2009.	  Selective	   induction	  of	   integrin	  beta1	  by	  hypoxia-­‐inducible	  factor:	  implications	  for	  wound	  healing.	  FASEB	  J,	  23,	  1338-­‐46.	  KESHARI,	  R.	  S.,	  JYOTI,	  A.,	  DUBEY,	  M.,	  KOTHARI,	  N.,	  KOHLI,	  M.,	  BOGRA,	  J.,	  BARTHWAL,	  M.	  K.	  &	  DIKSHIT,	  M.	  2012.	  Cytokines	   induced	  neutrophil	   extracellular	   traps	   formation:	  implication	  for	  the	  inflammatory	  disease	  condition.	  PLoS	  One,	  7,	  e48111.	  KESHARI,	   R.	   S.,	   VERMA,	   A.,	   BARTHWAL,	   M.	   K.	   &	   DIKSHIT,	   M.	   2013.	   Reactive	   oxygen	  species-­‐induced	   activation	   of	   ERK	   and	   p38	   MAPK	   mediates	   PMA-­‐induced	   NETs	  release	  from	  human	  neutrophils.	  J	  Cell	  Biochem,	  114,	  532-­‐40.	  KHANDPUR,	   R.,	   CARMONA-­‐RIVERA,	   C.,	   VIVEKANANDAN-­‐GIRI,	   A.,	   GIZINSKI,	   A.,	  YALAVARTHI,	  S.,	  KNIGHT,	  J.	  S.,	  FRIDAY,	  S.,	  LI,	  S.,	  PATEL,	  R.	  M.,	  SUBRAMANIAN,	  V.,	  THOMPSON,	  P.,	  CHEN,	  P.,	  FOX,	  D.	  A.,	  PENNATHUR,	  S.	  &	  KAPLAN,	  M.	  J.	  2013.	  NETs	  are	  a	  source	  of	  citrullinated	  autoantigens	  and	  stimulate	  inflammatory	  responses	  in	  rheumatoid	  arthritis.	  Sci	  Transl	  Med,	  5,	  178ra40.	  KIEFER,	  F.,	  BRUMELL,	  J.,	  AL-­‐ALAWI,	  N.,	  LATOUR,	  S.,	  CHENG,	  A.,	  VEILLETTE,	  A.,	  GRINSTEIN,	  S.	  &	  PAWSON,	  T.	  1998.	  The	  Syk	  protein	   tyrosine	  kinase	   is	  essential	   for	  Fcgamma	  receptor	  signaling	  in	  macrophages	  and	  neutrophils.	  Mol	  Cell	  Biol,	  18,	  4209-­‐20.	  KILSHAW,	  P.	  J.	  1999.	  Alpha	  E	  beta	  7.	  Mol	  Pathol,	  52,	  203-­‐7.	  KIM-­‐HOWARD,	  X.,	  MAITI,	  A.	  K.,	  ANAYA,	   J.	  M.,	  BRUNER,	  G.	  R.,	   BROWN,	  E.,	  MERRILL,	   J.	   T.,	  EDBERG,	   J.	  C.,	  PETRI,	  M.	  A.,	  REVEILLE,	   J.	  D.,	  RAMSEY-­‐GOLDMAN,	  R.,	  ALARCON,	  G.	  S.,	   VYSE,	   T.	   J.,	   GILKESON,	   G.,	   KIMBERLY,	   R.	   P.,	   JAMES,	   J.	   A.,	   GUTHRIDGE,	   J.	   M.,	  HARLEY,	   J.	  B.	  &	  NATH,	  S.	  K.	  2010.	   ITGAM	  coding	  variant	   (rs1143679)	   influences	  the	   risk	   of	   renal	   disease,	   discoid	   rash	   and	   immunological	   manifestations	   in	  patients	  with	  systemic	   lupus	  erythematosus	  with	  European	  ancestry.	  Ann	  Rheum	  
Dis,	  69,	  1329-­‐32.	  KIM,	  E.	  J.,	  ELICKER,	  B.	  M.,	  MALDONADO,	  F.,	  WEBB,	  W.	  R.,	  RYU,	  J.	  H.,	  VAN	  UDEN,	  J.	  H.,	  LEE,	  J.	  S.,	   KING,	   T.	   E.,	   JR.	   &	   COLLARD,	   H.	   R.	   2010.	   Usual	   interstitial	   pneumonia	   in	  rheumatoid	  arthritis-­‐associated	  interstitial	  lung	  disease.	  Eur	  Respir	  J,	  35,	  1322-­‐8.	  KIM,	  M.,	  CARMAN,	  C.	  V.	  &	  SPRINGER,	  T.	  A.	  2003.	  Bidirectional	  transmembrane	  signaling	  by	  cytoplasmic	  domain	  separation	  in	  integrins.	  Science,	  301,	  1720-­‐5.	  KITZING,	  T.	  M.,	  WANG,	  Y.,	  PERTZ,	  O.,	  COPELAND,	  J.	  W.	  &	  GROSSE,	  R.	  2010.	  Formin-­‐like	  2	  drives	  amoeboid	  invasive	  cell	  motility	  downstream	  of	  RhoC.	  Oncogene,	  29,	  2441-­‐8.	  KLEIN-­‐SCHNEEGANS,	   A.	   S.,	   KUNTZ,	   L.,	   FONTENEAU,	   P.	   &	   LOOR,	   F.	   1989.	   Serum	  concentrations	   of	   IgM,	   IgG1,	   IgG2b,	   IgG3	   and	   IgA	   in	   C57BL/6	   mice	   and	   their	  congenics	  at	  the	  lpr	  (lymphoproliferation)	  locus.	  J	  Autoimmun,	  2,	  869-­‐75.	  KLIMOVA,	   T.	   &	   CHANDEL,	   N.	   S.	   2008.	   Mitochondrial	   complex	   III	   regulates	   hypoxic	  activation	  of	  HIF.	  Cell	  Death	  Differ,	  15,	  660-­‐6.	  KLINGHOFFER,	  R.	   A.,	   SACHSENMAIER,	   C.,	   COOPER,	   J.	   A.	  &	   SORIANO,	   P.	   1999.	   Src	   family	  kinases	  are	   required	   for	   integrin	  but	  not	  PDGFR	  signal	   transduction.	  EMBO	  J,	  18,	  2459-­‐71.	  
References 
	   244	  
KLINMAN,	   D.	   M.,	   SHIRAI,	   A.,	   ISHIGATSUBO,	   Y.,	   CONOVER,	   J.	   &	   STEINBERG,	   A.	   D.	   1991.	  Quantitation	  of	   IgM-­‐	  and	   IgG-­‐secreting	  B	  cells	   in	   the	  peripheral	  blood	  of	  patients	  with	  systemic	  lupus	  erythematosus.	  Arthritis	  Rheum,	  34,	  1404-­‐10.	  KNIGHT,	   J.	   S.,	   ZHAO,	   W.,	   LUO,	   W.,	   SUBRAMANIAN,	   V.,	   O'DELL,	   A.	   A.,	   YALAVARTHI,	   S.,	  HODGIN,	   J.	   B.,	   EITZMAN,	   D.	   T.,	   THOMPSON,	   P.	   R.	   &	   KAPLAN,	   M.	   J.	   2013.	  Peptidylarginine	   deiminase	   inhibition	   is	   immunomodulatory	   and	  vasculoprotective	  in	  murine	  lupus.	  J	  Clin	  Invest,	  123,	  2981-­‐93.	  KONG,	   T.,	   ELTZSCHIG,	   H.	   K.,	   KARHAUSEN,	   J.,	   COLGAN,	   S.	   P.	   &	   SHELLEY,	   C.	   S.	   2004.	  Leukocyte	  adhesion	  during	  hypoxia	   is	  mediated	  by	  HIF-­‐1-­‐dependent	   induction	  of	  beta2	  integrin	  gene	  expression.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  101,	  10440-­‐5.	  KORMAN,	  B.	  D.,	  HUANG,	  C.	  C.,	   SKAMRA,	  C.,	  WU,	  P.,	  KOESSLER,	  R.,	  YAO,	  D.,	  HUANG,	  Q.	  Q.,	  PEARCE,	  W.,	   SUTTON-­‐TYRRELL,	   K.,	   KONDOS,	   G.,	   EDMUNDOWICZ,	   D.,	   POPE,	   R.	   &	  RAMSEY-­‐GOLDMAN,	   R.	   2014.	   Inflammatory	   expression	   profiles	   in	   monocyte-­‐to-­‐macrophage	   differentiation	   in	   patients	   with	   systemic	   lupus	   erythematosus	   and	  relationship	  with	  atherosclerosis.	  Arthritis	  Res	  Ther,	  16,	  R147.	  KOWALCZYK,	  A.	  P.,	  TULLOH,	  R.	  H.	  &	  MCKEOWN-­‐LONGO,	  P.	   J.	  1990.	  Polarized	  fibronectin	  secretion	  and	  localized	  matrix	  assembly	  sites	  correlate	  with	  subendothelial	  matrix	  formation.	  Blood,	  75,	  2335-­‐42.	  KRISHNAN,	   S.,	   JUANG,	  Y.	  T.,	   CHOWDHURY,	  B.,	  MAGILAVY,	  A.,	   FISHER,	  C.	  U.,	  NGUYEN,	  H.,	  NAMBIAR,	   M.	   P.,	   KYTTARIS,	   V.,	   WEINSTEIN,	   A.,	   BAHJAT,	   R.,	   PINE,	   P.,	   RUS,	   V.	   &	  TSOKOS,	  G.	   C.	   2008.	  Differential	   expression	   and	  molecular	   associations	   of	   Syk	   in	  systemic	  lupus	  erythematosus	  T	  cells.	  J	  Immunol,	  181,	  8145-­‐52.	  KRUISBEEK,	   A.	   M.	   1999.	   Introduction:	   regulation	   of	   T	   cell	   development	   by	   the	   thymic	  microenvironment.	  Semin	  Immunol,	  11,	  1-­‐2.	  KUNICKI,	   T.	   J.,	   PIDARD,	   D.,	   ROSA,	   J.	   P.	   &	   NURDEN,	   A.	   T.	   1981.	   The	   formation	   of	   Ca++-­‐dependent	  complexes	  of	  platelet	  membrane	  glycoproteins	  IIb	  and	  IIIa	   in	  solution	  as	  determined	  by	  crossed	  immunoelectrophoresis.	  Blood,	  58,	  268-­‐78.	  KUZNIK,	   A.,	   BENCINA,	   M.,	   SVAJGER,	   U.,	   JERAS,	   M.,	   ROZMAN,	   B.	   &	   JERALA,	   R.	   2011.	  Mechanism	   of	   endosomal	   TLR	   inhibition	   by	   antimalarial	   drugs	   and	  imidazoquinolines.	  J	  Immunol,	  186,	  4794-­‐804.	  KWAK-­‐KIM,	   J.,	  AGCAOILI,	  M.	  S.,	  ALETA,	  L.,	  LIAO,	  A.,	  OTA,	  K.,	  DAMBAEVA,	  S.,	  BEAMAN,	  K.,	  KIM,	   J.	   W.	   &	   GILMAN-­‐SACHS,	   A.	   2013.	   Management	   of	   women	   with	   recurrent	  pregnancy	  losses	  and	  antiphospholipid	  antibody	  syndrome.	  Am	  J	  Reprod	  Immunol,	  69,	  596-­‐607.	  KWOK,	   S.	   K.,	   LEE,	   J.	   Y.,	   PARK,	   S.	  H.,	   CHO,	  M.	   L.,	  MIN,	   S.	   Y.,	   KIM,	  H.	   Y.	  &	   CHO,	   Y.	   G.	   2008.	  Dysfunctional	   interferon-­‐alpha	   production	   by	   peripheral	   plasmacytoid	   dendritic	  cells	   upon	   Toll-­‐like	   receptor-­‐9	   stimulation	   in	   patients	   with	   systemic	   lupus	  erythematosus.	  Arthritis	  Res	  Ther,	  10,	  R29.	  KYOGOKU,	  C.,	  DIJSTELBLOEM,	  H.	  M.,	  TSUCHIYA,	  N.,	  HATTA,	  Y.,	  KATO,	  H.,	  YAMAGUCHI,	  A.,	  FUKAZAWA,	   T.,	   JANSEN,	   M.	   D.,	   HASHIMOTO,	   H.,	   VAN	   DE	   WINKEL,	   J.	   G.,	  KALLENBERG,	   C.	   G.	   &	   TOKUNAGA,	   K.	   2002.	   Fcgamma	   receptor	   gene	  polymorphisms	   in	   Japanese	   patients	   with	   systemic	   lupus	   erythematosus:	  contribution	  of	  FCGR2B	  to	  genetic	  susceptibility.	  Arthritis	  Rheum,	  46,	  1242-­‐54.	  KYTTARIS,	   V.	   C.	   &	   TSOKOS,	   G.	   C.	   2011.	   Targeting	   lymphocyte	   signaling	   pathways	   as	   a	  therapeutic	  approach	   to	   systemic	   lupus	  erythematosus.	  Curr	  Opin	  Rheumatol,	  23,	  449-­‐53.	  LAFFON,	   A.,	   GARCIA-­‐VICUNA,	   R.,	   HUMBRIA,	   A.,	   POSTIGO,	   A.	   A.,	   CORBI,	   A.	   L.,	   DE	  LANDAZURI,	   M.	   O.	   &	   SANCHEZ-­‐MADRID,	   F.	   1991.	   Upregulated	   expression	   and	  function	  of	  VLA-­‐4	  fibronectin	  receptors	  on	  human	  activated	  T	  cells	  in	  rheumatoid	  arthritis.	  J	  Clin	  Invest,	  88,	  546-­‐52.	  LAHITA,	  R.	  G.,	  KUNKEL,	  H.	  G.	  &	  BRADLOW,	  H.	  L.	  1983.	  Increased	  oxidation	  of	  testosterone	  in	  systemic	  lupus	  erythematosus.	  Arthritis	  Rheum,	  26,	  1517-­‐21.	  LAKI,	  J.,	  LUNDSTROM,	  E.,	  SNIR,	  O.,	  RONNELID,	  J.,	  GANJI,	  I.,	  CATRINA,	  A.	  I.,	  BENGTSSON,	  C.,	  SAEVARSDOTTIR,	  S.,	  WICK,	  M.	  C.,	  ALFREDSSON,	  L.,	  KLARESKOG,	  L.	  &	  PADYUKOV,	  
References 
	   245	  
L.	   2012.	   Very	   high	   levels	   of	   anti-­‐citrullinated	   protein	   antibodies	   are	   associated	  with	   HLA-­‐DRB1*15	   non-­‐shared	   epitope	   allele	   in	   patients	   with	   rheumatoid	  arthritis.	  Arthritis	  Rheum,	  64,	  2078-­‐84.	  LANDE,	   R.,	   GANGULY,	   D.,	   FACCHINETTI,	   V.,	   FRASCA,	   L.,	   CONRAD,	   C.,	   GREGORIO,	   J.,	  MELLER,	  S.,	  CHAMILOS,	  G.,	  SEBASIGARI,	  R.,	  RICCIERI,	  V.,	  BASSETT,	  R.,	  AMURO,	  H.,	  FUKUHARA,	   S.,	   ITO,	   T.,	   LIU,	   Y.	   J.	   &	   GILLIET,	   M.	   2011.	   Neutrophils	   activate	  plasmacytoid	  dendritic	  cells	  by	  releasing	  self-­‐DNA-­‐peptide	  complexes	  in	  systemic	  lupus	  erythematosus.	  Sci	  Transl	  Med,	  3,	  73ra19.	  LANDO,	  D.,	  PEET,	  D.	  J.,	  WHELAN,	  D.	  A.,	  GORMAN,	  J.	  J.	  &	  WHITELAW,	  M.	  L.	  2002.	  Asparagine	  hydroxylation	   of	   the	   HIF	   transactivation	   domain	   a	   hypoxic	   switch.	   Science,	   295,	  858-­‐61.	  LAVIGNE,	  L.	  M.,	  O'BRIEN,	  X.	  M.,	  KIM,	  M.,	  JANOWSKI,	  J.	  W.,	  ALBINA,	  J.	  E.	  &	  REICHNER,	  J.	  S.	  2007.	   Integrin	   engagement	   mediates	   the	   human	   polymorphonuclear	   leukocyte	  response	  to	  a	  fungal	  pathogen-­‐associated	  molecular	  pattern.	  J	  Immunol,	  178,	  7276-­‐82.	  LEAVESLEY,	  D.	  I.,	  OLIVER,	  J.	  M.,	  SWART,	  B.	  W.,	  BERNDT,	  M.	  C.,	  HAYLOCK,	  D.	  N.	  &	  SIMMONS,	  P.	   J.	   1994.	   Signals	   from	   platelet/endothelial	   cell	   adhesion	  molecule	   enhance	   the	  adhesive	  activity	  of	  the	  very	  late	  antigen-­‐4	  integrin	  of	  human	  CD34+	  hemopoietic	  progenitor	  cells.	  J	  Immunol,	  153,	  4673-­‐83.	  LEE,	   J.	   O.,	   RIEU,	   P.,	   ARNAOUT,	  M.	  A.	  &	   LIDDINGTON,	  R.	   1995.	   Crystal	   structure	   of	   the	  A	  domain	  from	  the	  alpha	  subunit	  of	  integrin	  CR3	  (CD11b/CD18).	  Cell,	  80,	  631-­‐8.	  LEE,	  K.	  M.,	   CHUANG,	  E.,	   GRIFFIN,	  M.,	  KHATTRI,	  R.,	  HONG,	  D.	  K.,	   ZHANG,	  W.,	   STRAUS,	  D.,	  SAMELSON,	  L.	  E.,	  THOMPSON,	  C.	  B.	  &	  BLUESTONE,	  J.	  A.	  1998.	  Molecular	  basis	  of	  T	  cell	  inactivation	  by	  CTLA-­‐4.	  Science,	  282,	  2263-­‐6.	  LEE,	  S.	  H.,	  LEE,	  Y.	  J.	  &	  HAN,	  H.	  J.	  2011.	  Role	  of	  hypoxia-­‐induced	  fibronectin-­‐integrin	  beta1	  expression	   in	   embryonic	   stem	   cell	   proliferation	   and	   migration:	   Involvement	   of	  PI3K/Akt	  and	  FAK.	  J	  Cell	  Physiol,	  226,	  484-­‐93.	  LEE,	  Y.	  H.,	  JI,	  J.	  D.	  &	  SONG,	  G.	  G.	  2009.	  Fcgamma	  receptor	  IIB	  and	  IIIB	  polymorphisms	  and	  susceptibility	   to	   systemic	   lupus	   erythematosus	   and	   lupus	   nephritis:	   a	   meta-­‐analysis.	  Lupus,	  18,	  727-­‐34.	  LEE,	   Y.	   W.,	   KUHN,	   H.,	   HENNIG,	   B.,	   NEISH,	   A.	   S.	   &	   TOBOREK,	   M.	   2001.	   IL-­‐4-­‐induced	  oxidative	  stress	  upregulates	  VCAM-­‐1	  gene	  expression	  in	  human	  endothelial	  cells.	  J	  
Mol	  Cell	  Cardiol,	  33,	  83-­‐94.	  LEFFLER,	   J.,	   MARTIN,	   M.,	   GULLSTRAND,	   B.,	   TYDEN,	   H.,	   LOOD,	   C.,	   TRUEDSSON,	   L.,	  BENGTSSON,	  A.	  A.	  &	  BLOM,	  A.	  M.	  2012.	  Neutrophil	  extracellular	  traps	  that	  are	  not	  degraded	  in	  systemic	  lupus	  erythematosus	  activate	  complement	  exacerbating	  the	  disease.	  J	  Immunol,	  188,	  3522-­‐31.	  LEFORT,	   C.	   T.,	   ROSSAINT,	   J.,	   MOSER,	   M.,	   PETRICH,	   B.	   G.,	   ZARBOCK,	   A.,	   MONKLEY,	   S.	   J.,	  CRITCHLEY,	  D.	  R.,	  GINSBERG,	  M.	  H.,	  FASSLER,	  R.	  &	  LEY,	  K.	  2012.	  Distinct	  roles	  for	  talin-­‐1	  and	  kindlin-­‐3	  in	  LFA-­‐1	  extension	  and	  affinity	  regulation.	  Blood,	  119,	  4275-­‐82.	  LEVINE,	  J.	  S.,	  BRANCH,	  D.	  W.	  &	  RAUCH,	  J.	  2002.	  The	  antiphospholipid	  syndrome.	  N	  Engl	  J	  
Med,	  346,	  752-­‐63.	  LI,	   B.,	   YUE,	   Y.,	   DONG,	   C.,	   SHI,	   Y.	   &	   XIONG,	   S.	   2014.	   Blockade	   of	   macrophage	   autophagy	  ameliorates	   activated	   lymphocytes-­‐derived	   DNA	   induced	   murine	   lupus	   possibly	  via	   inhibition	   of	   proinflammatory	   cytokine	   production.	   Clin	   Exp	   Rheumatol,	   32,	  705-­‐14.	  LI,	   P.,	   LI,	   M.,	   LINDBERG,	   M.	   R.,	   KENNETT,	   M.	   J.,	   XIONG,	   N.	   &	  WANG,	   Y.	   2010a.	   PAD4	   is	  essential	   for	   antibacterial	   innate	   immunity	  mediated	   by	   neutrophil	   extracellular	  traps.	  J	  Exp	  Med,	  207,	  1853-­‐62.	  LI,	  W.	  X.,	  PAN,	  H.	  F.,	  HU,	   J.	  L.,	  WANG,	  C.	  Z.,	  ZHANG,	  N.,	  LI,	   J.,	  LI,	  X.	  P.,	  XU,	   J.	  H.	  &	  YE,	  D.	  Q.	  2010b.	  Assay	  of	  T-­‐	  and	  NK-­‐cell	  subsets	  and	  the	  expression	  of	  NKG2A	  and	  NKG2D	  in	  patients	  with	  new-­‐onset	   systemic	   lupus	   erythematosus.	  Clin	  Rheumatol,	   29,	   315-­‐23.	  
References 
	   246	  
LINDSLEY,	   H.	   B.,	   SMITH,	   D.	   D.,	   COHICK,	   C.	   B.,	   KOCH,	   A.	   E.	   &	   DAVIS,	   L.	   S.	   1993.	  Proinflammatory	   cytokines	   enhance	  human	   synoviocyte	   expression	   of	   functional	  intercellular	  adhesion	  molecule-­‐1	  (ICAM-­‐1).	  Clin	  Immunol	  Immunopathol,	  68,	  311-­‐20.	  LINKER-­‐ISRAELI,	   M.,	   DEANS,	   R.	   J.,	   WALLACE,	   D.	   J.,	   PREHN,	   J.,	   OZERI-­‐CHEN,	   T.	   &	  KLINENBERG,	   J.	   R.	   1991.	   Elevated	   levels	   of	   endogenous	   IL-­‐6	   in	   systemic	   lupus	  erythematosus.	  A	  putative	  role	  in	  pathogenesis.	  J	  Immunol,	  147,	  117-­‐23.	  LIOSSIS,	  S.	  N.,	  KOVACS,	  B.,	  DENNIS,	  G.,	  KAMMER,	  G.	  M.	  &	  TSOKOS,	  G.	  C.	  1996.	  B	  cells	  from	  patients	   with	   systemic	   lupus	   erythematosus	   display	   abnormal	   antigen	   receptor-­‐mediated	  early	  signal	  transduction	  events.	  J	  Clin	  Invest,	  98,	  2549-­‐57.	  LISNEVSKAIA,	   L.,	   MURPHY,	   G.	   &	   ISENBERG,	   D.	   2014.	   Systemic	   lupus	   erythematosus.	  
Lancet,	  384,	  1878-­‐88.	  LIU,	  Y.,	  NUSRAT,	  A.,	  SCHNELL,	  F.	  J.,	  REAVES,	  T.	  A.,	  WALSH,	  S.,	  POCHET,	  M.	  &	  PARKOS,	  C.	  A.	  2000.	   Human	   junction	   adhesion	   molecule	   regulates	   tight	   junction	   resealing	   in	  epithelia.	  J	  Cell	  Sci,	  113	  (	  Pt	  13),	  2363-­‐74.	  LLORENTE,	   L.,	   RICHAUD-­‐PATIN,	   Y.,	   FIOR,	   R.,	   ALCOCER-­‐VARELA,	   J.,	   WIJDENES,	   J.,	  FOURRIER,	   B.	   M.,	   GALANAUD,	   P.	   &	   EMILIE,	   D.	   1994.	   In	   vivo	   production	   of	  interleukin-­‐10	   by	   non-­‐T	   cells	   in	   rheumatoid	   arthritis,	   Sjogren's	   syndrome,	   and	  systemic	   lupus	   erythematosus.	   A	   potential	   mechanism	   of	   B	   lymphocyte	  hyperactivity	  and	  autoimmunity.	  Arthritis	  Rheum,	  37,	  1647-­‐55.	  LLORENTE,	   L.,	   RICHAUD-­‐PATIN,	   Y.,	  WIJDENES,	   J.,	   ALCOCER-­‐VARELA,	   J.,	  MAILLOT,	  M.	   C.,	  DURAND-­‐GASSELIN,	   I.,	   FOURRIER,	   B.	   M.,	   GALANAUD,	   P.	   &	   EMILIE,	   D.	   1993.	  Spontaneous	   production	   of	   interleukin-­‐10	   by	   B	   lymphocytes	   and	   monocytes	   in	  systemic	  lupus	  erythematosus.	  Eur	  Cytokine	  Netw,	  4,	  421-­‐7.	  LLORENTE,	  L.,	  ZOU,	  W.,	  LEVY,	  Y.,	  RICHAUD-­‐PATIN,	  Y.,	  WIJDENES,	  J.,	  ALCOCER-­‐VARELA,	  J.,	  MOREL-­‐FOURRIER,	   B.,	   BROUET,	   J.	   C.,	   ALARCON-­‐SEGOVIA,	   D.,	   GALANAUD,	   P.	   &	  EMILIE,	   D.	   1995.	   Role	   of	   interleukin	   10	   in	   the	   B	   lymphocyte	   hyperactivity	   and	  autoantibody	  production	  of	  human	  systemic	  lupus	  erythematosus.	  J	  Exp	  Med,	  181,	  839-­‐44.	  LOPEZ-­‐PEDRERA,	   C.,	   CUADRADO,	   M.	   J.,	   HERANDEZ,	   V.,	   BUENDIA,	   P.,	   AGUIRRE,	   M.	   A.,	  BARBARROJA,	  N.,	  TORRES,	  L.	  A.,	  VILLALBA,	  J.	  M.,	  VELASCO,	  F.	  &	  KHAMASHTA,	  M.	  2008.	   Proteomic	   analysis	   in	   monocytes	   of	   antiphospholipid	   syndrome	   patients:	  deregulation	   of	   proteins	   related	   to	   the	   development	   of	   thrombosis.	   Arthritis	  
Rheum,	  58,	  2835-­‐44.	  LORD,	  P.	  C.,	  WILMOTH,	  L.	  M.,	  MIZEL,	  S.	  B.	  &	  MCCALL,	  C.	  E.	  1991.	  Expression	  of	  interleukin-­‐1	   alpha	   and	   beta	   genes	   by	   human	   blood	   polymorphonuclear	   leukocytes.	   J	   Clin	  
Invest,	  87,	  1312-­‐21.	  LOU,	  O.,	  ALCAIDE,	  P.,	  LUSCINSKAS,	  F.	  W.	  &	  MULLER,	  W.	  A.	  2007.	  CD99	  is	  a	  key	  mediator	  of	  the	  transendothelial	  migration	  of	  neutrophils.	  J	  Immunol,	  178,	  1136-­‐43.	  LOVGREN,	   T.,	   ELORANTA,	   M.	   L.,	   KASTNER,	   B.,	   WAHREN-­‐HERLENIUS,	   M.,	   ALM,	   G.	   V.	   &	  RONNBLOM,	   L.	   2006.	   Induction	   of	   interferon-­‐alpha	   by	   immune	   complexes	   or	  liposomes	   containing	   systemic	   lupus	   erythematosus	   autoantigen-­‐	   and	   Sjogren's	  syndrome	  autoantigen-­‐associated	  RNA.	  Arthritis	  Rheum,	  54,	  1917-­‐27.	  LUDWIG,	  R.	  J.,	  HARDT,	  K.,	  HATTING,	  M.,	  BISTRIAN,	  R.,	  DIEHL,	  S.,	  RADEKE,	  H.	  H.,	  PODDA,	  M.,	  SCHON,	  M.	  P.,	  KAUFMANN,	  R.,	  HENSCHLER,	  R.,	  PFEILSCHIFTER,	  J.	  M.,	  SANTOSO,	  S.	  &	   BOEHNCKE,	   W.	   H.	   2009.	   Junctional	   adhesion	   molecule	   (JAM)-­‐B	   supports	  lymphocyte	   rolling	   and	   adhesion	   through	   interaction	  with	   alpha4beta1	   integrin.	  
Immunology,	  128,	  196-­‐205.	  LUND-­‐OLESEN,	  K.	  1970.	  Oxygen	  tension	  in	  synovial	  fluids.	  Arthritis	  Rheum,	  13,	  769-­‐76.	  LUSCINSKAS,	   F.	   W.,	   KANSAS,	   G.	   S.,	   DING,	   H.,	   PIZCUETA,	   P.,	   SCHLEIFFENBAUM,	   B.	   E.,	  TEDDER,	  T.	  F.	  &	  GIMBRONE,	  M.	  A.,	  JR.	  1994.	  Monocyte	  rolling,	  arrest	  and	  spreading	  on	   IL-­‐4-­‐activated	   vascular	   endothelium	   under	   flow	   is	   mediated	   via	   sequential	  action	  of	  L-­‐selectin,	  beta	  1-­‐integrins,	  and	  beta	  2-­‐integrins.	  J	  Cell	  Biol,	  125,	  1417-­‐27.	  
References 
	   247	  
MA,	  C.	  Y.,	  JIAO,	  Y.	  L.,	  ZHANG,	  J.,	  YANG,	  Q.	  R.,	  ZHANG,	  Z.	  F.,	  SHEN,	  Y.	  J.,	  CHEN,	  Z.	  J.	  &	  ZHAO,	  Y.	  R.	   2012.	   Elevated	  plasma	   level	   of	  HMGB1	   is	   associated	  with	  disease	   activity	   and	  combined	   alterations	   with	   IFN-­‐alpha	   and	   TNF-­‐alpha	   in	   systemic	   lupus	  erythematosus.	  Rheumatol	  Int,	  32,	  395-­‐402.	  MA,	   L.,	   LIU,	   B.,	   JIANG,	   Z.	   &	   JIANG,	   Y.	   2014.	   Reduced	   numbers	   of	   regulatory	   B	   cells	   are	  negatively	  correlated	  with	  disease	  activity	  in	  patients	  with	  new-­‐onset	  rheumatoid	  arthritis.	  Clin	  Rheumatol,	  33,	  187-­‐95.	  MACKWORTH-­‐YOUNG,	   C.,	   CHAN,	   J.,	   HARRIS,	   N.,	   WALPORT,	   M.,	   BERNSTEIN,	   R.,	  BATCHELOR,	  R.,	  HUGHES,	  G.	  &	  GHARAVI,	  A.	  1987.	  High	  incidence	  of	  anticardiolipin	  antibodies	  in	  relatives	  of	  patients	  with	  systemic	  lupus	  erythematosus.	  J	  Rheumatol,	  14,	  723-­‐6.	  MACPHERSON,	  M.,	  LEK,	  H.	  S.,	  PRESCOTT,	  A.	  &	  FAGERHOLM,	  S.	  C.	  2011.	  A	  systemic	   lupus	  erythematosus-­‐associated	   R77H	   substitution	   in	   the	   CD11b	   chain	   of	   the	   Mac-­‐1	  integrin	   compromises	   leukocyte	   adhesion	   and	   phagocytosis.	   J	   Biol	   Chem,	   286,	  17303-­‐10.	  MAIGUEL,	  D.,	  FARIDI,	  M.	  H.,	  WEI,	  C.,	  KUWANO,	  Y.,	  BALLA,	  K.	  M.,	  HERNANDEZ,	  D.,	  BARTH,	  C.	   J.,	  LUGO,	  G.,	  DONNELLY,	  M.,	  NAYER,	  A.,	  MOITA,	  L.	  F.,	  SCHURER,	  S.,	  TRAVER,	  D.,	  RUIZ,	   P.,	   VAZQUEZ-­‐PADRON,	   R.	   I.,	   LEY,	   K.,	   REISER,	   J.	   &	   GUPTA,	   V.	   2011.	   Small	  molecule-­‐mediated	  activation	  of	   the	   integrin	  CD11b/CD18	   reduces	   inflammatory	  disease.	  Sci	  Signal,	  4,	  ra57.	  MAJMUNDAR,	  A.	   J.,	  WONG,	  W.	   J.	  &	  SIMON,	  M.	  C.	  2010.	  Hypoxia-­‐inducible	   factors	  and	   the	  response	  to	  hypoxic	  stress.	  Mol	  Cell,	  40,	  294-­‐309.	  MAJOR,	   E.	   O.	   2010.	   Progressive	   multifocal	   leukoencephalopathy	   in	   patients	   on	  immunomodulatory	  therapies.	  Annu	  Rev	  Med,	  61,	  35-­‐47.	  MAKINO,	   Y.,	   CAO,	   R.,	   SVENSSON,	   K.,	   BERTILSSON,	   G.,	   ASMAN,	   M.,	   TANAKA,	   H.,	   CAO,	   Y.,	  BERKENSTAM,	   A.	   &	   POELLINGER,	   L.	   2001.	   Inhibitory	   PAS	   domain	   protein	   is	   a	  negative	  regulator	  of	  hypoxia-­‐inducible	  gene	  expression.	  Nature,	  414,	  550-­‐4.	  MAKRYGIANNAKIS,	  D.,	  HERMANSSON,	  M.,	  ULFGREN,	  A.	  K.,	  NICHOLAS,	  A.	  P.,	  ZENDMAN,	  A.	  J.,	   EKLUND,	   A.,	   GRUNEWALD,	   J.,	   SKOLD,	   C.	   M.,	   KLARESKOG,	   L.	   &	   CATRINA,	   A.	   I.	  2008.	   Smoking	   increases	   peptidylarginine	   deiminase	   2	   enzyme	   expression	   in	  human	   lungs	   and	   increases	   citrullination	   in	   BAL	   cells.	   Annals	   of	   the	   rheumatic	  
diseases,	  67,	  1488-­‐92.	  MALAWISTA,	   S.	   E.	   &	   DE	   BOISFLEURY	   CHEVANCE,	   A.	   1982.	   The	   cytokineplast:	   purified,	  stable,	   and	   functional	   motile	   machinery	   from	   human	   blood	   polymorphonuclear	  leukocytes.	  J	  Cell	  Biol,	  95,	  960-­‐73.	  MALAWISTA,	   S.	   E.,	   SMITH,	   E.	   O.	   &	   SEIBYL,	   J.	   P.	   2006.	   Cryopreservable	   neutrophil	  surrogates:	   granule-­‐poor,	   motile	   cytoplasts	   from	   polymorphonuclear	   leukocytes	  home	  to	  inflammatory	  lesions	  in	  vivo.	  Cell	  Motil	  Cytoskeleton,	  63,	  254-­‐7.	  MALYAK,	   M.,	   SMITH,	   M.	   F.,	   JR.,	   ABEL,	   A.	   A.	   &	   AREND,	   W.	   P.	   1994.	   Peripheral	   blood	  neutrophil	  production	  of	  interleukin-­‐1	  receptor	  antagonist	  and	  interleukin-­‐1	  beta.	  
J	  Clin	  Immunol,	  14,	  20-­‐30.	  MAMDOUH,	  Z.,	  CHEN,	  X.,	  PIERINI,	  L.	  M.,	  MAXFIELD,	  F.	  R.	  &	  MULLER,	  W.	  A.	  2003.	  Targeted	  recycling	   of	   PECAM	   from	   endothelial	   surface-­‐connected	   compartments	   during	  diapedesis.	  Nature,	  421,	  748-­‐53.	  MANDEVILLE,	  J.	  T.	  &	  MAXFIELD,	  F.	  R.	  1997.	  Effects	  of	  buffering	  intracellular	  free	  calcium	  on	   neutrophil	   migration	   through	   three-­‐dimensional	   matrices.	   J	   Cell	   Physiol,	   171,	  168-­‐78.	  MARTIN-­‐PADURA,	   I.,	   LOSTAGLIO,	   S.,	   SCHNEEMANN,	   M.,	   WILLIAMS,	   L.,	   ROMANO,	   M.,	  FRUSCELLA,	  P.,	  PANZERI,	  C.,	  STOPPACCIARO,	  A.,	  RUCO,	  L.,	  VILLA,	  A.,	  SIMMONS,	  D.	  &	   DEJANA,	   E.	   1998.	   Junctional	   adhesion	   molecule,	   a	   novel	   member	   of	   the	  immunoglobulin	   superfamily	   that	   distributes	   at	   intercellular	   junctions	   and	  modulates	  monocyte	  transmigration.	  J	  Cell	  Biol,	  142,	  117-­‐27.	  MARTINEZ,	  A.,	  VALDIVIA,	  A.,	  PASCUAL-­‐SALCEDO,	  D.,	  LAMAS,	  J.	  R.,	  FERNANDEZ-­‐ARQUERO,	  M.,	  BALSA,	  A.,	   FERNANDEZ-­‐GUTIERREZ,	  B.,	  DE	  LA	  CONCHA,	  E.	  G.	  &	  URCELAY,	  E.	  
References 
	   248	  
2005.	   PADI4	  polymorphisms	   are	   not	   associated	  with	   rheumatoid	   arthritis	   in	   the	  Spanish	  population.	  Rheumatology	  (Oxford),	  44,	  1263-­‐6.	  MARUCHA,	  P.	  T.,	  ZEFF,	  R.	  A.	  &	  KREUTZER,	  D.	  L.	  1990.	  Cytokine	  regulation	  of	  IL-­‐1	  beta	  gene	  expression	  in	  the	  human	  polymorphonuclear	  leukocyte.	  J	  Immunol,	  145,	  2932-­‐7.	  MARUI,	   N.,	   OFFERMANN,	   M.	   K.,	   SWERLICK,	   R.,	   KUNSCH,	   C.,	   ROSEN,	   C.	   A.,	   AHMAD,	   M.,	  ALEXANDER,	   R.	  W.	   &	  MEDFORD,	   R.	   M.	   1993.	   Vascular	   cell	   adhesion	  molecule-­‐1	  (VCAM-­‐1)	  gene	  transcription	  and	  expression	  are	  regulated	  through	  an	  antioxidant-­‐sensitive	  mechanism	  in	  human	  vascular	  endothelial	  cells.	  J	  Clin	  Invest,	  92,	  1866-­‐74.	  MASSON,	   N.,	   WILLAM,	   C.,	   MAXWELL,	   P.	   H.,	   PUGH,	   C.	   W.	   &	   RATCLIFFE,	   P.	   J.	   2001.	  Independent	   function	   of	   two	   destruction	   domains	   in	   hypoxia-­‐inducible	   factor-­‐alpha	  chains	  activated	  by	  prolyl	  hydroxylation.	  EMBO	  J,	  20,	  5197-­‐206.	  MATSUDA,	  M.,	  PARK,	  J.	  G.,	  WANG,	  D.	  C.,	  HUNTER,	  S.,	  CHIEN,	  P.	  &	  SCHREIBER,	  A.	  D.	  1996.	  Abrogation	  of	  the	  Fc	  gamma	  receptor	  IIA-­‐mediated	  phagocytic	  signal	  by	  stem-­‐loop	  Syk	  antisense	  oligonucleotides.	  Mol	  Biol	  Cell,	  7,	  1095-­‐106.	  MATSUURA,	   E.,	   IGARASHI,	   Y.,	   FUJIMOTO,	   M.,	   ICHIKAWA,	   K.	   &	   KOIKE,	   T.	   1990.	  Anticardiolipin	   cofactor(s)	   and	   differential	   diagnosis	   of	   autoimmune	   disease.	  
Lancet,	  336,	  177-­‐8.	  MAURUS,	  C.	  F.,	  SCHMIDT,	  D.,	  SCHNEIDER,	  M.	  K.,	  TURINA,	  M.	  I.,	  SEEBACH,	  J.	  D.	  &	  ZUND,	  G.	  2003.	   Hypoxia	   and	   reoxygenation	   do	   not	   upregulate	   adhesion	   molecules	   and	  natural	  killer	  cell	  adhesion	  on	  human	  endothelial	  cells	  in	  vitro.	  Eur	  J	  Cardiothorac	  
Surg,	  23,	  976-­‐83;	  discussion	  983.	  MAXWELL,	   P.	   H.,	   PUGH,	   C.	   W.	   &	   RATCLIFFE,	   P.	   J.	   1993.	   Inducible	   operation	   of	   the	  erythropoietin	   3'	   enhancer	   in	   multiple	   cell	   lines:	   evidence	   for	   a	   widespread	  oxygen-­‐sensing	  mechanism.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  90,	  2423-­‐7.	  MAYNARD,	   M.	   A.,	   EVANS,	   A.	   J.,	   HOSOMI,	   T.,	   HARA,	   S.,	   JEWETT,	   M.	   A.	   &	   OHH,	   M.	   2005.	  Human	   HIF-­‐3alpha4	   is	   a	   dominant-­‐negative	   regulator	   of	   HIF-­‐1	   and	   is	   down-­‐regulated	  in	  renal	  cell	  carcinoma.	  FASEB	  J,	  19,	  1396-­‐406.	  MAYNARD,	   M.	   A.,	   QI,	   H.,	   CHUNG,	   J.,	   LEE,	   E.	   H.,	   KONDO,	   Y.,	   HARA,	   S.,	   CONAWAY,	   R.	   C.,	  CONAWAY,	   J.	   W.	   &	   OHH,	   M.	   2003.	   Multiple	   splice	   variants	   of	   the	   human	   HIF-­‐3	  alpha	  locus	  are	  targets	  of	  the	  von	  Hippel-­‐Lindau	  E3	  ubiquitin	  ligase	  complex.	  J	  Biol	  
Chem,	  278,	  11032-­‐40.	  MCEVER,	   R.	   P.	   &	   CUMMINGS,	   R.	   D.	   1997.	   Perspectives	   series:	   cell	   adhesion	   in	   vascular	  biology.	  Role	  of	  PSGL-­‐1	  binding	  to	  selectins	  in	  leukocyte	  recruitment.	  J	  Clin	  Invest,	  100,	  485-­‐91.	  MCGOVERN,	   N.	   N.,	   COWBURN,	   A.	   S.,	   PORTER,	   L.,	   WALMSLEY,	   S.	   R.,	   SUMMERS,	   C.,	  THOMPSON,	  A.	  A.,	  ANWAR,	  S.,	  WILLCOCKS,	  L.	  C.,	  WHYTE,	  M.	  K.,	  CONDLIFFE,	  A.	  M.	  &	  CHILVERS,	  E.	  R.	  2011.	  Hypoxia	  selectively	  inhibits	  respiratory	  burst	  activity	  and	  killing	  of	  Staphylococcus	  aureus	  in	  human	  neutrophils.	  J	  Immunol,	  186,	  453-­‐63.	  MCINTURFF,	  A.	  M.,	  CODY,	  M.	  J.,	  ELLIOTT,	  E.	  A.,	  GLENN,	  J.	  W.,	  ROWLEY,	  J.	  W.,	  RONDINA,	  M.	  T.	   &	   YOST,	   C.	   C.	   2012.	   Mammalian	   target	   of	   rapamycin	   regulates	   neutrophil	  extracellular	   trap	   formation	   via	   induction	   of	   hypoxia-­‐inducible	   factor	   1	   alpha.	  
Blood,	  120,	  3118-­‐25.	  MCKENZIE,	  S.	  E.	  &	  SCHREIBER,	  A.	  D.	  1998.	  Fc	  gamma	  receptors	   in	  phagocytes.	  Curr	  Opin	  
Hematol,	  5,	  16-­‐21.	  MCNEIL,	  H.	  P.,	  SIMPSON,	  R.	  J.,	  CHESTERMAN,	  C.	  N.	  &	  KRILIS,	  S.	  A.	  1990.	  Anti-­‐phospholipid	  antibodies	   are	   directed	   against	   a	   complex	   antigen	   that	   includes	   a	   lipid-­‐binding	  inhibitor	  of	   coagulation:	  beta	  2-­‐glycoprotein	   I	   (apolipoprotein	  H).	  Proc	  Natl	  Acad	  
Sci	  U	  S	  A,	  87,	  4120-­‐4.	  MCNEILL,	   L.	   A.,	   HEWITSON,	   K.	   S.,	   CLARIDGE,	   T.	   D.,	   SEIBEL,	   J.	   F.,	   HORSFALL,	   L.	   E.	   &	  SCHOFIELD,	  C.	   J.	   2002.	  Hypoxia-­‐inducible	   factor	   asparaginyl	  hydroxylase	   (FIH-­‐1)	  catalyses	  hydroxylation	  at	  the	  beta-­‐carbon	  of	  asparagine-­‐803.	  Biochem	  J,	  367,	  571-­‐5.	  
References 
	   249	  
MELANI,	  C.,	  MATTIA,	  G.	  F.,	  SILVANI,	  A.,	  CARE,	  A.,	  RIVOLTINI,	  L.,	  PARMIANI,	  G.	  &	  COLOMBO,	  M.	   P.	   1993.	   Interleukin-­‐6	   expression	   in	   human	   neutrophil	   and	   eosinophil	  peripheral	  blood	  granulocytes.	  Blood,	  81,	  2744-­‐9.	  MENON,	   M.,	   BLAIR,	   P.	   A.,	   ISENBERG,	   D.	   A.	   &	   MAURI,	   C.	   2016.	   A	   Regulatory	   Feedback	  between	   Plasmacytoid	   Dendritic	   Cells	   and	   Regulatory	   B	   Cells	   Is	   Aberrant	   in	  Systemic	  Lupus	  Erythematosus.	  Immunity.	  MERONI,	  P.	  L.,	  BORGHI,	  M.	  O.,	  RASCHI,	  E.,	  VENTURA,	  D.,	  SARZI	  PUTTINI,	  P.	  C.,	  ATZENI,	  F.,	  LONATI,	  L.,	  PARATI,	  G.,	  TINCANI,	  A.,	  MARI,	  D.	  &	  TEDESCO,	  F.	  2004.	  Inflammatory	  response	  and	  the	  endothelium.	  Thromb	  Res,	  114,	  329-­‐34.	  MERONI,	   P.	   L.	   &	   RIBOLDI,	   P.	   2001.	   Pathogenic	  mechanisms	  mediating	   antiphospholipid	  syndrome.	  Curr	  Opin	  Rheumatol,	  13,	  377-­‐82.	  METZLER,	  K.	  D.,	   FUCHS,	  T.	  A.,	  NAUSEEF,	  W.	  M.,	   REUMAUX,	  D.,	   ROESLER,	   J.,	   SCHULZE,	   I.,	  WAHN,	   V.,	   PAPAYANNOPOULOS,	   V.	   &	   ZYCHLINSKY,	   A.	   2011.	  Myeloperoxidase	   is	  required	   for	   neutrophil	   extracellular	   trap	   formation:	   implications	   for	   innate	  immunity.	  Blood,	  117,	  953-­‐9.	  MIAO,	  J.,	  GENG,	  J.,	  ZHANG,	  K.,	  LI,	  X.,	  LI,	  Q.,	  LI,	  C.	  &	  ZHU,	  P.	  2014.	  Frequencies	  of	  circulating	  IL-­‐17-­‐producing	   CD4+CD161+	   T	   cells	   and	   CD4+CD161+	   T	   cells	   correlate	   with	  disease	  activity	  in	  rheumatoid	  arthritis.	  Mod	  Rheumatol,	  24,	  265-­‐570.	  MIGITA,	   K.,	   MIYASHITA,	   T.,	   MAEDA,	   Y.,	   KIMURA,	   H.,	   NAKAMURA,	   M.,	   YATSUHASHI,	   H.,	  ISHIBASHI,	   H.	   &	   EGUCHI,	   K.	   2005.	   Reduced	   blood	   BDCA-­‐2+	   (lymphoid)	   and	  CD11c+	   (myeloid)	   dendritic	   cells	   in	   systemic	   lupus	   erythematosus.	   Clin	   Exp	  
Immunol,	  142,	  84-­‐91.	  MIN,	  J.	  K.,	  KIM,	  Y.	  M.,	  KIM,	  S.	  W.,	  KWON,	  M.	  C.,	  KONG,	  Y.	  Y.,	  HWANG,	  I.	  K.,	  WON,	  M.	  H.,	  RHO,	  J.	  &	  KWON,	  Y.	  G.	  2005.	  TNF-­‐related	  activation-­‐induced	  cytokine	  enhances	  leukocyte	  adhesiveness:	  induction	  of	  ICAM-­‐1	  and	  VCAM-­‐1	  via	  TNF	  receptor-­‐associated	  factor	  and	   protein	   kinase	   C-­‐dependent	   NF-­‐kappaB	   activation	   in	   endothelial	   cells.	   J	  
Immunol,	  175,	  531-­‐40.	  MINE,	  S.,	  TABATA,	  T.,	  WADA,	  Y.,	  FUJISAKI,	  T.,	  IIDA,	  T.,	  NOGUCHI,	  N.,	  NIKI,	  E.,	  KODAMA,	  T.	  &	  TANAKA,	   Y.	   2002.	   Oxidized	   low	   density	   lipoprotein-­‐induced	   LFA-­‐1-­‐dependent	  adhesion	   and	   transendothelial	   migration	   of	   monocytes	   via	   the	   protein	   kinase	   C	  pathway.	  Atherosclerosis,	  160,	  281-­‐8.	  MIOSSEC,	  P.,	  KORN,	  T.	  &	  KUCHROO,	  V.	  K.	  2009.	  Interleukin-­‐17	  and	  type	  17	  helper	  T	  cells.	  N	  
Engl	  J	  Med,	  361,	  888-­‐98.	  MITROULIS,	   I.,	  KAMBAS,	  K.,	  CHRYSANTHOPOULOU,	  A.,	  SKENDROS,	  P.,	  APOSTOLIDOU,	  E.,	  KOURTZELIS,	   I.,	   DROSOS,	   G.	   I.,	   BOUMPAS,	   D.	   T.	   &	   RITIS,	   K.	   2011.	   Neutrophil	  extracellular	   trap	   formation	   is	   associated	   with	   IL-­‐1beta	   and	   autophagy-­‐related	  signaling	  in	  gout.	  PLoS	  One,	  6,	  e29318.	  MITROULIS,	   I.,	   KOURTZELIS,	   I.,	   KAMBAS,	   K.,	   RAFAIL,	   S.,	   CHRYSANTHOPOULOU,	   A.,	  SPELETAS,	  M.	  &	  RITIS,	  K.	  2010.	  Regulation	  of	  the	  autophagic	  machinery	  in	  human	  neutrophils.	  Eur	  J	  Immunol,	  40,	  1461-­‐72.	  MIYAKE,	  S.,	  YAGITA,	  H.,	  MARUYAMA,	  T.,	  HASHIMOTO,	  H.,	  MIYASAKA,	  N.	  &	  OKUMURA,	  K.	  1993.	   Beta	   1	   integrin-­‐mediated	   interaction	   with	   extracellular	   matrix	   proteins	  regulates	   cytokine	  gene	  expression	   in	   synovial	   fluid	   cells	   of	   rheumatoid	   arthritis	  patients.	  J	  Exp	  Med,	  177,	  863-­‐8.	  MIYAKIS,	   S.,	   LOCKSHIN,	   M.	   D.,	   ATSUMI,	   T.,	   BRANCH,	   D.	   W.,	   BREY,	   R.	   L.,	   CERVERA,	   R.,	  DERKSEN,	  R.	  H.,	  PG,	  D.	  E.	  G.,	  KOIKE,	  T.,	  MERONI,	  P.	  L.,	  REBER,	  G.,	  SHOENFELD,	  Y.,	  TINCANI,	   A.,	   VLACHOYIANNOPOULOS,	   P.	   G.	   &	   KRILIS,	   S.	   A.	   2006.	   International	  consensus	   statement	   on	   an	   update	   of	   the	   classification	   criteria	   for	   definite	  antiphospholipid	  syndrome	  (APS).	  J	  Thromb	  Haemost,	  4,	  295-­‐306.	  MIYARA,	  M.,	  AMOURA,	  Z.,	  PARIZOT,	  C.,	  BADOUAL,	  C.,	  DORGHAM,	  K.,	  TRAD,	  S.,	  NOCHY,	  D.,	  DEBRE,	   P.,	   PIETTE,	   J.	   C.	   &	   GOROCHOV,	   G.	   2005.	   Global	   natural	   regulatory	   T	   cell	  depletion	  in	  active	  systemic	  lupus	  erythematosus.	  J	  Immunol,	  175,	  8392-­‐400.	  MO,	  L.	  &	  SALMON,	  J.	  E.	  2001.	  Intercellular	  adhesion	  molecule	  1	  expression	  is	  required	  for	  antiphospholipid	  antibody-­‐induced	  pregnancy	  loss.	  Arthritis	  Rheum,	  44,	  1225-­‐6.	  
References 
	   250	  
MOHAN,	   C.	   &	   PUTTERMAN,	   C.	   2015.	   Genetics	   and	   pathogenesis	   of	   systemic	   lupus	  erythematosus	  and	  lupus	  nephritis.	  Nat	  Rev	  Nephrol,	  11,	  329-­‐41.	  MOHANTY,	   T.,	   SJOGREN,	   J.,	   KAHN,	   F.,	   ABU-­‐HUMAIDAN,	   A.	   H.,	   FISKER,	   N.,	   ASSING,	   K.,	  MORGELIN,	  M.,	  BENGTSSON,	  A.	  A.,	  BORREGAARD,	  N.	  &	  SORENSEN,	  O.	  E.	  2015.	  A	  novel	  mechanism	  for	  NETosis	  provides	  antimicrobial	  defense	  at	   the	  oral	  mucosa.	  
Blood,	  126,	  2128-­‐37.	  MOISAN,	   J.,	   GRENNINGLOH,	   R.,	   BETTELLI,	   E.,	   OUKKA,	   M.	   &	   HO,	   I.	   C.	   2007.	   Ets-­‐1	   is	   a	  negative	  regulator	  of	  Th17	  differentiation.	  J	  Exp	  Med,	  204,	  2825-­‐35.	  MOK,	  C.	  C.	  &	  LAU,	  C.	  S.	  2000.	  Profile	  of	  sex	  hormones	  in	  male	  patients	  with	  systemic	  lupus	  erythematosus.	  Lupus,	  9,	  252-­‐7.	  MOLE,	  D.	  R.,	  BLANCHER,	  C.,	  COPLEY,	  R.	  R.,	  POLLARD,	  P.	  J.,	  GLEADLE,	  J.	  M.,	  RAGOUSSIS,	  J.	  &	  RATCLIFFE,	  P.	  J.	  2009.	  Genome-­‐wide	  association	  of	  hypoxia-­‐inducible	  factor	  (HIF)-­‐1alpha	  and	  HIF-­‐2alpha	  DNA	  binding	  with	  expression	  profiling	  of	  hypoxia-­‐inducible	  transcripts.	  J	  Biol	  Chem,	  284,	  16767-­‐75.	  MOLLINEDO,	   F.,	   NAKAJIMA,	   M.,	   LLORENS,	   A.,	   BARBOSA,	   E.,	   CALLEJO,	   S.,	   GAJATE,	   C.	   &	  FABRA,	   A.	   1997.	   Major	   co-­‐localization	   of	   the	   extracellular-­‐matrix	   degradative	  enzymes	   heparanase	   and	   gelatinase	   in	   tertiary	   granules	   of	   human	   neutrophils.	  
Biochem	  J,	  327	  (	  Pt	  3),	  917-­‐23.	  MOLLINEDO,	  F.,	   PULIDO,	  R.,	   LACAL,	  P.	  M.	  &	  SANCHEZ-­‐MADRID,	  F.	   1991.	  Mobilization	  of	  gelatinase-­‐rich	  granules	  as	  a	  regulatory	  mechanism	  of	  early	   functional	  responses	  in	  human	  neutrophils.	  Scand	  J	  Immunol,	  34,	  33-­‐43.	  MONNEAUX,	  F.	  &	  MULLER,	  S.	  2002.	  Epitope	  spreading	   in	  systemic	   lupus	  erythematosus:	  identification	  of	  triggering	  peptide	  sequences.	  Arthritis	  Rheum,	  46,	  1430-­‐8.	  MONTIEL-­‐MANZANO,	  G.,	  ROMAY-­‐PENABAD,	  Z.,	  PAPALARDO	  DE	  MARTINEZ,	  E.,	  MEILLON-­‐GARCIA,	  L.	  A.,	  GARCIA-­‐LATORRE,	  E.,	  REYES-­‐MALDONADO,	  E.	  &	  PIERANGELI,	  S.	  S.	  2007.	   In	   vivo	   effects	   of	   an	   inhibitor	   of	   nuclear	   factor-­‐kappa	   B	   on	   thrombogenic	  properties	  of	  antiphospholipid	  antibodies.	  Ann	  N	  Y	  Acad	  Sci,	  1108,	  540-­‐53.	  MORET,	  F.	  M.,	  HACK,	  C.	  E.,	  VAN	  DER	  WURFF-­‐JACOBS,	  K.	  M.,	  DE	  JAGER,	  W.,	  RADSTAKE,	  T.	  R.,	   LAFEBER,	   F.	   P.	   &	   VAN	   ROON,	   J.	   A.	   2013.	   Intra-­‐articular	   CD1c-­‐expressing	  myeloid	  dendritic	  cells	  from	  rheumatoid	  arthritis	  patients	  express	  a	  unique	  set	  of	  T	   cell-­‐attracting	   chemokines	   and	   spontaneously	   induce	   Th1,	   Th17	   and	   Th2	   cell	  activity.	  Arthritis	  Res	  Ther,	  15,	  R155.	  MORI,	  S.,	  CHO,	  I.,	  KOGA,	  Y.	  &	  SUGIMOTO,	  M.	  2008.	  Comparison	  of	  pulmonary	  abnormalities	  on	   high-­‐resolution	   computed	   tomography	   in	   patients	   with	   early	   versus	  longstanding	  rheumatoid	  arthritis.	  J	  Rheumatol,	  35,	  1513-­‐21.	  MOULTON,	  V.	  R.	  &	  TSOKOS,	  G.	  C.	  2011.	  Abnormalities	  of	  T	  cell	  signaling	  in	  systemic	  lupus	  erythematosus.	  Arthritis	  Res	  Ther,	  13,	  207.	  MUKAI,	  K.,	  MATSUOKA,	  K.,	  TAYA,	  C.,	  SUZUKI,	  H.,	  YOKOZEKI,	  H.,	  NISHIOKA,	  K.,	  HIROKAWA,	  K.,	   ETORI,	   M.,	   YAMASHITA,	   M.,	   KUBOTA,	   T.,	   MINEGISHI,	   Y.,	   YONEKAWA,	   H.	   &	  KARASUYAMA,	  H.	  2005.	  Basophils	  play	   a	   critical	   role	   in	   the	  development	  of	   IgE-­‐mediated	   chronic	   allergic	   inflammation	   independently	   of	   T	   cells	   and	  mast	   cells.	  
Immunity,	  23,	  191-­‐202.	  MULLA,	   M.	   J.,	   BROSENS,	   J.	   J.,	   CHAMLEY,	   L.	   W.,	   GILES,	   I.,	   PERICLEOUS,	   C.,	   RAHMAN,	   A.,	  JOYCE,	  S.	  K.,	  PANDA,	  B.,	  PAIDAS,	  M.	  J.	  &	  ABRAHAMS,	  V.	  M.	  2009.	  Antiphospholipid	  antibodies	   induce	   a	  pro-­‐inflammatory	   response	   in	   first	   trimester	   trophoblast	   via	  the	  TLR4/MyD88	  pathway.	  Am	  J	  Reprod	  Immunol,	  62,	  96-­‐111.	  MULLER,	  W.	  A.,	  WEIGL,	  S.	  A.,	  DENG,	  X.	  &	  PHILLIPS,	  D.	  M.	  1993.	  PECAM-­‐1	   is	   required	   for	  transendothelial	  migration	  of	  leukocytes.	  J	  Exp	  Med,	  178,	  449-­‐60.	  MYONES,	  B.	  L.,	  DALZELL,	  J.	  G.,	  HOGG,	  N.	  &	  ROSS,	  G.	  D.	  1988.	  Neutrophil	  and	  monocyte	  cell	  surface	  p150,95	  has	  iC3b-­‐receptor	  (CR4)	  activity	  resembling	  CR3.	  J	  Clin	  Invest,	  82,	  640-­‐51.	  NAKASHIMA,	   K.,	   HAGIWARA,	   T.	   &	   YAMADA,	   M.	   2002.	   Nuclear	   localization	   of	  peptidylarginine	  deiminase	  V	  and	  histone	  deimination	  in	  granulocytes.	  J	  Biol	  Chem,	  277,	  49562-­‐8.	  
References 
	   251	  
NAKAYAMADA,	  S.,	  SAITO,	  K.,	  FUJII,	  K.,	  YASUDA,	  M.,	  TAMURA,	  M.	  &	  TANAKA,	  Y.	  2003.	  beta1	  integrin-­‐mediated	  signaling	  induces	  intercellular	  adhesion	  molecule	  1	  and	  Fas	  on	  rheumatoid	  synovial	  cells	  and	  Fas-­‐mediated	  apoptosis.	  Arthritis	  Rheum,	  48,	  1239-­‐48.	  NAKAYAMADA,	   S.,	   SAITO,	   K.,	   NAKANO,	   K.	   &	   TANAKA,	   Y.	   2007.	   Activation	   signal	  transduction	   by	   beta1	   integrin	   in	   T	   cells	   from	   patients	   with	   systemic	   lupus	  erythematosus.	  Arthritis	  Rheum,	  56,	  1559-­‐68.	  NAKOU,	   M.,	   KNOWLTON,	   N.,	   FRANK,	   M.	   B.,	   BERTSIAS,	   G.,	   OSBAN,	   J.,	   SANDEL,	   C.	   E.,	  PAPADAKI,	  H.,	  RAPTOPOULOU,	  A.,	  SIDIROPOULOS,	  P.,	  KRITIKOS,	  I.,	  TASSIULAS,	  I.,	  CENTOLA,	   M.	   &	   BOUMPAS,	   D.	   T.	   2008.	   Gene	   expression	   in	   systemic	   lupus	  erythematosus:	   bone	  marrow	  analysis	   differentiates	   active	   from	   inactive	   disease	  and	  reveals	  apoptosis	  and	  granulopoiesis	  signatures.	  Arthritis	  Rheum,	  58,	  3541-­‐9.	  NATH,	  S.	  K.,	  HAN,	  S.,	  KIM-­‐HOWARD,	  X.,	  KELLY,	   J.	  A.,	  VISWANATHAN,	  P.,	  GILKESON,	  G.	  S.,	  CHEN,	  W.,	   ZHU,	   C.,	  MCEVER,	  R.	   P.,	   KIMBERLY,	  R.	   P.,	   ALARCON-­‐RIQUELME,	  M.	   E.,	  VYSE,	  T.	  J.,	  LI,	  Q.	  Z.,	  WAKELAND,	  E.	  K.,	  MERRILL,	  J.	  T.,	  JAMES,	  J.	  A.,	  KAUFMAN,	  K.	  M.,	  GUTHRIDGE,	   J.	  M.	  &	  HARLEY,	   J.	   B.	   2008.	  A	  nonsynonymous	   functional	   variant	   in	  integrin-­‐alpha(M)	   (encoded	   by	   ITGAM)	   is	   associated	   with	   systemic	   lupus	  erythematosus.	  Nat	  Genet,	  40,	  152-­‐4.	  NAZIRUDDIN,	  B.,	  DUFFY,	  B.	  F.,	  TUCKER,	  J.	  &	  MOHANAKUMAR,	  T.	  1992.	  Evidence	  for	  cross-­‐regulation	   of	   Fc	   gamma	  RIIIB	   (CD16)	   receptor-­‐mediated	   signaling	   by	   Fc	   gamma	  RII	  (CD32)	  expressed	  on	  polymorphonuclear	  neutrophils.	  J	  Immunol,	  149,	  3702-­‐9.	  NEELI,	  I.,	  DWIVEDI,	  N.,	  KHAN,	  S.	  &	  RADIC,	  M.	  2009.	  Regulation	  of	  extracellular	  chromatin	  release	  from	  neutrophils.	  J	  Innate	  Immun,	  1,	  194-­‐201.	  NERMUT,	  M.	  V.,	  GREEN,	  N.	  M.,	  EASON,	  P.,	  YAMADA,	  S.	  S.	  &	  YAMADA,	  K.	  M.	  1988.	  Electron	  microscopy	  and	  structural	  model	  of	  human	  fibronectin	  receptor.	  EMBO	  J,	  7,	  4093-­‐9.	  NEWBY,	  L.	  K.,	  MARBER,	  M.	  S.,	  MELLONI,	  C.,	  SAROV-­‐BLAT,	  L.,	  ABERLE,	  L.	  H.,	  AYLWARD,	  P.	  E.,	   CAI,	   G.,	   DE	  WINTER,	   R.	   J.,	   HAMM,	   C.	  W.,	   HEITNER,	   J.	   F.,	   KIM,	   R.,	   LERMAN,	   A.,	  PATEL,	  M.	  R.,	  TANGUAY,	   J.	  F.,	  LEPORE,	   J.	   J.,	  AL-­‐KHALIDI,	  H.	  R.,	  SPRECHER,	  D.	  L.	  &	  GRANGER,	  C.	  B.	  2014.	  Losmapimod,	  a	  novel	  p38	  mitogen-­‐activated	  protein	  kinase	  inhibitor,	  in	  non-­‐ST-­‐segment	  elevation	  myocardial	  infarction:	  a	  randomised	  phase	  2	  trial.	  Lancet,	  384,	  1187-­‐95.	  NICOLA,	   P.	   J.,	   CROWSON,	   C.	   S.,	   MARADIT-­‐KREMERS,	   H.,	   BALLMAN,	   K.	   V.,	   ROGER,	   V.	   L.,	  JACOBSEN,	  S.	  J.	  &	  GABRIEL,	  S.	  E.	  2006.	  Contribution	  of	  congestive	  heart	  failure	  and	  ischemic	  heart	  disease	  to	  excess	  mortality	  in	  rheumatoid	  arthritis.	  Arthritis	  Rheum,	  54,	  60-­‐7.	  NIE,	  Y.	   J.,	  MOK,	  M.	  Y.,	  CHAN,	  G.	  C.,	  CHAN,	  A.	  W.,	   JIN,	  O.	  U.,	  KAVIKONDALA,	  S.,	  LIE,	  A.	  K.	  &	  LAU,	  C.	  S.	  2010.	  Phenotypic	  and	  functional	  abnormalities	  of	  bone	  marrow-­‐derived	  dendritic	  cells	  in	  systemic	  lupus	  erythematosus.	  Arthritis	  Res	  Ther,	  12,	  R91.	  NING,	  L.,	  TIAN,	  L.,	  SMIRNOV,	  S.,	  VIHINEN,	  H.,	  LLANO,	  O.,	  VICK,	  K.,	  DAVIS,	  R.	  L.,	  RIVERA,	  C.	  &	  GAHMBERG,	  C.	  G.	  2013.	  Interactions	  between	  ICAM-­‐5	  and	  beta1	  integrins	  regulate	  neuronal	  synapse	  formation.	  J	  Cell	  Sci,	  126,	  77-­‐89.	  NISHIDA,	   N.,	   XIE,	   C.,	   SHIMAOKA,	   M.,	   CHENG,	   Y.,	   WALZ,	   T.	   &	   SPRINGER,	   T.	   A.	   2006.	  Activation	   of	   leukocyte	   beta2	   integrins	   by	   conversion	   from	   bent	   to	   extended	  conformations.	  Immunity,	  25,	  583-­‐94.	  NISHIKAWA,	  M.,	  MYOUI,	  A.,	  TOMITA,	  T.,	  TAKAHI,	  K.,	  NAMPEI,	  A.	  &	  YOSHIKAWA,	  H.	  2003.	  Prevention	  of	  the	  onset	  and	  progression	  of	  collagen-­‐induced	  arthritis	  in	  rats	  by	  the	  potent	  p38	  mitogen-­‐activated	  protein	  kinase	  inhibitor	  FR167653.	  Arthritis	  Rheum,	  48,	  2670-­‐81.	  NISHINO,	  H.,	  SHIBUYA,	  K.,	  NISHIDA,	  Y.	  &	  MUSHIMOTO,	  M.	  1981.	  Lupus	  erythematosus-­‐like	  syndrome	  with	  selective	  complete	  deficiency	  of	  C1q.	  Ann	  Intern	  Med,	  95,	  322-­‐4.	  NOCKHER,	  W.	  A.,	  WIGAND,	  R.,	  SCHOEPPE,	  W.	  &	  SCHERBERICH,	  J.	  E.	  1994.	  Elevated	  levels	  of	  soluble	  CD14	  in	  serum	  of	  patients	  with	  systemic	  lupus	  erythematosus.	  Clin	  Exp	  
Immunol,	  96,	  15-­‐9.	  
References 
	   252	  
NOJIMA,	   J.,	   MASUDA,	   Y.,	   IWATANI,	   Y.,	   SUEHISA,	   E.,	   FUTSUKAICHI,	   Y.,	   KURATSUNE,	   H.,	  WATANABE,	   Y.,	   TAKANO,	   T.,	   HIDAKA,	   Y.	   &	   KANAKURA,	   Y.	   2008.	   Tissue	   factor	  expression	  on	  monocytes	  induced	  by	  anti-­‐phospholipid	  antibodies	  as	  a	  strong	  risk	  factor	   for	   thromboembolic	   complications	   in	   SLE	   patients.	   Biochem	   Biophys	   Res	  
Commun,	  365,	  195-­‐200.	  NORDENFELT,	   P.	   &	   TAPPER,	   H.	   2011.	   Phagosome	   dynamics	   during	   phagocytosis	   by	  neutrophils.	  J	  Leukoc	  Biol,	  90,	  271-­‐84.	  NURCOMBE,	  H.	  L.,	  BUCKNALL,	  R.	  C.	  &	  EDWARDS,	  S.	  W.	  1991a.	  Activation	  of	  the	  neutrophil	  myeloperoxidase-­‐H2O2	   system	   by	   synovial	   fluid	   isolated	   from	   patients	   with	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  50,	  237-­‐42.	  NURCOMBE,	  H.	  L.,	  BUCKNALL,	  R.	  C.	  &	  EDWARDS,	  S.	  W.	  1991b.	  Neutrophils	   isolated	  from	  the	  synovial	  fluid	  of	  patients	  with	  rheumatoid	  arthritis:	  priming	  and	  activation	  in	  vivo.	  Ann	  Rheum	  Dis,	  50,	  147-­‐53.	  NUTTALL,	  A.	  &	  ISENBERG,	  D.	  A.	  2013.	  Assessment	  of	  disease	  activity,	  damage	  and	  quality	  of	   life	   in	   systemic	   lupus	   erythematosus:	   new	   aspects.	   Best	   Pract	   Res	   Clin	  
Rheumatol,	  27,	  309-­‐18.	  O'FLAHERTY,	   J.	  T.,	   JACOBSON,	  D.	  P.,	  REDMAN,	   J.	  F.	  &	  ROSSI,	  A.	  G.	  1990.	  Translocation	  of	  protein	   kinase	   C	   in	   human	   polymorphonuclear	   neutrophils.	   Regulation	   by	  cytosolic	   Ca2(+)-­‐independent	   and	   Ca2(+)-­‐dependent	   mechanisms.	   J	   Biol	   Chem,	  265,	  9146-­‐52.	  O'SHEA,	  J.	  J.,	  BROWN,	  E.	  J.,	  SELIGMANN,	  B.	  E.,	  METCALF,	  J.	  A.,	  FRANK,	  M.	  M.	  &	  GALLIN,	  J.	  I.	  1985.	   Evidence	   for	   distinct	   intracellular	   pools	   of	   receptors	   for	   C3b	   and	   C3bi	   in	  human	  neutrophils.	  J	  Immunol,	  134,	  2580-­‐7.	  OBATA,	   K.,	   MUKAI,	   K.,	   TSUJIMURA,	   Y.,	   ISHIWATA,	   K.,	   KAWANO,	   Y.,	   MINEGISHI,	   Y.,	  WATANABE,	  N.	   &	   KARASUYAMA,	  H.	   2007.	   Basophils	   are	   essential	   initiators	   of	   a	  novel	  type	  of	  chronic	  allergic	  inflammation.	  Blood,	  110,	  913-­‐20.	  OBERGFELL,	   A.,	   ETO,	   K.,	   MOCSAI,	   A.,	   BUENSUCESO,	   C.,	   MOORES,	   S.	   L.,	   BRUGGE,	   J.	   S.,	  LOWELL,	  C.	  A.	  &	  SHATTIL,	  S.	   J.	  2002.	  Coordinate	   interactions	  of	  Csk,	  Src,	  and	  Syk	  kinases	  with	  [alpha]IIb[beta]3	  initiate	  integrin	  signaling	  to	  the	  cytoskeleton.	  J	  Cell	  
Biol,	  157,	  265-­‐75.	  OBERMOSER,	   G.	   &	   PASCUAL,	   V.	   2010.	   The	   interferon-­‐alpha	   signature	   of	   systemic	   lupus	  erythematosus.	  Lupus,	  19,	  1012-­‐9.	  OFOSU-­‐APPIAH,	  W.,	  WARRINGTON,	  R.	  J.,	  MORGAN,	  K.	  &	  WILKINS,	  J.	  A.	  1989a.	  Lymphocyte	  extracellular	   matrix	   interactions.	   Induction	   of	   interferon	   by	   connective	   tissue	  components.	  Scand	  J	  Immunol,	  29,	  517-­‐25.	  OFOSU-­‐APPIAH,	   W.	   A.,	   WARRINGTON,	   R.	   J.	   &	   WILKINS,	   J.	   A.	   1989b.	   Interleukin	   2	  responsive	   T	   cell	   clones	   from	   rheumatoid	   and	   normal	   subjects:	   proliferative	  responses	  to	  connective	  tissue	  elements.	  Clin	  Immunol	  Immunopathol,	  50,	  264-­‐71.	  OGSTON,	   A.	   G.	   &	   STANIER,	   J.	   E.	   1953.	   The	   physiological	   function	   of	   hyaluronic	   acid	   in	  synovial	  fluid;	  viscous,	  elastic	  and	  lubricant	  properties.	  J	  Physiol,	  119,	  244-­‐52.	  OLSON,	   A.	   L.,	   SWIGRIS,	   J.	   J.,	   SPRUNGER,	   D.	   B.,	   FISCHER,	   A.,	   FERNANDEZ-­‐PEREZ,	   E.	   R.,	  SOLOMON,	   J.,	   MURPHY,	   J.,	   COHEN,	   M.,	   RAGHU,	   G.	   &	   BROWN,	   K.	   K.	   2011.	  Rheumatoid	   arthritis-­‐interstitial	   lung	   disease-­‐associated	   mortality.	   American	  
journal	  of	  respiratory	  and	  critical	  care	  medicine,	  183,	  372-­‐8.	  ONG,	   C.	   K.,	   LIRK,	   P.,	   TAN,	   C.	   H.	   &	   SEYMOUR,	   R.	   A.	   2007.	   An	   evidence-­‐based	   update	   on	  nonsteroidal	  anti-­‐inflammatory	  drugs.	  Clin	  Med	  Res,	  5,	  19-­‐34.	  OSTERMANN,	  G.,	  WEBER,	  K.	  S.,	  ZERNECKE,	  A.,	  SCHRODER,	  A.	  &	  WEBER,	  C.	  2002.	  JAM-­‐1	  is	  a	   ligand	   of	   the	   beta(2)	   integrin	   LFA-­‐1	   involved	   in	   transendothelial	   migration	   of	  leukocytes.	  Nat	  Immunol,	  3,	  151-­‐8.	  PALLUY,	   O.,	   MORLIERE,	   L.,	   GRIS,	   J.	   C.,	   BONNE,	   C.	   &	   MODAT,	   G.	   1992.	  Hypoxia/reoxygenation	   stimulates	   endothelium	   to	   promote	   neutrophil	   adhesion.	  
Free	  Radic	  Biol	  Med,	  13,	  21-­‐30.	  PALMA,	  C.,	   CASSONE,	  A.,	   SERBOUSEK,	  D.,	   PEARSON,	  C.	  A.	  &	  DJEU,	   J.	   Y.	   1992.	   Lactoferrin	  release	  and	   interleukin-­‐1,	   interleukin-­‐6,	  and	  tumor	  necrosis	   factor	  production	  by	  
References 
	   253	  
human	   polymorphonuclear	   cells	   stimulated	   by	   various	   lipopolysaccharides:	  relationship	  to	  growth	  inhibition	  of	  Candida	  albicans.	  Infect	  Immun,	  60,	  4604-­‐11.	  PANAYI,	   G.	   S.	   2006.	   Even	   though	   T-­‐cell-­‐directed	   trials	   have	   been	   of	   limited	   success,	   is	  there	  reason	  for	  optimism?	  Nat	  Clin	  Pract	  Rheumatol,	  2,	  58-­‐9.	  PANAYI,	  G.	  S.,	  LANCHBURY,	   J.	  S.	  &	  KINGSLEY,	  G.	  H.	  1992.	  The	  importance	  of	  the	  T	  cell	   in	  initiating	   and	  maintaining	   the	   chronic	   synovitis	   of	   rheumatoid	   arthritis.	  Arthritis	  
Rheum,	  35,	  729-­‐35.	  PANG,	  M.,	  ABE,	  T.,	  FUJIHARA,	  T.,	  MORI,	  S.,	  TSUZAKA,	  K.,	  AMANO,	  K.,	  KOIDE,	  J.	  &	  TAKEUCHI,	  T.	   1998.	   Up-­‐regulation	   of	   alphaEbeta7,	   a	   novel	   integrin	   adhesion	  molecule,	   on	   T	  cells	   from	   systemic	   lupus	   erythematosus	   patients	   with	   specific	   epithelial	  involvement.	  Arthritis	  Rheum,	  41,	  1456-­‐63.	  PAPAYANNOPOULOS,	  V.,	  METZLER,	  K.	  D.,	  HAKKIM,	  A.	  &	  ZYCHLINSKY,	  A.	  2010.	  Neutrophil	  elastase	   and	  myeloperoxidase	   regulate	   the	   formation	   of	   neutrophil	   extracellular	  traps.	  J	  Cell	  Biol,	  191,	  677-­‐91.	  PARDOS-­‐GEA,	   J.,	   CASTRO-­‐MARRERO,	   J.,	   CORTES-­‐HERNANDEZ,	   J.,	   BALADA,	   E.,	   PEDROSA,	  A.,	   VILARDELL-­‐TARRES,	   M.	   &	   ORDI-­‐ROS,	   J.	   2012.	   Beta2-­‐glycoprotein	   I	   gene	  polymorphisms	   Val247Leu	   and	   Trp316Ser	   in	   Spanish	   patients	   with	   primary	  antiphospholipid	  syndrome.	  Rheumatol	  Int,	  32,	  927-­‐32.	  PARK,	  Y.	  W.,	  KEE,	  S.	  J.,	  CHO,	  Y.	  N.,	  LEE,	  E.	  H.,	  LEE,	  H.	  Y.,	  KIM,	  E.	  M.,	  SHIN,	  M.	  H.,	  PARK,	  J.	  J.,	  KIM,	  T.	   J.,	   LEE,	   S.	   S.,	  YOO,	  D.	  H.	  &	  KANG,	  H.	   S.	  2009.	   Impaired	  differentiation	  and	  cytotoxicity	   of	   natural	   killer	   cells	   in	   systemic	   lupus	   erythematosus.	   Arthritis	  
Rheum,	  60,	  1753-­‐63.	  PARKER,	  C.	  M.,	  CEPEK,	  K.	  L.,	  RUSSELL,	  G.	  J.,	  SHAW,	  S.	  K.,	  POSNETT,	  D.	  N.,	  SCHWARTING,	  R.	  &	   BRENNER,	   M.	   B.	   1992.	   A	   family	   of	   beta	   7	   integrins	   on	   human	   mucosal	  lymphocytes.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  89,	  1924-­‐8.	  PARKES,	  H.	  G.,	  GROOTVELD,	  M.	  C.,	  HENDERSON,	  E.	  B.,	  FARRELL,	  A.	  &	  BLAKE,	  D.	  R.	  1991.	  Oxidative	  damage	  to	  synovial	  fluid	  from	  the	  inflamed	  rheumatoid	  joint	  detected	  by	  1H	  NMR	  spectroscopy.	  J	  Pharm	  Biomed	  Anal,	  9,	  75-­‐82.	  PASANEN,	   A.,	   HEIKKILA,	   M.,	   RAUTAVUOMA,	   K.,	   HIRSILA,	   M.,	   KIVIRIKKO,	   K.	   I.	   &	  MYLLYHARJU,	   J.	   2010.	   Hypoxia-­‐inducible	   factor	   (HIF)-­‐3alpha	   is	   subject	   to	  extensive	  alternative	  splicing	  in	  human	  tissues	  and	  cancer	  cells	  and	  is	  regulated	  by	  HIF-­‐1	  but	  not	  HIF-­‐2.	  Int	  J	  Biochem	  Cell	  Biol,	  42,	  1189-­‐200.	  PATEL,	   S.,	   KUMAR,	   S.,	   JYOTI,	   A.,	   SRINAG,	   B.	   S.,	   KESHARI,	   R.	   S.,	   SALUJA,	   R.,	   VERMA,	   A.,	  MITRA,	  K.,	  BARTHWAL,	  M.	  K.,	  KRISHNAMURTHY,	  H.,	  BAJPAI,	  V.	  K.	  &	  DIKSHIT,	  M.	  2010.	  Nitric	  oxide	  donors	   release	  extracellular	   traps	   from	  human	  neutrophils	  by	  augmenting	  free	  radical	  generation.	  Nitric	  Oxide,	  22,	  226-­‐34.	  PEEN,	  E.,	  ALMER,	  S.,	  BODEMAR,	  G.,	  RYDEN,	  B.	  O.,	  SJOLIN,	  C.,	  TEJLE,	  K.	  &	  SKOGH,	  T.	  1993.	  Anti-­‐lactoferrin	  antibodies	  and	  other	   types	  of	  ANCA	   in	  ulcerative	  colitis,	  primary	  sclerosing	  cholangitis,	  and	  Crohn's	  disease.	  Gut,	  34,	  56-­‐62.	  PEREZ-­‐SANCHEZ,	  C.,	  RUIZ-­‐LIMON,	  P.,	  AGUIRRE,	  M.	  A.,	  BERTOLACCINI,	  M.	  L.,	  KHAMASHTA,	  M.	   A.,	   RODRIGUEZ-­‐ARIZA,	   A.,	   SEGUI,	   P.,	   COLLANTES-­‐ESTEVEZ,	   E.,	   BARBARROJA,	  N.,	   KHRAIWESH,	   H.,	   GONZALEZ-­‐REYES,	   J.	   A.,	   VILLALBA,	   J.	   M.,	   VELASCO,	   F.,	  CUADRADO,	   M.	   J.	   &	   LOPEZ-­‐PEDRERA,	   C.	   2012.	   Mitochondrial	   dysfunction	   in	  antiphospholipid	   syndrome:	   implications	   in	   the	   pathogenesis	   of	   the	   disease	   and	  effects	  of	  coenzyme	  Q(10)	  treatment.	  Blood,	  119,	  5859-­‐5870.	  PERICLEOUS,	   C.,	   TAYLOR,	   V.,	   BOURKE,	   L.,	   STUCKEY,	   D.,	   WINGROVE,	   J.,	   LYTHGOE,	   M.,	  PIERANGELI,	   S.	   S.,	   RAHMAN,	   A.,	   GILES,	   I.	   &	   IOANNOU,	   Y.	   2014.	   IgG	  Antiphospholipid	   Antibodies	   Enhance	   Stroke	   Damage:	   An	   in	   Vivo	  Ischemia/Reperfusion	  Study.	  Arthritis	  &	  Rheumatology,	  66,	  S1251-­‐S1251.	  PETERS,	   J.	  H.,	  SPORN,	  L.	  A.,	  GINSBERG,	  M.	  H.	  &	  WAGNER,	  D.	  D.	  1990.	  Human	  endothelial	  cells	   synthesize,	   process,	   and	   secrete	   fibronectin	   molecules	   bearing	   an	  alternatively	  spliced	  type	  III	  homology	  (ED1).	  Blood,	  75,	  1801-­‐8.	  PETERS,	   M.	   A.,	   WENDHOLT,	   D.,	   STRIETHOLT,	   S.,	   FRANK,	   S.,	   PUNDT,	   N.,	   KORB-­‐PAP,	   A.,	  JOOSTEN,	  L.	  A.,	  VAN	  DEN	  BERG,	  W.	  B.,	  KOLLIAS,	  G.,	  ECKES,	  B.	  &	  PAP,	  T.	  2012.	  The	  
References 
	   254	  
loss	   of	   alpha2beta1	   integrin	   suppresses	   joint	   inflammation	   and	   cartilage	  destruction	  in	  mouse	  models	  of	  rheumatoid	  arthritis.	  Arthritis	  Rheum,	  64,	  1359-­‐68.	  PETREQUIN,	  P.	  R.,	  TODD,	  R.	  F.,	  3RD,	  DEVALL,	  L.	   J.,	  BOXER,	  L.	  A.	  &	  CURNUTTE,	   J.	  T.,	  3RD	  1987.	   Association	   between	   gelatinase	   release	   and	   increased	   plasma	   membrane	  expression	  of	  the	  Mo1	  glycoprotein.	  Blood,	  69,	  605-­‐10.	  PIALI,	  L.,	  ALBELDA,	  S.	  M.,	  BALDWIN,	  H.	  S.,	  HAMMEL,	  P.,	  GISLER,	  R.	  H.	  &	  IMHOF,	  B.	  A.	  1993.	  Murine	   platelet	   endothelial	   cell	   adhesion	   molecule	   (PECAM-­‐1)/CD31	   modulates	  beta	  2	  integrins	  on	  lymphokine-­‐activated	  killer	  cells.	  Eur	  J	  Immunol,	  23,	  2464-­‐71.	  PIERANGELI,	   S.	   S.,	   CHEN,	   P.	   P.,	   RASCHI,	   E.,	   SCURATI,	   S.,	   GROSSI,	   C.,	   BORGHI,	   M.	   O.,	  PALOMO,	  I.,	  HARRIS,	  E.	  N.	  &	  MERONI,	  P.	  L.	  2008.	  Antiphospholipid	  antibodies	  and	  the	   antiphospholipid	   syndrome:	   pathogenic	  mechanisms.	   Semin	  Thromb	  Hemost,	  34,	  236-­‐50.	  PIERANGELI,	   S.	   S.,	   COLDEN-­‐STANFIELD,	   M.,	   LIU,	   X.,	   BARKER,	   J.	   H.,	   ANDERSON,	   G.	   L.	   &	  HARRIS,	  E.	  N.	  1999.	  Antiphospholipid	  antibodies	  from	  antiphospholipid	  syndrome	  patients	  activate	  endothelial	  cells	  in	  vitro	  and	  in	  vivo.	  Circulation,	  99,	  1997-­‐2002.	  PIERANGELI,	  S.	  S.,	  ESPINOLA,	  R.	  G.,	  LIU,	  X.	  &	  HARRIS,	  E.	  N.	  2001.	  Thrombogenic	  effects	  of	  antiphospholipid	  antibodies	  are	  mediated	  by	  intercellular	  cell	  adhesion	  molecule-­‐1,	  vascular	  cell	  adhesion	  molecule-­‐1,	  and	  P-­‐selectin.	  Circ	  Res,	  88,	  245-­‐50.	  PIERANGELI,	  S.	  S.,	  GIRARDI,	  G.,	  VEGA-­‐OSTERTAG,	  M.,	  LIU,	  X.,	  ESPINOLA,	  R.	  G.	  &	  SALMON,	  J.	  2005.	   Requirement	   of	   activation	   of	   complement	   C3	   and	   C5	   for	   antiphospholipid	  antibody-­‐mediated	  thrombophilia.	  Arthritis	  Rheum,	  52,	  2120-­‐4.	  PIERANGELI,	   S.	   S.,	   LIU,	   X.,	   ESPINOLA,	  R.,	   OLEE,	   T.,	   ZHU,	  M.,	  HARRIS,	  N.	   E.	  &	  CHEN,	   P.	   P.	  2000.	   Functional	   analyses	   of	   patient-­‐derived	   IgG	   monoclonal	   anticardiolipin	  antibodies	  using	  in	  vivo	  thrombosis	  and	  in	  vivo	  microcirculation	  models.	  Thromb	  
Haemost,	  84,	  388-­‐95.	  PIERANGELI,	   S.	   S.,	   VEGA-­‐OSTERTAG,	  M.	  E.,	  RASCHI,	   E.,	   LIU,	  X.,	  ROMAY-­‐PENABAD,	  Z.,	  DE	  MICHELI,	  V.,	  GALLI,	  M.,	  MOIA,	  M.,	  TINCANI,	  A.,	  BORGHI,	  M.	  O.,	  NGUYEN-­‐OGHALAI,	  T.	   &	   MERONI,	   P.	   L.	   2007.	   Toll-­‐like	   receptor	   and	   antiphospholipid	   mediated	  thrombosis:	  in	  vivo	  studies.	  Ann	  Rheum	  Dis,	  66,	  1327-­‐33.	  PILCHER,	  B.	  K.,	  DUMIN,	  J.	  A.,	  SUDBECK,	  B.	  D.,	  KRANE,	  S.	  M.,	  WELGUS,	  H.	  G.	  &	  PARKS,	  W.	  C.	  1997.	  The	  activity	  of	  collagenase-­‐1	  is	  required	  for	  keratinocyte	  migration	  on	  a	  type	  I	  collagen	  matrix.	  J	  Cell	  Biol,	  137,	  1445-­‐57.	  PILSCZEK,	  F.	  H.,	  SALINA,	  D.,	  POON,	  K.	  K.,	  FAHEY,	  C.,	  YIPP,	  B.	  G.,	  SIBLEY,	  C.	  D.,	  ROBBINS,	  S.	  M.,	  GREEN,	  F.	  H.,	  SURETTE,	  M.	  G.,	  SUGAI,	  M.,	  BOWDEN,	  M.	  G.,	  HUSSAIN,	  M.,	  ZHANG,	  K.	  &	  KUBES,	  P.	  2010.	  A	  novel	  mechanism	  of	  rapid	  nuclear	  neutrophil	  extracellular	  trap	  formation	  in	  response	  to	  Staphylococcus	  aureus.	  J	  Immunol,	  185,	  7413-­‐25.	  PIPER,	  M.	  K.,	  RAZA,	  K.,	  NUTTALL,	  S.	  L.,	  STEVENS,	  R.,	  TOESCU,	  V.,	  HEATON,	  S.,	  GARDNER-­‐MEDWIN,	   J.,	   HILLER,	   L.,	   MARTIN,	   U.,	   TOWNEND,	   J.,	   BACON,	   P.	   A.	   &	   GORDON,	   C.	  2007.	   Impaired	  endothelial	   function	   in	   systemic	   lupus	   erythematosus.	  Lupus,	   16,	  84-­‐8.	  PITANGA,	   T.	   N.,	   DE	   ARAGAO	   FRANCA,	   L.,	   ROCHA,	   V.	   C.,	   MEIRELLES,	   T.,	   BORGES,	   V.	   M.,	  GONCALVES,	  M.	  S.,	  PONTES-­‐DE-­‐CARVALHO,	  L.	  C.,	  NORONHA-­‐DUTRA,	  A.	  A.	  &	  DOS-­‐SANTOS,	  W.	  L.	  2014.	  Neutrophil-­‐derived	  microparticles	   induce	  myeloperoxidase-­‐mediated	  damage	  of	  vascular	  endothelial	  cells.	  BMC	  Cell	  Biol,	  15,	  21.	  PLENGE,	  R.	  M.,	  PADYUKOV,	  L.,	  REMMERS,	  E.	  F.,	  PURCELL,	  S.,	  LEE,	  A.	  T.,	  KARLSON,	  E.	  W.,	  WOLFE,	  F.,	  KASTNER,	  D.	   L.,	  ALFREDSSON,	  L.,	  ALTSHULER,	  D.,	   GREGERSEN,	  P.	  K.,	  KLARESKOG,	   L.	   &	   RIOUX,	   J.	   D.	   2005.	   Replication	   of	   putative	   candidate-­‐gene	  associations	  with	  rheumatoid	  arthritis	  in	  >4,000	  samples	  from	  North	  America	  and	  Sweden:	  association	  of	  susceptibility	  with	  PTPN22,	  CTLA4,	  and	  PADI4.	  Am	  J	  Hum	  
Genet,	  77,	  1044-­‐60.	  PORTER,	   J.	   C.	   &	  HALL,	   A.	   2009.	   Epithelial	   ICAM-­‐1	   and	   ICAM-­‐2	   regulate	   the	   egression	   of	  human	  T	  cells	  across	  the	  bronchial	  epithelium.	  FASEB	  J,	  23,	  492-­‐502.	  POUBELLE,	   P.	   E.,	   CHAKRAVARTI,	   A.,	   FERNANDES,	   M.	   J.,	   DOIRON,	   K.	   &	   MARCEAU,	   A.	   A.	  2007.	  Differential	   expression	  of	  RANK,	  RANK-­‐L,	   and	  osteoprotegerin	  by	   synovial	  
References 
	   255	  
fluid	   neutrophils	   from	  patients	  with	   rheumatoid	   arthritis	   and	   by	   healthy	   human	  blood	  neutrophils.	  Arthritis	  Res	  Ther,	  9,	  R25.	  POULTON,	   K.,	   RIPOLL,	   V.	  M.,	   PERICLEOUS,	   C.,	  MERONI,	   P.	   L.,	   GEROSA,	  M.,	   IOANNOU,	   Y.,	  RAHMAN,	  A.	  &	  GILES,	  I.	  P.	  2015.	  Purified	  IgG	  from	  Patients	  with	  Obstetric	  but	  not	  IgG	  from	  Non-­‐obstetric	  Antiphospholipid	  Syndrome	  Inhibit	  Trophoblast	  Invasion.	  
Am	  J	  Reprod	  Immunol,	  73,	  390-­‐401.	  PRATESI,	  F.,	  DIONI,	   I.,	  TOMMASI,	  C.,	  ALCARO,	  M.	  C.,	  PAOLINI,	   I.,	  BARBETTI,	  F.,	  BOSCARO,	  F.,	   PANZA,	   F.,	   PUXEDDU,	   I.,	   ROVERO,	   P.	  &	  MIGLIORINI,	   P.	   2013.	   Antibodies	   from	  patients	   with	   rheumatoid	   arthritis	   target	   citrullinated	   histone	   4	   contained	   in	  neutrophils	  extracellular	  traps.	  Ann	  Rheum	  Dis.	  PRUYNE,	  D.,	  EVANGELISTA,	  M.,	  YANG,	  C.,	  BI,	  E.,	  ZIGMOND,	  S.,	  BRETSCHER,	  A.	  &	  BOONE,	  C.	  2002.	   Role	   of	   formins	   in	   actin	   assembly:	   nucleation	   and	   barbed-­‐end	   association.	  
Science,	  297,	  612-­‐5.	  PUXEDDU,	  I.,	  BONGIORNI,	  F.,	  CHIMENTI,	  D.,	  BOMBARDIERI,	  S.,	  MORETTA,	  A.,	  BOTTINO,	  C.	  &	   MIGLIORINI,	   P.	   2012.	   Cell	   surface	   expression	   of	   activating	   receptors	   and	   co-­‐receptors	  on	  peripheral	  blood	  NK	  cells	   in	  systemic	  autoimmune	  diseases.	  Scand	  J	  
Rheumatol,	  41,	  298-­‐304.	  QUANDT,	  D.,	  ROTHE,	  K.,	   SCHOLZ,	  R.,	  BAERWALD,	  C.	  W.	  &	  WAGNER,	  U.	   2014.	  Peripheral	  CD4CD8	   double	   positive	   T	   cells	   with	   a	   distinct	   helper	   cytokine	   profile	   are	  increased	  in	  rheumatoid	  arthritis.	  PLoS	  One,	  9,	  e93293.	  QUAYLE,	   J.	   A.,	   ADAMS,	   S.,	   BUCKNALL,	   R.	   C.	   &	   EDWARDS,	   S.	   W.	   1995.	   Interleukin-­‐1	  expression	  by	  neutrophils	  in	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  54,	  930-­‐3.	  RAFTERY,	  M.	  J.,	  LALWANI,	  P.,	  KRAUTKRMER,	  E.,	  PETERS,	  T.,	  SCHARFFETTER-­‐KOCHANEK,	  K.,	  KRUGER,	  R.,	  HOFMANN,	  J.,	  SEEGER,	  K.,	  KRUGER,	  D.	  H.	  &	  SCHONRICH,	  G.	  2014.	  beta2	   integrin	   mediates	   hantavirus-­‐induced	   release	   of	   neutrophil	   extracellular	  traps.	  J	  Exp	  Med,	  211,	  1485-­‐97.	  RAHMAN,	  A.	  &	   ISENBERG,	  D.	  A.	  2008.	  Systemic	   lupus	  erythematosus.	  N	  Engl	  J	  Med,	   358,	  929-­‐39.	  RAINGER,	   G.	   E.,	   FISHER,	   A.,	   SHEARMAN,	   C.	   &	   NASH,	   G.	   B.	   1995.	   Adhesion	   of	   flowing	  neutrophils	  to	  cultured	  endothelial	  cells	  after	  hypoxia	  and	  reoxygenation	  in	  vitro.	  
Am	  J	  Physiol,	  269,	  H1398-­‐406.	  RAMESH,	  S.,	  MORRELL,	  C.	  N.,	  TARANGO,	  C.,	  THOMAS,	  G.	  D.,	  YUHANNA,	   I.	   S.,	  GIRARDI,	  G.,	  HERZ,	  J.,	  URBANUS,	  R.	  T.,	  DE	  GROOT,	  P.	  G.,	  THORPE,	  P.	  E.,	  SALMON,	  J.	  E.,	  SHAUL,	  P.	  W.	  &	  MINEO,	  C.	  2011.	  Antiphospholipid	  antibodies	  promote	  leukocyte-­‐endothelial	  cell	   adhesion	   and	   thrombosis	   in	   mice	   by	   antagonizing	   eNOS	   via	   beta2GPI	   and	  apoER2.	  J	  Clin	  Invest,	  121,	  120-­‐31.	  RAMOS,	  P.	   S.,	   BROWN,	  E.	   E.,	   KIMBERLY,	  R.	   P.	  &	  LANGEFELD,	  C.	  D.	   2010.	  Genetic	   factors	  predisposing	  to	  systemic	  lupus	  erythematosus	  and	  lupus	  nephritis.	  Semin	  Nephrol,	  30,	  164-­‐76.	  RAND,	  J.	  H.,	  WU,	  X.	  X.,	  ANDREE,	  H.	  A.,	  LOCKWOOD,	  C.	  J.,	  GULLER,	  S.,	  SCHER,	  J.	  &	  HARPEL,	  P.	  C.	   1997.	   Pregnancy	   loss	   in	   the	   antiphospholipid-­‐antibody	   syndrome-­‐-­‐a	   possible	  thrombogenic	  mechanism.	  N	  Engl	  J	  Med,	  337,	  154-­‐60.	  RAND,	   J.	  H.,	  WU,	   X.	   X.,	   GULLER,	   S.,	   GIL,	   J.,	   GUHA,	  A.,	   SCHER,	   J.	  &	   LOCKWOOD,	   C.	   J.	   1994.	  Reduction	   of	   annexin-­‐V	   (placental	   anticoagulant	   protein-­‐I)	   on	   placental	   villi	   of	  women	  with	  antiphospholipid	  antibodies	  and	  recurrent	  spontaneous	  abortion.	  Am	  
J	  Obstet	  Gynecol,	  171,	  1566-­‐72.	  RANDI,	  A.	  M.	  &	  HOGG,	  N.	  1994.	  I	  domain	  of	  beta	  2	  integrin	  lymphocyte	  function-­‐associated	  antigen-­‐1	   contains	   a	   binding	   site	   for	   ligand	   intercellular	   adhesion	   molecule-­‐1.	   J	  
Biol	  Chem,	  269,	  12395-­‐8.	  RAPETTI,	  L.,	  CHAVELE,	  K.	  M.,	  EVANS,	  C.	  M.	  &	  EHRENSTEIN,	  M.	  R.	  2015.	  B	  cell	  resistance	  to	  Fas-­‐mediated	   apoptosis	   contributes	   to	   their	   ineffective	   control	   by	   regulatory	   T	  cells	  in	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  74,	  294-­‐302.	  
References 
	   256	  
RASCHI,	  E.,	  TESTONI,	  C.,	  BOSISIO,	  D.,	  BORGHI,	  M.	  O.,	  KOIKE,	  T.,	  MANTOVANI,	  A.	  &	  MERONI,	  P.	   L.	   2003.	   Role	   of	   the	   MyD88	   transduction	   signaling	   pathway	   in	   endothelial	  activation	  by	  antiphospholipid	  antibodies.	  Blood,	  101,	  3495-­‐500.	  RAVIKUMAR,	  B.,	   SARKAR,	   S.,	  DAVIES,	   J.	   E.,	   FUTTER,	  M.,	  GARCIA-­‐ARENCIBIA,	  M.,	  GREEN-­‐THOMPSON,	  Z.	  W.,	   JIMENEZ-­‐SANCHEZ,	  M.,	  KOROLCHUK,	  V.	   I.,	   LICHTENBERG,	  M.,	  LUO,	  S.,	  MASSEY,	  D.	  C.,	  MENZIES,	  F.	  M.,	  MOREAU,	  K.,	  NARAYANAN,	  U.,	  RENNA,	  M.,	  SIDDIQI,	  F.	  H.,	  UNDERWOOD,	  B.	  R.,	  WINSLOW,	  A.	  R.	  &	  RUBINSZTEIN,	  D.	  C.	  2010.	  Regulation	   of	  mammalian	   autophagy	   in	   physiology	   and	   pathophysiology.	  Physiol	  
Rev,	  90,	  1383-­‐435.	  REDECHA,	   P.,	   FRANZKE,	   C.	  W.,	   RUF,	  W.,	  MACKMAN,	   N.	   &	   GIRARDI,	   G.	   2008.	   Neutrophil	  activation	   by	   the	   tissue	   factor/Factor	   VIIa/PAR2	   axis	   mediates	   fetal	   death	   in	   a	  mouse	  model	  of	  antiphospholipid	  syndrome.	  J	  Clin	  Invest,	  118,	  3453-­‐61.	  REDECHA,	  P.,	  TILLEY,	  R.,	  TENCATI,	  M.,	  SALMON,	   J.	  E.,	  KIRCHHOFER,	  D.,	  MACKMAN,	  N.	  &	  GIRARDI,	  G.	  2007.	  Tissue	   factor:	   a	   link	  between	  C5a	  and	  neutrophil	   activation	   in	  antiphospholipid	  antibody	  induced	  fetal	  injury.	  Blood,	  110,	  2423-­‐31.	  REES,	  F.,	  DOHERTY,	  M.,	  GRAINGE,	  M.,	  DAVENPORT,	  G.,	  LANYON,	  P.	  &	  ZHANG,	  W.	  2016.	  The	  incidence	  and	  prevalence	  of	  systemic	  lupus	  erythematosus	  in	  the	  UK,	  1999-­‐2012.	  
Ann	  Rheum	  Dis,	  75,	  136-­‐41.	  REMIJSEN,	  Q.,	  KUIJPERS,	  T.	  W.,	  WIRAWAN,	  E.,	  LIPPENS,	  S.,	  VANDENABEELE,	  P.	  &	  VANDEN	  BERGHE,	   T.	   2011a.	   Dying	   for	   a	   cause:	   NETosis,	   mechanisms	   behind	   an	  antimicrobial	  cell	  death	  modality.	  Cell	  Death	  Differ,	  18,	  581-­‐8.	  REMIJSEN,	  Q.,	  VANDEN	  BERGHE,	  T.,	  WIRAWAN,	  E.,	  ASSELBERGH,	  B.,	  PARTHOENS,	  E.,	  DE	  RYCKE,	  R.,	  NOPPEN,	  S.,	  DELFORGE,	  M.,	  WILLEMS,	  J.	  &	  VANDENABEELE,	  P.	  2011b.	  Neutrophil	   extracellular	   trap	   cell	   death	   requires	   both	   autophagy	   and	   superoxide	  generation.	  Cell	  Res,	  21,	  290-­‐304.	  REPP,	  R.,	  VALERIUS,	  T.,	  SENDLER,	  A.,	  GRAMATZKI,	  M.,	  IRO,	  H.,	  KALDEN,	  J.	  R.	  &	  PLATZER,	  E.	  1991.	  Neutrophils	  express	  the	  high	  affinity	  receptor	  for	  IgG	  (Fc	  gamma	  RI,	  CD64)	  after	   in	   vivo	   application	   of	   recombinant	   human	   granulocyte	   colony-­‐stimulating	  factor.	  Blood,	  78,	  885-­‐9.	  RHODES,	  B.,	  FURNROHR,	  B.	  G.,	  ROBERTS,	  A.	  L.,	  TZIRCOTIS,	  G.,	  SCHETT,	  G.,	  SPECTOR,	  T.	  D.	  &	   VYSE,	   T.	   J.	   2012.	   The	   rs1143679	   (R77H)	   lupus	   associated	   variant	   of	   ITGAM	  (CD11b)	  impairs	  complement	  receptor	  3	  mediated	  functions	  in	  human	  monocytes.	  
Ann	  Rheum	  Dis,	  71,	  2028-­‐34.	  RIBATTI,	   D.,	   CRIVELLATO,	   E.	   &	   VACCA,	   A.	   2006.	   The	   contribution	   of	   Bruce	   Glick	   to	   the	  definition	  of	  the	  role	  played	  by	  the	  bursa	  of	  Fabricius	  in	  the	  development	  of	  the	  B	  cell	  lineage.	  Clin	  Exp	  Immunol,	  145,	  1-­‐4.	  RICHMAN,	  A.	  I.,	  SU,	  E.	  Y.	  &	  HO,	  G.,	  JR.	  1981.	  Reciprocal	  relationship	  of	  synovial	  fluid	  volume	  and	  oxygen	  tension.	  Arthritis	  Rheum,	  24,	  701-­‐5.	  RIISE,	  T.,	  JACOBSEN,	  B.	  K.,	  GRAN,	  J.	  T.,	  HAGA,	  H.	  J.	  &	  ARNESEN,	  E.	  2001.	  Total	  mortality	  is	  increased	  in	  rheumatoid	  arthritis.	  A	  17-­‐year	  prospective	  study.	  Clin	  Rheumatol,	  20,	  123-­‐7.	  RINALDI,	  N.,	  SCHWARZ-­‐EYWILL,	  M.,	  WEIS,	  D.,	  LEPPELMANN-­‐JANSEN,	  P.,	  LUKOSCHEK,	  M.,	  KEILHOLZ,	   U.	   &	   BARTH,	   T.	   F.	   1997a.	   Increased	   expression	   of	   integrins	   on	  fibroblast-­‐like	   synoviocytes	   from	   rheumatoid	   arthritis	   in	   vitro	   correlates	   with	  enhanced	  binding	  to	  extracellular	  matrix	  proteins.	  Ann	  Rheum	  Dis,	  56,	  45-­‐51.	  RINALDI,	  N.,	  WEIS,	  D.,	  BRADO,	  B.,	  SCHWARZ-­‐EYWILL,	  M.,	  LUKOSCHEK,	  M.,	  PEZZUTTO,	  A.,	  KEILHOLZ,	   U.	   &	   BARTH,	   T.	   F.	   1997b.	   Differential	   expression	   and	   functional	  behaviour	   of	   the	   alpha	   v	   and	   beta	   3	   integrin	   subunits	   in	   cytokine	   stimulated	  fibroblast-­‐like	   cells	   derived	   from	   synovial	   tissue	   of	   rheumatoid	   arthritis	   and	  osteoarthritis	  in	  vitro.	  Ann	  Rheum	  Dis,	  56,	  729-­‐36.	  RITIS,	  K.,	  DOUMAS,	  M.,	  MASTELLOS,	  D.,	  MICHELI,	  A.,	  GIAGLIS,	  S.,	  MAGOTTI,	  P.,	  RAFAIL,	  S.,	  KARTALIS,	   G.,	   SIDERAS,	   P.	   &	   LAMBRIS,	   J.	   D.	   2006.	   A	   novel	   C5a	   receptor-­‐tissue	  factor	   cross-­‐talk	   in	  neutrophils	   links	   innate	   immunity	   to	   coagulation	  pathways.	   J	  
Immunol,	  177,	  4794-­‐802.	  
References 
	   257	  
RIYAPA,	  D.,	  BUDDHISA,	  S.,	  KORBSRISATE,	  S.,	  CUCCUI,	  J.,	  WREN,	  B.	  W.,	  STEVENS,	  M.	  P.,	  ATO,	  M.	   &	   LERTMEMONGKOLCHAI,	   G.	   2012.	   Neutrophil	   extracellular	   traps	   exhibit	  antibacterial	   activity	   against	   burkholderia	   pseudomallei	   and	   are	   influenced	   by	  bacterial	  and	  host	  factors.	  Infect	  Immun,	  80,	  3921-­‐9.	  ROBBINS,	   D.	   L.,	   LEUNG,	   S.,	   MILLER-­‐BLAIR,	   D.	   J.	   &	   ZIBOH,	   V.	   1998.	   Effect	   of	  anticardiolipin/beta2-­‐glycoprotein	  I	  complexes	  on	  production	  of	  thromboxane	  A2	  by	   platelets	   from	  patients	  with	   the	   antiphospholipid	   syndrome.	   J	  Rheumatol,	   25,	  51-­‐6.	  ROBINSON,	   J.,	   WATSON,	   F.,	   BUCKNALL,	   R.	   C.	   &	   EDWARDS,	   S.	   W.	   1992.	   Activation	   of	  neutrophil	   reactive-­‐oxidant	   production	   by	   synovial	   fluid	   from	   patients	   with	  inflammatory	   joint	   disease.	   Soluble	   and	   insoluble	   immunoglobulin	   aggregates	  activate	  different	  pathways	   in	  primed	  and	  unprimed	  cells.	  Biochem	  J,	  286	  (	  Pt	  2),	  345-­‐51.	  ROBINSON,	   J.	   J.,	   WATSON,	   F.,	   PHELAN,	   M.,	   BUCKNALL,	   R.	   C.	   &	   EDWARDS,	   S.	   W.	   1993.	  Activation	   of	   neutrophils	   by	   soluble	   and	   insoluble	   immunoglobulin	   aggregates	  from	  synovial	  fluid	  of	  patients	  with	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  52,	  347-­‐53.	  RODESCH,	   F.,	   SIMON,	   P.,	   DONNER,	   C.	   &	   JAUNIAUX,	   E.	   1992.	   Oxygen	   measurements	   in	  endometrial	  and	  trophoblastic	  tissues	  during	  early	  pregnancy.	  Obstet	  Gynecol,	  80,	  283-­‐5.	  ROMAY-­‐PENABAD,	   Z.,	   AGUILAR-­‐VALENZUELA,	   R.,	   URBANUS,	   R.	   T.,	   DERKSEN,	   R.	   H.,	  PENNINGS,	   M.	   T.,	   PAPALARDO,	   E.,	   SHILAGARD,	   T.,	   VARGAS,	   G.,	   HWANG,	   Y.,	   DE	  GROOT,	  P.	  G.	  &	  PIERANGELI,	  S.	  S.	  2011.	  Apolipoprotein	  E	  receptor	  2	  is	  involved	  in	  the	   thrombotic	   complications	   in	   a	   murine	   model	   of	   the	   antiphospholipid	  syndrome.	  Blood,	  117,	  1408-­‐14.	  ROMAY-­‐PENABAD,	  Z.,	  CARRERA	  MARIN,	  A.	  L.,	  WILLIS,	  R.,	  WESTON-­‐DAVIES,	  W.,	  MACHIN,	  S.,	   COHEN,	   H.,	   BRASIER,	   A.	   &	   GONZALEZ,	   E.	   B.	   2014.	   Complement	   C5-­‐inhibitor	  rEV576	   (coversin)	   ameliorates	   in-­‐vivo	   effects	   of	   antiphospholipid	   antibodies.	  
Lupus,	  23,	  1324-­‐6.	  RONNEFARTH,	   V.	   M.,	   ERBACHER,	   A.	   I.,	   LAMKEMEYER,	   T.,	   MADLUNG,	   J.,	   NORDHEIM,	   A.,	  RAMMENSEE,	   H.	   G.	   &	   DECKER,	   P.	   2006.	   TLR2/TLR4-­‐independent	   neutrophil	  activation	   and	   recruitment	   upon	   endocytosis	   of	   nucleosomes	   reveals	   a	   new	  pathway	   of	   innate	   immunity	   in	   systemic	   lupus	   erythematosus.	   J	   Immunol,	   177,	  7740-­‐9.	  ROSE,	  H.	  M.,	  RAGAN,	  C.	  &	  ET	  AL.	  1948.	  Differential	  agglutination	  of	  normal	  and	  sensitized	  sheep	  erythrocytes	  by	  sera	  of	  patients	  with	  rheumatoid	  arthritis.	  Proc	  Soc	  Exp	  Biol	  
Med,	  68,	  1-­‐6.	  ROSETTI,	  F.,	  CHEN,	  Y.,	  SEN,	  M.,	  THAYER,	  E.,	  AZCUTIA,	  V.,	  HERTER,	  J.	  M.,	  LUSCINSKAS,	  F.	  W.,	  CULLERE,	  X.,	  ZHU,	  C.	  &	  MAYADAS,	  T.	  N.	  2015.	  A	  Lupus-­‐Associated	  Mac-­‐1	  Variant	  Has	   Defects	   in	   Integrin	   Allostery	   and	   Interaction	  with	   Ligands	   under	   Force.	  Cell	  
Rep,	  10(10),	  1655-­‐1664.	  ROSSAINT,	   J.,	   HERTER,	   J.	   M.,	   VAN	   AKEN,	   H.,	   NAPIREI,	   M.,	   DORING,	   Y.,	   WEBER,	   C.,	  SOEHNLEIN,	   O.	   &	   ZARBOCK,	   A.	   2014.	   Synchronized	   integrin	   engagement	   and	  chemokine	   activation	   is	   crucial	   in	   neutrophil	   extracellular	   trap-­‐mediated	   sterile	  inflammation.	  Blood,	  123,	  2573-­‐84.	  ROSSI,	   A.	   G.,	   SAWATZKY,	   D.	   A.,	  WALKER,	   A.,	  WARD,	   C.,	   SHELDRAKE,	   T.	   A.,	   RILEY,	   N.	   A.,	  CALDICOTT,	   A.,	   MARTINEZ-­‐LOSA,	   M.,	   WALKER,	   T.	   R.,	   DUFFIN,	   R.,	   GRAY,	   M.,	  CRESCENZI,	   E.,	   MARTIN,	   M.	   C.,	   BRADY,	   H.	   J.,	   SAVILL,	   J.	   S.,	   DRANSFIELD,	   I.	   &	  HASLETT,	   C.	   2006.	   Cyclin-­‐dependent	   kinase	   inhibitors	   enhance	   the	   resolution	   of	  inflammation	  by	  promoting	  inflammatory	  cell	  apoptosis.	  Nat	  Med,	  12,	  1056-­‐64.	  ROTSTEIN,	  O.	  D.,	  FIEGEL,	  V.	  D.,	  SIMMONS,	  R.	  L.	  &	  KNIGHTON,	  D.	  R.	  1988.	  The	  deleterious	  effect	  of	  reduced	  pH	  and	  hypoxia	  on	  neutrophil	  migration	   in	  vitro.	   J	  Surg	  Res,	  45,	  298-­‐303.	  
References 
	   258	  
ROUBEY,	  R.	  A.,	  ROSS,	  G.	  D.,	  MERRILL,	   J.	  T.,	  WALTON,	  F.,	  REED,	  W.,	  WINCHESTER,	  R.	   J.	  &	  BUYON,	   J.	   P.	   1991.	   Staurosporine	   inhibits	   neutrophil	   phagocytosis	   but	   not	   iC3b	  binding	  mediated	  by	  CR3	  (CD11b/CD18).	  J	  Immunol,	  146,	  3557-­‐62.	  ROWLAND,	   S.	   L.,	   RIGGS,	   J.	   M.,	   GILFILLAN,	   S.,	   BUGATTI,	   M.,	   VERMI,	   W.,	   KOLBECK,	   R.,	  UNANUE,	  E.	  R.,	  SANJUAN,	  M.	  A.	  &	  COLONNA,	  M.	  2014.	  Early,	  transient	  depletion	  of	  plasmacytoid	   dendritic	   cells	   ameliorates	   autoimmunity	   in	   a	   lupus	   model.	   J	   Exp	  
Med,	  211,	  1977-­‐91.	  SABROE,	   I.,	   JONES,	   E.	   C.,	   USHER,	   L.	   R.,	   WHYTE,	   M.	   K.	   &	   DOWER,	   S.	   K.	   2002.	   Toll-­‐like	  receptor	  (TLR)2	  and	  TLR4	  in	  human	  peripheral	  blood	  granulocytes:	  a	  critical	  role	  for	  monocytes	   in	   leukocyte	   lipopolysaccharide	   responses.	   J	   Immunol,	   168,	   4701-­‐10.	  SADIK,	  C.	  D.,	  KIM,	  N.	  D.,	  IWAKURA,	  Y.	  &	  LUSTER,	  A.	  D.	  2012.	  Neutrophils	  orchestrate	  their	  own	  recruitment	  in	  murine	  arthritis	  through	  C5aR	  and	  FcgammaR	  signaling.	  Proc	  
Natl	  Acad	  Sci	  U	  S	  A,	  109,	  E3177-­‐85.	  SALMON,	  J.	  E.,	  GIRARDI,	  G.	  &	  HOLERS,	  V.	  M.	  2002.	  Complement	  activation	  as	  a	  mediator	  of	  antiphospholipid	   antibody	   induced	   pregnancy	   loss	   and	   thrombosis.	   Ann	   Rheum	  
Dis,	  61	  Suppl	  2,	  ii46-­‐50.	  SALMON,	  J.	  E.,	  MILLARD,	  S.,	  SCHACHTER,	  L.	  A.,	  ARNETT,	  F.	  C.,	  GINZLER,	  E.	  M.,	  GOURLEY,	  M.	  F.,	  RAMSEY-­‐GOLDMAN,	  R.,	   PETERSON,	  M.	  G.	  &	  KIMBERLY,	  R.	  P.	   1996.	  Fc	   gamma	  RIIA	   alleles	   are	   heritable	   risk	   factors	   for	   lupus	   nephritis	   in	   African	   Americans.	   J	  
Clin	  Invest,	  97,	  1348-­‐54.	  SAMBANDAM,	   T.,	   BELOUSOVA,	   M.,	   ACCAVITI-­‐LOPER,	   M.	   A.,	   BLANQUICETT,	   C.,	  GUERCELLO,	   V.,	   RAIJMAKERS,	   R.	   &	   NICHOLAS,	   A.	   P.	   2004.	   Increased	  peptidylarginine	   deiminase	   type	   II	   in	   hypoxic	   astrocytes.	   Biochem	   Biophys	   Res	  
Commun,	  325,	  1324-­‐9.	  SANCHEZ-­‐MEJORADA,	  G.	  &	  ROSALES,	  C.	  1998.	  Signal	  transduction	  by	  immunoglobulin	  Fc	  receptors.	  J	  Leukoc	  Biol,	  63,	  521-­‐33.	  SATTA,	  N.,	  DUNOYER-­‐GEINDRE,	  S.,	  REBER,	  G.,	  FISH,	  R.	  J.,	  BOEHLEN,	  F.,	  KRUITHOF,	  E.	  K.	  &	  DE	   MOERLOOSE,	   P.	   2007.	   The	   role	   of	   TLR2	   in	   the	   inflammatory	   activation	   of	  mouse	  fibroblasts	  by	  human	  antiphospholipid	  antibodies.	  Blood,	  109,	  1507-­‐14.	  SATTA,	   N.,	   KRUITHOF,	   E.	   K.,	   FICKENTSCHER,	   C.,	   DUNOYER-­‐GEINDRE,	   S.,	   BOEHLEN,	   F.,	  REBER,	  G.,	  BURGER,	  D.	  &	  DE	  MOERLOOSE,	  P.	  2011.	  Toll-­‐like	  receptor	  2	  mediates	  the	   activation	   of	   human	   monocytes	   and	   endothelial	   cells	   by	   antiphospholipid	  antibodies.	  Blood,	  117,	  5523-­‐31.	  SAVILL,	  J.	  1997.	  Apoptosis	  in	  resolution	  of	  inflammation.	  J	  Leukoc	  Biol,	  61,	  375-­‐80.	  SCHELLEKENS,	  G.	  A.,	  DE	  JONG,	  B.	  A.,	  VAN	  DEN	  HOOGEN,	  F.	  H.,	  VAN	  DE	  PUTTE,	  L.	  B.	  &	  VAN	  VENROOIJ,	   W.	   J.	   1998.	   Citrulline	   is	   an	   essential	   constituent	   of	   antigenic	  determinants	   recognized	   by	   rheumatoid	   arthritis-­‐specific	   autoantibodies.	   J	   Clin	  
Invest,	  101,	  273-­‐81.	  SCHELLEKENS,	   G.	   A.,	   VISSER,	  H.,	   DE	   JONG,	   B.	   A.,	   VAN	  DEN	  HOOGEN,	   F.	  H.,	   HAZES,	   J.	  M.,	  BREEDVELD,	   F.	   C.	   &	   VAN	   VENROOIJ,	   W.	   J.	   2000.	   The	   diagnostic	   properties	   of	  rheumatoid	  arthritis	  antibodies	  recognizing	  a	  cyclic	  citrullinated	  peptide.	  Arthritis	  
Rheum,	  43,	  155-­‐63.	  SCHENKEL,	  A.	  R.,	  CHEW,	  T.	  W.	  &	  MULLER,	  W.	  A.	  2004a.	  Platelet	  endothelial	  cell	  adhesion	  molecule	   deficiency	   or	   blockade	   significantly	   reduces	   leukocyte	   emigration	   in	   a	  majority	  of	  mouse	  strains.	  J	  Immunol,	  173,	  6403-­‐8.	  SCHENKEL,	  A.	  R.,	  MAMDOUH,	  Z.,	  CHEN,	  X.,	  LIEBMAN,	  R.	  M.	  &	  MULLER,	  W.	  A.	  2002.	  CD99	  plays	   a	  major	   role	   in	   the	  migration	   of	  monocytes	   through	   endothelial	   junctions.	  
Nat	  Immunol,	  3,	  143-­‐50.	  SCHENKEL,	   A.	   R.,	  MAMDOUH,	   Z.	   &	  MULLER,	  W.	   A.	   2004b.	   Locomotion	   of	  monocytes	   on	  endothelium	  is	  a	  critical	  step	  during	  extravasation.	  Nat	  Immunol,	  5,	  393-­‐400.	  SCHEPIS,	  D.,	  GUNNARSSON,	  I.,	  ELORANTA,	  M.	  L.,	  LAMPA,	  J.,	  JACOBSON,	  S.	  H.,	  KARRE,	  K.	  &	  BERG,	  L.	  2009.	  Increased	  proportion	  of	  CD56bright	  natural	  killer	  cells	  in	  active	  and	  inactive	  systemic	  lupus	  erythematosus.	  Immunology,	  126,	  140-­‐6.	  
References 
	   259	  
SCHETT,	   G.	   &	   TEITELBAUM,	   S.	   L.	   2009.	   Osteoclasts	   and	   arthritis.	   J	   Bone	  Miner	   Res,	   24,	  1142-­‐6.	  SCHIEFERDECKER,	   H.	   L.,	   ULLRICH,	   R.,	   WEISS-­‐BRECKWOLDT,	   A.	   N.,	   SCHWARTING,	   R.,	  STEIN,	   H.,	   RIECKEN,	   E.	   O.	   &	   ZEITZ,	   M.	   1990.	   The	   HML-­‐1	   antigen	   of	   intestinal	  lymphocytes	  is	  an	  activation	  antigen.	  J	  Immunol,	  144,	  2541-­‐9.	  SCHORN,	  C.,	   JANKO,	  C.,	  KRENN,	  V.,	  ZHAO,	  Y.,	  MUNOZ,	  L.	  E.,	  SCHETT,	  G.	  &	  HERRMANN,	  M.	  2012.	   Bonding	   the	   foe	   -­‐	   NETting	   neutrophils	   immobilize	   the	   pro-­‐inflammatory	  monosodium	  urate	  crystals.	  Front	  Immunol,	  3,	  376.	  SELAK,	   M.	   A.,	   ARMOUR,	   S.	   M.,	   MACKENZIE,	   E.	   D.,	   BOULAHBEL,	   H.,	   WATSON,	   D.	   G.,	  MANSFIELD,	  K.	  D.,	  PAN,	  Y.,	  SIMON,	  M.	  C.,	  THOMPSON,	  C.	  B.	  &	  GOTTLIEB,	  E.	  2005.	  Succinate	   links	   TCA	   cycle	   dysfunction	   to	   oncogenesis	   by	   inhibiting	   HIF-­‐alpha	  prolyl	  hydroxylase.	  Cancer	  Cell,	  7,	  77-­‐85.	  SEMENZA,	   G.	   L.	   &	  WANG,	   G.	   L.	   1992.	   A	   nuclear	   factor	   induced	   by	   hypoxia	   via	   de	   novo	  protein	   synthesis	   binds	   to	   the	   human	   erythropoietin	   gene	   enhancer	   at	   a	   site	  required	  for	  transcriptional	  activation.	  Mol	  Cell	  Biol,	  12,	  5447-­‐54.	  SENGELOV,	   H.,	   BOULAY,	   F.,	   KJELDSEN,	   L.	   &	   BORREGAARD,	   N.	   1994a.	   Subcellular	  localization	   and	   translocation	   of	   the	   receptor	   for	   N-­‐formylmethionyl-­‐leucyl-­‐phenylalanine	  in	  human	  neutrophils.	  Biochem	  J,	  299	  (	  Pt	  2),	  473-­‐9.	  SENGELOV,	  H.,	  KJELDSEN,	  L.,	  DIAMOND,	  M.	  S.,	  SPRINGER,	  T.	  A.	  &	  BORREGAARD,	  N.	  1993.	  Subcellular	   localization	   and	   dynamics	   of	   Mac-­‐1	   (alpha	   m	   beta	   2)	   in	   human	  neutrophils.	  J	  Clin	  Invest,	  92,	  1467-­‐76.	  SENGELOV,	   H.,	   KJELDSEN,	   L.,	   KROEZE,	   W.,	   BERGER,	   M.	   &	   BORREGAARD,	   N.	   1994b.	  Secretory	   vesicles	   are	   the	   intracellular	   reservoir	   of	   complement	   receptor	   1	   in	  human	  neutrophils.	  J	  Immunol,	  153,	  804-­‐10.	  SENGELOV,	  H.,	  NIELSEN,	  M.	  H.	  &	  BORREGAARD,	  N.	  1992.	  Separation	  of	  human	  neutrophil	  plasma	  membrane	  from	  intracellular	  vesicles	  containing	  alkaline	  phosphatase	  and	  NADPH	  oxidase	  activity	  by	  free	  flow	  electrophoresis.	  J	  Biol	  Chem,	  267,	  14912-­‐7.	  SEQUEIRA,	  J.	  F.,	  KESER,	  G.,	  GREENSTEIN,	  B.,	  WHEELER,	  M.	  J.,	  DUARTE,	  P.	  C.,	  KHAMASHTA,	  M.	  A.	  &	  HUGHES,	  G.	  R.	  1993.	  Systemic	  lupus	  erythematosus:	  sex	  hormones	  in	  male	  patients.	  Lupus,	  2,	  315-­‐7.	  SESTAK,	   A.	   L.,	   FURNROHR,	   B.	   G.,	   HARLEY,	   J.	   B.,	  MERRILL,	   J.	   T.	   &	  NAMJOU,	   B.	   2011.	   The	  genetics	   of	   systemic	   lupus	   erythematosus	   and	   implications	   for	   targeted	   therapy.	  
Ann	  Rheum	  Dis,	  70	  Suppl	  1,	  i37-­‐43.	  SHAW,	  S.	  K.,	  MA,	  S.,	  KIM,	  M.	  B.,	  RAO,	  R.	  M.,	  HARTMAN,	  C.	  U.,	  FROIO,	  R.	  M.,	  YANG,	  L.,	  JONES,	  T.,	   LIU,	   Y.,	   NUSRAT,	   A.,	   PARKOS,	   C.	   A.	   &	   LUSCINSKAS,	   F.	   W.	   2004.	   Coordinated	  redistribution	   of	   leukocyte	   LFA-­‐1	   and	   endothelial	   cell	   ICAM-­‐1	   accompany	  neutrophil	  transmigration.	  J	  Exp	  Med,	  200,	  1571-­‐80.	  SHEN,	  B.,	  DELANEY,	  M.	  K.	  &	  DU,	  X.	   2012.	   Inside-­‐out,	   outside-­‐in,	   and	   inside-­‐outside-­‐in:	  G	  protein	   signaling	   in	   integrin-­‐mediated	   cell	   adhesion,	   spreading,	   and	   retraction.	  
Curr	  Opin	  Cell	  Biol,	  24,	  600-­‐6.	  SHENG,	   Y.,	   SALI,	   A.,	   HERZOG,	   H.,	   LAHNSTEIN,	   J.	   &	   KRILIS,	   S.	   A.	   1996.	   Site-­‐directed	  mutagenesis	   of	   recombinant	   human	   beta	   2-­‐glycoprotein	   I	   identifies	   a	   cluster	   of	  lysine	   residues	   that	   are	   critical	   for	   phospholipid	   binding	   and	   anti-­‐cardiolipin	  antibody	  activity.	  J	  Immunol,	  157,	  3744-­‐51.	  SHIMAOKA,	  M.,	  XIAO,	  T.,	  LIU,	  J.	  H.,	  YANG,	  Y.,	  DONG,	  Y.,	  JUN,	  C.	  D.,	  MCCORMACK,	  A.,	  ZHANG,	  R.,	  JOACHIMIAK,	  A.,	  TAKAGI,	  J.,	  WANG,	  J.	  H.	  &	  SPRINGER,	  T.	  A.	  2003.	  Structures	  of	  the	  alpha	  L	  I	  domain	  and	  its	  complex	  with	  ICAM-­‐1	  reveal	  a	  shape-­‐shifting	  pathway	  for	  integrin	  regulation.	  Cell,	  112,	  99-­‐111.	  SHIRAFUJI,	   N.,	   MATSUDA,	   S.,	   OGURA,	   H.,	   TANI,	   K.,	   KODO,	   H.,	   OZAWA,	   K.,	   NAGATA,	   S.,	  ASANO,	   S.	   &	   TAKAKU,	   F.	   1990.	   Granulocyte	   colony-­‐stimulating	   factor	   stimulates	  human	  mature	   neutrophilic	   granulocytes	   to	   produce	   interferon-­‐alpha.	  Blood,	   75,	  17-­‐9.	  SHOENFELD,	   Y.,	   BLANK,	   M.,	   CERVERA,	   R.,	   FONT,	   J.,	   RASCHI,	   E.	   &	   MERONI,	   P.	   L.	   2006.	  Infectious	  origin	  of	  the	  antiphospholipid	  syndrome.	  Ann	  Rheum	  Dis,	  65,	  2-­‐6.	  
References 
	   260	  
SIMANTOV,	  R.,	  LASALA,	  J.	  M.,	  LO,	  S.	  K.,	  GHARAVI,	  A.	  E.,	  SAMMARITANO,	  L.	  R.,	  SALMON,	  J.	  E.	  &	   SILVERSTEIN,	   R.	   L.	   1995.	   Activation	   of	   cultured	   vascular	   endothelial	   cells	   by	  antiphospholipid	  antibodies.	  J	  Clin	  Invest,	  96,	  2211-­‐9.	  SIMMS,	   H.	   H.	   &	   D'AMICO,	   R.	   1994.	   Regulation	   of	   whole	   blood	   polymorphonuclear	  leukocyte	   phagocytosis	   following	   hypoxemia	   and	   hypoxemia/reoxygenation.	  
Shock,	  1,	  10-­‐8.	  SIVAKUMAR,	   B.,	   AKHAVANI,	   M.	   A.,	   WINLOVE,	   C.	   P.,	   TAYLOR,	   P.	   C.,	   PALEOLOG,	   E.	   M.	   &	  KANG,	   N.	   2008.	   Synovial	   hypoxia	   as	   a	   cause	   of	   tendon	   rupture	   in	   rheumatoid	  arthritis.	  J	  Hand	  Surg	  Am,	  33,	  49-­‐58.	  SKOGH,	   T.	   &	   PEEN,	   E.	   1993.	   Lactoferrin,	   anti-­‐lactoferrin	   antibodies	   and	   inflammatory	  disease.	  Adv	  Exp	  Med	  Biol,	  336,	  533-­‐8.	  SMITH,	   G.	   P.,	   SHARP,	   G.	   &	   PETERS,	   T.	   J.	   1985.	   Isolation	   and	   characterization	   of	   alkaline	  phosphatase-­‐containing	   granules	   (phosphasomes)	   from	   human	  polymorphonuclear	  leucocytes.	  J	  Cell	  Sci,	  76,	  167-­‐78.	  SMOLEN,	   J.	   S.,	   ALETAHA,	   D.,	   KOELLER,	   M.,	   WEISMAN,	   M.	   H.	   &	   EMERY,	   P.	   2007.	   New	  therapies	  for	  treatment	  of	  rheumatoid	  arthritis.	  Lancet,	  370,	  1861-­‐74.	  SMOLEN,	  J.	  S.	  &	  STEINER,	  G.	  2003.	  Therapeutic	  strategies	  for	  rheumatoid	  arthritis.	  Nat	  Rev	  
Drug	  Discov,	  2,	  473-­‐88.	  SONG,	  G.,	  YANG,	  Y.,	  LIU,	  J.	  H.,	  CASASNOVAS,	  J.	  M.,	  SHIMAOKA,	  M.,	  SPRINGER,	  T.	  A.	  &	  WANG,	  J.	  H.	  2005.	  An	  atomic	   resolution	  view	  of	   ICAM	  recognition	   in	  a	   complex	  between	  the	  binding	  domains	  of	  ICAM-­‐3	  and	  integrin	  alphaLbeta2.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  102,	  3366-­‐71.	  SORICE,	  M.,	  LONGO,	  A.,	  CAPOZZI,	  A.,	  GAROFALO,	  T.,	  MISASI,	  R.,	  ALESSANDRI,	  C.,	  CONTI,	  F.,	  BUTTARI,	   B.,	   RIGANO,	   R.,	   ORTONA,	   E.	   &	   VALESINI,	   G.	   2007.	   Anti-­‐beta2-­‐glycoprotein	  I	  antibodies	  induce	  monocyte	  release	  of	  tumor	  necrosis	  factor	  alpha	  and	   tissue	   factor	   by	   signal	   transduction	   pathways	   involving	   lipid	   rafts.	   Arthritis	  
Rheum,	  56,	  2687-­‐97.	  SPENGLER,	   J.,	   LUGONJA,	   B.,	   JIMMY	   YTTERBERG,	   A.,	   ZUBAREV,	   R.	   A.,	   CREESE,	   A.	   J.,	  PEARSON,	   M.	   J.,	   GRANT,	   M.	   M.,	   MILWARD,	   M.,	   LUNDBERG,	   K.,	   BUCKLEY,	   C.	   D.,	  FILER,	  A.,	  RAZA,	  K.,	  COOPER,	  P.	  R.,	  CHAPPLE,	  I.	  L.	  &	  SCHEEL-­‐TOELLNER,	  D.	  2015.	  Release	   of	   Active	   Peptidyl	   Arginine	   Deiminases	   by	   Neutrophils	   Can	   Explain	  Production	   of	   Extracellular	   Citrullinated	   Autoantigens	   in	   Rheumatoid	   Arthritis	  Synovial	  Fluid.	  Arthritis	  Rheumatol,	  67,	  3135-­‐45.	  SPRINGER,	   T.	   A.	   &	   DUSTIN,	   M.	   L.	   2012.	   Integrin	   inside-­‐out	   signaling	   and	   the	  immunological	  synapse.	  Curr	  Opin	  Cell	  Biol,	  24,	  107-­‐15.	  SRIRAMARAO,	  P.,	  VON	  ANDRIAN,	  U.	  H.,	  BUTCHER,	  E.	  C.,	  BOURDON,	  M.	  A.	  &	  BROIDE,	  D.	  H.	  1994.	   L-­‐selectin	   and	   very	   late	   antigen-­‐4	   integrin	   promote	   eosinophil	   rolling	   at	  physiological	  shear	  rates	  in	  vivo.	  J	  Immunol,	  153,	  4238-­‐46.	  STAATZ,	  W.	  D.,	  RAJPARA,	  S.	  M.,	  WAYNER,	  E.	  A.,	  CARTER,	  W.	  G.	  &	  SANTORO,	  S.	  A.	  1989.	  The	  membrane	   glycoprotein	   Ia-­‐IIa	   (VLA-­‐2)	   complex	   mediates	   the	   Mg++-­‐dependent	  adhesion	  of	  platelets	  to	  collagen.	  J	  Cell	  Biol,	  108,	  1917-­‐24.	  STANLEY,	   P.,	   BATES,	   P.	  A.,	  HARVEY,	   J.,	   BENNETT,	  R.	   I.	  &	  HOGG,	  N.	   1994.	   Integrin	   LFA-­‐1	  alpha	   subunit	   contains	   an	   ICAM-­‐1	  binding	   site	   in	   domains	  V	   and	  VI.	  EMBO	  J,	   13,	  1790-­‐8.	  STEINER,	  B.,	  PARISE,	  L.	  V.,	  LEUNG,	  B.	  &	  PHILLIPS,	  D.	  R.	  1991.	  Ca(2+)-­‐dependent	  structural	  transitions	   of	   the	   platelet	   glycoprotein	   IIb-­‐IIIa	   complex.	   Preparation	   of	   stable	  glycoprotein	  IIb	  and	  IIIa	  monomers.	  J	  Biol	  Chem,	  266,	  14986-­‐91.	  STEVENSON,	  K.	  B.,	  NAUSEEF,	  W.	  M.	  &	  CLARK,	  R.	  A.	  1987.	  The	  neutrophil	  glycoprotein	  Mo1	  is	   an	   integral	   membrane	   protein	   of	   plasma	   membranes	   and	   specific	   granules.	   J	  
Immunol,	  139,	  3759-­‐63.	  STHOEGER,	   Z.	   M.,	   BEZALEL,	   S.,	   CHAPNIK,	   N.,	   ASHER,	   I.	   &	   FROY,	   O.	   2009.	   High	   alpha-­‐defensin	   levels	   in	  patients	  with	  systemic	   lupus	  erythematosus.	   Immunology,	  127,	  116-­‐22.	  
References 
	   261	  
STRAUB,	  R.	  H.,	  BIJLSMA,	   J.	  W.,	  MASI,	  A.	  &	  CUTOLO,	  M.	  2013.	  Role	  of	  neuroendocrine	  and	  neuroimmune	  mechanisms	   in	   chronic	   inflammatory	   rheumatic	   diseases-­‐-­‐the	   10-­‐year	  update.	  Semin	  Arthritis	  Rheum,	  43,	  392-­‐404.	  STRIETER,	  R.	  M.,	  KASAHARA,	  K.,	  ALLEN,	  R.	  M.,	  STANDIFORD,	  T.	  J.,	  ROLFE,	  M.	  W.,	  BECKER,	  F.	  S.,	  CHENSUE,	  S.	  W.	  &	  KUNKEL,	  S.	  L.	  1992.	  Cytokine-­‐induced	  neutrophil-­‐derived	  interleukin-­‐8.	  Am	  J	  Pathol,	  141,	  397-­‐407.	  STROHMEIER,	  G.	  R.,	  BRUNKHORST,	  B.	  A.,	  SEETOO,	  K.	  F.,	  MESHULAM,	  T.,	  BERNARDO,	  J.	  &	  SIMONS,	   E.	   R.	   1995.	   Role	   of	   the	   Fc	   gamma	   R	   subclasses	   Fc	   gamma	   RII	   and	   Fc	  gamma	   RIII	   in	   the	   activation	   of	   human	   neutrophils	   by	   low	   and	   high	   valency	  immune	  complexes.	  J	  Leukoc	  Biol,	  58,	  415-­‐22.	  SUCHARD,	  S.	  J.,	  BURTON,	  M.	  J.	  &	  STOEHR,	  S.	  J.	  1992.	  Thrombospondin	  receptor	  expression	  in	   human	   neutrophils	   coincides	   with	   the	   release	   of	   a	   subpopulation	   of	   specific	  granules.	  Biochem	  J,	  284	  (	  Pt	  2),	  513-­‐20.	  SUCHARD,	  S.	  J.,	  STETSKO,	  D.	  K.,	  DAVIS,	  P.	  M.,	  SKALA,	  S.,	  POTIN,	  D.,	  LAUNAY,	  M.,	  DHAR,	  T.	  G.,	  BARRISH,	   J.	   C.,	   SUSULIC,	   V.,	   SHUSTER,	   D.	   J.,	  MCINTYRE,	   K.	  W.,	  MCKINNON,	  M.	   &	  SALTER-­‐CID,	  L.	  2010.	  An	  LFA-­‐1	  (alphaLbeta2)	  small-­‐molecule	  antagonist	  reduces	  inflammation	  and	  joint	  destruction	  in	  murine	  models	  of	  arthritis.	  J	  Immunol,	  184,	  3917-­‐26.	  SUH,	  Y.	  H.,	  SHIN,	  Y.	  K.,	  KOOK,	  M.	  C.,	  OH,	  K.	  I.,	  PARK,	  W.	  S.,	  KIM,	  S.	  H.,	  LEE,	  I.	  S.,	  PARK,	  H.	  J.,	  HUH,	   T.	   L.	   &	   PARK,	   S.	   H.	   2003.	   Cloning,	   genomic	   organization,	   alternative	  transcripts	   and	   expression	   analysis	   of	   CD99L2,	   a	   novel	   paralog	   of	   human	   CD99,	  and	  identification	  of	  evolutionary	  conserved	  motifs.	  Gene,	  307,	  63-­‐76.	  SULLIVAN,	  K.	  E.,	  SURIANO,	  A.,	  DIETZMANN,	  K.,	  LIN,	  J.,	  GOLDMAN,	  D.	  &	  PETRI,	  M.	  A.	  2007.	  The	   TNFalpha	   locus	   is	   altered	   in	   monocytes	   from	   patients	   with	   systemic	   lupus	  erythematosus.	  Clin	  Immunol,	  123,	  74-­‐81.	  SUNDD,	  P.,	  GUTIERREZ,	  E.,	  KOLTSOVA,	  E.	  K.,	  KUWANO,	  Y.,	   FUKUDA,	  S.,	  POSPIESZALSKA,	  M.	  K.,	  GROISMAN,	  A.	  &	  LEY,	  K.	  2012.	  'Slings'	  enable	  neutrophil	  rolling	  at	  high	  shear.	  
Nature,	  488,	  399-­‐403.	  SUR	  CHOWDHURY,	  C.,	  GIAGLIS,	  S.,	  WALKER,	  U.	  A.,	  BUSER,	  A.,	  HAHN,	  S.	  &	  HASLER,	  P.	  2014.	  Enhanced	   neutrophil	   extracellular	   trap	   generation	   in	   rheumatoid	   arthritis:	  analysis	   of	   underlying	   signal	   transduction	   pathways	   and	   potential	   diagnostic	  utility.	  Arthritis	  Res	  Ther,	  16,	  R122.	  SUZUKI,	  T.,	   IKARI,	  K.,	  YANO,	  K.,	  INOUE,	  E.,	  TOYAMA,	  Y.,	  TANIGUCHI,	  A.,	  YAMANAKA,	  H.	  &	  MOMOHARA,	   S.	   2013.	   PADI4	   and	   HLA-­‐DRB1	   are	   genetic	   risks	   for	   radiographic	  progression	   in	  RA	  patients,	   independent	   of	  ACPA	   status:	   results	   from	   the	   IORRA	  cohort	  study.	  PLoS	  One,	  8,	  e61045.	  TAKAGI,	   J.,	   DEBOTTIS,	   D.	   P.,	   ERICKSON,	   H.	   P.	   &	   SPRINGER,	   T.	   A.	   2002a.	   The	   role	   of	   the	  specificity-­‐determining	   loop	   of	   the	   integrin	   beta	   subunit	   I-­‐like	   domain	   in	  autonomous	   expression,	   association	   with	   the	   alpha	   subunit,	   and	   ligand	   binding.	  
Biochemistry,	  41,	  4339-­‐47.	  TAKAGI,	   J.,	   PETRE,	   B.	   M.,	   WALZ,	   T.	   &	   SPRINGER,	   T.	   A.	   2002b.	   Global	   conformational	  rearrangements	   in	   integrin	   extracellular	   domains	   in	   outside-­‐in	   and	   inside-­‐out	  signaling.	  Cell,	  110,	  599-­‐11.	  TAKAGI,	   J.,	   STROKOVICH,	   K.,	   SPRINGER,	   T.	   A.	   &	   WALZ,	   T.	   2003.	   Structure	   of	   integrin	  alpha5beta1	  in	  complex	  with	  fibronectin.	  EMBO	  J,	  22,	  4607-­‐15.	  TAKAHASHI,	  G.	  W.,	  ANDREWS,	  D.	  F.,	  3RD,	  LILLY,	  M.	  B.,	  SINGER,	  J.	  W.	  &	  ALDERSON,	  M.	  R.	  1993.	  Effect	  of	  granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  and	  interleukin-­‐3	   on	   interleukin-­‐8	   production	   by	   human	   neutrophils	   and	   monocytes.	   Blood,	   81,	  357-­‐64.	  TAKAHASHI,	  K.,	  NAKAMURA,	  T.,	  ADACHI,	  H.,	  YAGITA,	  H.	  &	  OKUMURA,	  K.	  1991.	  Antigen-­‐independent	   T	   cell	   activation	   mediated	   by	   a	   very	   late	   activation	   antigen-­‐like	  extracellular	  matrix	  receptor.	  Eur	  J	  Immunol,	  21,	  1559-­‐62.	  TAKEI,	   H.,	   ARAKI,	   A.,	   WATANABE,	   H.,	   ICHINOSE,	   A.	   &	   SENDO,	   F.	   1996.	   Rapid	   killing	   of	  human	  neutrophils	  by	  the	  potent	  activator	  phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	  
References 
	   262	  
accompanied	  by	  changes	  different	  from	  typical	  apoptosis	  or	  necrosis.	  J	  Leukoc	  Biol,	  59,	  229-­‐40.	  TAKEUCHI,	  O.,	  HOSHINO,	  K.,	  KAWAI,	  T.,	  SANJO,	  H.,	  TAKADA,	  H.,	  OGAWA,	  T.,	  TAKEDA,	  K.	  &	  AKIRA,	   S.	   1999.	   Differential	   roles	   of	   TLR2	   and	   TLR4	   in	   recognition	   of	   gram-­‐negative	  and	  gram-­‐positive	  bacterial	  cell	  wall	  components.	  Immunity,	  11,	  443-­‐51.	  TAKEUCHI,	   T.,	   SUZUKI,	   K.,	   KONDO,	   T.,	   YOSHIMOTO,	   K.	   &	   TSUZAKA,	   K.	   2012.	   CD3	   zeta	  defects	  in	  systemic	  lupus	  erythematosus.	  Ann	  Rheum	  Dis,	  71	  Suppl	  2,	  i78-­‐81.	  TAMKUN,	   J.	  W.,	   DESIMONE,	  D.	  W.,	   FONDA,	  D.,	   PATEL,	   R.	   S.,	   BUCK,	   C.,	   HORWITZ,	   A.	   F.	   &	  HYNES,	   R.	   O.	   1986.	   Structure	   of	   integrin,	   a	   glycoprotein	   involved	   in	   the	  transmembrane	  linkage	  between	  fibronectin	  and	  actin.	  Cell,	  46,	  271-­‐82.	  TAMURA,	  D.	  Y.,	  MOORE,	  E.	  E.,	  PARTRICK,	  D.	  A.,	  JOHNSON,	  J.	  L.,	  OFFNER,	  P.	  J.	  &	  SILLIMAN,	  C.	  C.	   2002.	   Acute	   hypoxemia	   in	   humans	   enhances	   the	   neutrophil	   inflammatory	  response.	  Shock,	  17,	  269-­‐73.	  TANAKA,	  N.,	  KIM,	  J.	  S.,	  NEWELL,	  J.	  D.,	  BROWN,	  K.	  K.,	  COOL,	  C.	  D.,	  MEEHAN,	  R.,	  EMOTO,	  T.,	  MATSUMOTO,	  T.	  &	  LYNCH,	  D.	  A.	  2004.	  Rheumatoid	  arthritis-­‐related	  lung	  diseases:	  CT	  findings.	  Radiology,	  232,	  81-­‐91.	  TANAKA,	  S.,	  MAEDA,	  S.,	  HASHIMOTO,	  M.,	  FUJIMORI,	  C.,	  ITO,	  Y.,	  TERADAIRA,	  S.,	  HIROTA,	  K.,	  YOSHITOMI,	   H.,	   KATAKAI,	   T.,	   SHIMIZU,	   A.,	   NOMURA,	   T.,	   SAKAGUCHI,	   N.	   &	  SAKAGUCHI,	   S.	   2010.	   Graded	   attenuation	   of	   TCR	   signaling	   elicits	   distinct	  autoimmune	   diseases	   by	   altering	   thymic	   T	   cell	   selection	   and	   regulatory	   T	   cell	  function.	  J	  Immunol,	  185,	  2295-­‐305.	  TAPPER,	  H.	  &	  GRINSTEIN,	   S.	  1997.	  Fc	   receptor-­‐triggered	   insertion	  of	   secretory	  granules	  into	   the	   plasma	   membrane	   of	   human	   neutrophils:	   selective	   retrieval	   during	  phagocytosis.	  J	  Immunol,	  159,	  409-­‐18.	  TEICHMANN,	  L.	  L.,	  OLS,	  M.	  L.,	  KASHGARIAN,	  M.,	  REIZIS,	  B.,	  KAPLAN,	  D.	  H.	  &	  SHLOMCHIK,	  M.	  J.	  2010.	  Dendritic	  cells	  in	  lupus	  are	  not	  required	  for	  activation	  of	  T	  and	  B	  cells	  but	  promote	  their	  expansion,	  resulting	  in	  tissue	  damage.	  Immunity,	  33,	  967-­‐78.	  TERVAERT,	   J.	   W.,	   MULDER,	   L.,	   STEGEMAN,	   C.,	   ELEMA,	   J.,	   HUITEMA,	   M.,	   THE,	   H.	   &	  KALLENBERG,	  C.	  1993.	  Occurrence	  of	  autoantibodies	  to	  human	  leucocyte	  elastase	  in	  Wegener's	   granulomatosis	   and	   other	   inflammatory	   disorders.	  Ann	  Rheum	  Dis,	  52,	  115-­‐20.	  TIAN,	   H.,	   MCKNIGHT,	   S.	   L.	   &	   RUSSELL,	   D.	   W.	   1997.	   Endothelial	   PAS	   domain	   protein	   1	  (EPAS1),	   a	   transcription	   factor	   selectively	   expressed	   in	   endothelial	   cells.	   Genes	  
Dev,	  11,	  72-­‐82.	  TIAN,	   L.,	   KILGANNON,	   P.,	   YOSHIHARA,	   Y.,	   MORI,	   K.,	   GALLATIN,	   W.	   M.,	   CARPEN,	   O.	   &	  GAHMBERG,	   C.	   G.	   2000.	   Binding	   of	   T	   lymphocytes	   to	   hippocampal	   neurons	  through	   ICAM-­‐5	   (telencephalin)	   and	   characterization	   of	   its	   interaction	   with	   the	  leukocyte	  integrin	  CD11a/CD18.	  Eur	  J	  Immunol,	  30,	  810-­‐8.	  TKALCEVIC,	   J.,	   NOVELLI,	   M.,	   PHYLACTIDES,	   M.,	   IREDALE,	   J.	   P.,	   SEGAL,	   A.	  W.	   &	   ROES,	   J.	  2000.	  Impaired	  immunity	  and	  enhanced	  resistance	  to	  endotoxin	  in	  the	  absence	  of	  neutrophil	  elastase	  and	  cathepsin	  G.	  Immunity,	  12,	  201-­‐10.	  TODD,	  R.	  F.,	  3RD,	  ARNAOUT,	  M.	  A.,	  ROSIN,	  R.	  E.,	  CROWLEY,	  C.	  A.,	  PETERS,	  W.	  A.	  &	  BABIOR,	  B.	   M.	   1984.	   Subcellular	   localization	   of	   the	   large	   subunit	   of	   Mo1	   (Mo1	   alpha;	  formerly	   gp	   110),	   a	   surface	   glycoprotein	   associated	   with	   neutrophil	   adhesion.	   J	  
Clin	  Invest,	  74,	  1280-­‐90.	  TOMASONI,	   S.,	   NORIS,	   M.,	   ZAPPELLA,	   S.,	   GOTTI,	   E.,	   CASIRAGHI,	   F.,	   BONAZZOLA,	   S.,	  BENIGNI,	   A.	   &	   REMUZZI,	   G.	   1998.	   Upregulation	   of	   renal	   and	   systemic	  cyclooxygenase-­‐2	   in	   patients	   with	   active	   lupus	   nephritis.	   J	   Am	   Soc	   Nephrol,	   9,	  1202-­‐12.	  TOTOSON,	   P.,	   MAGUIN-­‐GATE,	   K.,	   PRATI,	   C.,	   WENDLING,	   D.	   &	   DEMOUGEOT,	   C.	   2014.	  Mechanisms	   of	   endothelial	   dysfunction	   in	   rheumatoid	   arthritis:	   lessons	   from	  animal	  studies.	  Arthritis	  Res	  Ther,	  16,	  202.	  TRAVERS,	   J.	   &	   ROTHENBERG,	   M.	   E.	   2015.	   Eosinophils	   in	   mucosal	   immune	   responses.	  
Mucosal	  Immunol,	  8,	  464-­‐75.	  
References 
	   263	  
TSAN,	  M.	  F.	  1980.	  Phorbol	  myristate	  acetate	  induced	  neutrophil	  autotoxicity.	  J	  Cell	  Physiol,	  105,	  327-­‐34.	  TSUJIMURA,	   Y.,	   OBATA,	   K.,	   MUKAI,	   K.,	   SHINDOU,	   H.,	   YOSHIDA,	   M.,	   NISHIKADO,	   H.,	  KAWANO,	  Y.,	  MINEGISHI,	  Y.,	  SHIMIZU,	  T.	  &	  KARASUYAMA,	  H.	  2008.	  Basophils	  play	  a	  pivotal	  role	  in	  immunoglobulin-­‐G-­‐mediated	  but	  not	  immunoglobulin-­‐E-­‐mediated	  systemic	  anaphylaxis.	  Immunity,	  28,	  581-­‐9.	  TSURUTA,	  D.,	  HOPKINSON,	  S.	  B.,	  LANE,	  K.	  D.,	  WERNER,	  M.	  E.,	  CRYNS,	  V.	  L.	  &	   JONES,	   J.	  C.	  2003.	  Crucial	  role	  of	  the	  specificity-­‐determining	  loop	  of	  the	  integrin	  beta4	  subunit	  in	  the	  binding	  of	  cells	  to	  laminin-­‐5	  and	  outside-­‐in	  signal	  transduction.	  J	  Biol	  Chem,	  278,	  38707-­‐14.	  TUCCI,	  M.,	  QUATRARO,	  C.,	  LOMBARDI,	  L.,	  PELLEGRINO,	  C.,	  DAMMACCO,	  F.	  &	  SILVESTRIS,	  F.	   2008.	  Glomerular	   accumulation	  of	   plasmacytoid	  dendritic	   cells	   in	   active	   lupus	  nephritis:	  role	  of	  interleukin-­‐18.	  Arthritis	  Rheum,	  58,	  251-­‐62.	  UEDA,	  T.,	  RIEU,	  P.,	  BRAYER,	   J.	  &	  ARNAOUT,	  M.	  A.	  1994.	   Identification	  of	  the	  complement	  iC3b	  binding	  site	  in	  the	  beta	  2	  integrin	  CR3	  (CD11b/CD18).	  Proc	  Natl	  Acad	  Sci	  U	  S	  
A,	  91,	  10680-­‐4.	  ULRICH,	   V.,	   GELBER,	   S.	   E.,	   VUKELIC,	  M.,	   SACHARIDOU,	   A.,	   HERZ,	   J.,	   URBANUS,	   R.	   T.,	   DE	  GROOT,	   P.	   G.,	   NATALE,	   D.	   R.,	   HARIHARA,	   A.,	   REDECHA,	   P.,	   ABRAHAMS,	   V.	   M.,	  SHAUL,	   P.	   W.,	   SALMON,	   J.	   E.	   &	   MINEO,	   C.	   2016.	   ApoE	   Receptor	   2	   Mediation	   of	  Trophoblast	   Dysfunction	   and	   Pregnancy	   Complications	   Induced	   by	  Antiphospholipid	  Antibodies	  in	  Mice.	  Arthritis	  Rheumatol,	  68,	  730-­‐9.	  URBAN,	   C.	   F.,	   REICHARD,	   U.,	   BRINKMANN,	   V.	   &	   ZYCHLINSKY,	   A.	   2006.	   Neutrophil	  extracellular	   traps	  capture	  and	  kill	  Candida	  albicans	  yeast	  and	  hyphal	   forms.	  Cell	  
Microbiol,	  8,	  668-­‐76.	  VALENCIA,	   X.,	   YARBORO,	   C.,	   ILLEI,	   G.	   &	   LIPSKY,	   P.	   E.	   2007.	   Deficient	   CD4+CD25high	   T	  regulatory	   cell	   function	   in	   patients	   with	   active	   systemic	   lupus	   erythematosus.	   J	  
Immunol,	  178,	  2579-­‐88.	  VAN	   DER	   WOUDE,	   D.,	   RANTAPAA-­‐DAHLQVIST,	   S.,	   IOAN-­‐FACSINAY,	   A.,	   ONNEKINK,	   C.,	  SCHWARTE,	  C.	  M.,	  VERPOORT,	  K.	  N.,	  DRIJFHOUT,	  J.	  W.,	  HUIZINGA,	  T.	  W.,	  TOES,	  R.	  E.	  &	  PRUIJN,	  G.	  J.	  2010.	  Epitope	  spreading	  of	  the	  anti-­‐citrullinated	  protein	  antibody	  response	  occurs	  before	  disease	  onset	  and	  is	  associated	  with	  the	  disease	  course	  of	  early	  arthritis.	  Ann	  Rheum	  Dis,	  69,	  1554-­‐61.	  VAN	  KOOYK,	  Y.,	  WEDER,	  P.,	  HEIJE,	  K.,	  DE	  WAAL	  MALEFIJT,	  R.	  &	  FIGDOR,	  C.	  G.	  1993.	  Role	  of	  intracellular	  Ca2+	  levels	  in	  the	  regulation	  of	  CD11a/CD18	  mediated	  cell	  adhesion.	  
Cell	  Adhes	  Commun,	  1,	  21-­‐32.	  VARGAS-­‐ROJAS,	   M.	   I.,	   CRISPIN,	   J.	   C.,	   RICHAUD-­‐PATIN,	   Y.	   &	   ALCOCER-­‐VARELA,	   J.	   2008.	  Quantitative	  and	  qualitative	  normal	  regulatory	  T	  cells	  are	  not	  capable	  of	  inducing	  suppression	  in	  SLE	  patients	  due	  to	  T-­‐cell	  resistance.	  Lupus,	  17,	  289-­‐94.	  VAUPEL,	   P.,	   BRAUNBECK,	   W.	   &	   THEWS,	   G.	   1973.	   Respiratory	   gas	   exchange	   and	   pO2-­‐distribution	  in	  splenic	  tissue.	  Adv	  Exp	  Med	  Biol,	  37A,	  401-­‐6.	  VEGA-­‐OSTERTAG,	   M.,	   CASPER,	   K.,	   SWERLICK,	   R.,	   FERRARA,	   D.,	   HARRIS,	   E.	   N.	   &	  PIERANGELI,	  S.	   S.	  2005.	   Involvement	  of	  p38	  MAPK	   in	   the	  up-­‐regulation	  of	   tissue	  factor	   on	   endothelial	   cells	   by	   antiphospholipid	   antibodies.	   Arthritis	   Rheum,	   52,	  1545-­‐54.	  VEGA,	   F.	  M.,	   FRUHWIRTH,	  G.,	  NG,	  T.	  &	  RIDLEY,	  A.	   J.	   2011.	  RhoA	  and	  RhoC	  have	  distinct	  roles	  in	  migration	  and	  invasion	  by	  acting	  through	  different	  targets.	  J	  Cell	  Biol,	  193,	  655-­‐65.	  VERPOORT,	  K.	  N.,	  VAN	  GAALEN,	  F.	  A.,	  VAN	  DER	  HELM-­‐VAN	  MIL,	  A.	  H.,	  SCHREUDER,	  G.	  M.,	  BREEDVELD,	  F.	  C.,	  HUIZINGA,	  T.	  W.,	  DE	  VRIES,	  R.	  R.	  &	  TOES,	  R.	  E.	  2005.	  Association	  of	   HLA-­‐DR3	   with	   anti-­‐cyclic	   citrullinated	   peptide	   antibody-­‐negative	   rheumatoid	  arthritis.	  Arthritis	  Rheum,	  52,	  3058-­‐62.	  VILLANUEVA,	  E.,	  YALAVARTHI,	  S.,	  BERTHIER,	  C.	  C.,	  HODGIN,	  J.	  B.,	  KHANDPUR,	  R.,	  LIN,	  A.	  M.,	  RUBIN,	  C.	   J.,	   ZHAO,	  W.,	  OLSEN,	   S.	  H.,	  KLINKER,	  M.,	   SHEALY,	  D.,	  DENNY,	  M.	  F.,	  PLUMAS,	   J.,	   CHAPEROT,	   L.,	   KRETZLER,	   M.,	   BRUCE,	   A.	   T.	   &	   KAPLAN,	   M.	   J.	   2011.	  
References 
	   264	  
Netting	   neutrophils	   induce	   endothelial	   damage,	   infiltrate	   tissues,	   and	   expose	  immunostimulatory	  molecules	   in	   systemic	   lupus	   erythematosus.	   J	   Immunol,	   187,	  538-­‐52.	  VINCENT,	   C.,	   NOGUEIRA,	   L.,	   SEBBAG,	   M.,	   CHAPUY-­‐REGAUD,	   S.,	   ARNAUD,	   M.,	  LETOURNEUR,	   O.,	   ROLLAND,	   D.,	   FOURNIE,	   B.,	   CANTAGREL,	   A.,	   JOLIVET,	   M.	   &	  SERRE,	  G.	  2002.	  Detection	  of	  antibodies	  to	  deiminated	  recombinant	  rat	  filaggrin	  by	  enzyme-­‐linked	   immunosorbent	   assay:	   a	   highly	   effective	   test	   for	   the	   diagnosis	   of	  rheumatoid	  arthritis.	  Arthritis	  Rheum,	  46,	  2051-­‐8.	  VINOGRADOVA,	  O.,	  VELYVIS,	  A.,	  VELYVIENE,	  A.,	  HU,	  B.,	  HAAS,	  T.,	  PLOW,	  E.	  &	  QIN,	  J.	  2002.	  A	   structural	   mechanism	   of	   integrin	   alpha(IIb)beta(3)	   "inside-­‐out"	   activation	   as	  regulated	  by	  its	  cytoplasmic	  face.	  Cell,	  110,	  587-­‐97.	  VOLKHOLZ,	  H.	  J.,	  HOPER,	  J.,	  BRUNNER,	  M.,	  FRANK,	  K.	  H.,	  HARRISON,	  D.	  K.,	  ELLERMANN,	  R.	  &	   KESSLER,	   M.	   1984.	   Measurement	   of	   local	   PO2	   and	   intracapillary	   hemoglobin	  oxygenation	  in	  lung	  tissue	  of	  rabbits.	  Adv	  Exp	  Med	  Biol,	  169,	  633-­‐41.	  VORDENBAUMEN,	  S.,	  FISCHER-­‐BETZ,	  R.,	  TIMM,	  D.,	  SANDER,	  O.,	  CHEHAB,	  G.,	  RICHTER,	   J.,	  BLECK,	  E.	  &	  SCHNEIDER,	  M.	  2010.	  Elevated	   levels	  of	  human	  beta-­‐defensin	  2	  and	  human	  neutrophil	  peptides	  in	  systemic	  lupus	  erythematosus.	  Lupus,	  19,	  1648-­‐53.	  VOSSENAAR,	  E.	  R.,	  NIJENHUIS,	  S.,	  HELSEN,	  M.	  M.,	  VAN	  DER	  HEIJDEN,	  A.,	  SENSHU,	  T.,	  VAN	  DEN	  BERG,	  W.	   B.,	   VAN	  VENROOIJ,	  W.	   J.	   &	   JOOSTEN,	   L.	   A.	   2003.	   Citrullination	   of	  synovial	   proteins	   in	  murine	  models	   of	   rheumatoid	   arthritis.	  Arthritis	  Rheum,	   48,	  2489-­‐500.	  WALKER,	  B.	  A.,	  HAGENLOCKER,	  B.	  E.,	  STUBBS,	  E.	  B.,	   JR.,	  SANDBORG,	  R.	  R.,	  AGRANOFF,	  B.	  W.	  &	  WARD,	  P.	  A.	  1991.	  Signal	  transduction	  events	  and	  Fc	  gamma	  R	  engagement	  in	  human	  neutrophils	  stimulated	  with	  immune	  complexes.	  J	  Immunol,	  146,	  735-­‐41.	  WALLBERG-­‐JONSSON,	   S.,	   JOHANSSON,	   H.,	   OHMAN,	   M.	   L.	   &	   RANTAPAA-­‐DAHLQVIST,	   S.	  1999.	  Extent	  of	  inflammation	  predicts	  cardiovascular	  disease	  and	  overall	  mortality	  in	   seropositive	   rheumatoid	   arthritis.	   A	   retrospective	   cohort	   study	   from	   disease	  onset.	  J	  Rheumatol,	  26,	  2562-­‐71.	  WALMSLEY,	  S.	  R.,	  COWBURN,	  A.	  S.,	  CLATWORTHY,	  M.	  R.,	  MORRELL,	  N.	  W.,	  ROPER,	  E.	  C.,	  SINGLETON,	  V.,	  MAXWELL,	  P.,	  WHYTE,	  M.	  K.	  &	  CHILVERS,	  E.	  R.	  2006.	  Neutrophils	  from	   patients	   with	   heterozygous	   germline	   mutations	   in	   the	   von	   Hippel	   Lindau	  protein	   (pVHL)	   display	   delayed	   apoptosis	   and	   enhanced	   bacterial	   phagocytosis.	  
Blood,	  108,	  3176-­‐8.	  WALMSLEY,	  S.	  R.,	  PRINT,	  C.,	  FARAHI,	  N.,	  PEYSSONNAUX,	  C.,	   JOHNSON,	  R.	  S.,	  CRAMER,	  T.,	  SOBOLEWSKI,	  A.,	  CONDLIFFE,	  A.	  M.,	  COWBURN,	  A.	  S.,	  JOHNSON,	  N.	  &	  CHILVERS,	  E.	  R.	   2005.	   Hypoxia-­‐induced	   neutrophil	   survival	   is	   mediated	   by	   HIF-­‐1alpha-­‐dependent	  NF-­‐kappaB	  activity.	  J	  Exp	  Med,	  201,	  105-­‐15.	  WANG,	   F.,	   WANG,	   C.	   L.,	   TAN,	   C.	   T.	   &	   MANIVASAGAR,	   M.	   1997.	   Systemic	   lupus	  erythematosus	  in	  Malaysia:	  a	  study	  of	  539	  patients	  and	  comparison	  of	  prevalence	  and	  disease	  expression	  in	  different	  racial	  and	  gender	  groups.	  Lupus,	  6,	  248-­‐53.	  WANG,	  G.	  L.,	  JIANG,	  B.	  H.,	  RUE,	  E.	  A.	  &	  SEMENZA,	  G.	  L.	  1995.	  Hypoxia-­‐inducible	  factor	  1	  is	  a	  basic-­‐helix-­‐loop-­‐helix-­‐PAS	  heterodimer	  regulated	  by	  cellular	  O2	  tension.	  Proc	  Natl	  
Acad	  Sci	  U	  S	  A,	  92,	  5510-­‐4.	  WANG,	  J.	  S.	  &	  LIU,	  H.	  C.	  2009.	  Systemic	  hypoxia	  enhances	  bactericidal	  activities	  of	  human	  polymorphonuclear	  leuocytes.	  Clin	  Sci	  (Lond),	  116,	  805-­‐17.	  WANG,	  Y.,	  WYSOCKA,	  J.,	  SAYEGH,	  J.,	  LEE,	  Y.	  H.,	  PERLIN,	  J.	  R.,	  LEONELLI,	  L.,	  SONBUCHNER,	  L.	  S.,	  MCDONALD,	  C.	  H.,	  COOK,	  R.	  G.,	  DOU,	  Y.,	  ROEDER,	  R.	  G.,	  CLARKE,	  S.,	  STALLCUP,	  M.	  R.,	  ALLIS,	  C.	  D.	  &	  COONROD,	  S.	  A.	  2004.	  Human	  PAD4	  regulates	  histone	  arginine	  methylation	  levels	  via	  demethylimination.	  Science,	  306,	  279-­‐83.	  WARCHOL,	  T.,	  LIANERI,	  M.,	  LACKI,	  J.	  K.,	  OLESINSKA,	  M.	  &	  JAGODZINSKI,	  P.	  P.	  2011.	  ITGAM	  Arg77His	  is	  associated	  with	  disease	  susceptibility,	  arthritis,	  and	  renal	  symptoms	  in	  systemic	   lupus	   erythematosus	   patients	   from	   a	   sample	   of	   the	   Polish	   population.	  
DNA	  Cell	  Biol,	  30,	  33-­‐8.	  
References 
	   265	  
WATTS,	  G.	  M.,	  BEURSKENS,	  F.	  J.,	  MARTIN-­‐PADURA,	  I.,	  BALLANTYNE,	  C.	  M.,	  KLICKSTEIN,	  L.	  B.,	  BRENNER,	  M.	  B.	  &	  LEE,	  D.	  M.	  2005.	  Manifestations	  of	  inflammatory	  arthritis	  are	  critically	  dependent	  on	  LFA-­‐1.	  J	  Immunol,	  174,	  3668-­‐75.	  WEISMAN,	  M.	  H.	  2002.	  Newly	  diagnosed	  rheumatoid	  arthritis.	  Ann	  Rheum	  Dis,	  61,	  287-­‐9.	  WELLS,	  G.,	  BECKER,	  J.	  C.,	  TENG,	  J.,	  DOUGADOS,	  M.,	  SCHIFF,	  M.,	  SMOLEN,	  J.,	  ALETAHA,	  D.	  &	  VAN	  RIEL,	  P.	  L.	  2009.	  Validation	  of	  the	  28-­‐joint	  Disease	  Activity	  Score	  (DAS28)	  and	  European	   League	   Against	   Rheumatism	   response	   criteria	   based	   on	   C-­‐reactive	  protein	   against	   disease	   progression	   in	   patients	   with	   rheumatoid	   arthritis,	   and	  comparison	  with	  the	  DAS28	  based	  on	  erythrocyte	  sedimentation	  rate.	  Ann	  Rheum	  
Dis,	  68,	  954-­‐60.	  WEST,	   B.	   C.,	   ROSENTHAL,	   A.	   S.,	   GELB,	   N.	   A.	   &	   KIMBALL,	   H.	   R.	   1974.	   Separation	   and	  characterization	  of	  human	  neutrophil	  granules.	  Am	  J	  Pathol,	  77,	  41-­‐66.	  WIESENER,	  M.	  S.,	   JURGENSEN,	   J.	   S.,	  ROSENBERGER,	  C.,	   SCHOLZE,	  C.	  K.,	  HORSTRUP,	   J.	  H.,	  WARNECKE,	   C.,	   MANDRIOTA,	   S.,	   BECHMANN,	   I.,	   FREI,	   U.	   A.,	   PUGH,	   C.	   W.,	  RATCLIFFE,	   P.	   J.,	   BACHMANN,	   S.,	   MAXWELL,	   P.	   H.	   &	   ECKARDT,	   K.	   U.	   2003.	  Widespread	   hypoxia-­‐inducible	   expression	   of	   HIF-­‐2alpha	   in	   distinct	   cell	  populations	  of	  different	  organs.	  FASEB	  J,	  17,	  271-­‐3.	  WIESENER,	  M.	   S.,	   TURLEY,	   H.,	   ALLEN,	  W.	   E.,	  WILLAM,	   C.,	   ECKARDT,	   K.	   U.,	   TALKS,	   K.	   L.,	  WOOD,	   S.	   M.,	   GATTER,	   K.	   C.,	   HARRIS,	   A.	   L.,	   PUGH,	   C.	   W.,	   RATCLIFFE,	   P.	   J.	   &	  MAXWELL,	  P.	  H.	  1998.	  Induction	  of	  endothelial	  PAS	  domain	  protein-­‐1	  by	  hypoxia:	  characterization	  and	  comparison	  with	  hypoxia-­‐inducible	   factor-­‐1alpha.	  Blood,	  92,	  2260-­‐8.	  WILLIS,	   R.,	   SEIF,	   A.	   M.,	   MCGWIN,	   G.,	   JR.,	   MARTINEZ-­‐MARTINEZ,	   L.	   A.,	   GONZALEZ,	   E.	   B.,	  DANG,	  N.,	   PAPALARDO,	   E.,	   LIU,	   J.,	   VILA,	   L.	  M.,	   REVEILLE,	   J.	   D.,	   ALARCON,	   G.	   S.	  &	  PIERANGELI,	   S.	   S.	   2012.	   Effect	   of	   hydroxychloroquine	   treatment	   on	   pro-­‐inflammatory	   cytokines	   and	   disease	   activity	   in	   SLE	   patients:	   data	   from	   LUMINA	  (LXXV),	  a	  multiethnic	  US	  cohort.	  Lupus,	  21,	  830-­‐5.	  WILLIS,	  V.	  C.,	  GIZINSKI,	  A.	  M.,	  BANDA,	  N.	  K.,	  CAUSEY,	  C.	  P.,	  KNUCKLEY,	  B.,	  CORDOVA,	  K.	  N.,	  LUO,	  Y.,	   LEVITT,	  B.,	  GLOGOWSKA,	  M.,	  CHANDRA,	  P.,	  KULIK,	  L.,	  ROBINSON,	  W.	  H.,	  AREND,	  W.	   P.,	   THOMPSON,	   P.	   R.	   &	  HOLERS,	   V.	  M.	   2011.	   N-­‐alpha-­‐benzoyl-­‐N5-­‐(2-­‐chloro-­‐1-­‐iminoethyl)-­‐L-­‐ornithine	   amide,	   a	   protein	   arginine	   deiminase	   inhibitor,	  reduces	   the	   severity	   of	  murine	   collagen-­‐induced	   arthritis.	   J	   Immunol,	   186,	   4396-­‐404.	  WILSON,	  W.	  A.,	  GHARAVI,	  A.	  E.,	  KOIKE,	  T.,	  LOCKSHIN,	  M.	  D.,	  BRANCH,	  D.	  W.,	  PIETTE,	  J.	  C.,	  BREY,	   R.,	   DERKSEN,	   R.,	   HARRIS,	   E.	   N.,	   HUGHES,	   G.	   R.,	   TRIPLETT,	   D.	   A.	   &	  KHAMASHTA,	   M.	   A.	   1999.	   International	   consensus	   statement	   on	   preliminary	  classification	   criteria	   for	   definite	   antiphospholipid	   syndrome:	   report	   of	   an	  international	  workshop.	  Arthritis	  Rheum,	  42,	  1309-­‐11.	  WIPKE,	   B.	   T.	   &	   ALLEN,	   P.	   M.	   2001.	   Essential	   role	   of	   neutrophils	   in	   the	   initiation	   and	  progression	  of	  a	  murine	  model	  of	  rheumatoid	  arthritis.	  J	  Immunol,	  167,	  1601-­‐8.	  WONG,	  C.	  K.,	  HO,	  C.	  Y.,	  LI,	  E.	  K.	  &	  LAM,	  C.	  W.	  2000.	  Elevation	  of	  proinflammatory	  cytokine	  (IL-­‐18,	   IL-­‐17,	   IL-­‐12)	   and	   Th2	   cytokine	   (IL-­‐4)	   concentrations	   in	   patients	   with	  systemic	  lupus	  erythematosus.	  Lupus,	  9,	  589-­‐93.	  WOODFIN,	  A.,	  VOISIN,	  M.	  B.,	  IMHOF,	  B.	  A.,	  DEJANA,	  E.,	  ENGELHARDT,	  B.	  &	  NOURSHARGH,	  S.	   2009.	   Endothelial	   cell	   activation	   leads	   to	   neutrophil	   transmigration	   as	  supported	   by	   the	   sequential	   roles	   of	   ICAM-­‐2,	   JAM-­‐A,	   and	   PECAM-­‐1.	   Blood,	   113,	  6246-­‐57.	  WORTHEN,	  G.	  S.,	  AVDI,	  N.,	  BUHL,	  A.	  M.,	  SUZUKI,	  N.	  &	  JOHNSON,	  G.	  L.	  1994.	  FMLP	  activates	  Ras	  and	  Raf	  in	  human	  neutrophils.	  Potential	  role	  in	  activation	  of	  MAP	  kinase.	  J	  Clin	  
Invest,	  94,	  815-­‐23.	  WU,	  C.	  H.,	  HSIEH,	  S.	  C.,	  LI,	  K.	  J.,	  LU,	  M.	  C.	  &	  YU,	  C.	  L.	  2007.	  Premature	  telomere	  shortening	  in	  polymorphonuclear	  neutrophils	  from	  patients	  with	  systemic	  lupus	  erythematosus	  is	  related	  to	  the	  lupus	  disease	  activity.	  Lupus,	  16,	  265-­‐72.	  
References 
	   266	  
WU,	  J.,	  EDBERG,	  J.	  C.,	  REDECHA,	  P.	  B.,	  BANSAL,	  V.,	  GUYRE,	  P.	  M.,	  COLEMAN,	  K.,	  SALMON,	  J.	  E.	  &	  KIMBERLY,	  R.	  P.	  1997.	  A	  novel	  polymorphism	  of	  FcgammaRIIIa	  (CD16)	  alters	  receptor	  function	  and	  predisposes	  to	  autoimmune	  disease.	  J	  Clin	  Invest,	  100,	  1059-­‐70.	  WURM,	  H.	  1984.	  beta	  2-­‐Glycoprotein-­‐I	  (apolipoprotein	  H)	  interactions	  with	  phospholipid	  vesicles.	  Int	  J	  Biochem,	  16,	  511-­‐5.	  XIAO,	  T.,	  TAKAGI,	  J.,	  COLLER,	  B.	  S.,	  WANG,	  J.	  H.	  &	  SPRINGER,	  T.	  A.	  2004.	  Structural	  basis	  for	  allostery	  in	  integrins	  and	  binding	  to	  fibrinogen-­‐mimetic	  therapeutics.	  Nature,	  432,	  59-­‐67.	  XIE,	   J.,	   LI,	   R.,	   KOTOVUORI,	   P.,	   VERMOT-­‐DESROCHES,	   C.,	   WIJDENES,	   J.,	   ARNAOUT,	   M.	   A.,	  NORTAMO,	   P.	   &	   GAHMBERG,	   C.	   G.	   1995.	   Intercellular	   adhesion	   molecule-­‐2	  (CD102)	   binds	   to	   the	   leukocyte	   integrin	   CD11b/CD18	   through	   the	   A	   domain.	   J	  
Immunol,	  155,	  3619-­‐28.	  XIONG,	   J.	   P.,	   STEHLE,	   T.,	   DIEFENBACH,	   B.,	   ZHANG,	   R.,	   DUNKER,	   R.,	   SCOTT,	   D.	   L.,	  JOACHIMIAK,	  A.,	  GOODMAN,	  S.	  L.	  &	  ARNAOUT,	  M.	  A.	  2001.	  Crystal	  structure	  of	  the	  extracellular	  segment	  of	  integrin	  alpha	  Vbeta3.	  Science,	  294,	  339-­‐45.	  XIONG,	   J.	   P.,	   STEHLE,	   T.,	   ZHANG,	   R.,	   JOACHIMIAK,	   A.,	   FRECH,	   M.,	   GOODMAN,	   S.	   L.	   &	  ARNAOUT,	  M.	   A.	   2002.	   Crystal	   structure	   of	   the	   extracellular	   segment	   of	   integrin	  alpha	  Vbeta3	  in	  complex	  with	  an	  Arg-­‐Gly-­‐Asp	  ligand.	  Science,	  296,	  151-­‐5.	  XU,	  C.,	  MAO,	  D.,	  HOLERS,	  V.	  M.,	  PALANCA,	  B.,	  CHENG,	  A.	  M.	  &	  MOLINA,	  H.	  2000.	  A	  critical	  role	  for	  murine	  complement	  regulator	  crry	  in	  fetomaternal	  tolerance.	  Science,	  287,	  498-­‐501.	  YAKUBENKO,	   V.	   P.,	   YADAV,	   S.	   P.	   &	   UGAROVA,	   T.	   P.	   2006.	   Integrin	   alphaDbeta2,	   an	  adhesion	   receptor	   up-­‐regulated	   on	  macrophage	   foam	   cells,	   exhibits	  multiligand-­‐binding	  properties.	  Blood,	  107,	  1643-­‐50.	  YALAVARTHI,	  S.,	  GOULD,	  T.	  J.,	  RAO,	  A.	  N.,	  MAZZA,	  L.	  F.,	  MORRIS,	  A.	  E.,	  NUNEZ-­‐ALVAREZ,	  C.,	  HERNANDEZ-­‐RAMIREZ,	   D.,	   BOCKENSTEDT,	   P.	   L.,	   LIAW,	   P.	   C.,	   CABRAL,	   A.	   R.	   &	  KNIGHT,	   J.	   S.	   2015.	   Release	   of	   neutrophil	   extracellular	   traps	   by	   neutrophils	  stimulated	   with	   antiphospholipid	   antibodies:	   a	   newly	   identified	   mechanism	   of	  thrombosis	  in	  the	  antiphospholipid	  syndrome.	  Arthritis	  Rheumatol,	  67,	  2990-­‐3003.	  YAMASHITA,	   T.,	   OHNEDA,	   O.,	   NAGANO,	   M.,	   IEMITSU,	   M.,	   MAKINO,	   Y.,	   TANAKA,	   H.,	  MIYAUCHI,	   T.,	   GOTO,	   K.,	   OHNEDA,	   K.,	   FUJII-­‐KURIYAMA,	   Y.,	   POELLINGER,	   L.	   &	  YAMAMOTO,	  M.	  2008.	  Abnormal	  heart	  development	  and	  lung	  remodeling	  in	  mice	  lacking	   the	   hypoxia-­‐inducible	   factor-­‐related	   basic	   helix-­‐loop-­‐helix	   PAS	   protein	  NEPAS.	  Mol	  Cell	  Biol,	  28,	  1285-­‐97.	  YANG,	  N.,	  ISBEL,	  N.	  M.,	  NIKOLIC-­‐PATERSON,	  D.	  J.,	  LI,	  Y.,	  YE,	  R.,	  ATKINS,	  R.	  C.	  &	  LAN,	  H.	  Y.	  1998a.	   Local	  macrophage	   proliferation	   in	   human	   glomerulonephritis.	  Kidney	   Int,	  54,	  143-­‐51.	  YANG,	  R.	  B.,	  MARK,	  M.	  R.,	  GRAY,	  A.,	  HUANG,	  A.,	  XIE,	  M.	  H.,	  ZHANG,	  M.,	  GODDARD,	  A.,	  WOOD,	  W.	   I.,	   GURNEY,	   A.	   L.	   &	   GODOWSKI,	   P.	   J.	   1998b.	   Toll-­‐like	   receptor-­‐2	   mediates	  lipopolysaccharide-­‐induced	  cellular	  signalling.	  Nature,	  395,	  284-­‐8.	  YANG,	  W.,	  ZHAO,	  M.,	  HIRANKARN,	  N.,	  LAU,	  C.	  S.,	  MOK,	  C.	  C.,	  CHAN,	  T.	  M.,	  WONG,	  R.	  W.,	  LEE,	  K.	  W.,	  MOK,	  M.	  Y.,	  WONG,	  S.	  N.,	  AVIHINGSANON,	  Y.,	  LIN,	  I.	  O.,	  LEE,	  T.	  L.,	  HO,	  M.	  H.,	  LEE,	  P.	  P.,	  WONG,	  W.	  H.,	  SHAM,	  P.	  C.	  &	  LAU,	  Y.	  L.	  2009.	   ITGAM	  is	  associated	  with	  disease	  susceptibility	  and	  renal	  nephritis	  of	  systemic	  lupus	  erythematosus	  in	  Hong	  Kong	  Chinese	  and	  Thai.	  Hum	  Mol	  Genet,	  18,	  2063-­‐70.	  YE,	  Z.,	  MA,	  N.,	  ZHAO,	  L.,	  JIANG,	  Z.	  Y.	  &	  JIANG,	  Y.	  F.	  2014.	  Differential	  expression	  of	  natural	  killer	   activating	   and	   inhibitory	   receptors	   in	   patients	   with	   newly	   diagnosed	  systemic	  lupus	  erythematosus.	  Int	  J	  Rheum	  Dis.	  YI,	   Y.,	   MCNERNEY,	   M.	   &	   DATTA,	   S.	   K.	   2000.	   Regulatory	   defects	   in	   Cbl	   and	   mitogen-­‐activated	   protein	   kinase	   (extracellular	   signal-­‐related	   kinase)	   pathways	   cause	  persistent	  hyperexpression	  of	  CD40	  ligand	  in	  human	  lupus	  T	  cells.	  J	  Immunol,	  165,	  6627-­‐34.	  
References 
	   267	  
YIPP,	  B.	  G.,	  PETRI,	  B.,	  SALINA,	  D.,	  JENNE,	  C.	  N.,	  SCOTT,	  B.	  N.,	  ZBYTNUIK,	  L.	  D.,	  PITTMAN,	  K.,	  ASADUZZAMAN,	  M.,	  WU,	  K.,	  MEIJNDERT,	  H.	  C.,	  MALAWISTA,	  S.	  E.,	  DE	  BOISFLEURY	  CHEVANCE,	  A.,	  ZHANG,	  K.,	  CONLY,	  J.	  &	  KUBES,	  P.	  2012.	  Infection-­‐induced	  NETosis	  is	  a	  dynamic	  process	  involving	  neutrophil	  multitasking	  in	  vivo.	  Nat	  Med,	  18,	  1386-­‐93.	  YOUNG,	   A.	   &	   KODURI,	   G.	   2007.	   Extra-­‐articular	   manifestations	   and	   complications	   of	  rheumatoid	  arthritis.	  Best	  Pract	  Res	  Clin	  Rheumatol,	  21,	  907-­‐27.	  YOUNG,	  A.,	  KODURI,	  G.,	  BATLEY,	  M.,	  KULINSKAYA,	  E.,	  GOUGH,	  A.,	  NORTON,	  S.	  &	  DIXEY,	  J.	  2007.	  Mortality	  in	  rheumatoid	  arthritis.	  Increased	  in	  the	  early	  course	  of	  disease,	  in	  ischaemic	   heart	   disease	   and	   in	   pulmonary	   fibrosis.	   Rheumatology	   (Oxford),	   46,	  350-­‐7.	  YOUSEFI,	   S.,	   MIHALACHE,	   C.,	   KOZLOWSKI,	   E.,	   SCHMID,	   I.	   &	   SIMON,	   H.	   U.	   2009.	   Viable	  neutrophils	  release	  mitochondrial	  DNA	  to	  form	  neutrophil	  extracellular	  traps.	  Cell	  
Death	  Differ,	  16,	  1438-­‐44.	  YU,	  F.,	  WHITE,	  S.	  B.,	  ZHAO,	  Q.	  &	  LEE,	  F.	  S.	  2001.	  HIF-­‐1alpha	  binding	  to	  VHL	  is	  regulated	  by	  stimulus-­‐sensitive	  proline	  hydroxylation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  98,	  9630-­‐5.	  ZANDMAN-­‐GODDARD,	  G.,	   SOLOMON,	  M.,	  ROSMAN,	  Z.,	  PEEVA,	  E.	  &	  SHOENFELD,	  Y.	  2012.	  Environment	  and	  lupus-­‐related	  diseases.	  Lupus,	  21,	  241-­‐50.	  ZENG,	  B.	  X.,	  FUJIWARA,	  H.,	  SATO,	  Y.,	  NISHIOKA,	  Y.,	  YAMADA,	  S.,	  YOSHIOKA,	  S.,	  UEDA,	  M.,	  HIGUCHI,	   T.	   &	   FUJII,	   S.	   2007.	   Integrin	   alpha5	   is	   involved	   in	   fibronectin-­‐induced	  human	  extravillous	  trophoblast	  invasion.	  J	  Reprod	  Immunol,	  73,	  1-­‐10.	  ZHANG,	   H.,	   CASASNOVAS,	   J.	   M.,	   JIN,	   M.,	   LIU,	   J.	   H.,	   GAHMBERG,	   C.	   G.,	   SPRINGER,	   T.	   A.	   &	  WANG,	  J.	  H.	  2008.	  An	  unusual	  allosteric	  mobility	  of	  the	  C-­‐terminal	  helix	  of	  a	  high-­‐affinity	  alphaL	  integrin	  I	  domain	  variant	  bound	  to	  ICAM-­‐5.	  Mol	  Cell,	  31,	  432-­‐7.	  ZHANG,	  K.	  &	  CHEN,	  J.	  2012.	  The	  regulation	  of	  integrin	  function	  by	  divalent	  cations.	  Cell	  Adh	  
Migr,	  6,	  20-­‐9.	  ZHANG,	  P.,	  LU,	  L.,	  YAO,	  Q.,	  LI,	  Y.,	  ZHOU,	  J.,	  LIU,	  Y.	  &	  DUAN,	  C.	  2012.	  Molecular,	   functional,	  and	   gene	   expression	   analysis	   of	   zebrafish	   hypoxia-­‐inducible	   factor-­‐3alpha.	   Am	   J	  
Physiol	  Regul	  Integr	  Comp	  Physiol,	  303,	  R1165-­‐74.	  ZHANG,	  P.,	  YAO,	  Q.,	  LU,	  L.,	  LI,	  Y.,	  CHEN,	  P.	  J.	  &	  DUAN,	  C.	  2014.	  Hypoxia-­‐inducible	  factor	  3	  is	  an	   oxygen-­‐dependent	   transcription	   activator	   and	   regulates	   a	   distinct	  transcriptional	  response	  to	  hypoxia.	  Cell	  Rep,	  6,	  1110-­‐21.	  ZHAO,	   H.,	   JIANG,	   Y.,	   CAO,	   Q.,	   HOU,	   Y.	   &	   WANG,	   C.	   2012.	   Role	   of	   integrin	   switch	   and	  transforming	   growth	   factor	   Beta	   3	   in	   hypoxia-­‐induced	   invasion	   inhibition	   of	  human	  extravillous	  trophoblast	  cells.	  Biol	  Reprod,	  87,	  47.	  ZHAO,	  M.	  H.,	   JONES,	  S.	   J.	  &	  LOCKWOOD,	  C.	  M.	  1995.	  Bactericidal/permeability-­‐increasing	  protein	   (BPI)	   is	   an	   important	   antigen	   for	   anti-­‐neutrophil	   cytoplasmic	  autoantibodies	  (ANCA)	  in	  vasculitis.	  Clin	  Exp	  Immunol,	  99,	  49-­‐56.	  ZHAO,	  M.	  H.	  &	  LOCKWOOD,	  C.	  M.	  1996.	  Azurocidin	   is	  a	  novel	  antigen	   for	  anti-­‐neutrophil	  cytoplasmic	  autoantibodies	  (ANCA)	   in	  systemic	  vasculitis.	  Clin	  Exp	  Immunol,	  103,	  397-­‐402.	  ZHOU,	   L.,	   LEE,	   D.	   H.,	   PLESCIA,	   J.,	   LAU,	   C.	   Y.	   &	   ALTIERI,	   D.	   C.	   1994.	   Differential	   ligand	  binding	   specificities	   of	   recombinant	   CD11b/CD18	   integrin	   I-­‐domain.	   J	  Biol	  Chem,	  269,	  17075-­‐9.	  ZHOU,	  M.,	  TODD,	  R.	  F.,	  3RD,	  VAN	  DE	  WINKEL,	  J.	  G.	  &	  PETTY,	  H.	  R.	  1993.	  Cocapping	  of	  the	  leukoadhesin	   molecules	   complement	   receptor	   type	   3	   and	   lymphocyte	   function-­‐associated	  antigen-­‐1	  with	  Fc	  gamma	  receptor	   III	  on	  human	  neutrophils.	  Possible	  role	  of	  lectin-­‐like	  interactions.	  J	  Immunol,	  150,	  3030-­‐41.	  ZHOU,	   M.	   J.,	   LUBLIN,	   D.	   M.,	   LINK,	   D.	   C.	   &	   BROWN,	   E.	   J.	   1995.	   Distinct	   tyrosine	   kinase	  activation	   and	   Triton	   X-­‐100	   insolubility	   upon	   Fc	   gamma	   RII	   or	   Fc	   gamma	   RIIIB	  ligation	   in	   human	   polymorphonuclear	   leukocytes.	   Implications	   for	   immune	  complex	  activation	  of	  the	  respiratory	  burst.	  J	  Biol	  Chem,	  270,	  13553-­‐60.	  ZHOU,	   Y.,	   FISHER,	   S.	   J.,	   JANATPOUR,	   M.,	   GENBACEV,	   O.,	   DEJANA,	   E.,	   WHEELOCK,	   M.	   &	  DAMSKY,	  C.	  H.	  1997.	  Human	  cytotrophoblasts	  adopt	  a	  vascular	  phenotype	  as	  they	  
References 
	   268	  
differentiate.	   A	   strategy	   for	   successful	   endovascular	   invasion?	   J	   Clin	   Invest,	   99,	  2139-­‐51.	  ZHOU,	  Y.,	  WU,	  J.,	  KUCIK,	  D.	  F.,	  WHITE,	  N.	  B.,	  REDDEN,	  D.	  T.,	  SZALAI,	  A.	  J.,	  BULLARD,	  D.	  C.	  &	  EDBERG,	   J.	   C.	   2013.	   Multiple	   lupus-­‐associated	   ITGAM	   variants	   alter	   Mac-­‐1	  functions	  on	  neutrophils.	  Arthritis	  Rheum,	  65,	  2907-­‐16.	  ZHU,	  J.	  &	  SPRINGER,	  T.	  A.	  2013.	  Complete	  integrin	  headpiece	  opening	  in	  eight	  steps.	  J	  Cell	  
Biol,	  201,	  1053-­‐68.	  ZHU,	  J.,	  YAMANE,	  H.	  &	  PAUL,	  W.	  E.	  2010.	  Differentiation	  of	  effector	  CD4	  T	  cell	  populations	  (*).	  Annu	  Rev	  Immunol,	  28,	  445-­‐89.	  ZIMMERMANN,	   M.,	   ARRUDA-­‐SILVA,	   F.,	   BIANCHETTO-­‐AGUILERA,	   F.,	   FINOTTI,	   G.,	  CALZETTI,	  F.,	  SCAPINI,	  P.,	  LUNARDI,	  C.,	  CASSATELLA,	  M.	  A.	  &	  TAMASSIA,	  N.	  2016.	  IFNalpha	   enhances	   the	   production	   of	   IL-­‐6	   by	   human	   neutrophils	   activated	   via	  TLR8.	  Sci	  Rep,	  6,	  19674.	  ZINKERNAGEL,	  A.	  S.,	  PEYSSONNAUX,	  C.,	  JOHNSON,	  R.	  S.	  &	  NIZET,	  V.	  2008.	  Pharmacologic	  augmentation	   of	   hypoxia-­‐inducible	   factor-­‐1alpha	   with	   mimosine	   boosts	   the	  bactericidal	  capacity	  of	  phagocytes.	  J	  Infect	  Dis,	  197,	  214-­‐7.	  ZUND,	  G.,	  NELSON,	  D.	  P.,	  NEUFELD,	  E.	  J.,	  DZUS,	  A.	  L.,	  BISCHOFF,	  J.,	  MAYER,	  J.	  E.	  &	  COLGAN,	  S.	  P.	  1996.	  Hypoxia	  enhances	  stimulus-­‐dependent	  induction	  of	  E-­‐selectin	  on	  aortic	  endothelial	  cells.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  93,	  7075-­‐80.	  ZWERINA,	  J.,	  HAYER,	  S.,	  REDLICH,	  K.,	  BOBACZ,	  K.,	  KOLLIAS,	  G.,	  SMOLEN,	  J.	  S.	  &	  SCHETT,	  G.	  2006.	   Activation	   of	   p38	   MAPK	   is	   a	   key	   step	   in	   tumor	   necrosis	   factor-­‐mediated	  inflammatory	  bone	  destruction.	  Arthritis	  Rheum,	  54,	  463-­‐72.	  	  
 	  	  	  	  	  
	  269	  
Appendix I: General Materials and Equipment 	  
 
 
15ml conical centrifuge tube          Falcon centrifuge tube (Corning, UK) 
50ml conical centrifuge tube          Falcon centrifuge tube (Corning, UK) 
1.5ml microcentrifuge tubes         Epindorf tubes (VWR, UK) 
Centrifuges           Sorvall Legend XT (Thermo Scientific, UK) 
               Megafuge 40R (Thermo Scientific, UK) 
Plate reader           Tecan GENios Spectra FLUOR (Tecan UK Ltd., UK) 
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Appendix II: General Buffers 	  
 
 
For all buffers prepared, solutions were made using distilled and deionised water (ddH2O) and 
adjusted to the correct pH with 0.1M HCl or 0.1M NaOH. Buffers were then either autoclaved 
or filter sterilised with a 0.22µm syringe driven filter unit (Millipore, Ireland). 
 
Phosphate-buffered saline (PBS) pH 7.4.  
One PBS tablet (Life Technologies, UK) was added per 500ml ddH2O and allowed to 
completely dissolve before being autoclaved prior to use. For assays requiring PBS washes, a 
10xPBS stock solution was prepared using the PBS tablets and diluted using ddH2O. To make 
PBS/0.1% Tween-20, 1ml of Tween-20 was added to 1L PBS. 
 
Tris-buffered saline (TBS) pH 7.4.  
A 10xTBS stock solution was prepared by dissolving 160g of NaCl (1.37M), 4g of KCl (0.27M) 
and 60g (0.25M) of Tris base in 1.8L of ddH2O. The solution was subsequently adjusted to pH 
7.4 and made up to 2L. The 10xTBS stock solution was autoclaved and diluted to 1xTBS using 
ddH2O. To prepare TBS/0.1% Tween-20, 1ml of Tween-20 was added to 1L TBS. 
 
Sodium HEPES buffer 
To prepare the HEPES buffer, 4.77g HEPES (20mM) (Sigma, UK), 8,18g NaCl (140mM) 
(Sigma, UK), 2g glucose (2mg/ml) (Sigma, UK) and 3g BSA (0.3% w/v) (Sigma, UK) was 
dissolved in 800ml ddH2O. The pH was adjusted to pH 7.4 using 10M NaOH before making the 
solution up to 1L with ddH2O. The HEPES buffer was subsequently filter sterilised through a 
0.22µm vacuum driven filter unit (Millipore, Ireland) and stored at 4oC 
 
IgG Binding buffer 
The binding buffer used for IgG purification is a 0.1M phosphate buffer comprised of both 
monobasic and dibasic buffers. First 13.9g of monobasic sodium phosphate (0.2M) (Sigma, 
UK) was dissolved in 500ml of ddH2O and 28.4g dibasic sodium phosphate (0.2M) (Sigma,  
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UK) was dissolved in 1L of ddH2O to make the two stock solutions, which were subsequently 
autoclaved. To make the working binding buffer, 117ml of the 0.2M monobasic phosphate 
buffer was added to 183ml of the dibasic phosphate buffer that was adjusted to pH 7.2 and made 
up to 600ml with ddH2O to achieve a 0.1M phosphate buffer. The binding buffer was filter 
sterilised through with a 0.22µm syringe driven filter unit (Millipore, Ireland) when required. 
 
IgG Elution buffer 
To elute bound IgG, a 0.1M glycine buffer (elution buffer) was used. To prepare this a 1M stock 
solution was prepared in 800ml of ddH2O and the pH adjusted to pH 3.0 and made up to 1L. 
The stock solution was autoclaved and working solutions were prepared by diluting further 
using ddH2O. The elution buffer was filter sterilised through with a 0.22µm syringe driven filter 
unit (Millipore, Ireland) before use. 
 
IgG Neutralisation buffer 
A neutralisation buffer was used to neutralise the acidic elution buffer to prevent denaturation of 
purified IgG. This was a 1M solution of Tris (Sigma, UK) that hade been adjusted to pH 9.0 and 
autoclaved. As with the other solutions, the neutralisation buffer was filtered sterilised through 
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